



US 20250250337A1

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2025/0250337 A1
(43) Pub. Date: Aug. 7, 2025(54) TRISPECIFIC BINDING PROTEINS,
METHODS, AND USES THEREOF

(71) Applicant: Sanofi, Paris (FR)

(72) Inventors: Christian BEIL, Frankfurt am Main (DE); Jochen BENINGA, Frankfurt am Main (DE); Joerg BIRKENFELD, Frankfurt am Main (DE); Gary J. NABEL, Cambridge, MA (US); Huawei QIU, Westborough, MA (US); Ercole RAO, Mörfelden-Walldorf (DE); Joerg REGULA, Munich (DE); Edward SEUNG, Cambridge, MA (US); Ronnie WEI, Cambridge, MA (US); Lan WU, Cambridge, MA (US); Zhen XING, Cambridge, MA (US); Ling XU, Cambridge, MA (US); Zhi-Yong YANG, Cambridge, MA (US); Béatrice CAMERON, Paris (FR); Tarik DABDOUBI, Paris (FR); Cendrine LEMOINE, Paris (FR); Catherine PRADES, Paris (FR)

(21) Appl. No.: 19/012,367

(22) Filed: Jan. 7, 2025

Related U.S. Application Data

- (62) Division of application No. 18/183,107, filed on Mar. 13, 2023, now Pat. No. 12,227,573, which is a division of application No. 16/843,792, filed on Apr. 8, 2020, now Pat. No. 11,613,576.
- (60) Provisional application No. 62/831,572, filed on Apr. 9, 2019, provisional application No. 62/831,415, filed on Apr. 9, 2019.

(30) Foreign Application Priority Data

Oct. 2, 2019 (EP) 19306261.9
Oct. 8, 2019 (EP) 19306312.0

Publication Classification

(51) Int. Cl.

C07K 16/28 (2006.01)
A61K 39/395 (2006.01)
A61K 45/06 (2006.01)
A61P 35/00 (2006.01)
C07K 16/32 (2006.01)
C07K 16/46 (2006.01)
CI2N 15/63 (2006.01)


(52) U.S. Cl.

CPC *C07K 16/2809* (2013.01); *A61K 39/3955* (2013.01); *A61K 39/3958* (2013.01); *A61K 45/06* (2013.01); *A61P 35/00* (2018.01); *C07K 16/2818* (2013.01); *C07K 16/2896* (2013.01); *C07K 16/32* (2013.01); *C07K 16/468* (2013.01); *CI2N 15/63* (2013.01); *C07K 2317/31* (2013.01); *C07K 2317/52* (2013.01); *C07K 2317/522* (2013.01); *C07K 2317/524* (2013.01); *C07K 2317/526* (2013.01); *C07K 2317/53* (2013.01); *C07K 2317/565* (2013.01)

ABSTRACT

Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Specification includes a Sequence Listing.






FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 2A




FIG. 2B




FIG. 2C






FIG. 3






FIG. 4A




FIG. 4B




FIG. 5A





FIG. 5B






FIG. 6C




FIG. 6D




FIG. 6F

FIG. 6E




FIG. 6G




FIG. 6H




FIG. 6I




FIG. 6J




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 7E




FIG. 7F




FIG. 7G




FIG. 7H




FIG. 7I




FIG. 7J




FIG. 8A





FIG. 8B






FIG. 8E






FIG. 8F








FIG. 9A





FIG. 9B






FIG. 9E




FIG. 9F




FIG. 9G




FIG. 10




FIG. 11




FIG. 12




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 14A

Results of Efficacy study of ZR-75-1 Her2-CD28-CD3 dose titration




FIG. 14B

FIG. 14C




FIG. 15A




FIG. 15B





FIG. 15C







FIG. 16B



HCC1954




FIG. 17A

HCC1954




FIG. 17B

BT20




FIG. 17C





FIG. 17D

MDA-MB-231




FIG. 17E




FIG. 17F

	#1	#2	#3	#4	#5	#6	Control
HCC1954 (HER2-high)	134.3	52.0	91.6	93.7	84.5	138.0	208.4
BT20 (HER2-mid)	427.6	393.9	413.6	491.4	1023.0	350.2	605.1
MDA-MB231 (HER2-low)	761.2	471.1	665.4	1109.3	636.3	645.1	2368.7

FIG. 18A

	#1	#2	#3	#4	#5	#6	Control
OE19 (HER2-hi)	34.3	46.5	62.8	93.2	180.6	424.4	50.4
GSU (HER2-mid)	140.4	64.2	77.6	87.3	133.0	215.2	181.9

FIG. 18B




FIG. 19

Destruction of the HIV-1 Reservoir by Re-directed T Cell Killing

Trispecific T cell Engager Strategy




FIG. 20

**TRISPECIFIC BINDING PROTEINS,
METHODS, AND USES THEREOF****CROSS REFERENCE TO RELATED
APPLICATIONS**

[0001] This application claims priority to U.S. Provisional Application No. 62/831,572, filed Apr. 9, 2019; U.S. Provisional Application No. 62/831,415, filed Apr. 9, 2019; EP Application No. EP19306312.0, filed Oct. 8, 2019; and EP Application No. EP19306311.2, filed Oct. 8, 2019, the disclosures of each of which are incorporated herein by reference in their entirety.

**SUBMISSION OF SEQUENCE LISTING ON
ASCII TEXT FILE**

[0002] The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 183952032000SEQLIST.TXT, date recorded: Apr. 8, 2020, size: 1,107 KB).

FIELD

[0003] The disclosure relates to trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

BACKGROUND

[0004] Monoclonal antibody based biotherapeutics have become an important avenue for new drug development. Monoclonal antibody technology offers specific targeting, precise signaling delivery and/or payload to specific cell population, and provides long lasting biological effect through its Fc functions. Efforts in antibody engineering have allowed developing bispecific antibodies combining the specificities of two monoclonal antibodies for various biological applications, expanding the scope of antibody drug development. Newly discovered neutralizing antibodies with improved breadth and potency may provide more options for developing biotherapeutics to treat complexed diseases such as cancer, arthritis, and/or inflammatory disorders.

[0005] Immuno-oncology is a promising, emerging therapeutic approach to disease management in cancer. The immune system is the first line of defense against cancer development and progression. There is now large evidence that T cells are able to control tumor growth and prolong the survival of cancer patients in both early and late stages of disease. However, T cells specific for tumors can be limited in a number of ways preventing them from controlling the disease.

[0006] As part of the human adaptive immunity, T cell immunity plays crucial role in controlling viral infection and cancer, possibly eliminating infected cells and malignant cells which result in clearance of viral infection or cure of cancer. In chronic infectious diseases such as Herpes viral infection (HSV, CMV, EBV, etc.), HIV, and HBV, viruses establish their persistence in humans by various mechanisms including immune suppression, T cell exhaustion, and

latency establishment. Nevertheless, viral infection generally induces viral antigen specific immunity including antigen specific CD8 T cells that can readily recognize infected cells for controlling or killing through cytokine release or cytotoxic T cell (CTL) mediated killing processes.

[0007] Thus, viral antigen specific T cell activation and/or amplification in vivo and/or ex vivo may provide therapeutic strategies against chronic viral infections.

[0008] Anti-retroviral therapy (ART) has been the standard of care for HIV/AIDS patients in the past decades. ART drugs target internal proteins such as reverse transcriptase (RT), integrase (IN), and viral protease (PI) by inhibiting reverse transcription of HIV-1 genome, integration of HIV-1 genome, and proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles. Treatment using ART or combination of different classes of ART results in inhibition of HIV-1 replication and subsequent reduction of viremia, often to undetectable level (aviremic status). Although ART greatly helps HIV patients in controlling their disease progression, and containing the global HIV epidemic, it does require patients taking daily medicines often following a strict regimen. About 10% patients fail therapy each year due to drug toxicity, suboptimal adherence and emerging drug resistance. As more HIV patients can live a normal life span (over 80 years), chronic complications are of particular concern, such as aging and drug-drug interaction, and cardiovascular/renal/bone toxicities. The economic burden treating HIV/AIDS has not subsided thus far.

[0009] HIV latently infects long-lived resting memory CD4+ T cells and others as a form of proviral DNA integrated into the host genome. The latently infected cells survive for decades and self-renew like stem cells via homeostatic proliferation, which is regarded as an HIV-1 reservoir. The HIV-1 reservoirs are neither affected by ART nor the host immune system as they do not express viral proteins. Yet, a small proportion of cells among the reservoirs are randomly reactivated by unknown mechanism(s), which are responsible for recurrence of viremia once ART is stopped.

[0010] Therefore, a need exists for developing HIV/AIDS treatments to target the HIV-1 reservoir(s), and ultimately eliminate them completely, achieving a cure, or long term remission of HIV without any further treatment. Any therapeutic strategy to eliminate the HIV-1 reservoir needs to activate the reservoir first, followed by elimination of the activated HIV-1 reservoir cells.

[0011] All references cited herein, including patent applications, patent publications, and UniProtKB/Swiss-Prot Accession numbers are herein incorporated by reference in their entirety, as if each individual reference were specifically and individually indicated to be incorporated by reference.

BRIEF SUMMARY

[0012] To meet these and other needs, provided herein are trispecific binding proteins (e.g., antibodies) that form three antigen binding sites. These binding proteins can specifically bind one, two, or three antigen targets or target proteins, such as CD28, CD3, and a tumor target protein. Some tumors express specific antigens. For example, HER2 amplification and overexpression can be found in molecular subtypes of breast cancer, and also in gastric, ovarian, lung and prostate carcinomas. Optimal activation of T cells

requires two factors: 1. Antigen recognition and 2. Co-stimulation. Using the trispecific HER2/CD28xCD3 trispecific binding proteins described herein, Signal 1 is provided by an agonist anti-CD3 binding site, and Signal 2 is provided by an agonist anti-CD28 binding site. The trispecific binding protein recruits T cells to the tumor via HER2, CD38, or a binding site recognizing another tumor target protein and activates the engaged T cells via anti-CD3 and -CD28. The resulting activation induces the killing potential of the immune cells against the nearby tumor cells. In addition, anti-CD3 binding sites are described with high affinity binding to human CD3 polypeptides and potential manufacturing liabilities (e.g., deamidation sites) removed.


[0013] Further provided herein are anti-CD38/CD28xCD3 trispecific antibodies that were developed and evaluated for their potential in activating T cells, and subsequent proliferation and/or amplification of antigen specific T cells. These trispecific Abs can effectively expand CD4 and CD8 effector and memory populations, including antigen specific CD8 T central memory and effector memory cells in vitro. Specifically, in vitro expansion of CMV, EBV, HIV-1, Influenza specific CD8 central memory and effector memory cells were demonstrated. The anti-CD38/CD28xCD3 trispecific antibodies described herein exhibited novel properties by engaging CD3/CD28/CD38, providing signaling pathways to stimulate and expand T cells, which may offer an effective strategy treating chronic infectious diseases such as HSV, CMV, EBV, HIV-1, and HBV infections.

[0014] To meet these and other needs, provided herein are binding proteins that bind CD38 polypeptides (e.g., human and cynomolgus monkey CD38 polypeptides), including monospecific, bispecific, or trispecific binding proteins with at least one antigen binding site that binds a CD38 polypeptide. Advantageously, these binding proteins have the ability to recruit T cells to the proximity of cancer cells, subsequently to activate T cells and promote the activated T cells killing of adjacent cancer cells through a Granzyme/Perforin mechanism, providing a different mode of action for anti-tumor activity from anti-CD38 antibodies such as DARZALEX® (daratumumab). Moreover, the ability to bind both human and cynomolgus monkey CD38 polypeptides allows binding proteins to be readily tested in preclinical toxicological studies, e.g., to evaluate their safety profiles for later clinical use.


[0015] In some embodiments, provided herein are binding proteins comprising four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

[0016] V_{L1} is a first immunoglobulin light chain variable domain;

[0017] V_{L2} is a second immunoglobulin light chain variable domain;

[0018] V_{L3} is a third immunoglobulin light chain variable domain;

[0019] V_{H1} is a first immunoglobulin heavy chain variable domain;

[0020] V_{H2} is a second immunoglobulin heavy chain variable domain;

[0021] V_{H3} is a third immunoglobulin heavy chain variable domain;

[0022] C_L is an immunoglobulin light chain constant domain;

[0023] C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

[0024] C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

[0025] C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

[0026] hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

[0027] L_1, L_2, L_3 and L_4 are amino acid linkers;

wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and

wherein V_{H1} and V_{L1} form a first antigen binding site; wherein V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide,

wherein the V_{H2} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX₁NX₂X₃TY, wherein X₁ is E or Q, X₂ is A or L, and X₃ is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65); and wherein V_{H3} and V_{L3} form a third antigen binding site.

[0028] In some embodiments, the first binding site binds a CD28 polypeptide. In some embodiments, the V_{H1} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTTSYY (SEQ ID NO:49), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:50), and a CDR-H3 sequence comprising the amino acid sequence of TRSHY-GLDWNFDV (SEQ ID NO:51), and the V_{L1} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:52), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:53), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTYPY (SEQ ID NO:54). In some embodiments, the V_{H1} domain comprises the amino acid sequence of QVQLVQSGAEVVKPGASVKVSCK-ASGYTFTSYIHWVRQAPGQGLEWIGSIYPGN VNTNYAQKFQGRATLTVDTSISTAYMELSRLRSDD-TAVYYCTRSHYGLDWNFDV WGKGTVTVSS (SEQ ID NO:91), and/or the V_{L1} domain comprises the amino acid sequence of DIQMKTQSPSSLASVGDRVITTC QASQNIYVWLWYQQKPGKAPKLLIYKASNLLHT GPVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQGQ-TYPYTFGQGKLEIK (SEQ ID NO:92).

[0029] In some embodiments, the CDR-L1 sequence of the V₂ domain comprises an amino acid sequence selected from the group consisting of QSLVHQNAQTY (SEQ ID NO:59), QSLVHENLQTY (SEQ ID NO:60), QSLVHENLFTY (SEQ ID NO:61), and QSLVHENLRTY (SEQ ID NO:62). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSN-SYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHQNAQTY (SEQ ID NO:59), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSN-SYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLQTY (SEQ ID NO:60), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLFTY (SEQ ID NO:61), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLRTY (SEQ ID NO:62), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, the V_{H2} domain comprises the amino acid sequence of QVQLVESGGGVVQPGRSLRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKD

KSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSL-RAEDTAVYYCRGVYYALSPF DYWGQGTLVTVSS (SEQ ID NO:93), and/or the V_{L2} domain comprises an amino acid sequence selected from the group consisting of DIVMTQTPLSLSVTPGQPASICKSSQLVHQNAQ-TYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:95), DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:96), DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:97), and DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:98). In some embodiments, the V_{H2} domain comprises the amino acid sequence of QVQLVESGGGVVQPGRSLRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKD KSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSL-RAEDTAVYYCRGVYYALSPF DYWGQGTLVTVSS (SEQ ID NO:93) or QVQLVESGGGVVQPGRSLRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKD KSNSYATYYASSVKGRFTISRDDSKNTLYLQMNSL-RAEDTAVYYCRGVYYALSPF DYWGQGTLVTVSS (SEQ ID NO:595), and/or the V_{L2} domain comprises an amino acid sequence selected from the group consisting of DIVMTQTPLSLSVTPGQPASICKSSQLVHQNAQ-TYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:95), DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:96), DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:97), and DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:98). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:95. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:595, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:95. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable

(VL) domain comprising the amino acid sequence of SEQ ID NO:96. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:97. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:98.

[0030] In some embodiments, the third antigen binding site binds a tumor target protein. In some embodiments, the tumor target protein is a CD38 polypeptide (e.g., a human CD38 polypeptide). In some embodiments, the tumor target protein is a HER2 polypeptide (e.g., a human HER2 polypeptide). In some embodiments, a tumor target protein of the present disclosure includes, without limitation, A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H4 (also known as VTCN1), B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2 (also known as MCP-1), CCL3 (also known as MIP-1a), CCL4 (also known as MIP-1b), CCL5 (also known as RANTES), CCL7 (also known as MCP-3), CCL8 (also known as mcp-2), CCL 11 (also known as eotaxin), CCL15 (also known as MIP-1d), CCL17 (also known as TARC), CCL19 (also known as MIP-3b), CCL20 (also known as MIP-3a), CCL21 (also known as MIP-2), CCL24 (also known as MPIF-2/eotaxin-2), CCL25 (also known as TECK), CCL26 (also known as eotaxin-3), CCR3, CCR4, CD3, CD19, CD20, CD23 (also known as FCER2, a receptor for IgE), CD24, CD27, CD28, CD38, CD39, CD40, CD70, CD80 (also known as B7-1), CD86 (also known as B7-2), CD122, CD137 (also known as 41BB), CD137L, CD152 (also known as CTLA4), CD154 (also known as CD40L), CD160, CD272, CD273 (also known as PDL2), CD274 (also known as PDL1), CD275 (also known as B7H2), CD276 (also known as B7H3), CD278 (also known as ICOS), CD279 (also known as PD-1), CDH1 (also known as E-cadherin), chitinase, CLEC9, CLEC91, CRTH2, CSF-1 (also known as M-CSF), CSF-2 (also known as GM-CSF), CSF-3 (also known as GCSF), CX3CL1 (also known as SCYD1), CXCL12 (also known as SDF1), CXCL13, CXCR3, DNGR-1, ectonucleoside triphosphate diphosphohydrolase 1, EGFR, ENTPD1, FCER1A, FCER1, FLAP, FOLH1, Gi24, GITR, GITRL, GM-CSF, Her2, HHLA2, HMGB1, HVEM, ICOSLG, IDO, IFN α , IgE, IGF1R, IL2Rbeta, IL1, IL1A, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL10, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb (also known as a receptor for IL25), IL18, IL22, IL23, IL25, IL27, IL33, IL35, ITGB4 (also known as b4 integrin), ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1, NCR3LGL1, NKG2D, NTPDase-1, OX40, OX40L, PD-1H, platelet receptor, PROM1, S152, SISP1, SLC, SPG64, ST2 (also known as a receptor for IL33), STEAP2, Syk kinase, TACI, TDO, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP (also known as a co-receptor for IL7Ra), TSLPR, TWEAK, VEGF, VISTA, Vstm3, WUCAM, and XCR1 (also known as GPR5/CCXCR1). In some embodiments, one or more of the above antigen targets are human antigen targets.

[0031] In some embodiments, the third antigen binding site binds a human CD38 polypeptide. In some embodiments, the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:13), a CDR-H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO:14), and a CDR-H3 sequence comprising the amino acid sequence of ARTG-GLRRAYFTY (SEQ ID NO:15), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVSSYQQGF (SEQ ID NO:16), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:17), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:18). In some embodiments, the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTLTEFS (SEQ ID NO:19), a CDR-H2 sequence comprising the amino acid sequence of FDPEDGET (SEQ ID NO:20), and a CDR-H3 sequence comprising the amino acid sequence of TTGRFFDW (SEQ ID NO:21), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVISRF (SEQ ID NO:22), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:23), and a CDR-L3 sequence comprising the amino acid sequence of QQDSNLPT (SEQ ID NO:24). In some embodiments, the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYAFTTYL (SEQ ID NO:25), a CDR-H2 sequence comprising the amino acid sequence of INPGSGST (SEQ ID NO:26), and a CDR-H3 sequence comprising the amino acid sequence of ARYAYGY (SEQ ID NO:27), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QNVGTA (SEQ ID NO:28), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:29), and a CDR-L3 sequence comprising the amino acid sequence of QQYSTYPFT (SEQ ID NO:30). In some embodiments, the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYSFTNYA (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of ISPYYGDT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARRFEGLFYYSMDY (SEQ ID NO:33), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHSNGNTY (SEQ ID NO:34), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:35), and a CDR-L3 sequence comprising the amino acid sequence of SQSTHVPLT (SEQ ID NO:36).

[0032] In some embodiments, the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IWYDGDSNK (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARDPGLRYFDGGMDV (SEQ ID NO:39), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QGISSY (SEQ ID NO:40), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:41), and a CDR-L3 sequence comprising the amino acid sequence of QQLNNSFPYT (SEQ ID NO:42). In some embodiments, the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:43), a CDR-H2 sequence comprising the amino acid sequence of IWYDGDSNK (SEQ ID NO:44), and a CDR-H3 sequence comprising the amino acid sequence of ARMFRGAFDY (SEQ ID NO:45), and the V_{L3} domain comprises a CDR-L1 sequence

comprising the amino acid sequence of QGIRND (SEQ ID NO:46), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:47), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:48). In some embodiments, the V_{H3} domain comprises the amino acid sequence of QVQLVQSGAEVVKP-GASVKVSCKASGYTFTSYAMHWVKEAPGQRLEWI-GYIYPG QGGTNYNQKFQGRATLTADTSASTAYMELSSLRSED-TAVYFCARTGGLRRAYFTY WGQGTLTVSS (SEQ ID NO:79), and/or the V_{L3} domain comprises the amino acid sequence of DIVLTQSPATLSLSPGER-ATISCRASQSVSSYQGQFMHWYQQKPGQPPRLLIY-GASS RATGIPARFSGSGSGTDFTLTISPLEPED-FAVYYCQQNKEDPWTFFGGTKLEIK (SEQ ID NO:80). In some embodiments, the V_{H3} domain comprises the amino acid sequence of QVQLVQSGAEVKKP-GASVKVSCKVSGYTLTEFSIHWRVHQAPGQ-GLEWMMGGFDPE DGETIYAQKFQGRVIMTEDTSTD-TAYMEMNSLRSEDTAIYYCTTGRFFDWFWGQG TLTVSS (SEQ ID NO:81), and/or the V_{L3} domain comprises the amino acid sequence of EIILTQSPAILSLSPGER-ATLSCRASQSVISRFLSWYQVKPGLAPRLLIYGAS-TRATGIP VRFGSGSGTDFSLTISSLQPEDCAVYYCQQDSNL-PITFGQQGTRLEIK (SEQ ID NO:82). In some embodiments, the V_{H3} domain comprises the amino acid sequence of QVQLVQSGAEVKPGASVKVSCKASGYAFTTYL-VEWIRQRPGQGLEWMGVINPG SGSTNYAQKFQGRVTMTVDRSST-TAYMELSRLRSDDTAVYYCARYAYGYWGQG TLTVSS (SEQ ID NO:83), and/or the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSL-SASVGDRVITICRASQNVGTAVAWYQQKPGK-SPKQLIYSASNRYT GVPSRFSGSGSGTDFLTISLQPED-LATYYCQQYSTYPFTFGQGTKEIK (SEQ ID NO:84). In some embodiments, the V_{H3} domain comprises the amino acid sequence of QVQLVESGGGVQPGRSRLRS-CAASGFTFSSYGMWVRQAPGKGLEWVAIWYD GSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAE-DTAVYHCARDPGLRYFDGG MDVWGQGTTVTVSS (SEQ ID NO:87), and/or the V_{L3} domain comprises the amino acid sequence of DIQLTQSPLSASVGDRVIT-CRASQGISSYLAWYQQKPGKAPKLLIIFAASTLHSG VPSRFSGSGSGTEFTLTISLQPEDFA-TYYCQLNNSFPYTFGQGTKEIK (SEQ ID NO:88). In some embodiments, the V_{H3} domain comprises the amino acid sequence of QVQLVESGGGVQPGRSRLRS-CAASGFTFSSYGMWVRQAPGKGLEWVAIWYD GSNKYY ADSVKGRFTISGDNSKNTLYLQMNSLRAE-DTAVYYCARMFRGAFDYWG QTGLTVSS (SEQ ID NO:89), and/or the V_{L3} domain comprises the amino acid sequence of AIQMTQSPSSLASVGDRVITICRASQ-GIRNDLGWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTDFLTISLQPEDSATYY-CLQDYIYYPTFGQGTKEIK (SEQ ID NO:90). In some embodiments, the V_{H3} domain comprises the amino acid sequence of QVQLVQSGAEVKPGASVKVSCK-ASGYSFNTYAVHWVRQAPGQGLEWMGVISPY YGDT-TYAQKFQGRVTMTVDKSSSTAYMELSRLRSDD-TAVYYCARRFEGFYYSMD YWGQGTLTVSS (SEQ ID NO:85), and/or the V_{L3} domain comprises the amino acid

sequence of DVVMTQSPLSLPVTLGQPASISCRP-SQSLVHSNGNTYLNWYQQRPGQSPKLLIYKV SKRFSGPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCSQSTHVPLTFGGGTKEIK (SEQ ID NO:86).

[0033] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:156 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:156; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:157 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:157; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:158 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:158; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:159 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:159. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:160 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:160; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:161 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:161; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:162 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:162; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:163 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:163. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:164 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:164; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:165 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:165; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:166 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:166; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:167 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:167. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:168 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:168; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:169 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:169; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:170 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:170; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:171 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:171. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:172 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:172; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:173 or an amino acid

sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:173; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:174 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:174; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:175 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:175. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:176 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:176; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:177 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:177; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:178 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:178; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:179 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:179. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:181 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:181; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:182 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:182; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:183 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:183; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:184 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:184. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:185 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:185; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:186 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:186; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:187 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:187; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:188 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:188.

[0034] In some embodiments, the third antigen binding site binds a human HER2 polypeptide. In some embodiments, the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIKDTY (SEQ ID NO:1) or GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3), 1YPTQGYT (SEQ ID NO:4), or IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6), SRWGEGGFYAMDY (SEQ ID NO:7), or SRWGGSGFYAMDY (SEQ ID NO:8), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9) or QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid

amino acid sequence of QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12). In some embodiments, the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWRQAPGKGLEWVARIYPTN GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDGFYAMDY WGQGTLVTVSS (SEQ ID NO:72), EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWRQAPGKGLEWVARIYPTQ GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDGFYAMDY WGQGTLVTVSS (SEQ ID NO:73), EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWRQAPGKGLEWVARIYPTQ GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDGFYAMDY WGQGTLVTVSS (SEQ ID NO:74), and/or the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSLASVGDRVTIT-CRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS GVPSRSGSRSQGTDFTLTISLQPEDFA-TYYCQQHYTTPPTFGQGQTKEIK (SEQ ID NO:77) or DIQMTQSPSSLASVGDRVTITCRASQDVQTA-VAWYQQKPGKAPKLLIYSASFLYS GVPSRSGSRSQGTDFTLTISLQPEDFA-TYYCQQHYTTPPTFGQGQTKEIK (SEQ ID NO:78). In some embodiments, the VW domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWRQAPGKGLEWVARIYPTN GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDGFYAMDY WGQGTLVTVSS (SEQ ID NO:72), and/or the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSLASVGDRVTIT-CRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS GVPSRSGSRSQGTDFTLTISLQPEDFA-TYYCQQHYTTPPTFGQGQTKEIK (SEQ ID NO:77). In some embodiments, the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWRQAPGKGLEWVARIYPTQ GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDGFYAMDY WGQGTLVTVSS (SEQ ID NO:73), and/or the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSLASVGDRVTIT-CRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS GVPSRSGSRSQGTDFTLTISLQPEDFA-TYYCQQHYTTPPTFGQGQTKEIK (SEQ ID NO:77). In some embodiments, the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWRQAPGKGLEWVARIYPTN GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDGFYAMDY WGQGTLVTVSS (SEQ ID NO:75), and/or the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSLASVGDRVTIT-CRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS GVPSRSGSRSQGTDFTLTISLQPEDFA-TYYCQQHYTTPPTFGQGQTKEIK (SEQ ID NO:77). In

some embodiments, the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWRQAPGKGLEWVARIYPTQ GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDGFYAMDY WGQGTLVTVSS (SEQ ID NO:74), and/or the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSLASVGDRVTIT-CRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS GVPSRSGSRSQGTDFTLTISLQPEDFA-TYYCQQHYTTPPTFGQGQTKEIK (SEQ ID NO:77). In some embodiments, the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWRQAPGKGLEWVARIYPTQ GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDGFYAMDY WGQGTLVTVSS (SEQ ID NO:76), and/or the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSLASVGDRVTIT-CRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS GVPSRSGSRSQGTDFTLTISLQPEDFA-TYYCQQHYTTPPTFGQGQTKEIK (SEQ ID NO:78).

[0035] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:100 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:100; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:101 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:101; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:102 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:102; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:103 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:103. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:104 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:104; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:105 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:105; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:106 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:106; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:107 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:107. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:112 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:112; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:113 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:113; the third poly-

the amino acid sequence of SEQ ID NO:152 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:152; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:153 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:153; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:154 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:154; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:155 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:155. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:286 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:286; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:287 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:287; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:288 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:288; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:289 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:289. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:290 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:290; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:291 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:291; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:292 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:292; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:293 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:293. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:294 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:294; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:295 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:295; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:296 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:296; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:297 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:297. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:298 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:298; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:299 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:299; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:300 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:300; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:300.

NO:301 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:301.

[0036] In some embodiments that may be combined with any other embodiments described herein, at least one of L₁, L₂, L₃ or L₄ is independently 0 amino acids in length. In some embodiments, L₁, L₂, L₃ and L₄ each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:69), GGGGSGGGGSGGGGS (SEQ ID NO: 70), S, RT, TKGPS (SEQ ID NO: 68), GQPKAAP (SEQ ID NO: 67), and GGSGSSGSGG (SEQ ID NO: 71). In some embodiments, L₁, L₂, L₃ and L₄ each independently comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:69), GGGGSGGGGSGGGGS (SEQ ID NO:70), S, RT, TKGPS (SEQ ID NO:68), GQPKAAP (SEQ ID NO: 67), and GGSGSSGSGG (SEQ ID NO:71). In some embodiments, L₁ comprises the sequence GQPKAAP (SEQ ID NO: 67), L₂ comprises the sequence TKGPS (SEQ ID NO:68), L₃ comprises the sequence S, and L₄ comprises the sequence RT. In some embodiments, at least one of L₁, L₂, L₃ or L₄ comprises the sequence DKTHT (SEQ ID NO:66). In some embodiments, L₁, L₂, L₃ and L₄ comprise the sequence DKTHT (SEQ ID NO:66).

[0037] In some embodiments that may be combined with any other embodiments described herein, the hinge-C_{H2}-C_{H3} domains of the second and the third polypeptide chains are human IgG4 hinge-C_{H2}-C_{H3} domains, and wherein the hinge-C_{H2}-C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A. In some embodiments, the hinge-C_{H2}-C_{H3} domains of the second and the third polypeptide chains are human IgG4 hinge-C_{H2}-C_{H3} domains, and wherein the hinge-C_{H2}-C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index, wherein the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236. In some embodiments, the hinge-C_{H2}-C_{H3} domains of the second and the third polypeptide chains are human IgG4 hinge-C_{H2}-C_{H3} domains, and wherein the hinge-C_{H2}-C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, the hinge-C_{H2}-C_{H3} domains of the second and the third polypeptide chains are human IgG1 hinge-C_{H2}-C_{H3} domains, and wherein the hinge-C_{H2}-C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the hinge-C_{H2}-C_{H3} domains of the second and the third polypeptide chains are human IgG1 hinge-C_{H2}-C_{H3} domains, and wherein the hinge-C_{H2}-C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 298, 299, and 300 of human IgG1 according to EU Index, wherein the amino acid substitutions are S298N, T299A, and Y300S. In some embodiments, the hinge-C_{H2}-C_{H3} domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and

wherein the hinge- C_{H2} - C_{H3} domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the hinge- C_{H2} - C_{H3} domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the hinge- C_{H2} - C_{H3} domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

[0038] In some embodiments, provided herein are isolated nucleic acid molecules comprising a nucleotide sequence encoding the binding protein of any one of the above embodiments. In some embodiments, provided herein are expression vectors comprising the nucleic acid molecule of any one of the above embodiments. In some embodiments, provided herein are isolated host cells comprising the nucleic acid molecule of any one of the above embodiments or the expression vector of any one of the above embodiments. In some embodiments, the host cell is a mammalian or insect cell.

[0039] In some embodiments, provided herein are pharmaceutical compositions comprising the binding protein of any one of the above embodiments and a pharmaceutically acceptable carrier.

[0040] In some embodiments, provided herein are methods of preventing and/or treating cancer in a patient comprising administering to the patient a therapeutically effective amount of at least one binding protein or pharmaceutical composition of any one of the above embodiments. In some embodiments, provided herein is a binding protein or pharmaceutical composition according to any one of the above embodiments for use in a method of preventing and/or treating cancer in a patient, wherein the method comprises administering to the patient a therapeutically effective amount of the binding protein or pharmaceutical composition. In some embodiments, provided herein is a binding protein or pharmaceutical composition according to any one of the above embodiments for use in manufacturing a medicament for preventing and/or treating cancer in a patient.

[0041] In some embodiments, the at least one binding protein is co-administered with a chemotherapeutic agent. In some embodiments, the patient is a human.


[0042] In some embodiments, the third antigen binding site binds a human CD38 polypeptide, and wherein cancer cells from the individual or patient express CD38. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or a B cell lymphoma. In some embodiments, prior to administration of the binding protein, the patient has been treated with daratumumab without a wash-out period.

[0043] In some embodiments, the third antigen binding site binds a human HER2 polypeptide, and wherein cancer cells from the individual or patient express HER2. In some embodiments, the cancer is breast cancer, colorectal cancer, gastric cancer, or non-small cell lung cancer (NSCLC).

[0044] In some embodiments, provided herein is a method for expanding virus-specific memory T cells, comprising contacting a virus-specific memory T cell with a binding protein, wherein the binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

[0045] V_{L1} is a first immunoglobulin light chain variable domain;

[0046] V_{L2} is a second immunoglobulin light chain variable domain;

[0047] V_{L3} ; is a third immunoglobulin light chain variable domain;

[0048] V_{H1} is a first immunoglobulin heavy chain variable domain;

[0049] V_{H2} is a second immunoglobulin heavy chain variable domain;

[0050] V_{H3} is a third immunoglobulin heavy chain variable domain;

[0051] C_L is an immunoglobulin light chain constant domain;

[0052] C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

[0053] C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

[0054] C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

[0055] hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

[0056] L_1 , L_2 , L_3 and L_4 are amino acid linkers;


wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and

wherein V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide, wherein V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, wherein the V_{H2} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVH X_1 N X_2 X X_3 TY, wherein X_1 is E or Q, X_2 is A or L, and X_3 is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V_{H3} and V_{L3} form a third antigen binding site that binds a CD38 polypeptide.

[0057] In some embodiments, provided herein is a binding protein that comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

[0058] V_{L1} is a first immunoglobulin light chain variable domain;

[0059] V_{L2} is a second immunoglobulin light chain variable domain;

[0060] V_{L3} ; is a third immunoglobulin light chain variable domain;

[0061] V_{H1} is a first immunoglobulin heavy chain variable domain;

[0062] V_{H2} is a second immunoglobulin heavy chain variable domain;

[0063] V_{H3} is a third immunoglobulin heavy chain variable domain;

[0064] C_L is an immunoglobulin light chain constant domain;

[0065] C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

[0066] C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

[0067] C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

[0068] hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

[0069] L_1, L_2, L_3 and L_4 are amino acid linkers;

wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and

wherein V_{H1} and VL form a first antigen binding site that binds a CD28 polypeptide, wherein V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, wherein the V_{H2} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX₁NX₂X₃TY, wherein X₁ is E or Q, X₂ is A or L, and X₃ is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V_{H3} and V_{L3} form a third antigen binding site that binds a CD38 polypeptide for use in expanding virus-specific memory T cells.


[0070] In some embodiments, the virus-specific memory T cell is contacted with the binding protein in vitro or ex vivo.

In some embodiments, contacting the virus-specific memory T cell with the binding protein causes activation and/or proliferation of virus-specific memory T cells.

[0071] In some embodiments, provided herein is a method for expanding T cells, comprising contacting a T cell with a binding protein in vitro or ex vivo, wherein the binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

[0072] V_{L1} is a first immunoglobulin light chain variable domain;

[0073] V_{L2} is a second immunoglobulin light chain variable domain;

[0074] V_{L3} ; is a third immunoglobulin light chain variable domain;

[0075] V_{H1} is a first immunoglobulin heavy chain variable domain;

[0076] V_{H2} is a second immunoglobulin heavy chain variable domain;

[0077] V_{H3} is a third immunoglobulin heavy chain variable domain;

[0078] C_L is an immunoglobulin light chain constant domain;

[0079] C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

[0080] C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

[0081] C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

[0082] hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

[0083] L_1, L_2, L_3 and L_4 are amino acid linkers;


wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and wherein V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide, wherein V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, wherein the V_{H2} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX₁NX₂X₃TY, wherein X₁ is E or Q, X₂ is A or L, and X₃ is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V_{H3} and V_{L3} form a third antigen binding site that binds a CD38 polypeptide for use in expanding virus-specific memory T cells.

acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V_{H3} and V_{L3} form a third antigen binding site that binds a CD38 polypeptide.

[0084] In some embodiments, provided herein is a binding protein that comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

[0085] V_{L1} is a first immunoglobulin light chain variable domain;

[0086] V_{L2} is a second immunoglobulin light chain variable domain;

[0087] V_{L3} ; is a third immunoglobulin light chain variable domain;

[0088] V_{H1} is a first immunoglobulin heavy chain variable domain;

[0089] V_{H2} is a second immunoglobulin heavy chain variable domain;

[0090] V_{H3} is a third immunoglobulin heavy chain variable domain;

[0091] C_L is an immunoglobulin light chain constant domain;

[0092] C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

[0093] C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

[0094] C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

[0095] hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

[0096] L_1 , L_2 , L_3 and L_4 are amino acid linkers;

wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and

wherein V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide, wherein V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, wherein the V_{H2} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX₁NX₂X₃TY, wherein X₁ is E or Q, X₂ is A or L, and X₃ is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and


wherein V_{H3} and V_{L3} form a third antigen binding site that binds a CD38 polypeptide for use in a method for expanding T cells.

[0097] In some embodiments, the T cell is a memory T cell or an effector T cell. In some embodiments, the T cell expresses a chimeric antigen receptor (CAR) on its cell surface or comprises a polynucleotide encoding a CAR.

[0098] In some embodiments, provided herein is a method for treating chronic viral infection, comprising administering to an individual or patient in need thereof an effective amount of a binding protein, wherein the binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

[0099] V_{L1} is a first immunoglobulin light chain variable domain;

[0100] V_{L2} is a second immunoglobulin light chain variable domain;

[0101] V_{L3} ; is a third immunoglobulin light chain variable domain;

[0102] V_{H1} is a first immunoglobulin heavy chain variable domain;

[0103] V_{H2} is a second immunoglobulin heavy chain variable domain;

[0104] V_{H3} is a third immunoglobulin heavy chain variable domain;

[0105] C_L is an immunoglobulin light chain constant domain;

[0106] C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

[0107] C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

[0108] C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

[0109] hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

[0110] L_1 , L_2 , L_3 and L_4 are amino acid linkers;

wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and


wherein V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide, wherein V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, wherein the V_{H2} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX₁NX₂X₃TY

sequence of QSLVHX₁NX₂X₃TY, wherein X₁ is E or Q, X₂ is A or L, and X₃ is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V_{H3} and V_{L3} form a third antigen binding site that binds a CD38 polypeptide.

[0111] In some embodiments, provided herein is a binding protein that comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

[0112] V_{L1} is a first immunoglobulin light chain variable domain;

[0113] V_{L2} is a second immunoglobulin light chain variable domain;

[0114] V_{L3}; is a third immunoglobulin light chain variable domain;

[0115] V_{H1} is a first immunoglobulin heavy chain variable domain;

[0116] V_{H2} is a second immunoglobulin heavy chain variable domain;

[0117] V_{H3} is a third immunoglobulin heavy chain variable domain;

[0118] C_L is an immunoglobulin light chain constant domain;

[0119] C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

[0120] C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

[0121] C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

[0122] hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

[0123] L₁, L₂, L₃ and L₄ are amino acid linkers;

wherein the polypeptide of formula 1 and the polypeptide of formula 11 form a cross-over light chain-heavy chain pair; and

wherein V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide, wherein V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, wherein the V_{H2} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX₁NX₂X₃TY, wherein X₁ is E or Q, X₂ is A or L, and X₃ is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ

ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V_{H3} and V_{L3} form a third antigen binding site that binds a CD38 polypeptide for use in a method for treating chronic viral infection, wherein said method comprises administering to an individual or patient in need thereof an effective amount of the binding protein.

[0124] In some embodiments, the individual or patient is a human. In some embodiments, the binding protein is administered to the individual or patient in pharmaceutical formulation comprising the binding protein and a pharmaceutically acceptable carrier. In some embodiments, administration of the binding protein results in activation and/or proliferation of virus-specific memory T cells in the individual or patient.

[0125] In some embodiments that may be combined with any other embodiments described herein, the memory T cells are CD8+ or CD4+ memory T cells. In some embodiments, the memory T cells are central memory T cells (T_{CM}) or effector memory T cells (T_{EM}).

[0126] In some embodiments that may be combined with any other embodiments described herein, the virus is a human immunodeficiency virus (HIV), influenza virus, cytomegalovirus (CMV), hepatitis B virus (HBV), human papillomavirus (HPV), Epstein-barr virus (EBV), human foamy virus (HFV), herpes simplex virus 1 (HSV-1), or herpes simplex virus 1 (HSV-2).

[0127] In some embodiments that may be combined with any other embodiments described herein, the CD28 polypeptide is a human CD28 polypeptide, wherein the CD3 polypeptide is a human CD3 polypeptide, and wherein the CD38 polypeptide is a human CD38 polypeptide.

[0128] In some embodiments, provided herein is a vector system comprising one or more vectors encoding a first, second, third, and fourth polypeptide chain of a binding protein of any one of the above embodiments. In some embodiments, the vector system comprises a first vector encoding the first polypeptide chain of the binding protein, a second vector encoding the second polypeptide chain of the binding protein, a third vector encoding the third polypeptide chain of the binding protein, and a fourth vector encoding the fourth polypeptide chain of the binding protein.

[0129] In some embodiments, provided herein are kits comprising one, two, three, or four polypeptide chains of a binding protein according to any one of the above embodiments. In some embodiments, the kits further comprise instructions for using the polypeptide chain or binding protein according to any of the methods or uses described herein, e.g., supra.

[0130] In some embodiments, provided herein are kits comprising one, two, three, or four polynucleotides according to any one of the above embodiments. In some embodiments, provided herein are kits of polynucleotides comprising one, two, three, or four polynucleotides of a kit of polynucleotides comprising: (a) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:189, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:190, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:191, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:192; (b) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:193, a second polynucleotide comprising the polynucleotide


[0131] To meet these and other needs, further provided herein are multispecific binding proteins (e.g., antibodies) that form three antigen binding sites, e.g., binding proteins that bind one or more HIV target proteins and a CD3

polypeptide, or an HIV target protein, a CD28 polypeptide, and a CD3 polypeptide. The trispecific anti-HIV/CD28xCD3 T cell engager (TCE) concept disclosed herein is thought to be an effective eliminator of the HIV-1 reservoir through activation by anti-CD3, co-activation by anti-CD28, and subsequent killing of activated HIV-1 reservoir cells through anti-HIV/anti-CD28 by engaging activated CD8 T cells, providing a potential strategy for attacking the HIV-1 reservoir. In addition, anti-CD3 binding sites are described with high affinity binding to human CD3 polypeptides and potential manufacturing liabilities (e.g., deamidation sites) removed.


[0132] In some embodiments, provided herein are binding proteins comprising four polypeptide chains that form the three antigen binding sites that specifically bind one or more HIV target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

- [0133] V_{L1} is a first immunoglobulin light chain variable domain;
- [0134] V_{L2} is a second immunoglobulin light chain variable domain;
- [0135] V_{L3} is a third immunoglobulin light chain variable domain;
- [0136] V_{H1} is a first immunoglobulin heavy chain variable domain;
- [0137] V_{H2} is a second immunoglobulin heavy chain variable domain;
- [0138] V_{H3} is a third immunoglobulin heavy chain variable domain;
- [0139] C_L is an immunoglobulin light chain constant domain;
- [0140] C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;
- [0141] C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;
- [0142] C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;
- [0143] hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and
- [0144] L_1 , L_2 , L_3 and L_4 are amino acid linkers; wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; wherein V_{H1} and V_{L1} form a first antigen binding site; wherein V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, wherein the V_{H2} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and wherein V_{H3} and V_{L3} form a third antigen binding site that binds an HIV target protein.

(SEQ ID NO:323), and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVH X_1 NX $_2$ X $_3$ TY, wherein X_1 is E or Q, X_2 is A or L, and X_3 is Q, R, or F (SEQ ID NO:594), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331); and wherein V_{H3} and V_{L3} form a third antigen binding site that binds an HIV target protein.

[0145] In some embodiments, the first binding site binds a CD28 polypeptide (e.g., a human CD28 polypeptide). In some embodiments, the V_{H1} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFT-SYY (SEQ ID NO:332), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:333), and a CDR-H3 sequence comprising the amino acid sequence of TRSHYGLDWNFDV (SEQ ID NO:334), and the V_{L1} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:335), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:336), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTYPY (SEQ ID NO:337). In some embodiments, the V_{H1} domain comprises the amino acid sequence of QVQLVQSGAEVVKP-GASVKVSCKASGYTFTSYYIHWVRQAPGQ-GLEWIGSIYPGN VNTNYAQKFQGRATLTVDTSIS-TAYMELSRLRSDDTAVYYCTRSHYGLDWNFDV WGKGTTVTVSS (SEQ ID NO:360), and/or the V_{L1} domain comprises the amino acid sequence of DIQMKTQSPSSLASAVGDRVTITCQASQNIYVWLNW YQQKPGKAPKLIIYKASNLT GVPSRFSGSGSGTDFITLTISQLQPEDIATYYCQQGQ-TYPYTFGQGTKLEIK (SEQ ID NO:361).

[0146] In some embodiments, the CDR-L1 sequence of the V_{L2} domain comprises an amino acid sequence selected from the group consisting of QSLVHQNAQTY (SEQ ID NO:325), QSLVHENLQTY (SEQ ID NO:326), QSLVHENLFTY (SEQ ID NO:327), and QSLVHENLRTY (SEQ ID NO:328). In some embodiments, the V_{H2} domain comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHQNAQTY (SEQ ID NO:325), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, the V_{H2} domain comprises: a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLQTY (SEQ ID NO:326), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, the V_{H2} domain comprises: a CDR-H1 sequence comprising

the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKNSNYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLFTY (SEQ ID NO:327), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, the V_{H2} domain comprises: a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKNSNYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLRTY (SEQ ID NO:328), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, the V_{H2} domain comprises the amino acid sequence of QVQLVESGGVVQPGRSRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKD KSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSL-RAEDTAVYYCRGVYYALSPF DYWGQQGLTVTVSS (SEQ ID NO:353), and/or the V_{L2} domain comprises an amino acid sequence selected from the group consisting of DIVMTQTPLSLSVTPGQPASICKSSQLVHQNAQ-TYLSWYLQKPGQSPQSLIYKVS NRFGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:355), DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS NRFGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:356), DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVS NRFGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:357), and DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVS NRFGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:358). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:355. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:356. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:357. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site com-

prising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:358.

[0147] In some embodiments, the third antigen binding site binds an HIV target protein selected from the group consisting of glycoprotein 120, glycoprotein 41 and glycoprotein 160. In some embodiments, the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of NCPIN (SEQ ID NO:302) a CDR-H2 sequence comprising the amino acid sequence of WMKPRHGAVS-YARQLQG (SEQ ID NO:303), and a CDR-H3 sequence comprising the amino acid sequence of GKYC-TARDYYNWDFEH (SEQ ID NO:304), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of RTSQYGS LA (SEQ ID NO:305), a CDR-L2 sequence comprising the amino acid sequence of SGSTRAA (SEQ ID NO:306), and a CDR-L3 sequence comprising the amino acid sequence of QQYEF (SEQ ID NO:307). In some embodiments, the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTF-TAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAV (SEQ ID NO:309) or IKPQYGA T (SEQ ID NO:310), and a CDR-H3 sequence comprising the amino acid sequence of DRSYGDSS-WALDA (SEQ ID NO:311), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of DCTLN (SEQ ID NO:315) a CDR-H2 sequence comprising the amino acid sequence of WLKPRWGAVNYARPLQG (SEQ ID NO:316), and a CDR-H3 sequence comprising the amino acid sequence of GKNCDYNWDFEH (SEQ ID NO:317), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of RTSQYGS LA (SEQ ID NO:318), a CDR-L2 sequence comprising the amino acid sequence of SGSTRAA (SEQ ID NO:319), and a CDR-L3 sequence comprising the amino acid sequence of QQYEF (SEQ ID NO:320). In some embodiments, the V_{H3} domain comprises the amino acid sequence of QVRLSQSGGQMKPGDSMRISCRASGYE-FINCPINWIRLAGPKRPEWMGWMKPRH GAVSYAR-QLQGRVTMTRDMYSETAFLELRSLTSDDTAVYFC-TRGKYCTARDYYN WDFEHWGQGTPVTVSS (SEQ ID NO:344), and/or the V_{L3} domain comprises the amino acid sequence of SLTQSPGTLSSLSPGETAIIS-CRTSQYGS LAWYQQRPGQAPRLVIYSGSTRAA-GIPDRF SGSRWGPDPDYNLTISNLESGDFGVYYCQQY-EFFGQGTKVQVDIK (SEQ ID NO:346).

[0148] In some embodiments, the V_{H3} domain comprises the amino acid sequence of QVRLSQSGGQMKPGDSMRISCRASGYE-FINCPINWIRLAGPKRPEWMGWMKPRH GAVSYAR-QLQGRVTMTRQLSQD PDDPDWGTAFLELRSLTSDDTAVYFC TRGKYC TAR-DYYNWDFEHWGQGTPVTVSS (SEQ ID NO:345), and/or the V_{L3} domain comprises the amino acid sequence of SLTQSPGTLSSLSPGETAIIS-CRTSQYGS LAWYQQRPGQAPRLVIYSGSTRAA-GIPDRF SGSRWGPDPDYNLTISNLESGDFGVYYCQQY-EFFGQGTKVQVDIK (SEQ ID NO:346).

[0149] In some embodiments, the V_{H3} domain comprises the amino acid sequence of RAHLVQSGTAMKKP-GASVRVSCQTSGYFTAHILFWFRQAPGR-GLEWVGWIKPQ YGAVNFGGGFRDRVTLTRDVYRE-IAYMDIRGLKPDDTAVYYCARDRSYGDSSWA LDAWGQQGTTVVVSA (SEQ ID NO:347), and/or the V_{L3} domain comprises the amino acid sequence of YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHWYQ HKPGRAPKLLIHHHTSSVEDG VPSRFSGSGFHTSFNLTISDLQADDI-ATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, the V_{H3} domain comprises the amino acid sequence of RAHLVQSGTAMKKP-GASVRVSCQTSGYFTAHILFWFRQAPGR-GLEWVGWIKPQ YGATNFGGGFRDRVTLTRDVYRE-IAYMDIRGLKPDDTAVYYCARDRSYGDSSWA LDAWGQQGTTVVVSA (SEQ ID NO:348), and/or the V_{L3} domain comprises the amino acid sequence of YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHWYQ HKPGRAPKLLIHHHTSSVEDG VPSRFSGSGFHTSFNLTISDLQADDI-ATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, the V_{H3} domain comprises the amino acid sequence of RAHLVQSGTAMKKP-GASVRVSCQTSGYFTAHILFWFRQAPGR-GLEWVGWIKPQ YGAVNFGGGFRDRVTLTRQ LSQDPDDPDWGIAYMDIRGLKPDDTAVYYCARDRS YGDSSWALDAWGQQGTTVVVSA (SEQ ID NO:349), and/or the V_{L3} domain comprises the amino acid sequence of YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHWYQ HKPGRAPKLLIHHHTSSVEDG VPSRFSGSGFHTSFNLTISDLQADDI-ATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, the V_{H3} domain comprises the amino acid sequence of QVQLVQSGGQMKKPGESMRISCRASGYE-FIDCTLNWIRLAPGKRPEWMGWLKPR WGAVNYAR-PLQGRVTMTRQLSQDPDDPDWGTAFLELRSLTVDD-TAVYFCTRGKN CDYNWDFEHWGRGTPIVSS (SEQ ID NO:351), and/or the V_{L3} domain comprises the amino acid sequence of LTQSPGTLSSLSPGETAIIS-CRTSQYGS LAWYQQRPGQAPRLVIYSGSTRAA-GIPDRFS GSRWGPDPYNTLNLSLESGDFGVYYCQQY-EFFGQGTKVQVDIK (SEQ ID NO:352).

[0150] In some embodiments that may be combined with any other embodiments described herein, at least one of L_1 , L_2 , L_3 or L_4 is independently 0 amino acids in length. In some embodiments, L_1 , L_2 , L_3 and L_4 each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:341), GGGGSGGGGGGGGGS (SEQ ID NO:342), S, RT, TKGPS (SEQ ID NO: 340), GQPKAAP (SEQ ID NO: 339), and GGSGSSGS GG (SEQ ID NO: 343). In some embodiments, L_1 , L_2 , L_3 and L_4 each independently comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:341), GGGGSGGGGGGGGGS (SEQ ID NO:342), S, RT, TKGPS (SEQ ID NO:340), GQPKAAP (SEQ ID NO: 339), and GGSGSSGS GG (SEQ ID NO:343). In some embodiments, L_1 comprises the sequence GQPKAAP (SEQ ID NO: 339), L_2 comprises the sequence TKGPS (SEQ ID NO:340), L_3 comprises the sequence S, and L_4 comprises the sequence RT. In some embodiments, at least one of L_1 , L_2 , L_3 or L_4

comprises the sequence DKHT (SEQ ID NO:338). In some embodiments, L_1 , L_2 , L_3 and L_4 comprise the sequence DKTHT (SEQ ID NO:338).

[0151] In some embodiments that may be combined with any other embodiments described herein, the hinge- C_{H2} - C_{H3} domains of the second and the third polypeptide chains are human IgG4 hinge- C_{H2} - C_{H3} domains, and wherein the hinge- C_{H2} - C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A. In some embodiments, the hinge- C_{H2} - C_{H3} domains of the second and the third polypeptide chains are human IgG4 hinge- C_{H2} - C_{H3} domains, and wherein the hinge- C_{H2} - C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index, wherein the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236. In some embodiments, the hinge- C_{H2} - C_{H3} domains of the second and the third polypeptide chains are human IgG4 hinge- C_{H2} - C_{H3} domains, and wherein the hinge- C_{H2} - C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, the hinge- C_{H2} - C_{H3} domains of the second and the third polypeptide chains are human IgG1 hinge- C_{H2} - C_{H3} domains, and wherein the hinge- C_{H2} - C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the hinge- C_{H2} - C_{H3} domains of the second and the third polypeptide chains are human IgG1 hinge- C_{H2} - C_{H3} domains, and wherein the hinge- C_{H2} - C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 298, 299, and 300 of human IgG1 according to EU Index, wherein the amino acid substitutions are S298N, T299A, and Y300S. In some embodiments, the hinge- C_{H2} - C_{H3} domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the hinge- C_{H2} - C_{H3} domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the hinge- C_{H2} - C_{H3} domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the hinge- C_{H2} - C_{H3} domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

[0152] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:362 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:362; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:363 or an amino acid sequence that is at least 95%

acid sequence of SEQ ID NO:463 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:463; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:464 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:464; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:465 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:465. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:466 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:466; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:467 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:467; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:468 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:468; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:469 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:469. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:470 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:470; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:471 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:471; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:472 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:472; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:473 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:473. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:474 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:474; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:475 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:475; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:476 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:476; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:477 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:477.

[0153] In some embodiments, provided herein are isolated nucleic acid molecules comprising a nucleotide sequence encoding the binding protein of any one of the above embodiments. In some embodiments, provided herein are expression vectors comprising the nucleic acid molecule of any one of the above embodiments. In some embodiments, provided herein are isolated host cells comprising the nucleic acid molecule of any one of the above embodiments or the expression vector of any one of the above embodiments. In some embodiments, the host cell is a mammalian or insect cell.

[0154] In some embodiments, provided herein are pharmaceutical compositions comprising the binding protein of any one of the above embodiments and a pharmaceutically acceptable carrier.

[0155] In some embodiments, provided herein are methods of preventing and/or treating HIV infection in a patient comprising administering to the patient a therapeutically effective amount of at least one binding protein of any one of the above embodiments or the pharmaceutical composition of any one of the above embodiments. In some embodiments, the binding protein is co-administered with standard anti-retroviral therapy. In some embodiments, administration of the at least one binding protein results in the elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, the patient is a human.

[0156] In some embodiments, the binding protein or pharmaceutical composition of any one of the above embodiments is provided for the prevention and/or treatment of HIV infection in a patient. In some embodiments, the binding protein is to be co-administered with standard anti-retroviral therapy. In some embodiments, the binding protein causes the elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, the patient is a human.

[0157] In some embodiments, the binding protein or pharmaceutical composition of any one of the above embodiments is provided for use in the manufacture of a medicament for the prevention and/or treatment of HIV infection in a patient. In some embodiments, the binding protein is to be co-administered with standard anti-retroviral therapy. In some embodiments, the binding protein causes the elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, the patient is a human.

[0158] In some embodiments, provided herein is a vector system comprising one or more vectors encoding a first, second, third, and fourth polypeptide chain of a binding protein of any one of the above embodiments. In some embodiments, the vector system comprises a first vector encoding the first polypeptide chain of the binding protein, a second vector encoding the second polypeptide chain of the binding protein, a third vector encoding the third polypeptide chain of the binding protein, and a fourth vector encoding the fourth polypeptide chain of the binding protein.

[0159] In some embodiments, provided herein are kits comprising one, two, three, or four polypeptide chains of a binding protein according to any one of the above embodiments. In some embodiments, the kits further comprise instructions for using the polypeptide chain or binding protein according to any of the methods or uses described herein, e.g., supra.

[0160] In some embodiments, provided herein are kits comprising one, two, three, or four polynucleotides according to any one of the above embodiments. In some embodiments, provided herein are kits of polynucleotides comprising one, two, three, or four polynucleotides of a kit of polynucleotides comprising: (a) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:478, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:479, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:480, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:481; (b) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:482, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:483, a third polynucleotide com-

prising the polynucleotide sequence of SEQ ID NO:484, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:485; (c) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:486, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:487, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:488, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:489; (d) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:490, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:491, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:492, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:493; (e) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:494, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:495, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:496, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:497; (f) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:498, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:499, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:500, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:501; (g) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:502, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:503, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:504, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:505; (h) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:506, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:507, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:508, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:509; (i) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:510, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:511, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:512, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:513; (j) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:514, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:515, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:516, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:517; (k) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:518, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:519, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:520, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:521; (l) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:522, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:523, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:524, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:525; (m) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:526,

a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:527, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:528, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:529; (n) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:530, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:531, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:532, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:533; (o) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:534, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:535, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:536, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:537; (p) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:538, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:539, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:540, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:541; (q) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:542, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:543, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:544, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:545; (r) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:546, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:547, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:548, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:549; (s) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:550, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:551, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:552, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:553; (t) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:554, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:555, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:556, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:557; (u) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:558, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:559, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:560, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:561; (v) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:562, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:563, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:564, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:565; (w) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:566, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:567, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:568, and a fourth polynucleotide comprising the polynucleotide

sequence of SEQ ID NO:569; (x) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:570, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:571, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:572, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:573; (y) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:574, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:575, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:576, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:577; (z) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:578, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:579, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:580, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:581, (aa) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:582, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:583, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:584, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:585; (bb) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:586, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:587, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:588, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:589; or (cc) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:590, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:591, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:592, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:593. In some embodiments, the first, second, third, and fourth polynucleotides are present on one or more expression vectors, e.g., one, two, three, or four expression vectors.

[0161] It is to be understood that one, some, or all of the properties of the various embodiments described herein may be combined to form other embodiments of the present invention. These and other aspects of the invention will become apparent to one of skill in the art. These and other embodiments of the invention are further described by the detailed description that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

[0162] FIG. 1A provides a schematic representation of a trispecific binding protein comprising four polypeptide chains that form three antigen binding sites that binds three target proteins: CD28, CD3, and HER2. A first pair of polypeptides possess dual variable domains having a cross-over orientation (VH1-VH2 and VL2-VL1) forming two antigen binding sites that recognize CD3 and CD28, and a second pair of polypeptides possess a single variable domain (VH3 and VL3) forming a single antigen binding site that recognizes HER2. The trispecific binding protein shown in FIG. 1A uses a constant region with a “knobs-into-holes” mutation, where the knob is on the second pair of polypeptides with a single variable domain.

[0163] FIG. 1B provides the fold change (vs. parental) in binding affinities of anti-CD28/CD3/HER2 trispecific anti-

body variants using the indicated anti-HER2, anti-CD3, and anti-CD28 binding domains. Mutations 3233QQ to QEQQ (top to bottom) refer to mutations introduced into residues 32-35 of the VL domain of the anti-CD3 binding site (indicated by *); the remaining mutations were introduced into the VH or VL domain of the trastuzumab anti-HER2 binding site (indicated by #; numbering according to Kabat). For the mutations in the anti-HER2 binding site, mutation 30Q was introduced into the VL domain, and the remaining mutations were introduced into the VH domain. The binding affinities were measured by ELISA, and the values provided are relative to parental trispecific antibody.

[0164] FIG. 1C provides binding curves for the indicated trispecific antibodies binding to human HER2, human CD28, and CD3, as determined by ELISA.

[0165] FIG. 1D provides a proposed mechanism of action for HER2/CD28xCD3 trispecific antibody-mediated T cell activation and HER2+ cancer cell killing.

[0166] FIG. 2A provides a schematic representation of a trispecific binding protein comprising four polypeptide chains that form three antigen binding sites that binds three target proteins: CD28, CD3, and CD38. A first pair of polypeptides possess dual variable domains having a cross-over orientation (VH1-VH2 and VL2-VL1) forming two antigen binding sites that recognize CD3 and CD28, and a second pair of polypeptides possess a single variable domain (VH3 and VL3) forming a single antigen binding site that recognizes CD38. The trispecific binding protein shown in FIG. 2A uses an IgG4 constant region with a “knobs-into-holes” mutation, where the knob is on the second pair of polypeptides with a single variable domain.

[0167] FIGS. 2B-2E show the binding affinities, as measured by ELISA, of CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated anti-CD38 binding domains for the target antigens human CD38 (FIG. 2B), cynomolgus monkey CD38 (FIG. 2C), human CD3 (FIG. 2D), and human CD28 (FIG. 2E).

[0168] FIG. 3 shows SPR competition assays for binding to CD38 by Daratumumab and anti-CD38 monospecific antibodies with the indicated anti-CD38 binding domains. If an antibody recognized an epitope on CD38 which was different from that of Daratumumab, injection of the antibody resulted in an increased SPR signal. If an antibody recognized an overlapping epitope as Daratumumab, injection of the antibody did not increase SPR signal.

[0169] FIGS. 4A-4B show the in vitro cell killing activity of CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated anti-CD38 binding domains against human multiple myeloma NCI-H929 cells (CD38+/CD28+). The assays were carried out in the presence of 5 nM isotype control antibody (FIG. 4A) or Daratumumab (FIG. 4B). In the presence of daratumumab, the trispecific antibodies continued to exhibit cell killing activity.

[0170] FIGS. 5A-5B show the in vitro cell killing activity of CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated anti-CD38 binding domains against human lymphoma OCI-Ly19 cells (CD38+/CD28-). The assays were carried out in the presence of 5 nM isotype control antibody (FIG. 5A) or Daratumumab (FIG. 5B). Daratumumab caused a decrease in the cell killing activity of anti-CD38/CD28xCD3 trispecific antibodies.

[0171] FIGS. 6A-6J show the characterization of in vitro T cell subset expansion in PBMCs collected from CMV-infected Donor D in response to CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated alternative anti-CD38 binding domains. A trispecific antibody lacking the CD38VH1 anti-CD38 binding domain was used as a negative control (ΔCD38VH1/ΔCD28sup x ΔCD3mid IgG4 FALA). T cell populations were measured at indicated time points (D3 refers to day 3; D7 refers to day 7). The indicated trispecific antibodies were tested at the indicated concentrations of 0.2 nM and 1 nM. Flow cytometry was used to quantify CMV-specific CD8+ T cells (FIGS. 6A-6B), CMV-specific T_{cm} CD8+ cells (FIGS. 6C-6D), and CMV-specific T_{em} CD8+ cells (FIGS. 6E-6F). In addition, the percentages of CMV-specific T_{cm} (FIGS. 6G-6H) and T_{em} (FIGS. 6I-6J) CD8+ cells were quantified at the indicated time points. All tested trispecific antibodies promoted the proliferation of CMV-specific memory CD8+ T cells with different potency and kinetics in a dose-responsive manner.

[0172] FIGS. 7A-7J show the characterization of in vitro T cell subset expansion in PBMCs collected from CMV-infected Donor E in response to CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated anti-CD38 binding domains. A trispecific antibody lacking the CD38VH1 anti-CD38 binding domain was used as a negative control (ΔCD38VH1/ΔCD28sup x ΔCD3mid IgG4 FALA). Antibodies shown in legend from top to bottom are shown in the graphs from left to right. T cell populations were measured at indicated time points (D3 refers to day 3; D7 refers to day 7). The indicated trispecific antibodies were tested at the indicated concentrations of 0.2 nM, 1 nM, and 2 nM. Flow cytometry was used to quantify CMV-specific CD8+ T cells (FIGS. 7A-7B), CMV-specific T_{cm} CD8+ cells (FIGS. 7C-7D), and CMV-specific T_{em} CD8+ cells (FIGS. 7E-7F). In addition, the percentages of CMV-specific T_{cm} (FIGS. 7G-7H) and T_{em} (FIGS. 7I-7J) CD8+ cells were quantified at the indicated time points. All tested trispecific antibodies promoted the proliferation of CMV-specific memory CD8+ T cells with different potency and kinetics in dose response manner.

[0173] FIGS. 8A-8J show the characterization of in vitro T cell subset expansion in PBMCs collected from EBV-infected Donor C in response to CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated alternative anti-CD38 binding domains. A trispecific antibody lacking the CD38VH1 anti-CD38 binding domain was used as a negative control (ΔCD38VH1/ΔCD28sup x ΔCD3mid IgG4 FALA). T cell populations were measured at indicated time points (D3 refers to day 3; D7 refers to day 7). The indicated trispecific antibodies were tested at the indicated concentrations of 0.2 nM and 1 nM. Flow cytometry was used to quantify EBV-specific CD8+ T cells (FIGS. 8A-8B), CMV-specific T_{cm} CD8+ cells (FIGS. 8C-8D), and CMV-specific T_{em} CD8+ cells (FIGS. 8E-8F). In addition, the percentages of EBV-specific T_{cm} (FIGS. 8G-8H) and T_{em} (FIGS. 8I-8J) CD8+ cells were quantified at the indicated time points. All tested trispecific antibodies promoted the proliferation of CMV-specific memory CD8+ T cells with different potency and kinetics in dose response manner.

[0174] FIGS. 9A-12 show the characterization of in vitro T cell subset expansion in PBMCs collected from EBV-infected Donor D in response to CD38/CD28sup x

CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated alternative anti-CD38 binding domains. A trispecific antibody lacking the CD38VH1 anti-CD38 binding domain was used as a negative control (Δ CD38VH1/ Δ CD28sup x Δ CD3mid IgG4 FALA). T cell populations were measured at indicated time points (D3 refers to day 3; D7 refers to day 7). The indicated trispecific antibodies were tested at the indicated concentrations of 0.2 nM and 1 nM. Flow cytometry was used to quantify EBV-specific CD8+ T cells (FIGS. 9A-9B), EBV-specific T_{cm} CD8+ cells (FIGS. 9C-9D), and EBV-specific T_{em} CD8+ cells (FIGS. 9E-9F). In addition, the percentages of EBV-specific T_{cm} (FIGS. 9G-10) and T_{em} (FIGS. 11-12) CD8+ cells were quantified at the indicated time points. All tested trispecific antibodies promoted the proliferation of EBV-specific memory CD8+ T cells with different potency and kinetics in dose response manner.

[0175] FIGS. 13A-13D show the change over time (days) in tumor volume (FIG. 13A) and body weight (FIG. 13B) in ZR-75-1 tumor bearing NSG mice engrafted with in vitro expanded human CD3+ T cells. Groups of 10 mice were either treated with vehicle or Her2/CD28 x CD3 trispecific antibody at the indicated dosages. Arrow heads indicate days of administration. Tumor volume is depicted as mean \pm SEM, mm³. Body weight change is depicted as % change, mean \pm SEM. X-axis shows days after implantation with ZR-75-1 cells. Tumor volume (mm³) over time for individual mice in each treatment group are shown in FIG. 13C. Tumor weight (mg) for each treatment group is shown in FIG. 13D. **=p<0.001; ***=p<0.0003 (two-way ANOVA, control vs. 100 & 10 ug/kg).

[0176] FIGS. 14A-14C show the effect of Her2/CD28 x CD3 trispecific antibody treatment on T cells from whole blood. FIG. 14A shows the analysis of hCD45+, CD8+, CD4+, and mCD45+ cells by flow cytometry. FIG. 14B shows the effect of control or Her2/CD28 x CD3 trispecific antibody treatment (at the indicated doses) on hCD45+, CD8+, CD4+, and mCD45+ cell counts. FIG. 14C shows the effect of control or Her2/CD28 x CD3 trispecific antibody treatment (at the indicated doses) on human cell ratios (CD4+/CD45+ and CD8+/CD45+). For each x-axis parameter shown in FIGS. 14B & 14C, conditions are (left to right): control, 100 ug/kg trispecific antibody, 10 ug/kg trispecific antibody, 1 ug/kg trispecific antibody, and 0.1 ug/kg trispecific antibody. Percentages shown in FIGS. 14B & 14C are based on control sample vs. 100 ug/kg.

[0177] FIGS. 15A-15C show the effect of Her2/CD28 x CD3 trispecific antibody treatment on tumor infiltrating lymphocytes (TILs), as examined by immunohistochemistry (IHC). Arrows indicate tumor infiltrating T cells identified in ZR-75-1 breast tumors. Upper images are at 1x magnification; lower images are at 20x magnification. In both sets of images, staining for human CD45, human CD4, and human CD8 are shown from left to right. Shown are tumors from mice treated with vehicle control (FIG. 15A), 100 ug/kg trispecific antibody (FIG. 15B), or 0.1 ug/kg trispecific antibody (FIG. 15C).

[0178] FIGS. 16A-16C show quantitation of the effect of Her2/CD28 x CD3 trispecific antibody treatment on TILs as measured by IHC. Each dot represents one tumor from an individual mouse; rectangles represent group means; and error bars indicate standard deviation. *=p<0.05 compared to vehicle control group (ANOVA). Numbers of CD45+ (FIG. 16A), CD4+ (FIG. 16B), or CD8+(FIG. 16C) cells are

shown. In FIG. 16C, a \$ area quantitation approach was used for CD8+ cells instead of cell counting algorithm due to excessive non-specific signal in the CD8 IHC slide.

[0179] FIGS. 17A-17F show in vitro cell lysis of HER2+ breast cancer target cells in the presence of human CD8+ T cells by Her2/CD28 x CD3 trispecific antibody with wild-type trastuzumab antigen binding domain and an anti-CD3 antigen binding domain without 32/35 QQ mutations in the VL domain ("ctl") as compared to a Her2/CD28 x CD3 trispecific antibodies having mutations in the anti-HER2 arm and the VL domain of the anti-CD3 arm (numbering as shown in Table 1). Cell killing activities against cell lines with varying expression of HER2 are depicted: HCC1954 for high HER2 expression (FIG. 17A), BT20 for intermediate HER2 expression (FIG. 17C), and MDA-MD-231 for low HER2 expression (FIG. 17E). Graphs depicting cell killing as a function of antibody concentration against target cells HCC1954 (FIG. 17B), BT20 (FIG. 17D), and MDA-MD-231 (FIG. 17F) are shown, comparing binding protein #2 vs. ctl or binding protein #1 and #5 vs. ctl.

[0180] FIGS. 18A & 18B summarize the mean EC50 (pM) of in vitro cell killing by experimental or control Her2/CD28 x CD3 trispecific antibodies against the indicated breast cancer (FIG. 18A) or gastric cancer cell lines (FIG. 18B). Amino acid sequences of the indicated trispecific antibodies are provided in Table 1.

[0181] FIG. 19 provides a schematic representation of a trispecific binding protein comprising four polypeptide chains that form three antigen binding sites that binds three target proteins: CD28, CD3, and HIV Env. A first pair of polypeptides possess dual variable domains having a cross-over orientation (VH1-VH2 and VL2-VL1) forming two antigen binding sites (VH1 and VL1; VH2 and VL2) that recognize CD28 and CD3, respectively, and a second pair of polypeptides possess a single variable domain (VH3 and VL3) forming a single antigen binding site that recognizes HIV Env. The trispecific binding protein shown in FIG. 19 uses a constant region with a "knobs-into-holes" mutation, where the knob is on the second pair of polypeptides with a single variable domain

[0182] FIG. 20 shows a schematic representation of a trispecific T cell Engager (TCE) strategy for using the anti-HIV trispecific binding protein shown in FIG. 19 to target and eliminate the HIV reservoir.

DETAILED DESCRIPTION

[0183] The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind to one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation.

[0184] The present disclosure further provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind to one or more human immunodeficiency virus (HIV) target proteins and/or one or more T-cell receptor target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein a second pair of polypeptides possess a single variable domain.

I. General Definitions

[0185] As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0186] It is understood that aspects and embodiments of the disclosure described herein include "comprising," "consisting," and "consisting essentially of" aspects and embodiments.

[0187] The term "polynucleotide" as used herein refers to single-stranded or double-stranded nucleic acid polymers of at least 10 nucleotides in length. In certain embodiments, the nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. Such modifications include base modifications such as bromouridine, ribose modifications such as arabinoside and 2',3'-dideoxyribose, and internucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroiselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranylilate and phosphoramidate. The term "polynucleotide" specifically includes single-stranded and double-stranded forms of DNA.

[0188] An "isolated polynucleotide" is a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which: (1) is not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature, (2) is linked to a polynucleotide to which it is not linked in nature, or (3) does not occur in nature as part of a larger sequence.

[0189] An "isolated polypeptide" is one that: (1) is free of at least some other polypeptides with which it would normally be found, (2) is essentially free of other polypeptides from the same source, e.g., from the same species, (3) is expressed by a cell from a different species, (4) has been separated from at least about 50 percent of polynucleotides, lipids, carbohydrates, or other materials with which it is associated in nature, (5) is not associated (by covalent or noncovalent interaction) with portions of a polypeptide with which the "isolated polypeptide" is associated in nature, (6) is operably associated (by covalent or noncovalent interaction) with a polypeptide with which it is not associated in nature, or (7) does not occur in nature. Such an isolated polypeptide can be encoded by genomic DNA, cDNA, mRNA or other RNA, of synthetic origin, or any combination thereof. Preferably, the isolated polypeptide is substantially free from polypeptides or other contaminants that are found in its natural environment that would interfere with its use (therapeutic, diagnostic, prophylactic, research or otherwise).

[0190] Naturally occurring antibodies typically comprise a tetramer. Each such tetramer is typically composed of two identical pairs of polypeptide chains, each pair having one full-length "light" chain (typically having a molecular weight of about 25 kDa) and one full-length "heavy" chain (typically having a molecular weight of about 50-70 kDa). The terms "heavy chain" and "light chain" as used herein refer to any immunoglobulin polypeptide having sufficient variable domain sequence to confer specificity for a target antigen. The amino-terminal portion of each light and heavy chain typically includes a variable domain of about 100 to 110 or more amino acids that typically is responsible for antigen recognition. The carboxy-terminal portion of each chain typically defines a constant domain responsible for

effector function. Thus, in a naturally occurring antibody, a full-length heavy chain immunoglobulin polypeptide includes a variable domain (V_H) and three constant domains (C_{H1} , C_{H2} , and C_{H3}), wherein the V_H domain is at the amino-terminus of the polypeptide and the C_{H3} domain is at the carboxyl-terminus, and a full-length light chain immunoglobulin polypeptide includes a variable domain (V_L) and a constant domain (C_L), wherein the V_L domain is at the amino-terminus of the polypeptide and the C_L domain is at the carboxyl-terminus.

[0191] Human light chains are typically classified as kappa and lambda light chains, and human heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subclasses, including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM has subclasses including, but not limited to, IgM1 and IgM2. IgA is similarly subdivided into subclasses including, but not limited to, IgA1 and IgA2. Within full-length light and heavy chains, the variable and constant domains typically are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. See, e.g., FUNDAMENTAL IMMUNOLOGY (Paul, W., ed., Raven Press, 2nd ed., 1989), which is incorporated by reference in its entirety for all purposes. The variable regions of each light/heavy chain pair typically form an antigen binding site. The variable domains of naturally occurring antibodies typically exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair typically are aligned by the framework regions, which may enable binding to a specific epitope. From the amino-terminus to the carboxyl-terminus, both light and heavy chain variable domains typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0192] The term "CDR set" refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Chothia and coworkers (Chothia and Lesk, 1987, *J. Mol. Biol.* 196: 901-17; Chothia et al., 1989, *Nature* 342: 877-83) found that certain sub-portions within Kabat CDRs adopt nearly identical peptide backbone conformations, despite having great diversity at the level of amino acid sequence. These sub-portions were designated as L1, L2, and L3 or H1, H2, and H3 where the "L" and the "H" designates the light chain and the heavy chain regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan, 1995, *FASEB J.* 9: 133-39; MacCallum, 1996, *J. Mol. Biol.* 262(5): 732-45; and Lefranc, 2003, *Dev. Comp. Immunol.* 27: 55-77. Still other CDR boundary definitions may not strictly follow one of the herein systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or length-


ened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. The methods used herein may utilize CDRs defined according to any of these systems, although certain embodiments use Kabat or Chothia defined CDRs. Identification of predicted CDRs using the amino acid sequence is well known in the field, such as in Martin, A. C. "Protein sequence and structure analysis of antibody variable domains," *In Antibody Engineering*, Vol. 2. Kontermann R., Dübel S., eds. Springer-Verlag, Berlin, p. 33-51 (2010). The amino acid sequence of the heavy and/or light chain variable domain may be also inspected to identify the sequences of the CDRs by other conventional methods, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hyper-variability. The numbered sequences may be aligned by eye, or by employing an alignment program such as one of the CLUSTAL suite of programs, as described in Thompson, 1994, *Nucleic Acids Res.* 22: 4673-80. Molecular models are conventionally used to correctly delineate framework and CDR regions and thus correct the sequence-based assignments.

[0193] The term "Fc" as used herein refers to a molecule comprising the sequence of a non-antigen-binding fragment resulting from digestion of an antibody or produced by other means, whether in monomeric or multimeric form, and can contain the hinge region. The original immunoglobulin source of the native Fc is preferably of human origin and can be any of the immunoglobulins, although IgG1 and IgG2 are preferred. Fc molecules are made up of monomeric polypeptides that can be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, and IgGA2). One example of a Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG. The term "native Fc" as used herein is generic to the monomeric, dimeric, and multimeric forms.


[0194] A F(ab) fragment typically includes one light chain and the V_H and C_{H1} domains of one heavy chain, wherein the V_H-C_{H1} heavy chain portion of the F(ab) fragment cannot form a disulfide bond with another heavy chain polypeptide. As used herein, a F(ab) fragment can also include one light chain containing two variable domains separated by an amino acid linker and one heavy chain containing two variable domains separated by an amino acid linker and a C_{H1} domain.

[0195] A F(ab') fragment typically includes one light chain and a portion of one heavy chain that contains more of the constant region (between the C_{H1} and C_{H2} domains), such that an interchain disulfide bond can be formed between two heavy chains to form a F(ab')₂ molecule.

[0196] The term "binding protein" as used herein refers to a non-naturally occurring (or recombinant or engineered) molecule that specifically binds to at least one target antigen. A trispecific binding protein of the present disclosure, unless otherwise specified, typically comprises four polypeptide chains that form at least three antigen binding sites, wherein a first polypeptide chain has a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

[0197] V_{L1} is a first immunoglobulin light chain variable domain;

[0198] V_{L2} is a second immunoglobulin light chain variable domain;

[0199] V_{L3} is a third immunoglobulin light chain variable domain;

[0200] V_{H1} is a first immunoglobulin heavy chain variable domain;

[0201] V_{H2} is a second immunoglobulin heavy chain variable domain;

[0202] V_{H3} is a third immunoglobulin heavy chain variable domain;

[0203] C_L is an immunoglobulin light chain constant domain;

[0204] C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

[0205] C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

[0206] C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

[0207] hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

[0208] L₁, L₂, L₃ and L₄ are amino acid linkers;

nd wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

[0209] A "recombinant" molecule is one that has been prepared, expressed, created, or isolated by recombinant means.

[0210] One embodiment of the disclosure provides binding proteins having biological and immunological specificity to between one and three target antigens. Another embodiment of the disclosure provides nucleic acid molecules comprising nucleotide sequences encoding polypeptide chains that form such binding proteins. Another embodiment of the disclosure provides expression vectors comprising nucleic acid molecules comprising nucleotide sequences encoding polypeptide chains that form such binding proteins. Yet another embodiment of the disclosure provides host cells that express such binding proteins (i.e., comprising nucleic acid molecules or vectors encoding polypeptide chains that form such binding proteins).

[0211] The term "swapability" as used herein refers to the interchangeability of variable domains within the binding protein format and with retention of folding and ultimate binding affinity. "Full swapability" refers to the ability to swap the order of both V_{H1} and V_{H2} domains, and therefore the order of V_{L1} and V_{L2} domains, in the polypeptide chain of formula I or the polypeptide chain of formula II (i.e., to reverse the order) while maintaining full functionality of the binding protein as evidenced by the retention of binding affinity. Furthermore, it should be noted that the designations V_H and V_L refer only to the domain's location on a particular

protein chain in the final format. For example, V_{H1} and V_{H2} could be derived from V_{L1} and V_{L2} domains in parent antibodies and placed into the V_{H1} and V_{H2} positions in the binding protein. Likewise, V_{L1} and V_{L2} could be derived from V_{H1} and V_{H2} domains in parent antibodies and placed in the V_{H1} and V_{H2} positions in the binding protein. Thus, the V_H and V_L designations refer to the present location and not the original location in a parent antibody. V_H and V_L domains are therefore "swappable."

[0212] The term "antigen" or "target antigen" or "antigen target" as used herein refers to a molecule or a portion of a molecule that is capable of being bound by a binding protein, and additionally is capable of being used in an animal to produce antibodies capable of binding to an epitope of that antigen. A target antigen may have one or more epitopes. With respect to each target antigen recognized by a binding protein, the binding protein is capable of competing with an intact antibody that recognizes the target antigen.

[0213] The term "Her2" refers to human epidermal growth factor receptor 2 which is a member of the epidermal growth factor receptor family.

[0214] "CD3" is cluster of differentiation factor 3 polypeptide and is a T-cell surface protein that is typically part of the T cell receptor (TCR) complex.

[0215] "CD28" is cluster of differentiation 28 polypeptide and is a T-cell surface protein that provides co-stimulatory signals for T-cell activation and survival.

[0216] "CD38" is cluster of differentiation 38 polypeptide and is a glycoprotein found on the surface of many immune cells.

[0217] The term "monospecific binding protein" refers to a binding protein that specifically binds to one antigen target.

[0218] The term "monovalent binding protein" refers to a binding protein that has one antigen binding site.

[0219] The term "bispecific binding protein" refers to a binding protein that specifically binds to two different antigen targets.

[0220] The term "bivalent binding protein" refers to a binding protein that has two binding sites.

[0221] The term "trispecific binding protein" refers to a binding protein that specifically binds to three different antigen targets.

[0222] The term "trivalent binding protein" refers to a binding protein that has three binding sites. In particular embodiments the trivalent binding protein can bind to one antigen target. In other embodiments, the trivalent binding protein can bind to two antigen targets. In other embodiments, the trivalent binding protein can bind to three antigen targets.

[0223] An "isolated" binding protein is one that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the binding protein, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, the binding protein will be purified: (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight. (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under

reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated binding proteins include the binding protein in situ within recombinant cells since at least one component of the binding protein's natural environment will not be present.

[0224] The terms "substantially pure" or "substantially purified" as used herein refer to a compound or species that is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition). In some embodiments, a substantially purified fraction is a composition wherein the species comprises at least about 50% (on a molar basis) of all macromolecular species present. In other embodiments, a substantially pure composition will comprise more than about 80%, 85%, 90%, 95%, or 99% of all macromolar species present in the composition. In still other embodiments, the species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

[0225] The term "epitope" includes any determinant, preferably a polypeptide determinant, capable of specifically binding to an immunoglobulin or T-cell receptor. In certain embodiments, epitope determinants include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and, in certain embodiments, may have specific three-dimensional structural characteristics and/or specific charge characteristics. An epitope is a region of an antigen that is bound by an antibody or binding protein. In certain embodiments, a binding protein is said to specifically bind an antigen when it preferentially recognizes its target antigen in a complex mixture of proteins and/or macromolecules. In some embodiments, a binding protein is said to specifically bind an antigen when the equilibrium dissociation constant is $\leq 10^{-8}$ M, more preferably when the equilibrium dissociation constant is $\leq 10^{-9}$ M, and most preferably when the dissociation constant is $\leq 10^{-10}$ M.

[0226] The dissociation constant (K_D) of a binding protein can be determined, for example, by surface plasmon resonance. Generally, surface plasmon resonance analysis measures real-time binding interactions between ligand (a target antigen on a biosensor matrix) and analyte (a binding protein in solution) by surface plasmon resonance (SPR) using the BIACore system (Pharmacia Biosensor; Piscataway, NJ). Surface plasmon analysis can also be performed by immobilizing the analyte (binding protein on a biosensor matrix) and presenting the ligand (target antigen). The term " K_D ," as used herein refers to the dissociation constant of the interaction between a particular binding protein and a target antigen.

[0227] The term "specifically binds" as used herein refers to the ability of a binding protein or an antigen-binding fragment thereof to bind to an antigen containing an epitope with an K_D of at least about 1×10^{-6} M, 1×10^{-7} M, 1×10^{-8} M, 1×10^{-9} M, 1×10^{-10} M, 1×10^{-11} M, 1×10^{-12} M, or more, and/or to bind to an epitope with an affinity that is at least two-fold greater than its affinity for a nonspecific antigen.

[0228] In some embodiments, an antigen binding domain and/or binding protein of the present disclosure "cross reacts" with human and cynomolgus monkey CD38 polypeptides, e.g., CD38 extracellular domains, human CD38 isoform A, human CD38 isoform E, and cynomolgus monkey CD38. A binding protein binding to antigen 1 (Ag1) is

“cross-reactive” to antigen 2 (Ag2) when the EC₅₀s are in a similar range for both antigens. In the present application, a binding protein binding to Ag1 is cross-reactive to Ag2 when the ratio of affinity of Ag2 to affinity of Ag1 is equal or less than 20, affinities being measured with the same method for both antigens.

[0229] The term “linker” as used herein refers to one or more amino acid residues inserted between immunoglobulin domains to provide sufficient mobility for the domains of the light and heavy chains to fold into cross over dual variable region immunoglobulins. A linker is inserted at the transition between variable domains or between variable and constant domains, respectively, at the sequence level. The transition between domains can be identified because the approximate size of the immunoglobulin domains are well understood. The precise location of a domain transition can be determined by locating peptide stretches that do not form secondary structural elements such as beta-sheets or alpha-helices as demonstrated by experimental data or as can be assumed by techniques of modeling or secondary structure prediction. The linkers described herein are referred to as L₁, which is located on the light chain between the C-terminus of the V_{L2} and the N-terminus of the V_{L1} domain; and L₂, which is located on the light chain between the C-terminus of the V_{L1} and the N-terminus of the C_L domain. The heavy chain linkers are known as L₃, which is located between the C-terminus of the V_{H1} and the N-terminus of the V_{H2} domain; and L₄, which is located between the C-terminus of the V_{H2} and the N-terminus of the C_{H1} domain.

[0230] The term “vector” as used herein refers to any molecule (e.g., nucleic acid, plasmid, or virus) that is used to transfer coding information to a host cell. The term “vector” includes a nucleic acid molecule that is capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid,” which refers to a circular double-stranded DNA molecule into which additional DNA segments may be inserted. Another type of vector is a viral vector, wherein additional DNA segments may be inserted into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell and thereby are replicated along with the host genome. In addition, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. The terms “plasmid” and “vector” may be used interchangeably herein, as a plasmid is the most commonly used form of vector. However, the disclosure is intended to include other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses, and adeno-associated viruses), which serve equivalent functions.

[0231] The phrase “recombinant host cell” (or “host cell”) as used herein refers to a cell into which a recombinant expression vector has been introduced. A recombinant host cell or host cell is intended to refer not only to the particular

subject cell, but also to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but such cells are still included within the scope of the term “host cell” as used herein. A wide variety of host cell expression systems can be used to express the binding proteins, including bacterial, yeast, bacloviral, and mammalian expression systems (as well as phage display expression systems). An example of a suitable bacterial expression vector is pUC19. To express a binding protein recombinantly, a host cell is transformed or transfected with one or more recombinant expression vectors carrying DNA fragments encoding the polypeptide chains of the binding protein such that the polypeptide chains are expressed in the host cell and, preferably, secreted into the medium in which the host cells are cultured, from which medium the binding protein can be recovered.

[0232] The term “transformation” as used herein refers to a change in a cell’s genetic characteristics, and a cell has been transformed when it has been modified to contain a new DNA. For example, a cell is transformed where it is genetically modified from its native state. Following transformation, the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, or may be maintained transiently as an episomal element without being replicated, or may replicate independently as a plasmid. A cell is considered to have been stably transformed when the DNA is replicated with the division of the cell. The term “transfection” as used herein refers to the uptake of foreign or exogenous DNA by a cell, and a cell has been “transfected” when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art. Such techniques can be used to introduce one or more exogenous DNA molecules into suitable host cells.

[0233] The term “naturally occurring” as used herein and applied to an object refers to the fact that the object can be found in nature and has not been manipulated by man. For example, a polynucleotide or polypeptide that is present in an organism (including viruses) that can be isolated from a source in nature and that has not been intentionally modified by man is naturally-occurring. Similarly, “non-naturally occurring” as used herein refers to an object that is not found in nature or that has been structurally modified or synthesized by man.

[0234] As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids; unnatural amino acids and analogs such as α-, α-disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for the polypeptide chains of the binding proteins. Examples of unconventional amino acids include: 4-hydroxyproline, γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserrine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxyl-terminal direction, in accordance with standard usage and convention.

[0235] Naturally occurring residues may be divided into classes based on common side chain properties:

- [0236] (1) hydrophobic: Met, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Pro;
- [0237] (2) polar hydrophilic: Arg, Asn, Asp, Gin, Glu, His, Lys, Ser, Thr;
- [0238] (3) aliphatic: Ala, Gly, Ile, Leu, Val, Pro;
- [0239] (4) aliphatic hydrophobic: Ala, Ile, Leu, Val, Pro;
- [0240] (5) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin;
- [0241] (6) acidic: Asp, Glu;
- [0242] (7) basic: His, Lys, Arg;
- [0243] (8) residues that influence chain orientation: Gly, Pro;
- [0244] (9) aromatic: His, Trp, Tyr, Phe; and
- [0245] (10) aromatic hydrophobic: Phe, Trp, Tyr.

[0246] Conservative amino acid substitutions may involve exchange of a member of one of these classes with another member of the same class. Non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class.

[0247] A skilled artisan will be able to determine suitable variants of the polypeptide chains of the binding proteins using well-known techniques. For example, one skilled in the art may identify suitable areas of a polypeptide chain that may be changed without destroying activity by targeting regions not believed to be important for activity. Alternatively, one skilled in the art can identify residues and portions of the molecules that are conserved among similar polypeptides. In addition, even areas that may be important for biological activity or for structure may be subject to conservative amino acid substitutions without destroying the biological activity or without adversely affecting the polypeptide structure.

[0248] The term "patient" as used herein includes human and animal subjects.

[0249] The terms "pharmaceutical composition" or "therapeutic composition" as used herein refer to a compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient.

[0250] The term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" as used herein refers to one or more formulation materials suitable for accomplishing or enhancing the delivery of a binding protein.


[0251] The terms "effective amount" and "therapeutically effective amount" when used in reference to a pharmaceutical composition comprising one or more binding proteins refer to an amount or dosage sufficient to produce a desired therapeutic result. More specifically, a therapeutically effective amount is an amount of a binding protein sufficient to inhibit, for some period of time, one or more of the clinically defined pathological processes associated with the condition being treated. The effective amount may vary depending on the specific binding protein that is being used, and also depends on a variety of factors and conditions related to the patient being treated and the severity of the disorder. For example, if the binding protein is to be administered *in vivo*, factors such as the age, weight, and health of the patient as well as dose response curves and toxicity data obtained in preclinical animal work would be among those factors considered. The determination of an effective amount or therapeutically effective amount of a given pharmaceutical composition is well within the ability of those skilled in the art.

[0252] One embodiment of the disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a binding protein.


II. Trispecific and/or Trivalent Binding Proteins for Treating and/or Preventing Cancer

[0253] Certain aspects of the present disclosure relate to trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind to one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Any of the CDRs or variable domains of any of the antigen binding proteins described herein may find use in a trispecific binding protein of the present disclosure.

[0254] In some embodiments, each of the three antigen binding sites binds a different target (e.g., polypeptide antigen). In some embodiments, the trispecific binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

[0255] V_{L1} is a first immunoglobulin light chain variable domain;

[0256] V_{L2} is a second immunoglobulin light chain variable domain;

[0257] V_{L3} is a third immunoglobulin light chain variable domain;

[0258] V_{H1} is a first immunoglobulin heavy chain variable domain;

[0259] V_{H2} is a second immunoglobulin heavy chain variable domain;

[0260] V_{H3} is a third immunoglobulin heavy chain variable domain;

[0261] C_L is an immunoglobulin light chain constant domain;

[0262] C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

[0263] C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

[0264] C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

[0265] hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

[0266] L_1, L_2, L_3 and L_4 are amino acid linkers; wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

[0267] In some embodiments, e.g., as used in reference to binding proteins of the present disclosure for treating and/or preventing cancer, the term “T-cell engager” refers to binding proteins directed to a host’s immune system, more specifically the T cells’ cytotoxic activity as well as directed to a tumor target protein.

[0268] In some embodiments, e.g., as used in reference to binding proteins of the present disclosure that target cancer, the terms “treatment” or “treat” as used herein refer to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those having a disorder as well as those prone to have the disorder or those in which the disorder is to be prevented. In particular embodiments, binding proteins can be used to treat humans with cancer, or humans susceptible to cancer, or ameliorate cancer in a human subject. The binding proteins can also be used to prevent cancer in a human patient. In particular embodiments, the cancer is multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, lymphoma, breast cancer such as Her2+ breast cancer, germinal center B-cell lymphoma or B-cell acute lymphoblastic leukemia. In other embodiments, the binding proteins can be used to treat humans with inflammatory disorders, or humans susceptible to inflammatory disorders, or ameliorate inflammatory disorders in a human subject.

[0269] It is contemplated that any of the antigen binding sites described herein may find use in a trispecific binding protein of the present disclosure. e.g., comprising four polypeptide chains having the structures described supra. For example, in some embodiments, a trispecific binding protein of the present disclosure comprises a V_{H1} and V_{L1} domain pair that form a first antigen binding site, a V_{H2} and V_{L2} domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V_{H3} and V_{L3} domain pair that form a third antigen binding site. In some embodiments, a trispecific binding protein of the present disclosure comprises a V_{H1} and V_{L1} domain pair that form a first antigen binding site that binds a CD28 polypeptide, a V_{H2} and V_{L2} domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V_{H3} and V_{L3} domain pair that form a third antigen binding site. In some embodiments, a trispecific binding protein of the present disclosure comprises a V_{H1} and V_{L1} domain pair that form a first antigen binding site, a V_{H2} and V_{L2} domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V_{H3} and V_{L3} domain pair that form a third antigen binding site that binds a tumor target protein. In some embodiments, a trispecific binding protein of the present disclosure comprises a V_{H1} and V_{L1} domain pair that form a first antigen binding site that binds a CD28 polypeptide, a V_{H2} and V_{L2} domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V_{H3} and V_{L3} domain pair that form a third antigen binding site that binds a tumor target protein. In some embodiments, a trispecific binding protein of the present disclosure comprises a V_{H1} and V_{L1} domain pair that form a first antigen binding site that binds a CD28 polypeptide, a V_{H2} and V_{L2} domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V_{H3} and V_{L3} domain pair that form a third antigen binding site that binds a CD38 polypeptide. In some embodiments, a trispecific binding protein of the present disclosure comprises a V_{H1} and V_{L1} domain pair that form a first antigen binding site that binds a CD28 polypeptide, a V_{H2} and V_{L2} domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V_{H3} and V_{L3} domain pair that form a third antigen binding site that binds a CD38 polypeptide.

and V_{L2} domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V_{H3} and V_{L3} domain pair that form a third antigen binding site that binds a HER2 polypeptide.

[0270] In some embodiments, a binding protein of the present disclosure binds one or more tumor target proteins and one or more T cell target proteins. In some embodiments, the binding protein is capable of specifically binding one tumor target protein and two different epitopes on a single T cell target protein. In some embodiments, the binding protein is capable of specifically binding one tumor target protein and two different T cell target proteins (e.g., CD28 and CD3). In some embodiments, the first and second polypeptide chains of the binding protein form two antigen binding sites that specifically target two T cell target proteins, and the third and fourth polypeptide chains of the binding protein form an antigen binding site that specifically binds a tumor target protein. In some embodiments, the target protein is CD38 or HER2. Additional tumor target proteins are provided infra. In some embodiments, the one or more T cell target proteins are one or more of CD3 and CD28. Exemplary and non-limiting polypeptides that may find use in any of the trispecific binding proteins described herein are provided in Table 1.

[0271] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:156 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:156; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:157 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:157; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:158 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:158; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:159 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:159.

[0272] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:160 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:160; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:161 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:161; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:162 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:162; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:163 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:163.

[0273] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:164 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:164; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:165 or an amino acid sequence that

is at least 95% identical to the amino acid sequence of SEQ ID NO:145; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:146 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:146; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:147 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:147.

[0290] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:148 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:148; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:149 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:149; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:150 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:150; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:151 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:151.

[0291] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:152 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:152; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:153 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:153; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:154 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:154; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:155 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:155.

[0292] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:286 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:286; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:287 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:287; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:288 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:288; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:289 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:289.

[0293] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:290 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:290; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:291 or an amino acid sequence that

is at least 95% identical to the amino acid sequence of SEQ ID NO:291; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:292 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:292; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:293 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:293.

[0294] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:294 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:294; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:295 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:295; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:296 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:296; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:297 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:297.

[0295] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:298 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:298; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:299 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:299; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:300 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:300; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:301 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:301.

Anti-CD38 Binding Sites

[0296] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a CD38 polypeptide. In some embodiments, the CD38 polypeptide is a human CD38 polypeptide, also known as ADPRC1. Human CD38 polypeptides are known in the art and include, without limitation, the polypeptide represented by NCBI Accession Number NP_001766.2, or a polypeptide produced from NCBI Gene ID Number 952. In some embodiments, the antigen binding site binds a human CD38 polypeptide, a non-human primate (e.g., cynomolgus monkey) CD38 polypeptide, or a human CD38 polypeptide and a non-human primate (e.g., cynomolgus monkey) CD38 polypeptide. In some embodiments, a binding protein comprising an antigen binding site that binds a CD38 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent.

[0297] In some embodiments, any of the CDRs and/or variable domains of the anti-CD38 binding sites described below can be used in a monospecific antibody.

[0298] In other embodiments, any of the CDRs and/or variable domains of the anti-CD38 binding sites described

below can be used in any binding site of a trispecific binding protein comprising four polypeptides that form three antigen binding sites, e.g., as described supra. In certain embodiments, a binding protein that comprises an antigen binding site that binds a CD38 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites as described supra, wherein the V_{H3} and V_{L3} domains pair and form a third antigen binding site that binds a CD38 polypeptide.

[0299] A variety of features of exemplary binding sites and binding proteins are described herein. For example, in some embodiments, an anti-CD38 binding site cross-reacts with human CD38 (e.g., a human CD38 isoform A and/or isoform E polypeptide) and cynomolgus monkey CD38. In some embodiments, a binding protein comprising an anti-CD38 binding site induces apoptosis of a CD38+ cell. In some embodiments, a binding protein comprising an anti-CD38 binding site recruits a T cell to a CD38+ cell and optionally activates the T cell (e.g., through TCR stimulation and/or costimulation).

[0300] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:13), a CDR-H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO:14), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:15); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSVSSYQQGF (SEQ ID NO:16), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:17), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:18). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:13), a CDR-H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO:14), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:15); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSVSSYQQGF (SEQ ID NO:16), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:17), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:18).

[0301] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTLTEFS (SEQ ID NO:19), a CDR-H2 sequence comprising the amino acid sequence of FDPEDEGET (SEQ ID NO:20), and a CDR-H3 sequence comprising the amino acid sequence of TTGRFFDW (SEQ ID NO:21); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSVISRF (SEQ ID NO:22), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:23), and a CDR-L3 sequence comprising the amino acid sequence of QQDSNLPI (SEQ ID NO:24). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTLTEFS (SEQ ID NO:19), a CDR-H2

sequence comprising the amino acid sequence of FDPEDEGET (SEQ ID NO:20), and a CDR-H3 sequence comprising the amino acid sequence of TTGRFFDW (SEQ ID NO:21); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSVISRF (SEQ ID NO:22), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:23), and a CDR-L3 sequence comprising the amino acid sequence of QQDSNLPI (SEQ ID NO:24).

[0302] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYAFATTYL (SEQ ID NO:25), a CDR-H2 sequence comprising the amino acid sequence of INPGSGST (SEQ ID NO:26), and a CDR-H3 sequence comprising the amino acid sequence of ARYAYGY (SEQ ID NO:27); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNVGTA (SEQ ID NO:28), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:29), and a CDR-L3 sequence comprising the amino acid sequence of QQYSTYPFT (SEQ ID NO:30). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYAFATTYL (SEQ ID NO:25), a CDR-H2 sequence comprising the amino acid sequence of INPGSGST (SEQ ID NO:26), and a CDR-H3 sequence comprising the amino acid sequence of ARYAYGY (SEQ ID NO:27); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNVGTA (SEQ ID NO:28), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:29), and a CDR-L3 sequence comprising the amino acid sequence of QQYSTYPFT (SEQ ID NO:30).

[0303] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYSFTNYA (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of ISPYYGDT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARR-FEGFYYSMFY (SEQ ID NO:33); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHSNGNTY (SEQ ID NO:34), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:35), and a CDR-L3 sequence comprising the amino acid sequence of SQSTHVPLT (SEQ ID NO:36). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYSFTNYA (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of ISPYYGDT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARR-FEGFYYSMFY (SEQ ID NO:33); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHSNGNTY (SEQ ID NO:34), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:35), and a CDR-L3 sequence comprising the amino acid sequence of SQSTHVPLT (SEQ ID NO:36).

[0304] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH)

domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFSSY (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARDPGL-RYFDGGMDV (SEQ ID NO:39); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGISSY (SEQ ID NO:40), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:41), and a CDR-L3 sequence comprising the amino acid sequence of QQLNSFPYT (SEQ ID NO:42). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFSSY (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARDPGL-RYFDGGMDV (SEQ ID NO:39); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGISSY (SEQ ID NO:40), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:41), and a CDR-L3 sequence comprising the amino acid sequence of QQLNSFPYT (SEQ ID NO:42).

[0305] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFSSY (SEQ ID NO:43), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:44), and a CDR-H3 sequence comprising the amino acid sequence of ARMFRGAFDY (SEQ ID NO:45); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:46), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:47), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:48). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFSSY (SEQ ID NO:43), a CDR-H2 sequence comprising the amino acid sequence of IWYDG-SNK (SEQ ID NO:44), and a CDR-H3 sequence comprising the amino acid sequence of ARMFRGAFDY (SEQ ID NO:45); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:46), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:47), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:48).

[0306] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVQSGAEVVKPGASVKVSCKASGYTFTSY-AMHWVKEAPGQRLEWIGYIYPGQ GGTNYNQKFQGRATLTADTSASTAYMELSSLRSED-TAVYFCARTGGLRAYFTYWG QGTLTVSS (SEQ ID NO:79), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least

85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVLTQSPATLSLSPGER-ATISCRASQSVSSYQGGFMHWYQQKPGQPPRLLIY-GASSR ATGIPARFSGSQGTDFLTISPLEPED-FAVYYCQQNKEDPWTFGGGTKEIK (SEQ ID NO:80). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:79, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:80. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:79, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:80.

[0307] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVQSGAEVKKP-GASVKVSCKVSGYTLTEFSIHWRQAPGQ-GLEWMGGFDPED GETIYAQKFQGRVIMTEDTSTD-TAYMEMNSLRSEDTAIYYCTTGRFFDWFWGQGTL VTVSS (SEQ ID NO:81), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of EIILTQSPAILSLSPGER-ATLSCRASQSVISRFLSWYQVKPGLAPRLLIYGAS-TRATGIPV RFSGSGSGTDFSLTISSLQPEDCA-VYYCQQDSNLPIFGQGTRLEIK (SEQ ID NO:82). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:81, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:82. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:81, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:82.

[0308] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVQSGAEVKPGASVKVSCKASGYAFTTYL-VEWIRQRPGQGLEWMGVINPGS GSTNYAQKFQGRVTMTVDRSSTTAYMELSRLRSDD-TAVYYCARYAYGYWGQGTL VTVSS (SEQ ID NO:83), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least

95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLASAVGDRVTITCRASQNVGTA-VAWYQQKPGKSPKQLIYSASNRYTG VPSRFSGSQSGTDFTLTISSLQPED-LATYYCQQYSTYPFTFGQGTKEIK (SEQ ID NO:84). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:83, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:84. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:83, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:84.

[0309] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTSSYGMWVRQAPGKGLEWWAVIHYDG SNKYY-ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYH-CARDPGLRYFDGGMD VWGQGTTVTVSS (SEQ ID NO:87), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DILQTQSPSFLSASVGDRVTITCRASQGISSY-LAWYQQKPGKAPKLLIFAASTLHSGVP SRFSGSGSGTEFTLTISLQPEDFATYYCQQLNSFPY-TFGQGTKEIK (SEQ ID NO:88). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:87, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:88. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:87, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:88.

[0310] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTSSYGMWVRQAPGKGLEWWAVIHYDG SNKYYADSVKGRFTISGDNSKNTLYLQMNSLRAEDTAVYYCARMFRGAFDYWQGQ TLTVSS (SEQ ID NO:89), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of AIQMTQSPSSLASAVGDRVTITCRASQ-

GIRNDLGWYQQKPGKAPKLLIYAASSLQSG VPSRFSGSQSGTDFTLTISSLQPEDSATYY-CLQDYIYYPTFGQGTKEIK (SEQ ID NO:90). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:89, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:90. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:89, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:90.

[0311] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVQSGAEVKKPGASVKVSCK-ASGYASFTNYAVHWVRQAPGQGLEWMGVISPY YGDT-

TYAQKFQGRVTMTVDKSSSTAYMELSRLRSDD-TAVYYCARRFEGFYYSMDY WGQGTLTVSS (SEQ ID NO:85), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DVMTQSPLSLPVTLGGPASISCRPSQSLVHSNGNTYLNWYQQRPGQSPKLLIYKVS KRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCSQSTHVPLTGGGTKEIK (SEQ ID NO:86). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:85, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:86. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:85, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:86.

[0312] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLQQSGPELVRPGTSVKVSCKASGYAFTTYL-VEWIKQRPGQGLEWIGVINPGSGS TNYNEFKKGKATLTVDRSSSTAYMHLGLTSDD-SAVYFCARYAYGYWGQGTTLV SS (SEQ ID NO:277), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQSQKFMMSASVGDRVSITCKASQNVGTA-VAWYQQQPGHSPKQLIYSASNRYT

GVPDRFTGSGAGTDFLTISNIQSEDLA-DYFCQQYSTYPFTFGSGTKLEIK (SEQ ID NO:278). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:277, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:278. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:277, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:278. In some embodiments, the VH and/or VL domains are humanized.

[0313] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLLQSGAELVRPGVSVKIS-CTGSGYSFTNYAVHWVKQSHVKSLWIGVISPYYGD-TTYNQKFTGKATMTVDKSSSTAYMELARLTSED-SAIYFCARRFEGFYYSMDYWQGQ TS TVT VSS (SEQ ID NO:279), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DVVMIQTPLSLPVSLGDQASISCRPSQSLVHSNGNTYLNWYLQRPGQSPKLLIYKVSK-RFSGVPDRFSGSGSGTDFTLKISRVEADLGVYL-CSQSTHVPLTFGSGTQLEIK (SEQ ID NO:280). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:279, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:280. In some embodiments, a

binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:279, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:280. In some embodiments, the VH and/or VL domains are humanized.

[0314] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds a CD38 polypeptide, an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD38 antigen binding sites described above represent V_{H3} and V_{L3} and form a third antigen binding site that binds a CD38 polypeptide. In some embodiments, V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide, V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, and the VH and VL domains of any of the anti-CD38 antigen binding sites described above and/or in Table 2 represent V_{H3} and V_{L3} and form a third antigen binding site that binds a CD38 polypeptide.

[0315] Sequences of exemplary anti-CD38 antigen binding sites are provided in Table 2. In some embodiments, a binding protein comprising an anti-CD38 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-CD38 antibody described in Table 2. In some embodiments, a binding protein comprising an anti-CD38 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-CD38 antibody described in Table 2.

TABLE 2

Anti-CD38 binding protein sequences.

Se- quence Type	Molecule	Descrip- tion	SEQ ID NO	Sequence	
CDR	Anti-CD38 (VH1)	CDR-H1	13	GYTFTSYA	
		CDR-H2	14	IYPGQQGTT	
		CDR-H3	15	ARTGGLRRAYFTY	
		CDR-L1	16	QSVSSYGGQF	
		CDR-L2	17	GAS	
		CDR-L3	18	QQNKEDPWT	
	Anti-CD38 (hyb992)	CDR-H1	19	GYTILTEFS	
		CDR-H2	20	FDPEDGET	
		CDR-H3	21	TTGRFFFDWF	
		CDR-L1	22	QSVISRF	
		CDR-L2	23	GAS	
		CDR-L3	24	QQDSNLPI	
Anti-CD38 (hyb5739)		CDR-H1	25	GYAFTTYL	
		CDR-H2	26	INPGSGST	
		CDR-H3	27	ARYAYGY	
		CDR-L1	28	QNVGTA	
		CDR-L2	29	SAS	
		CDR-L3	30	QQYSTYPFT	
Anti-CD38 (hyb6284)		CDR-H1	31	GYSFTNYA	
		CDR-H2	32	ISPYYGDT	
		CDR-H3	33	ARRFEGFYYSMDY	
		CDR-L1	34	QSLVHSNGNTY	
		CDR-L2	35	KVS	
		CDR-L3	36	SQSTHVPLT	

TABLE 2-continued

Anti-CD38 binding protein sequences.				
Se- quence Type	Molecule	Descrip- tion	SEQ ID NO	Sequence
Anti-CD38 (hhy1195)		CDR-H1	37	GFTFSSYG
		CDR-H2	38	IWYDGSNK
		CDR-H3	39	ARDPGLRYFDGGMDV
		CDR-L1	40	QGISSY
		CDR-L2	41	AAS
		CDR-L3	42	QQLNSFPYT
		CDR-H1	43	GFTFSSYG
		CDR-H2	44	IWYDGSNK
		CDR-H3	45	ARMFRGAFDY
		CDR-L1	46	QGIRND
Anti-CD38 (hhy1370)		CDR-L2	47	AAS
		CDR-L3	48	LQDYIYYPT
		Vari- able domain	79	QVQLVQSGAEVVKPGASVKVSCKASG YTFTSYAMHWKEAPGQRLEWIGYIYP GQGGTNYNQKFQGRATLTADTSASTA YMEMLSSLRSEDTAVYFCARTGGLRRAY FTYWGQGTLVTVSS
		VH	80	DIVLTQSPATLSLSPGERATISCRASQSV SSYGGQGFMHWYQQKPGOPPRLLIYGAS SRATGIPARFSGGSGTDFTLTISPLEPED FAVYYCQQNKEPDWTFGGGTKLEIK
		VL	81	QVQLVQSGAEVKKPGASVKVSCKVSG YTLTEFSIHWWVRQAPGQGLEWMGGFDP EDGETIYAQKFGQRVIMTEDTSTDAY MEMNSLRSEDTAIYYCTTGRFFDWFWG QGTLVTVSS
		VH	82	EIILTQSPAILSLSPGERATLSCRASQSVI SRFLSWYQVKPGLAPRLLIYGASTRATG IPVRFSGSGSGTDFSLTISSLQPEDCAVY YCQQDSNLPIITFGQGTRLEIK
		VL	83	QVQLVQSGAEVKKPGASVKVSCKASG YAFTTYLVEWIQRQPGQGLEWMGVINP GSGSTNYAQKFQGRVTMTVDRSSTTAY MELSLRLRSDDTAVYYCARYAYGYWGQ GTIQLVTVSS
		VH	84	DIQMTQSPSSLSASVGDRVITICRASQN VGTAVAWYQQKPGKSPQLIYSASNRV TGVPSPRFSGGSGTDFTLTISSLQPEDLA TYYCQQYSTYPPTFGQGTRLEIK
		VL	85	QVQLVQSGAEVKKPGASVKVSCKASG YSFTNYAVHWVRQAPGQGLEWMGVIS PYYGDTTYAQKFGQRVITMVDKSSSTA YMEMLSSLRSEDTAVYYCARRFEGFYYS MDYWGQGTLVTVSS
		VH	86	DVVMTOQSPSLPVTLQGPASISCRPSQS LVHSNGNTLYLNWYQQRPQGSPKLLIYK VSKRFSGPDRFSGGSGTDFTLKISRV EAEDVGVYYCSQSTHVPVLTFGGGTKVE IK
CD38 hhy1195		VH	87	QVQLVESGGVVQPGRSRLSCAASGF TFSSYGMWVVRQAPGKGLEWAVIWy DGSNKYYADSVKGRFTISRDMSKNTLY LQMNSLRAEDTAVYHCARDPGLRYFD GGMDVWGGTTTVSS
		VL	88	DIQLTQSPSFLSASVGDRVITICRASQGI SSYLAWSQQKPGKAPKLLIIFAASTLHS GVPSRFSGGSGTDFTLTISSLQPEDFAT YYCQQLNSFPYTFGQGTRLEIK
		VH	89	QVQLVESGGVVQPGRSRLSCAASGF TFSSYGMWVVRQAPGKGLEWAVIWy DGSNKYYADSVKGRFTISGDMSKNTLY LQMNSLRAEDTAVYHCARDPGLRYFD WGQGTLVTVSS
		VL	90	AIQMTQSPSSLSASVGDRVITICRASQGI RNDLGWYQQKPGKAPKLLIYAASSLQS GVPSRFSGGSGTDFTLTISSLQPEDSAT YYCQQLNSFPYTFGQGTRLEIK
		VH	91	QVQLVESGGVVQPGRSRLSCAASGF TFSSYGMWVVRQAPGKGLEWAVIWy DGSNKYYADSVKGRFTISGDMSKNTLY LQMNSLRAEDTAVYHCARDPGLRYFD WGQGTLVTVSS
		VL	92	AIQMTQSPSSLSASVGDRVITICRASQGI RNDLGWYQQKPGKAPKLLIYAASSLQS GVPSRFSGGSGTDFTLTISSLQPEDSAT YYCQQLNSFPYTFGQGTRLEIK
		VH	93	QVQLVESGGVVQPGRSRLSCAASGF TFSSYGMWVVRQAPGKGLEWAVIWy DGSNKYYADSVKGRFTISGDMSKNTLY LQMNSLRAEDTAVYHCARDPGLRYFD WGQGTLVTVSS
		VL	94	AIQMTQSPSSLSASVGDRVITICRASQGI RNDLGWYQQKPGKAPKLLIYAASSLQS GVPSRFSGGSGTDFTLTISSLQPEDSAT YYCQQLNSFPYTFGQGTRLEIK
		VH	95	QVQLVESGGVVQPGRSRLSCAASGF TFSSYGMWVVRQAPGKGLEWAVIWy DGSNKYYADSVKGRFTISGDMSKNTLY LQMNSLRAEDTAVYHCARDPGLRYFD WGQGTLVTVSS
		VL	96	AIQMTQSPSSLSASVGDRVITICRASQGI RNDLGWYQQKPGKAPKLLIYAASSLQS GVPSRFSGGSGTDFTLTISSLQPEDSAT YYCQQLNSFPYTFGQGTRLEIK
CD38 hhy1370		VH	97	QVQLVESGGVVQPGRSRLSCAASGF TFSSYGMWVVRQAPGKGLEWAVIWy DGSNKYYADSVKGRFTISGDMSKNTLY LQMNSLRAEDTAVYHCARDPGLRYFD WGQGTLVTVSS
		VL	98	AIQMTQSPSSLSASVGDRVITICRASQGI RNDLGWYQQKPGKAPKLLIYAASSLQS GVPSRFSGGSGTDFTLTISSLQPEDSAT YYCQQLNSFPYTFGQGTRLEIK
		VH	99	QVQLVESGGVVQPGRSRLSCAASGF TFSSYGMWVVRQAPGKGLEWAVIWy DGSNKYYADSVKGRFTISGDMSKNTLY LQMNSLRAEDTAVYHCARDPGLRYFD WGQGTLVTVSS
		VL	100	AIQMTQSPSSLSASVGDRVITICRASQGI RNDLGWYQQKPGKAPKLLIYAASSLQS GVPSRFSGGSGTDFTLTISSLQPEDSAT YYCQQLNSFPYTFGQGTRLEIK

TABLE 2-continued

Anti-CD38 binding protein sequences.				
Se- quence Type	Molecule	Descrip- tion	SEQ ID NO	Sequence
CD38 hyb5739	VH		277	QVQLQQSGPELVRPGTSVKVSCKASGY AFTTYLVEWIKQRPQGLEWIGVINPGS GSTNYNEKFKGKATLTVDRSSSTAYMH LSGLTSDDSAVYFCARYAYGYWGQGT TLTVSS
			278	DIVMTQSQFKMSASVGDRVSITCKASQ NVGTAVAWYQQQPGHSPKQLIYSASNQ YTGVPPDRFTGSGAGTDFTLTISNIQSEDL ADYFCQQYSTYPTFGSGTKLEIK
CD38 hyb6284	VH		279	QVQLQQSGAEVLVRPGVSVKISCTGSGYS FTNYAVHWVKQSHVKSLEWIVGIVSPYY GDTTYNQKFTGKATMTVDKSSSTAYM ELARLTSEDSAIFCARRFEGFYYSMDY WGQGTSVTVSS
			280	DVVMIQTPLSLPVSLGDQASISCRPSQL VHSNGNTYLNWYLQRPGQSPKLLIYKV SKRFSGVPDRFSGSGSGTDFTLKISRVE AEDLGVYLCSQSTHVPLTFGSGTQLEIK

[0316] Further provided herein are antibodies (e.g., monospecific antibodies) comprising any of the anti-CD38 CDRs and/or variable domains described supra.

[0317] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site that binds an extracellular domain of a human CD38 polypeptide and an extracellular domain of a cynomolgus monkey CD38 polypeptide. Exemplary assays for determining whether an antigen binding site binds an antigen are described herein and known in the art, including (without limitation) ELISA, SPR, and flow cytometry assays.

Anti-HER2 Binding Sites

[0318] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a HER2 polypeptide. In some embodiments, the HER2 polypeptide is a human HER2 polypeptide, also known as NEU, NGL, ERBB2, TKR1, CD340, HER-2, MLN19, and HER-2/neu. Human HER2 polypeptides are known in the art and include, without limitation, the polypeptides represented by NCBI Accession Numbers XP_024306411.1, XP_024306410.1, XP_024306409.1, NP_001276867.1, NP_001276866.1, NP_001276865.1, NP_001005862.1, or NP_004439.2, or a polypeptide produced from NCBI Gene ID Number 2064. In some embodiments, a binding protein comprising an antigen binding site that binds a HER2 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds a HER2 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites as described supra, wherein V_{H3} and V_{L3} domain pair that form a third antigen binding site that binds a HER2 polypeptide.

[0319] In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFNIKDTY (SEQ ID NO:1) or GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3)

NO:3), IYPTQGYT (SEQ ID NO:4), or IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6), SRWGEGFYAMDY (SEQ ID NO:7), or SRWGSGFYAMDY (SEQ ID NO:8); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9) or QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12). In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFNIKDTY (SEQ ID NO:1) or GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3), IYPTQGYT (SEQ ID NO:4), or IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6), SRWGEGFYAMDY (SEQ ID NO:7), or SRWGSGFYAMDY (SEQ ID NO:8); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9) or QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12).

[0320] In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFNIKDTY (SEQ ID NO:1), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of

CDR-L1 sequence comprising the amino acid sequence of QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYHTTP (SEQ ID NO:12).

[0330] In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDGFYAMDYWGQGTLTVSS (SEQ ID NO:72), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLIYSASFYSGVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGQTKVEIK (SEQ ID NO:77) or DIQMTQSPSSLSASVGDRVTITCRASQDVQTA-VAWYQQKPGKAPKLIYSASFYSGVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGQTKVEIK (SEQ ID NO:78). In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, or SEQ ID NO:76; and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77 or SEQ ID NO:78. In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, or SEQ ID NO:76; and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77 or SEQ ID NO:78.

[0331] In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least

94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDGFYAMDYWGQGTLTVSS (SEQ ID NO:72), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLIYSASFYSGVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGQTKVEIK (SEQ ID NO:77). In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:72, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77. In some embodiments, a binding site that binds HER2 comprises:: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:72, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77.

[0332] In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDGFYAMDYWGQGTLTVSS (SEQ ID NO:72), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLIYSASFYSGVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGQTKVEIK (SEQ ID NO:77) or DIQMTQSPSSLSASVGDRVTITCRASQDVQTA-VAWYQQKPGKAPKLIYSASFYSGVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGQTKVEIK (SEQ ID NO:78). In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:73, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77. In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:73, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77.

[0333] In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence

of EVQLVESGGGLVQPGGSLRLS-CAASGFNIRDYIHWVRQAPGKGLEWVARIYPTNA YTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGSGFYAMDYW GQGTLVTVSS (SEQ ID NO:75), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLASAVGDRVTITCRASQDVNTA-VAWYQQKPGKAPKLLIYSASFYSG VPSRSGSRSGTDFTLTISLQPEDFA-TYYCQQHYTPPTFGQQGTKEIK (SEQ ID NO:77). In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:75, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO: 77. In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:75, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77.

[0334] In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQG YTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGSGFYAMDYW GQGTLVTVSS (SEQ ID NO:74), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLASAVGDRVTITCRASQDVNTA-VAWYQQKPGKAPKLLIYSASFYSG VPSRSGSRSGTDFTLTISLQPEDFA-

TYYCQQHYTPPTFGQQGTKEIK (SEQ ID NO:77). In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:74, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77. In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:74, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77.

[0335] In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIRDYIHWVRQAPGKGLEWVARIYPTNA

YTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGEGFYAMDYW GQGTLVTVSS (SEQ ID NO:76), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLASAVGDRVTITCRASQDVNTA-VAWYQQKPGKAPKLLIYSASFYSG VPSRSGSRSGTDFTLTISLQPEDFA-TYYCQQHYTPPTFGQQGTKEIK (SEQ ID NO:77). In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:76, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77. In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:76, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77.

[0336] In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNG YTRYADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRGGDFYAMDYW GQGTLVTVSS (SEQ ID NO:72), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLASAVGDRVTITCRASQDVNTA-VAWYQQKPGKAPKLLIYSASFYSG VPSRSGSRSGTDFTLTISLQPEDFA-

TYYCQQHYTPPTFGQQGTKEIK (SEQ ID NO:78). In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:72, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:78. In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:72, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:78.

[0337] In some embodiments, an anti-HER2 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of anti-HER2 antibody trastuzumab, 30R/55Q/102E, 30R/56A/102S, 30R/55Q/102S, 30R/56A/102E, or 30Q. In some embodiments, an anti-HER2 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of anti-HER2 antibody trastuzumab, 30R/55Q/102E, 30R/56A/102S, 30R/55Q/102S, 30R/56A/102E, or 30Q.

[0338] Sequences of exemplary anti-HER2 antigen binding sites are provided in Table 3. In some embodiments, an anti-HER2 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-HER2 antibody described in Table 3. In some embodiments, an anti-HER2 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-HER2 antibody described in Table 3.

Other Anti-Tumor Target Binding Sites

[0339] In some embodiments, a binding protein of the present disclosures comprises an antigen binding site that binds a tumor target protein. In some embodiments, the tumor target protein is a CD38 polypeptide (e.g., a human CD38 polypeptide). In some embodiments, the tumor target protein is a HER2 polypeptide (e.g., a human HER2 polypeptide). In some embodiments, a tumor target protein of the present disclosure includes, without limitation. A2AR,

TABLE 3

Anti-HER2 binding protein sequences.				
Sequence Type	Molecule	Description	ID NO	SEQ
CDR	Anti-Her2 (trastuzumab)	CDR-H1 (original)	1	GFNIKDTY
	Heavy chain CDRs	CDR-H1 30R	2	GFNIRDY
		CDR-H2 (original)	3	IYPTNGYT
		CDR-H2 55Q	4	IYPTQGYT
		CDR-H2 56A	5	IYPTNAYT
		CDR-H3 (original)	6	SRWGGDGFYAMDY
		CDR-H3 102E	7	SRWGGEGLFYAMDY
		CDR-H3 102S	8	SRWGGSGFYAMDY
	Anti-Her2 (trastuzumab)	CDR-L1 (original)	9	QDVNTA
	Light chain CDRs	CDR-L1 30Q	10	QDVQTA
		CDR-L2 (original)	11	SAS
		CDR-L3 (original)	12	QQHYTTP
Variable domain	Anti-Her2 Trastuzumab and variant VH	VH wt	72	EVQLVESGGGLVQPGGSLRLSCAASGF NIKDTYIHWRQAPGKGLEWVARIYP TNGYTRYADSVKGRFTISADTSKNTAYL LQMNSLRRAEDTAVYYCSRWGGDGFY AMDYWGQGTIVTVSS
		VH 30R/55Q/102E	73	EVQLVESGGGLVQPGGSLRLSCAASGF NIRDYIHWRQAPGKGLEWVARIYPT QGYTRYADSVKGRFTISADTSKNTAYL QMNSLRRAEDTAVYYCSRWGGEGFYA MDYWGQGTIVTVSS
		VH 30R/55Q/102S	74	EVQLVESGGGLVQPGGSLRLSCAASGF NIRDYIHWRQAPGKGLEWVARIYPT QGYTRYADSVKGRFTISADTSKNTAYL QMNSLRRAEDTAVYYCSRWGGSGFYA MDYWGQGTIVTVSS
		VH 30R/56A/102S	75	EVQLVESGGGLVQPGGSLRLSCAASGF NIRDYIHWRQAPGKGLEWVARIYPT NAYTRYADSVKGRFTISADTSKNTAYL QMNSLRRAEDTAVYYCSRWGGSGFYA MDYWGQGTIVTVSS
		VH 30R/56A/102E	76	EVQLVESGGGLVQPGGSLRLSCAASGF NIRDYIHWRQAPGKGLEWVARIYPT NAYTRYADSVKGRFTISADTSKNTAYL QMNSLRRAEDTAVYYCSRWGGEGFYA MDYWGQGTIVTVSS
	Anti-Her2 Trastuzumab and variant VL	VL wt	77	DIQMTQSPSSLSASVGDRVTITCRASQ DVNTAVAWYQQKPGKAPKLLIYSASF LYSGVPSPRSFGSRSGTDFTLTISSLQPE DFATYYCQQHYTTPTFCGGTKEIK
		VL 30Q	78	DIQMTQSPSSLSASVGDRVTITCRASQ DVQTAVAWYQQKPGKAPKLLIYSASF LYSGVPSPRSFGSRSGTDFTLTISSLQPE DFATYYCQQHYTTPTFCGGTKEIK

APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H4 (also known as VTCN1), B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2 (also known as MCP-1), CCL3 (also known as MIP-1a), CCL4 (also known as MIP-1b), CCL5 (also known as RANTES), CCL7 (also known as MCP-3), CCL8 (also known as mcp-2), CCL11 (also known as eotaxin), CCL15 (also known as MIP-1d), CCL17 (also known as TARC), CCL19 (also known as MIP-3b), CCL20 (also known as MIP-3a), CCL21 (also known as MIP-2), CCL24 (also known as MPIF-2/eotaxin-2), CCL25 (also known as TECK), CCL26 (also known as eotaxin-3), CCR3, CCR4, CD3, CD19, CD20, CD23 (also known as FCER2, a receptor for IgE), CD24, CD27, CD28, CD38, CD39, CD40, CD70, CD80 (also known as B7-1), CD86 (also known as B7-2), CD122, CD137 (also known as 41BB), CD137L, CD152 (also known as CTLA4), CD154 (also known as CD40L), CD160, CD272, CD273 (also known as PDL2), CD274 (also known as PDL1), CD275 (also known as B7H2), CD276 (also known as B7H3), CD278 (also known as ICOS), CD279 (also known as PD-1), CDH1 (also known as E-cadherin), chitinase, CLEC9, CLEC91, CRTH2, CSF-1 (also known as M-CSF), CSF-2 (also known as GM-CSF), CSF-3 (also known as GCSF), CX3CL1 (also known as SCYD1), CXCL12 (also known as SDF1), CXCL13, CXCR3, DNGR-1, ectonucleoside triphosphate diphosphohydrolase 1, EGFR, ENTPD1, FCER1A, FCER1, FLAP, FOLH1, Gi24, GITR, GITRL, GM-CSF, Her2, HHLA2, HMGB1, HVEM, ICOSLG, IDO, IFNa, IgE, IGF1R, IL2Rbeta, IL1, IL1A, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL10, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb (also known as a receptor for IL25), IL18, IL22, IL23, IL25, IL27, IL33, IL35, ITGB4 (also known as b4 integrin), ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1, NCR3LG1, NKG2D, NTPDase-1, OX40, OX40L, PD-1H, platelet receptor, PROM1, 5152, SISP1, SLC, SPG64, ST2 (also known as a receptor for IL33), STEAP2, Syk kinase, TAC1, TDO, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP (also known as a co-receptor for IL7Ra), TSLPR, TWEAK, VEGF, VISTA, Vstm3, WUCAM, and XCR1 (also known as GPR5/CCXCR1). In some embodiments, one or more of the above antigen targets are human antigen targets.

Anti-CD28 Binding Sites

[0340] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a CD28 polypeptide. In some embodiments, the CD28 polypeptide is a human CD28 polypeptide, also known as Tp44. Human CD28 polypeptides are known in the art and include, without limitation, the polypeptides represented by NCBI Accession Numbers XP_011510499.1, XP_011510497.1, XP_011510496.1, NP_001230007.1, NP_001230006.1, or NP_006130.1, or a polypeptide produced from NCBI Gene ID Number 940. In some embodiments, a binding protein comprising an antigen binding site that binds a CD28 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD28 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites. In some embodiments, a binding protein that

comprises an antigen binding site that binds a CD28 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, and one of which binds a CD3 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a CD38 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a HER2 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a tumor target protein.

[0341] In some embodiments, a binding site that binds CD28 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYY (SEQ ID NO:49), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:50), and a CDR-H3 sequence comprising the amino acid sequence of TRSHY-GLDWNFDV (SEQ ID NO:51) and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:52), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:53), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTYPY (SEQ ID NO:54). In some embodiments, a binding site that binds CD28 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYY (SEQ ID NO:49), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:50), and a CDR-H3 sequence comprising the amino acid sequence of TRSHY-GLDWNFDV (SEQ ID NO:51); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:52), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:53), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTYPY (SEQ ID NO:54).

[0342] In some embodiments, a binding site that binds CD28 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVQSGAEVVVKPGASVKVSCKASGYTFT-SYYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTAYMELSRLSDD-TAVYYCTRSHYGLDWNFDVWG KGTIVTVSS (SEQ ID NO:91), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least

94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLASAVGDRVTITCQASQNIYVWLWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFLTISLQPEDIATYYCQQGQTY-PYTFQGQGTKEIK (SEQ ID NO:92). In some embodiments, a binding site that binds CD28 comprises: an anti-

anti-CD28 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-CD28 antibody described in Table 4. In some embodiments, an anti-CD28 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-CD28 antibody described in Table 4.

TABLE 4

Anti-CD28 binding protein sequences.				
Sequence Type	Molecule	Description	SEQ ID NO	Sequence
CDR	Anti-CD28 (sup)	CDR-H1	49	GYTFTSY
		CDR-H2	50	IYPGNVNT
		CDR-H3	51	TRSHYGLDWNPDV
		CDR-L1	52	QNIYVW
		CDR-L2	53	KAS
		CDR-L3	54	QQGQTYPY
Variable domain	Anti-CD28 (sup)	VH	91	QVQLVQSGAEVVVKPGASVKVSCKASGYFTSYYIHWRQAPGQGLEWIGSIYPGNVTNYAQKFQGRATLTVDTSISTAYMELSRRLSDDTAVYYCTRSHYGLDWNPFDVWGKGTTVTVSS
VL		VL	92	DIQMTQSPSSLASAVGDRVTITCQASQNIYVWLWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFLTISLQPEDIATYYCQQGQTY-PYTFQGQGTKEIK

body heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:91, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:92. In some embodiments, a binding site that binds CD28 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:91, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:92.

[0343] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds a tumor target protein (including, without limitation, CD38 or HER2), an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD28 antigen binding sites described above represent V_{H1} and V_{L1} and form a first antigen binding site that binds a CD28 polypeptide. In some embodiments, the VH and VL domains of any of the anti-CD28 antigen binding sites described above and/or in Table 4 represent V_{H1} and V_{L1} and form a first antigen binding site that binds a CD28 polypeptide, V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, and V_{H3} and V_{L3} and form a third antigen binding site that binds a tumor target protein (including, without limitation, CD38 or HER2).

[0344] Sequences of exemplary anti-CD28 antigen binding sites are provided in Table 4. In some embodiments, an

Anti-CD3 Binding Sites

[0345] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a CD3 polypeptide. In some embodiments, the CD3 polypeptide is a human CD3 polypeptide, including CD3-delta (also known as T3D, IMD19, and CD3-DELTA), CD3-epsilon (also known as T3E, IMD18, and TCRE), and CD3-gamma (also known as T3G, IMD17, and CD3-GAMMA). Human CD3 polypeptides are known in the art and include, without limitation, the polypeptides represented by NCBI Accession Numbers XP_006510029.1 or NP_031674.1, or a polypeptide produced from NCBI Gene ID Numbers 915, 916, or 917. In some embodiments, a binding protein comprising an antigen binding site that binds a CD3 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, and one of which binds a CD3 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a CD38 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a CD38 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a CD38 polypeptide.

domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLRTY (SEQ ID NO:62), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65).

[0351] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of **QVQLVESGGGVVQPGRSLRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAE-DTAVYYCRGVYYALSPFDY WGQGTLTVSS** (SEQ ID NO:93), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to an amino acid sequence selected from the group consisting of **DIVMTQTPLSLSVTPGQPASICKSSQLVHQNAQ-TYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK** (SEQ ID NO:95), **DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK** (SEQ ID NO:%), **DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK** (SEQ ID NO:97), and **DIVMTQTPLSLSVTPGQPASICKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK** (SEQ ID NO:98). In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, and SEQ ID NO:98. In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and an antibody light chain variable (VL) domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:95, SEQ ID NO:%, SEQ ID NO:97, and SEQ ID NO:98.

[0352] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least %%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of **QVQLVESGGGVVQPGRSLRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAE-DTAVYYCRGVYYALSPFDY WGQGTLTVSS** (SEQ ID NO:93), and/or an antibody light chain variable (VL)

domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least %%%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of **DIVMTQTPLSLSVTPGQPASICKSSQLVHQNAQ-TYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK** (SEQ ID NO:95). In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:95. In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:95.

[0353] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least %%%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of **QVQLVESGGGVVQPGRSLRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAE-DTAVYYCRGVYYALSPFDY WGQGTLTVSS** (SEQ ID NO:93), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of **DIVMTQTPLSLSVTPGQPASICKSSQLVHENLQ-TYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK** (SEQ ID NO:96). In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:96. In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:96.

[0354] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of **QVQLVESGGGVVQPGRSLRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAE-DTAVYYCRGVYYALSPFDY WGQGTLTVSS** (SEQ ID NO:93), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%,

at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVSNR FSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:97). In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:97. In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:97.

[0355] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least %%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAE-DTAVYYCRGVYYALSPFDY WGQGTLTVSS (SEQ ID NO:93), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVSN

FSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:98). In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:98. In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:98.

[0356] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSRLS-

CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSYATYYASSVKGRFTISRDDSKNTLYLQMNSLRAE-DTAVYYCRGVYYALSPFDY GQGTLTVSS (SEQ ID NO:595), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQ-TYLSWYLQKPGQSPQSLIYKVSN FSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:95). In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:595, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:95. In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:595, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:95

[0357] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds a tumor target protein (including, without limitation, CD38 or HER2), an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD3 antigen binding sites described above represent V_{H2} and V_{L2} and form a second antigen binding site that binds a CD3 polypeptide. In some embodiments, V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide, the VH and VL domains of any of the anti-CD3 antigen binding sites described above and/or in Table 5 represent V_{H2} and V_{L2} and form a second antigen binding site that binds a CD3 polypeptide, and V_{H3} and V_{L3} form a third antigen binding site that binds a tumor target protein (including, without limitation, CD38 or HER2).

[0358] Sequences of exemplary anti-CD3 antigen binding sites are provided in Table 5. In some embodiments, an anti-CD3 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-CD3 antibody described in Table 5. In some embodiments, an anti-CD3 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-CD3 antibody described in Table 5.

TABLE 5

Anti-CD3 binding protein sequences.					
Sequence Type	Molecule	Description	SEQ ID NO	Sequence	
CDR	Anti-CD3 (mid)	CDR-H1 original	55	GFTFTKAW	

TABLE 5-continued

Anti-CD3 binding protein sequences.

Sequence Type	Molecule	Description	SEQ ID NO	Sequence
	CDR-H2 original		56	IKDKSNSYAT
	CDR-H3 original		57	RGVYYALSPFDY
	CDR-L1 original		58	QSLVHNNNANTY
	CDR-L1 QQ		59	QSLVHQNAQTY
	CDR-L1 ENLQ		60	QSLVHENLQTY
	CDR-L1 ENLF		61	QSLVHENLFTY
	CDR-L1 ENLR		62	QSLVHENLRTY
	CDR-L1 DNAQ		63	QSLVHDNAQTY
	CDR-L2 original		64	KVS
	CDR-L3 Original		65	GQGTQYPFT
	CD3mid consensus		180	QSLVHX,NX ₁ X ₂ TY, wherein X ₁ is E or Q, X ₂ is A or L, and X ₃ is Q, R, or F
Variable Domain	Anti-CD3 (mid)	VH	93	QVQLVESGGGVVQPGRSRLSCAASGFT FTKAWMHWVRQAPGKQLEWVAQIKDK SNSYATYYADSVKGRFTISRDDSKNTLY LQMNSLRAEDTAVYYCGRVYYALSPFD YWQQGTLVTVSS
	VL Original		94	DIVMTQTPLSLSVTPGQPASISCKSSQSL VHNNAQNTYLSWYLQKPGQSPQSILYKV NRFSGVPDRFSGSGSGTDFTLKISRVEAE DVGVYYCGQGTQYPFTFGSGTKVEIK
	VL 32/35 QQ		95	DIVMTQTPLSLSVTPGQPASISCKSSQSL VHQNAQTYLSWYLQKPGQSPQSILYKV NRFSGVPDRFSGSGSGTDFTLKISRVEAE DVGVYYCGQGTQYPFTFGSGTKVEIK
	VL ENLQ		96	DIVMTQTPLSLSVTPGQPASISCKSSQSL VHENLQTYLSWYLQKPGQSPQSILYKV NRFSGVPDRFSGSGSGTDFTLKISRVEAE DVGVYYCGQGTQYPFTFGSGTKVEIK
	VL ENLF		97	DIVMTQTPLSLSVTPGQPASISCKSSQSL VHENLFTYLSWYLQKPGQSPQSILYKV NRFSGVPDRFSGSGSGTDFTLKISRVEAE DVGVYYCGQGTQYPFTFGSGTKVEIK
	VL ENLR		98	DIVMTQTPLSLSVTPGQPASISCKSSQSL VHENLRTYLSWYLQKPGQSPQSILYKV NRFSGVPDRFSGSGSGTDFTLKISRVEAE DVGVYYCGQGTQYPFTFGSGTKVEIK
	VL DNAQ		99	DIVMTQTPLSLSVTPGQPASISCKSSQSL VHDNAQTYLSWYLQKPGQSPQSILYKV NRFSGVPDRFSGSGSGTDFTLKISRVEAE DVGVYYCGQGTQYPFTFGSGTKVEIK
	VH 185S		595	QVQLVESGGGVVQPGRSRLSCAASGFT FTKAWMHWVRQAPGKQLEWVAQIKDK SNSYATYYASSVKGRFTISRDDSKNTLY LQMNSLRAEDTAVYYCGRVYYALSPFD YWQQGTLVTVSS

Linkers

[0359] In some embodiments, the linkers L₁, L₂, L₃, and L₄ range from no amino acids (length=0) to about 100 amino acids long, or less than 100, 50, 40, 30, 20, or 15 amino acids or less. The linkers can also be 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acids long. L₁, L₂, L₃, and L₄ in one binding protein may all have the same amino acid sequence or may all have different amino acid sequences.

[0360] Examples of suitable linkers include, for example, GGGGGGGGG (SEQ ID NO:69), GGGGGGGGGGGGG (SEQ ID NO: 70), S, RT, TKGPS (SEQ ID NO: 68), GQPKAAP (SEQ ID NO: 67), GGSGSSGS (SEQ ID NO: 71), and DKTH (SEQ ID NO:66), as well as those disclosed in International Publication Nos. WO2017/074878 and WO2017/180913. The examples listed above are not intended to limit the scope of the disclosure in any way, and linkers comprising randomly

selected amino acids selected from the group consisting of valine, leucine, isoleucine, serine, threonine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, glycine, and proline have been shown to be suitable in the binding proteins.

[0361] The identity and sequence of amino acid residues in the linker may vary depending on the type of secondary structural element necessary to achieve in the linker. For example, glycine, serine, and alanine are best for linkers having maximum flexibility. Some combination of glycine, proline, threonine, and serine are useful if a more rigid and extended linker is necessary. Any amino acid residue may be considered as a linker in combination with other amino acid residues to construct larger peptide linkers as necessary depending on the desired properties.

[0362] In some embodiments, the length of L₁ is at least twice the length of L₃. In some embodiments, the length of L₂ is at least twice the length of L₄. In some embodiments, the length of L₁ is at least twice the length of L₃, and the length of L₂ is at least twice the length of L₄. In some embodiments, L₁ is 3 to 12 amino acid residues in length, L₂ is 3 to 14 amino acid residues in length, L₃ is 1 to 8 amino acid residues in length, and L₄ is 1 to 3 amino acid residues in length. In some embodiments, L₁ is 5 to 10 amino acid residues in length, L₂ is 5 to 8 amino acid residues in length, L₃ is 1 to 5 amino acid residues in length, and L₄ is 1 to 2 amino acid residues in length. In some embodiments, L₁ is 7 amino acid residues in length, L₂ is 5 amino acid residues in length, L₃ is 1 amino acid residue in length, and L₄ is 2 amino acid residues in length.

[0363] In some embodiments, L₁, L₂, L₃ and L₄ each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:69), GGGGSGGGGSGGGGS (SEQ ID NO: 70), S, RT, TKGPS (SEQ ID NO: 68), GQPKAAP (SEQ ID NO: 67), and GGSGSSGSGG (SEQ ID NO: 71). In some embodiments, L₁, L₂, L₃ and L₄ each independently comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:69), GGGGSGGGGSGGGGS (SEQ ID NO: 70), S, RT, TKGPS (SEQ ID NO: 68), GQPKAAP (SEQ ID NO: 67), and GGSGSSGSGG (SEQ ID NO: 71). In some embodiments, L₁ comprises the sequence GQPKAAP (SEQ ID NO: 67), L₂ comprises the sequence TKGPS (SEQ ID NO:68), L₃ comprises the sequence S, and L₄ comprises the sequence RT.

[0364] In some embodiments, at least one of L₁, L₂, L₃ or L₄ comprises the sequence DKTHT (SEQ ID NO:66). In some embodiments, L₁, L₂, L₃ and L₄ comprise the sequence DKTHT (SEQ ID NO:66).

Fc Regions and Constant Domains

[0365] In some embodiments, a binding protein of the present disclosure comprises a second polypeptide chain further comprising an Fc region linked to C_{H1}, the Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains. In some embodiments, a binding protein of the present disclosure comprises a third polypeptide chain further comprising an Fc region linked to C_{H1}, the Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains. In some embodiments, a binding protein of the present disclosure comprises a second polypeptide chain further comprising an Fc region

linked to C_{H1}, the Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising an Fc region linked to C_{H1}, the Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains.

[0366] In some embodiments, a binding protein of the present disclosure comprises a full-length antibody heavy chain or a polypeptide chain comprising an Fc region. In some embodiments, the Fc region is a human Fc region, e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region. In some embodiments, the Fc region includes an antibody hinge, C_{H1}, C_{H2}, C_{H3}, and optionally C_{H4} domains. In some embodiments, the Fc region is a human IgG1 Fc region. In some embodiments, the Fc region is a human IgG4 Fc region. In some embodiments, the Fc region includes one or more of the mutations described infra. In some embodiments, the Fc region is an Fc region of one of the heavy chain polypeptides (e.g., polypeptide 2 or 3) of a binding protein shown in Table 4. In some embodiments, the heavy chain constant region is a constant region of one of the heavy chain polypeptides (e.g., polypeptide 2 or 3) of a binding protein shown in Table 4. In some embodiments, the light chain constant region is a constant region of one of the light chain polypeptides (e.g., polypeptide 1 or 4) of a binding protein shown in Table 4.

[0367] In some embodiments, a binding protein of the present disclosure includes one or two Fc variants. The term "Fc variant" as used herein refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage receptor, FcRn (neonatal Fc receptor). Exemplary Fc variants, and their interaction with the salvage receptor, are known in the art. Thus, the term "Fc variant" can comprise a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises regions that can be removed because they provide structural features or biological activity that are not required for the antibody-like binding proteins of the invention. Thus, the term "Fc variant" comprises a molecule or sequence that lacks one or more native Fc sites or residues, or in which one or more Fc sites or residues has been modified, that affect or are involved in: (1) disulfide bond formation, (2) incompatibility with a selected host cell, (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC).

[0368] In some embodiments, a binding protein of the present disclosure (e.g., a trispecific binding protein) comprises a "knob" mutation on the second polypeptide chain and a "hole" mutation on the third polypeptide chain. In some embodiments, a binding protein of the present disclosure comprises a "knob" mutation on the third polypeptide chain and a "hole" mutation on the second polypeptide chain. In some embodiments, the "knob" mutation comprises substitution(s) at positions corresponding to positions 354 and/or 366 of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S354C, T366W, T366Y, S354C and T366W, or S354C and T366Y. In some embodiments, the "knob" mutation comprises substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S354C and T366W. In some embodiments, the "hole"

mutation comprises substitution(s) at positions corresponding to positions 407 and, optionally, 349, 366, and/or 368 and of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are Y407V or Y407T and optionally Y349C, T366S, and/or L368A. In some embodiments, the "hole" mutation comprises substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

[0369] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution(s) at positions corresponding to positions 366 and optionally 354 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366W or T366Y and optionally S354C; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution(s) at positions corresponding to positions 407 and optionally 349, 366, and/or 368 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y407V or Y407T and optionally Y349C, T366S, and/or L368A.

[0370] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution(s) at positions corresponding to positions 407 and optionally 349, 366, and/or 368 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y407V or Y407T and optionally Y349C, T366S, and/or L368A; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution(s) at positions corresponding to positions 366 and optionally 354 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366W or T366Y and optionally S354C.

[0371] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution at position corresponding to position 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitution is T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution(s) at positions corresponding to positions 366, 368, and/or 407 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366S, L368A, and/or Y407V.

[0372] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the

first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution(s) at positions corresponding to positions 366, 368, and/or 407 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366S, L368A, and/or Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution at position corresponding to position 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitution is T366W.

[0373] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the first and/or second Fc regions are human IgG1 Fc regions. In some embodiments, the first and/or second Fc regions are human IgG4 Fc regions.

[0374] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, S354C, T366W, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second

Fc region comprises amino acid substitutions at positions corresponding to positions 228, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, Y349C, T366S, L368A, Y407V, and R409K. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, Y349C, T366S, L368A, Y407V, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, S354C, T366W, and R409K.

[0375] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 354, and 366 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, S354C, and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 349, 366, 368, and 407 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 349, 366, 368, and 407 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 354, and 366 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, S354C, and T366W.

[0376] In some embodiments, a binding protein of the present disclosure comprises one or more mutations to reduce effector function, e.g., Fc receptor-mediated antibody-dependent cellular phagocytosis (ADCP), comple-

ment-dependent cytotoxicity (CDC), and/or antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_{H1}, the first Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; wherein the third polypeptide chain further comprises a second Fc region linked to C_{H1}, the second Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG1 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A and L235A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG1 Fc regions, and wherein the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A and L235A. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_{H1}, the first Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; wherein the third polypeptide chain further comprises a second Fc region linked to C_{H1}, the second Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG1 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG1 Fc regions, and wherein the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG4 Fc regions, and the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A. In some embodiments, the binding protein comprises a second polypeptide chain further comprising a first Fc region linked to C_{H1}, the first Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising a second Fc region linked to C_{H1}, the second Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A.

[0377] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains,

wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, S354C, T366W, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to C_{H1}, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, Y349C, T366S, L368A, Y407V, and R409K. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, Y349C, T366S, L368A, Y407V, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, S354C, T366W, and R409K.

[0378] In some embodiments, the Fc region is a human IgG4 Fc region comprising one or more mutations that reduce or eliminate FcγI and/or FcγII binding. In some embodiments, the Fc region is a human IgG4 Fc region comprising one or more mutations that reduce or eliminate FcγI and/or FcγII binding but do not affect FcRn binding. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 228 and/or 409 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S228P and/or R409K. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 234 and/or 235 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are F234A and/or L235A. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 228, 234, 235, and/or 409 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S228P, F234A, L235A, and/or R409K. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid mutations at substitutions corresponding to positions 228, 233-236, and/or 409 of human IgG4 according to EU Index. In some

embodiments, the amino acid mutations are S228P; E233P, F234V, L235A, and a deletion at 236; and/or R409K.

[0379] In some embodiments, the Fc region comprises one or more mutations that reduce or eliminate Fc receptor binding and/or effector function of the Fc region (e.g., Fc receptor-mediated antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and/or antibody-dependent cellular cytotoxicity (ADCC)).

[0380] In some embodiments, the Fc region is a human IgG1 Fc region comprising one or more amino acid substitutions at positions corresponding to positions 234, 235, and/or 329 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are L234A, L235A, and/or P329A. In some embodiments, the Fc region is a human IgG1 Fc region comprising amino acid substitutions at positions corresponding to positions 298, 299, and/or 300 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are S298N, T299A, and/or Y300S.

[0381] In some embodiments, a binding protein of the present disclosure comprises one or more mutations to improve stability, e.g., of the hinge region and/or dimer interface of IgG4 (See e.g., Spiess, C. et al. (2013) *J. Biol. Chem.* 288:26583-26593). In some embodiments, the mutation comprises substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, the binding protein comprises a second polypeptide chain further comprising a first Fc region linked to C_{H1}, the first Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising a second Fc region linked to C_{H1}, the second Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG4 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, a binding protein of the present disclosure comprises knob and hole mutations and one or more mutations to improve stability. In some embodiments, the first and/or second Fc regions are human IgG4 Fc regions.

[0382] In some embodiments, the Fc region is a human IgG1 Fc region comprising one or more amino acid substitutions at positions corresponding to positions 234, 235, and/or 329 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are L234A, L235A, and/or P329A. In some embodiments, the Fc region is a human IgG1 Fc region comprising amino acid substitutions at positions corresponding to positions 298, 299, and/or 300 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are S298N, T299A, and/or Y300S.

Nucleic Acids

[0383] Other aspects of the present disclosure relate to isolated nucleic acid molecules comprising a nucleotide sequence encoding any of the binding proteins described herein. Exemplary and non-limiting nucleic acid sequences are provided in Table 5.

[0384] Other aspects of the present disclosure relate to kits of polynucleotides, e.g., that encode one or more polypeptides of a binding protein as described herein. In some embodiments, a kit of polynucleotides of the present disclosure comprises one, two, three, or four polynucleotides of a kit of polynucleotides comprising: (a) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:189, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:190, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:191, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:192; (b) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:193, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:194, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:195, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:196; (c) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:197, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:198, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:199, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:200; (d) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:201, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:202, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:203, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:204; (e) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:205, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:206, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:207, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:208; (f) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:209, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:210, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:211, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:212; (g) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:213, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:214, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:215, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:216; (h) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:217, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:218, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:219, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:220; (i) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:221, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:222, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:223, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:224; (j) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:225, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:226, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:227, and

sequence of SEQ ID NO:270, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:271, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:272; or (v) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:273, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:274, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:275, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:276.

[0385] Other aspects of the present disclosure relate to a vector system comprising one or more vectors encoding a first, second, third, and fourth polypeptide chain of any of the binding proteins described herein. In some embodiments, the vector system comprises a first vector encoding the first polypeptide chain of the binding protein, a second vector encoding the second polypeptide chain of the binding protein, a third vector encoding the third polypeptide chain of the binding protein, and a fourth vector encoding the fourth polypeptide chain of the binding protein, e.g., as shown in the polynucleotides of Table 6. In some embodiments, the vector system comprises a first vector encoding the first and second polypeptide chains of the binding protein, and a second vector encoding the third and fourth polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and third polypeptide chains of the binding protein, and a second vector encoding the second and fourth polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and fourth polypeptide chains of the binding protein, and a second vector encoding the second and third polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first, second, third, and fourth polypeptide chains of the binding protein. The one or more vectors of the vector system may be any of the vectors described herein. In some embodiments, the one or more vectors are expression vectors. In some embodiments, the first, second, third, and fourth polynucleotides are present on one or more expression vectors, e.g., one, two, three, or four expression vectors.

[0386] Standard recombinant DNA methodologies are used to construct the polynucleotides that encode the polypeptides which form the binding proteins, incorporate these polynucleotides into recombinant expression vectors, and introduce such vectors into host cells. See e.g., Sambrook et al., 2001, MOLECULAR CLONING: A LABORATORY MANUAL (Cold Spring Harbor Laboratory Press, 3rd ed.). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications, as commonly accomplished in the art, or as described herein. Unless specific definitions are provided, the nomenclature utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Similarly, conventional techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, delivery, and treatment of patients.

[0387] In some embodiments, the isolated nucleic acid is operably linked to a heterologous promoter to direct transcription of the binding protein-coding nucleic acid sequence. A promoter may refer to nucleic acid control sequences which direct transcription of a nucleic acid. A first

nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence of a binding protein if the promoter affects the transcription or expression of the coding sequence. Examples of promoters may include, but are not limited to, promoters obtained from the genomes of viruses (such as polyoma virus, smallpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus, Simian Virus 40 (SV40), and the like), from heterologous eukaryotic promoters (such as the actin promoter, an immunoglobulin promoter, from heat-shock promoters, and the like), the CAG-promoter (Niwa et al., Gene 108(2):193-9, 1991), the phosphoglycerate kinase (PGK)-promoter, a tetracycline-inducible promoter (Masui et al., Nucleic Acids Res. 33:e43, 2005), the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, and the promoter of the yeast alpha-mating factors. Polynucleotides encoding binding proteins of the present disclosure may be under the control of a constitutive promoter, an inducible promoter, or any other suitable promoter described herein or other suitable promoter that will be readily recognized by one skilled in the art.

[0388] In some embodiments, the isolated nucleic acid is incorporated into a vector. In some embodiments, the vector is an expression vector. Expression vectors may include one or more regulatory sequences operatively linked to the polynucleotide to be expressed. The term "regulatory sequence" includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Examples of suitable enhancers may include, but are not limited to, enhancer sequences from mammalian genes (such as globin, elastase, albumin, (α -fetoprotein, insulin and the like), and enhancer sequences from a eukaryotic cell virus (such as SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, adenovirus enhancers, and the like). Examples of suitable vectors may include, for example, plasmids, cosmids, episomes, transposons, and viral vectors (e.g., adenoviral, vaccinia viral, Sindbis-viral, measles, herpes viral, lentiviral, retroviral, adeno-associated viral vectors, etc.). Expression vectors can be used to transfect host cells, such as, for example, bacterial cells, yeast cells, insect cells, and mammalian cells. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art, and can be used to transfect any cell of interest.

Host Cells

[0389] Other aspects of the present disclosure relate to a host cell (e.g., an isolated host cell) comprising one or more isolated polynucleotides, vectors, and/or vector systems described herein. In some embodiments, an isolated host cell of the present disclosure is cultured in vitro. In some embodiments, the host cell is a bacterial cell (e.g., an *E. coli* cell). In some embodiments, the host cell is a yeast cell (e.g., an *S. cerevisiae* cell). In some embodiments, the host cell is an insect cell. Examples of insect host cells may include, for example, *Drosophila* cells (e.g., S2 cells), *Trichophysa ni*

cells (e.g., High Five™ cells), and *Spodoptera frugiperda* cells (e.g., Sf21 or Sf9 cells). In some embodiments, the host cell is a mammalian cell. Examples of mammalian host cells may include, for example, human embryonic kidney cells (e.g., 293 or 293 cells subcloned for growth in suspension culture), Expi293™ cells, CHO cells, baby hamster kidney cells (e.g., BHK, ATCC CCL 10), mouse sertoli cells (e.g., TM4 cells), monkey kidney cells (e.g., CV1 ATCC CCL 70), African green monkey kidney cells (e.g., VERO-76, ATCC CRL-1587), human cervical carcinoma cells (e.g., HELA, ATCC CCL 2), canine kidney cells (e.g., MDCK, ATCC CCL 34), buffalo rat liver cells (e.g., BRL 3A, ATCC CRL 1442), human lung cells (e.g., W138, ATCC CCL 75), human liver cells (e.g., Hep G2, HB 8065), mouse mammary tumor cells (e.g., MMT 060562, ATCC CCL51), TRI cells, MRC 5 cells, FS4 cells, a human hepatoma line (e.g., Hep G2), and myeloma cells (e.g., NS0 and Sp2/0 cells).

[0390] Other aspects of the present disclosure relate to a method of producing any of the binding proteins described herein. In some embodiments, the method includes a) culturing a host cell (e.g., any of the host cells described herein) comprising an isolated nucleic acid, vector, and/or vector system (e.g., any of the isolated nucleic acids, vectors, and/or vector systems described herein) under conditions such that the host cell expresses the binding protein; and b) isolating the binding protein from the host cell. Methods of culturing host cells under conditions to express a protein are well known to one of ordinary skill in the art. Methods of isolating proteins from cultured host cells are well known to one of ordinary skill in the art, including, for example, by affinity chromatography (e.g., two step affinity chromatography comprising protein A affinity chromatography followed by size exclusion chromatography).

Pharmaceutical Compositions for Treating and/or Preventing Cancer

[0391] Therapeutic or pharmaceutical compositions comprising binding proteins are within the scope of the disclosure. Such therapeutic or pharmaceutical compositions can comprise a therapeutically effective amount of a binding protein, or binding protein-drug conjugate, in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration.

[0392] Acceptable formulation materials are nontoxic to recipients at the dosages and concentrations employed.

[0393] The pharmaceutical composition can contain formulation materials for modifying, maintaining, or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption, or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine, or lysine), antimicrobials, antioxidants (such as ascorbic acid, sodium sulfite, or sodium hydrogen-sulfite), buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates, or other organic acids), bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose, or dextrans), proteins (such as serum albumin, gelatin, or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents, hydrophilic polymers (such as polyvinyl-

nylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfactants or wetting agents (such as pluronics; PEG; sorbitan esters; polysorbates such as polysorbate 20 or polysorbate 80; triton; tromethamine; lecithin; cholesterol or tyloxapal), stability enhancing agents (such as sucrose or sorbitol), tonicity enhancing agents (such as alkali metal halides—e.g., sodium or potassium chloride—or mannitol sorbitol), delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES (18th Ed., A. R. Gennaro, ed., Mack Publishing Company 1990), and subsequent editions of the same, incorporated herein by reference for any purpose).

[0394] The optimal pharmaceutical composition will be determined by a skilled artisan depending upon, for example, the intended route of administration, delivery format, and desired dosage. Such compositions can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the binding protein.

[0395] The primary vehicle or carrier in a pharmaceutical composition can be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier for injection can be water, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include sorbitol or a suitable substitute. In one embodiment of the disclosure, binding protein compositions can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents in the form of a lyophilized cake or an aqueous solution. Further, the binding protein can be formulated as a lyophilizate using appropriate excipients such as sucrose.

[0396] The pharmaceutical compositions of the disclosure can be selected for parenteral delivery or subcutaneous. Alternatively, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.

[0397] The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.

[0398] When parenteral administration is contemplated, the therapeutic compositions for use can be in the form of a pyrogen-free, parenterally acceptable, aqueous solution comprising the desired binding protein in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which a binding protein is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid),

beads, or liposomes, that provides for the controlled or sustained release of the product which can then be delivered via a depot injection. Hyaluronic acid can also be used, and this can have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

[0399] In one embodiment, a pharmaceutical composition can be formulated for inhalation. For example, a binding protein can be formulated as a dry powder for inhalation. Binding protein inhalation solutions can also be formulated with a propellant for aerosol delivery. In yet another embodiment, solutions can be nebulized.

[0400] It is also contemplated that certain formulations can be administered orally. In one embodiment of the disclosure, binding proteins that are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract where bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the binding protein. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders can also be employed.

[0401] Another pharmaceutical composition can involve an effective quantity of binding proteins in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

[0402] Additional pharmaceutical compositions of the disclosure will be evident to those skilled in the art, including formulations involving binding proteins in sustained- or controlled-delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices can include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and gamma ethyl-L-glutamate, poly(2-hydroxyethyl-methacrylate), ethylene vinyl acetate, or poly-D(-)-3-hydroxybutyric acid. Sustained-release compositions can also include liposomes, which can be prepared by any of several methods known in the art.

[0403] Pharmaceutical compositions to be used for in vivo administration typically must be sterile. This can be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method can be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration can be stored in lyophilized form or in a solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[0404] Once the pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder. Such formulations can be stored either in a ready-to-use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.

[0405] The disclosure also encompasses kits for producing a single-dose administration unit. The kits can each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this disclosure are kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lyosyringes).

[0406] The effective amount of a binding protein pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the binding protein is being used, the route of administration, and the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician can titer the dosage and modify the route of administration to obtain the optimal therapeutic effect.

[0407] Dosing frequency will depend upon the pharmacokinetic parameters of the binding protein in the formulation being used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition can therefore be administered as a single dose, as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages can be ascertained through use of appropriate dose-response data.

[0408] The route of administration of the pharmaceutical composition is in accord with known methods, e.g., orally; through injection by intravenous, intraperitoneal, intracerebral (intraparenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal, or intralesional routes; by sustained release systems; or by implantation devices. Where desired, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device.

[0409] The composition can also be administered locally via implantation of a membrane, sponge, or other appropriate material onto which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed-release bolus, or continuous administration.

[0410] The pharmaceutical compositions can be used to prevent and/or treat HIV infection. The pharmaceutical compositions can be used as a standalone therapy or in combination with standard anti-retroviral therapy.

[0411] The disclosure also relates to a kit comprising a binding protein and other reagents useful for detecting target antigen levels in biological samples. Such reagents can include a detectable label, blocking serum, positive and negative control samples, and detection reagents. In some embodiments, the kit comprises a composition comprising

any binding protein, polynucleotide, vector, vector system, and/or host cell described herein. In some embodiments, the kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing a condition (e.g., HIV infection) and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). In some embodiments, the label or package insert indicates that the composition is used for preventing, diagnosing, and/or treating the condition of choice. Alternatively, or additionally, the article of manufacture or kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Methods and Uses for Binding Proteins

Virus

[0412] Certain aspects of the present disclosure relate to methods for expanding virus-specific memory T cells. In some embodiments, the methods comprise contacting a virus-specific memory T cell with a binding protein of the present disclosure, e.g., a trispecific binding protein that comprises a first antigen binding site that binds a CD28 polypeptide, a second antigen binding site that binds a CD3 polypeptide, and a third antigen binding site that binds a CD38 polypeptide.

[0413] In some embodiments, the virus-specific memory T cell is contacted with the binding protein in vitro or ex vivo.

[0414] In some embodiments, contacting the virus-specific memory T cell with the binding protein causes activation and/or proliferation of virus-specific memory T cells.

[0415] Other aspects of the present disclosure relate to methods for expanding T cells. In some embodiments, the methods comprise contacting a T cell with a binding protein of the present disclosure, e.g., a trispecific binding protein that comprises a first antigen binding site that binds a CD28 polypeptide, a second antigen binding site that binds a CD3 polypeptide, and a third antigen binding site that binds a CD38 polypeptide.

[0416] In some embodiments, the T cell is a memory T cell or an effector T cell.

[0417] In some embodiments, the T cell expresses a chimeric antigen receptor (CAR) on its cell surface or comprises a polynucleotide encoding a CAR.

[0418] Other aspects of the present disclosure relate to methods for treating chronic viral infection, e.g., in an individual in need thereof. In some embodiments, the methods comprise administering to an individual in need thereof an effective amount of a binding protein of the present disclosure, e.g., a trispecific binding protein that comprises a first antigen binding site that binds a CD28 polypeptide, a second antigen binding site that binds a CD3 polypeptide, and a third antigen binding site that binds a CD38 polypeptide.

[0419] In some embodiments, the individual is a human.
[0420] In some embodiments, the binding protein is administered to the individual in pharmaceutical formulation comprising the binding protein and a pharmaceutically acceptable carrier.

[0421] In some embodiments, administration of the binding protein results in activation and/or proliferation of virus-specific memory T cells in the individual.

[0422] In any of the above methods, memory T cells can be CD8+ or CD4+ memory T cells. In any of the above methods, memory T cells can be central memory T cells (T_{CM}) or effector memory T cells (T_{EM}).

Cancer

[0423] Certain aspects of the present disclosure relate to methods for preventing and/or treating cancer in a patient. In some embodiments, the methods comprise administering to the patient a therapeutically effective amount of a binding protein or pharmaceutical composition of the present disclosure.

[0424] In some embodiments, a binding protein of the present disclosure is administered to a patient in need thereof for the treatment or prevention of cancer. In some embodiments, the present disclosure relates to a method of preventing and/or treating a proliferative disease or disorder (e.g., cancer). In some embodiments, the method comprises administering to a patient a therapeutically effective amount of at least one of the binding proteins, or pharmaceutical compositions related thereto, described herein. In some embodiments, the present disclosure relates to uses of at least one of the binding proteins, or pharmaceutical compositions related thereto, described herein for preventing and/or treating a proliferative disease or disorder (e.g., cancer) in a patient in need thereof. In some embodiments, the present disclosure relates to at least one of the binding proteins, or pharmaceutical compositions related thereto, described herein for use in the manufacture of a medicament for preventing and/or treating a proliferative disease or disorder (e.g., cancer) in a patient in need thereof. In some embodiments, the patient is a human.

[0425] In some embodiments, the at least one binding protein is administered (or is to be administered) in combination with one or more anti-cancer therapies (e.g., any anti-cancer therapy known in the art, such as a chemotherapeutic agent or therapy). In some embodiments, the at least one binding protein is administered (or is to be administered) before the one or more anti-cancer therapies. In some embodiments, the at least one binding protein is administered (or is to be administered) concurrently with the one or more anti-cancer therapies. In some embodiments, the at least one binding protein is administered (or is to be administered) after the one or more anti-cancer therapies.

[0426] In some embodiments, the binding protein comprises one or two antigen binding site(s) that binds a T-cell surface protein and another antigen binding site that binds the extracellular domain of a human HER2 polypeptide. In some embodiments, the binding protein comprises an antigen binding site that binds the extracellular domain of a human HER2 polypeptide, an antigen binding site that binds a human CD28 polypeptide, and an antigen binding site that binds a human CD3 polypeptide.

[0427] In some embodiments, cancer cells from the individual express HER2. In some embodiments, the patient is selected for treatment on the basis that the cells of the cancer

express a human HER2 polypeptide. Assays known in the art suitable for detecting HER2 expression by cancer cells include, without limitation, immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) assays.

[0428] In some embodiments, the cancer (e.g., HER2-positive cancer) is breast cancer, colorectal cancer, gastric cancer, or non-small cell lung cancer (NSCLC).

[0429] In some embodiments, the binding protein comprises one or two antigen binding site(s) that binds a T-cell surface protein and another antigen binding site that binds the extracellular domain of a human CD38 polypeptide. In some embodiments, the binding protein comprises an antigen binding site that binds the extracellular domain of a human CD38 polypeptide, an antigen binding site that binds a human CD28 polypeptide, and an antigen binding site that binds a human CD3 polypeptide.

[0430] In some embodiments, cancer cells from the individual express CD38. In some embodiments, cells of the cancer express a human CD38 isoform A polypeptide on their cell surface. In some embodiments, cells of the cancer express a human CD38 isoform E polypeptide on their cell surface. In some embodiments, the patient is selected for treatment on the basis that the cells of the cancer express a human CD38 isoform E polypeptide on their cell surface. In some embodiments, the cancer cells express CD38 and CD28. In some embodiments, the cancer cells express CD38 and do not express CD28.

[0431] In some embodiments, the cancer (e.g., CD38-positive cancer) is multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, lymphoma, breast cancer such as Her2+ breast cancer, prostate cancer, germinal center B-cell lymphoma or B-cell acute lymphoblastic leukemia. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the cancer is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or a B cell lymphoma.

[0432] In certain embodiments, the cancer is multiple myeloma. Anti-CD38 antibodies have been tested for the treatment of multiple myeloma, such as daratumumab. However, while multiple myeloma is considered treatable, relapse is inevitable in almost all patients, leading to the development of treatment-refractory disease. In some embodiments, the cancer is relapsed or refractory multiple myeloma. In some embodiments, the patient has been treated with a prior multiple myeloma treatment. In some embodiments, a binding protein of the present disclosure is administered to the patient as a 1st, 2nd, or 3rd line treatment for multiple myeloma. Without wishing to be bound to theory, it is thought that an anti-CD38xanti-CD28xanti-CD3 binding protein of the present disclosure may be useful in treating multiple myeloma, e.g., by recruiting T cells to tumor cells via anti-CD38 (or anti-CD28/anti-CD38), activation of engaged T cells via anti-CD3/anti-CD28, and/or killing of tumor cells through perforin/granzyme-based mechanisms. CD28 has been reported as a novel cancer marker for multiple myeloma. See Nair, J. R. et al. (2011) *J. Immunol.* 187:1243-1253.

[0433] Any of the binding proteins described herein may find use in the methods of the present disclosure.

[0434] In some embodiments of any of the methods of the present disclosure, prior to administration of the binding protein, the patient has been treated with daratumumab. As described herein, the present disclosure provides anti-CD38

binding proteins and sites that do not compete for binding CD38 with daratumumab. Without wishing to be bound to theory, it is thought that this is advantageous because a patient previously treated with daratumumab can be treated with a binding protein of the present disclosure, e.g., without a wash-out period prior to treatment.

[0435] The binding proteins can be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays for the detection and quantitation of one or more target antigens. The binding proteins will bind the one or more target antigens with an affinity that is appropriate for the assay method being employed.

[0436] For diagnostic applications, in certain embodiments, binding proteins can be labeled with a detectable moiety. The detectable moiety can be any one that is capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety can be a radioisotope, such as ³H, ¹⁴C, ³²P, ³⁵S, ¹²⁵I, ⁹⁹Tc, ¹¹¹In, or ⁶⁷Ga; a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; or an enzyme, such as alkaline phosphatase, β-galactosidase, or horseradish peroxidase.

[0437] The binding proteins are also useful for in vivo imaging. A binding protein labeled with a detectable moiety can be administered to an animal, preferably into the bloodstream, and the presence and location of the labeled antibody in the host assayed. The binding protein can be labeled with any moiety that is detectable in an animal, whether by nuclear magnetic resonance, radiology, or other detection means known in the art.

[0438] For clinical or research applications, in certain embodiments, binding proteins can be conjugated to a cytotoxic agent. A variety of antibodies coupled to cytotoxic agents (i.e., antibody-drug conjugates) have been used to target cytotoxic payloads to specific tumor cells. Cytotoxic agents and linkers that conjugate the agents to an antibody are known in the art; see, e.g., Parslow, A. C. et al. (2016) *Biomedicines* 4:14 and Kalim, M. et al. (2017) *Drug Des. Devel. Ther.* 11:2265-2276.

Binding Protein Therapeutic Compositions and Administration Thereof for Treating and/or Preventing Cancer

[0439] Therapeutic or pharmaceutical compositions comprising binding proteins are within the scope of the disclosure. Such therapeutic or pharmaceutical compositions can comprise a therapeutically effective amount of a binding protein, or binding protein-drug conjugate, in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration. These pharmaceutical compositions may find use in any of the methods and uses described herein (e.g., ex vivo, in vitro, and/or in vivo).

[0440] Acceptable formulation materials preferably are nontoxic to recipients at the dosages and concentrations employed.

[0441] The pharmaceutical composition can contain formulation materials for modifying, maintaining, or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption, or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine, or lysine), antimicrobials, antioxidants (such as ascorbic acid, sodium sulfite, or sodium hydrogen-sulfite), buffers

(such as borate, bicarbonate, Tris-HCl, citrates, phosphates, or other organic acids), bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose, or dextrins), proteins (such as serum albumin, gelatin, or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents, hydrophilic polymers (such as polyvinylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfactants or wetting agents (such as pluronics; PEG; sorbitan esters; polysorbates such as polysorbate 20 or polysorbate 80; triton; tromethamine; lecithin; cholesterol or tyloxapal), stability enhancing agents (such as sucrose or sorbitol), tonicity enhancing agents (such as alkali metal halides—preferably sodium or potassium chloride—or mannitol sorbitol), delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES (18th Ed., A. R. Gennaro, ed., Mack Publishing Company 1990), and subsequent editions of the same, incorporated herein by reference for any purpose).

[0442] The optimal pharmaceutical composition will be determined by a skilled artisan depending upon, for example, the intended route of administration, delivery format, and desired dosage. Such compositions can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the binding protein.

[0443] The primary vehicle or carrier in a pharmaceutical composition can be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier for injection can be water, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include sorbitol or a suitable substitute. In one embodiment of the disclosure, binding protein compositions can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents in the form of a lyophilized cake or an aqueous solution. Further, the binding protein can be formulated as a lyophilizate using appropriate excipients such as sucrose.

[0444] The pharmaceutical compositions of the disclosure can be selected for parenteral delivery or subcutaneous. Alternatively, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.

[0445] The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.

[0446] When parenteral administration is contemplated, the therapeutic compositions for use can be in the form of a pyrogen-free, parenterally acceptable, aqueous solution comprising the desired binding protein in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which a binding protein is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid), beads, or liposomes, that provides for the controlled or sustained release of the product which can then be delivered via a depot injection. Hyaluronic acid can also be used, and this can have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

[0447] In one embodiment, a pharmaceutical composition can be formulated for inhalation. For example, a binding protein can be formulated as a dry powder for inhalation. Binding protein inhalation solutions can also be formulated with a propellant for aerosol delivery. In yet another embodiment, solutions can be nebulized.

[0448] It is also contemplated that certain formulations can be administered orally. In one embodiment of the disclosure, binding proteins that are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the binding protein. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders can also be employed.

[0449] Another pharmaceutical composition can involve an effective quantity of binding proteins in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

[0450] Additional pharmaceutical compositions of the disclosure will be evident to those skilled in the art, including formulations involving binding proteins in sustained- or controlled-delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices can include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and gamma ethyl-L-glutamate, poly(2-hydroxyethyl-methacrylate), ethylene vinyl acetate, or poly-D(-)-3-hydroxybutyric acid. Sustained-release compositions can also include liposomes, which can be prepared by any of several methods known in the art.

[0451] Pharmaceutical compositions to be used for in vivo administration typically must be sterile. This can be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method can be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration can be stored in lyophilized form or in a solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[0452] Once the pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder. Such formulations can be stored either in a ready-to-use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.

[0453] The disclosure also relates to a kit comprising a binding protein and other reagents useful for detecting target antigen levels in biological samples. Such reagents can include a detectable label, blocking serum, positive and negative control samples, and detection reagents. In some embodiments, the kit comprises a composition comprising any binding protein, polynucleotide, vector, vector system, and/or host cell described herein. In some embodiments, the kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing a condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). In some embodiments, the label or package insert indicates that the composition is used for preventing, diagnosing, and/or treating the condition of choice. Alternatively, or additionally, the article of manufacture or kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0454] The disclosure also encompasses kits for producing a single-dose administration unit. The kits can each contain both a first container having a dried protein and a second

container having an aqueous formulation. Also included within the scope of this disclosure are kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lysyringes).

[0455] The effective amount of a binding protein pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the binding protein is being used, the route of administration, and the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician can titrate the dosage and modify the route of administration to obtain the optimal therapeutic effect.

[0456] Dosing frequency will depend upon the pharmacokinetic parameters of the binding protein in the formulation being used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition can therefore be administered as a single dose, as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages can be ascertained through use of appropriate dose-response data.

[0457] The route of administration of the pharmaceutical composition is in accord with known methods, e.g., orally; through injection by intravenous, intraperitoneal, intracerebral (intraparenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal, or intralesional routes; by sustained release systems; or by implantation devices. Where desired, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device.

[0458] The composition can also be administered locally via implantation of a membrane, sponge, or other appropriate material onto which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed-release bolus, or continuous administration.

TABLE 1

Trispecific binding protein polypeptide sequences				
Molecule	Poly-peptide Number (acc. to formula)	SEQ (ID NO.)	Sequence	
HER2 (WT-trastuzumab)/CD28sup x CD3mid (32/35 QQ (LC); DKTHT linkers on HC/LC) IgG4 FALA BP # 1	1	100	DIVMTQTPLSLSVTPGQPASICKSSQSLVHQNAQTYLSWYLQKPGQSPQLIYKVSNRFGVPDRFSGSGSG TDFTLK1SRVAEDVGVYCYCQGTQYPFTFGSGTKVEIKDTHDIQMTPSPSSLASVGDRVTITCQASQN YVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDIAATYYCQQGQTYPYTFGQG TKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	
	2	101	QVQLVQSGAEVVKPGAVSVKVSCKASGYTFTSYYIHWRQAPGQGLEWIGSIYPGNVNTMYAQKFQGRATL TVDTIS1STAYMELSRLRSDDTAVYYCTRSHYGLDWNFVDWGKTTVTVSSDKHTQVQLVESGGVVQPG RSLRLSCAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSYATYYADSVKGRFTISRDDSKNLYLQM	

TABLE 1 - continued

Trispecific binding protein polypeptide sequences					
Molecule	Poly-peptide Number (acc. to formula)	SEQ ID NO.	Sequence		
			NSLRAEDTAVYYCRGVYVYALSPFDWQGQTLTVVSSDKTHTASTKGPSVFLAPCSRSTS ESTAALGCLVK DYFPEPVTVWSNNGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTTCNVDHKPSNTKVDKRVESKY GPPCPCPAPEAAGGSPVFLFPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVVGVEVHNAKTKPREE QFNSTYRVSVS LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPVQVTLPPSQEEMTKNQVSL SCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGSSFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYT QKSLSLSLG		
	3	102	EVQLVSEGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWARIYPTNGYTRYADSVKGRFTIS ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDFYAMDYWGQTLTVVSSASTKGPSVFLAPCSRSTS ES TAALGCLVKDYFPEPVTVWSNNGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTTCNVDHKPSNTK VDKRVESKYGPPCPCPAPEAAGGSPVFLFPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVVGVEV HNAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPVQVTLPPCQE EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGSSFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSG		
	4	103	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSRSRGTDFTL TISSLQPFEDFATYCYQOHYTTPTFGQGTKEIKRTVAAPS VFIFPPSDEQLKSGTASVVCVLLNNFYPREA KVQWKVDNALQSGNSQESVTEQDSKDSTSYLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2 (30R/55Q/102E + LC-WT-trastuzumab) / CD28 ^{sup} × CD3 ^{mid} (32/35 QQ (LC); DKTHT linkers on HC/LC) IgG4 FALA BP # 2	1	104	DIVMTQTPLSLSVTPGQPASISCKSSQS L VHQNAAQTYLSWYLOQKPGQSPQSLIYKVSNRFSGV PDRFSGS GSD TDFTLKI SRV EAEDVGVYVYCGQGTQYPTFGSGTKEIKDTKHTDIQMTQSPSSLSASVGDRVTITCQASQNI YVWLWNYQOKPGKAPKLLIYKASNLHTGVPSRFSGS GSTDFTLTISSLQPFEDIATYYCQGQTYPYTFQGQ TKLEIKDKTHTRTVAAPS VFIFPPSDEQLKSGTASVVCVLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	105	QVQLVQSGAEVVKPGASVKVSKCASGYTFTSYYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTSISTAYMELSLRSLRSDDTAVYYCTRSHYGLDNFWDVWKGTTTVVSSDKTHTQVQLVESGGGVQPG RSLRLSCAASGFTFKAWMHWRQAPGKOLEWAQIKDKNSYATYYADSVKGRFTISRDDS KNTLYLQM NSLRAEDTAVYYCRGVYVYALSPFDWQGQTLTVVSSDKTHTASTKGPSVFLAPCSRSTS ESTAALGCLVK DYFPEPVTVWSNNGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTTCNVDHKPSNTKVDKRVESKY GPPCPCPAPEAAGGSPVFLFPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVVGVEVHNAKTKPREE QFNSTYRVSVS LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPVQVTLPPSQEEMTKNQVSL SCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGSSFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYT QKSLSLSLG		
	3	106	EVQLVSEGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWARIYPTQGYTRYADSVKGRFTIS ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDFYAMDYWGQTLTVVSSASTKGPSVFLAPCSRSTS ES TAALGCLVKDYFPEPVTVWSNNGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTTCNVDHKPSNTK VDKRVESKYGPPCPCPAPEAAGGSPVFLFPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVVGVEV HNAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPVQVTLPPCQE EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGSSFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSG		
	4	107	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSRSRGTDFTL TISSLQPFEDFATYCYQOHYTTPTFGQGTKEIKRTVAAPS VFIFPPSDEQLKSGTASVVCVLLNNFYPREAK KVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2 (30R/55Q/102E + LC-WT-trastuzumab) / CD28 ^{sup} × CD3 ^{mid} (DNAQ (LC); DKTHT linkers on HC/LC) IgG4 FALA BP # 8	1	108	DIVMTQTPLSLSVTPGQPASISCKSSQS L VHDNAAQTYLSWYLOQKPGQSPQSLIYKVSNRFSGV PDRFSGS GSD TDFTLKI SRV EAEDVGVYVYCGQGTQYPTFGSGTKEIKDTKHTDIQMTQSPSSLSASVGDRVTITCQASQNI YVWLWNYQOKPGKAPKLLIYKASNLHTGVPSRFSGS GSTDFTLTISSLQPFEDIATYYCQGQTYPYTFQGQ TKLEIKDKTHTRTVAAPS VFIFPPSDEQLKSGTASVVCVLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	109	QVQLVQSGAEVVKPGASVKVSKCASGYTFTSYYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTSISTAYMELSLRSLRSDDTAVYYCTRSHYGLDNFWDVWKGTTTVVSSDKTHTQVQLVESGGGVQPG RSLRLSCAASGFTFKAWMHWRQAPGKOLEWAQIKDKNSYATYYADSVKGRFTISRDDS KNTLYLQM NSLRAEDTAVYYCRGVYVYALSPFDWQGQTLTVVSSDKTHTASTKGPSVFLAPCSRSTS ESTAALGCLVK DYFPEPVTVWSNNGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTTCNVDHKPSNTKVDKRVESKY GPPCPCPAPEAAGGSPVFLFPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVVGVEVHNAKTKPREE QFNSTYRVSVS LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPVQVTLPPSQEEMTKNQVSL SCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGSSFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYT QKSLSLSLG		
	3	110	EVQLVSEGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWARIYPTQGYTRYADSVKGRFTIS ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDFYAMDYWGQTLTVVSSASTKGPSVFLAPCSRSTS ES		

TABLE 1 - continued

Trispecific binding protein polypeptide sequences					
Molecule	Poly-peptide Number (acc. to formula)	SEQ NO	Sequence		
			TAALGCLVKDYPFPEPVTVWSWNSGALTSGVHTFPAAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVNDHKPSNTK VDKRVESKYGPPCPCCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV HNATKTPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGSFFLYSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSG		
	4	111	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRSRGTDFTL TISSLQPEDFATYYCQHQHYPPTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWV KVQWKVDNALQSGNSQESVTEQDSKDSTSYLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2 (30R/56A/ 102S + LC-WT- trastuzumab)/ CD28sup x CD3mid (32/35QQ185E) IgG4 FALA BP # 3	1	286	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSILYKVSNRFSGVDPDRFGSGSG TDFDTLKISRVEAEDVGVYYCGGQTQYFPTFGSGTKVEIKDKTHTDIQMTOQSPSSLSASVGDRVTITCQAQNI YVWLWYQQKPGKAPKLLIYKASNLHTGVPSRSFGSGSGTDFTLTISLQFEDIATYYCQHQGTYPFTFGQG TKLEIKDKTHTRTVAAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWV KDSTYSLSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	287	QVQLVQSGAEVVKPGASVKVSKCASGYTFTSYYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRSDDTAVYYCTRSHYGLWDNFVWKGTTTVVSSDKTHTQVQLVESGGVVQPG RSLRLSCAASGFTFKAWMHWRQAPGKQLEWVAQIKDKSNSYATYADSVKGRFTISRDDSNTKLYLQM NSLRAEDTAVYYCRGVYYALSFPDYWQGQTLTVTSSDKTHTASTKGPSPVFLAPCSRSTSESTAALGCLVK DYFPEPVTVWSNGALTSVGHTFPAAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVNDHKPSNTKVDKRVESKY GPPCPCCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE CAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYT QKSLSLSG		
	3	288	EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWARTYPTNAYTRYADSVKGRFTIS ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDYWGQGTLTVTSSAATKGPSPVFLAPCSRSTSES TAALGCLVKDYPFPEPVTVWSNGALTSVGHTFPAAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVNDHKPSNTK VDKRVESKYGPPCPCCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV NAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGSFFLYSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSG		
	4	289	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRSRGTDFTL TISSLQPEDFATYYCQHQHYPPTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKV KVQWKVDNALQSGNSQESVTEQDSKDSTSYLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2 (30R/55Q/102E + LC-WT- trastuzumab)/ CD28sup x CD3mid (32/35QQ185E) IgG4 FALA BP # 4	1	290	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSILYKVSNRFSGVDPDRFGSGSG TDFDTLKISRVEAEDVGVYYCGGQTQYFPTFGSGTKVEIKGPKAIDPDIQMTOQSPSSLSASVGDRVTITCQAQSO NIYVWLWYQQKPGKAPKWWYKASNLHTGVPSRSFGSGTDFTLTISLQFEDIATYYCQHQGTYPFTFG QGTTKLEIKTKGPRTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWV DSKDSTYSLSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	291	QVQLVQSGAEVVKPGASVKVSKCASGYTFTSYYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRSDDTAVYYCTRSHYGLWDNFVWKGTTTVVSSDKTHTQVQLVESGGVVQPG RSLRLSCAASGFTFKAWMHWRQAPGKQLEWVAQIKDKSNSYATYAEHSVKGRFTISRDDSNTKLYLQM NSLRAEDTAVYYCRGVYYALSFPDYWQGQTLTVTSSDKTHTASTKGPSPVFLAPCSRSTSESTAALGCLVK DYFPEPVTVWSNGALTSVGHTFPAAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVNDHKPSNTKVDKRVESKY GPPCPCCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE CAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYT QKSLSLSG		
	3	292	EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWARIYPTQGYTRYADSVKGRFTIS ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGGEFYAMDYWGQGTLTVTSSAATKGPSPVFLAPCSRSTSES TAALGCLVKDYPFPEPVTVWSNGALTSVGHTFPAAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVNDHKPSNTK VDKRVESKYGPPCPCCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV HNATKTPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGSFFLYSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSG		
	4	293	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRSRGTDFTL TISSLQPEDFATYYCQHQHYPPTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAK VQWV KVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		

TABLE 1 - continued

Trispecific binding protein polypeptide sequences					
Molecule	Poly-peptide Number (acc. to formula)	SEQ ID NO	Sequence		
HER2 (30R/55Q/102E + LC-WT-trastuzumab) / CD28 ^{sup} × CD3 ^{mid} (32/35QQ185S) IgG4 FALA BP # 5	1	294	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLOKPGQSPQSLIYKVSNRFSGVPDFRGSGSG TDFTLKLISRVEADVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLASAVGDRVTITCQASQ NIYVWLWYQQKPGKAPKLLIYKASNLTGVPSPRSFSGSGSGTDFTLTISSLQPEDIAATYYCQQGQTYPTFG QGTKLEIKTKGPSRTVAAPSVIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	295	QVQLVQSGAEVVKGPGASVKVSCKASGYTFTSYYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTSISTAYMELSLRSDDTAVYYCTRSHYGLWDNFDVWGKTTTVSSSQVQLVESGGGVQPGRSLR LSCAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSNSYATYYASSVKGRFTISRDDSKNLYLQMNSLR AEDTAVVYCRGYYALSFPDYWGQGTLTVTSSRTASTKGPSVFLPACSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTFVPSVSSSLGTTKTYTCNVDHFKPSNTKVDKRVESKYGPPCP APEAAGGSVFLPPPKDITLMISRTPEVTCVVVDSQEDPEVQFNWYVDPGEVHNAAKTKPREEQFNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISAKGQPREPVQVCTLPPSQEEMTKNQVSLCAVKGF YPSDIAVEWESENQOPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYTQKSLSL SLG		
	3	296	EVLQVESGGGLVQPGGSLRLSCAASGFNIRDYIHWWRQAPGKGLEWARIYPTQGYTRYADSVKGRFTIS ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDYWGQGTLTVDVSSASTKGPSVFLPACSRSTSE TAALGCLVKDYFPEPVTWSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSVSSSLGTTKTYTCNVDHKPSNTK VDKRVESKYGPPCPCPAPEAAGGSVFLPFPKPKDITLMISRTPEVTCVVVDSQEDPEVQFNWYVDPGEV HNAKTKPREEQFNSTYRVSVSLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISAKGQPREPVQVYTLPPCQE EMTKNQVSLWCLVKGFYPSDIAVEWESENQOPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLG		
	4	297	DIQMTQSPSSLASVGDRTVITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVSPRSFSGSGTDFTL TISSLQPEDFATYYCQOHYTPPTFGQGTKEIKRTVAAPSVIFPPSDEQLKSGTASVVCLLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2 (30R/55Q/102E + LC-WT-trastuzumab) / CD28 ^{sup} × CD3 ^{mid} (32/33/35QS) IgG4 FALA BP # 6	1	298	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQSAQTYLSWYLOKPGQSPQSLIYKVSNRFSGVPDFRGSGSG GTDFTLKLISRVEADVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLASAVGDRVTITCQASQ QNIYVWLWYQQKPGKAPKLLIYKASNLTGVPSPRSFSGSGSGTDFTLTISSLQPEDIAATYYCQQGQTYPTFG QGTKLEIKTKGPSRTVAAPSVIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	299	QVQLVQSGAEVVKGPGASVKVSCKASGYTFTSYYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTSISTAYMELSLRSDDTAVYYCTRSHYGLWDNFDVWGKTTTVSSSQVQLVESGGGVQPGRSLR LSCAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSNSYATYYASSVKGRFTISRDDSKNLYLQMNSLR AEDTAVVYCRGYYALSFPDYWGQGTLTVTSSRTASTKGPSVFLPACSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSVSSSLGTTKTYTCNVDHFKPSNTKVDKRVESKYGPPCP APEAAGGSVFLPPPKDITLMISRTPEVTCVVVDSQEDPEVQFNWYVDPGEVHNAAKTKPREEQFNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISAKGQPREPVQVCTLPPSQEEMTKNQVSLCAVKGF YPSDIAVEWESENQOPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYTQKSLSL SLG		
	3	300	EVLQVESGGGLVQPGGSLRLSCAASGFNIRDYIHWWRQAPGKGLEWARIYPTQGYTRYADSVKGRFTIS ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDYWGQGTLTVDVSSASTKGPSVFLPACSRSTSE TAALGCLVKDYFPEPVTWSWNSGALTSGVHTFPAVLOSSGLYSLSSVTVPSVSSSLGTTKTYTCNVDHKPSNTK VDKRVESKYGPPCPCPAPEAAGGSVFLPFPKPKDITLMISRTPEVTCVVVDSQEDPEVQFNWYVDPGEV HNAKTKPREEQFNSTYRVSVSLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISAKGQPREPVQVYTLPPCQE EMTKNQVSLWCLVKGFYPSDIAVEWESENQOPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLG		
	4	301	DIQMTQSPSSLASVGDRTVITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVSPRSFSGSGTDFTL TISSLQPEDFATYYCQOHYTPPTFGQGTKEIKRTVAAPSVIFPPSDEQLKSGTASVVCLLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2 (30R/55Q/102E + LC-WT-trastuzumab) / CD28 ^{sup} × CD3 ^{mid} (32/35QQ (LC) ; L1 linker) IgG4 FALA BP # 9	1	112	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLOKPGQSPQSLIYKVSNRFSGVPDFRGSGSG TDFTLKLISRVEADVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLASAVGDRVTITCQASQ NIYVWLWYQQKPGKAPKLLIYKASNLTGVPSPRSFSGSGSGTDFTLTISSLQPEDIAATYYCQQGQTYPTFG QGTKLEIKTKGPSRTVAAPSVIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	113	QVQLVQSGAEVVKGPGASVKVSCKASGYTFTSYYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTSISTAYMELSLRSDDTAVYYCTRSHYGLWDNFDVWGKTTTVSSSQVQLVESGGGVQPGRSLR		

TABLE 1 -continued

Trispecific binding protein polypeptide sequences					
Molecule	Poly-peptide Number (acc. to formula)	SEQ ID NO.	Sequence		
HER2-30R/ 55Q/102S + LC-WT- trastuzumab/ CD28sup × CD3mid L1 linker IgG4 FALA BP # 10	3	114	LSAACASGFTFKAWMHWRQAPGKQLEWVAQIKDKNSNSYATYYADSVKGRFTISRDDSKNLTLQMNSLR AEDTAVYYCRGVYVYALSPFDYWGQGLTVSSRTASTKGPSVFLAPCSRSTSEESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPVALQSSGLYSLSSVVTPVSSSLGTKTCTCNVDHKPSNTKVDKRVESKYGPPCPCCP APEAAGGPSVFLFPPPKDITLMIISRTPEVTCVVDDVSQEDPEVQFNWYVTDGVEVHNAKTKPREEQFNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSLSCAVKGF YPSDIAVEWESENQOPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLG		
HER2-30R/ 55Q/102S + LC-WT- trastuzumab/ CD28sup × CD3mid L1 linker IgG4 FALA BP # 10	4	115	EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQGYTRYADSVKGRFTIS ADTSKNTAYLQMNSLRAEDTAVYYCRGVYVYALSPFDYWGQGLTVSSASTKGPSVFLAPCSRSTSES TAALGCLVKDYFPEPVTWSWNSGALTSGVHTFPVALQSSGLYSLSSVVTPVSSSLGTKTCTCNVDHKPSNTK VDKRVESKYGPPCPCCPAPEAAGGPSVFLFPPPKDITLMIISRTPEVTCVVDDVSQEDPEVQFNWYVTDGVEV HNAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE EMTKNQVSLWLCLVKGFYPSDIAVEWESENQOPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVM MHEALHNHYTQKSLSL		
HER2-30R/ 55Q/102S + LC-WT- trastuzumab/ CD28sup × CD3mid L1 linker IgG4 FALA BP # 10	1	116	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNANNTYLSWYLQKPGQSPSOLIYKVSNRFSGVPDFRGSGSG TDFTLKRISRVEAEVDGVVYCYCGQGTQYPFTFGSGTKVEIKGQPKAAAPDIQMTQSPSSLASVGDRVTITCQASQ NIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSTDFLTILTISLQPEDIATYYCQQGQTYPYTFG QGKTLIEKTKGPSRTVAAPSVIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSLTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2-30R/ 55Q/102S + LC-WT- trastuzumab/ CD28sup × CD3mid L1 linker IgG4 FALA BP # 10	2	117	EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRLSDDTAVYYCTRSHYGLWDWNFDVGKGTTVVSSQVQLVESGGGVQPGRSLR LSAACASGFTFKAWMHWRQAPGKQLEWVAQIKDKNSNSYATYYADSVKGRFTISRDDSKNLTLQMNSLR AEDTAVYYCRGVYVYALSPFDYWGQGLTVSSRTASTKGPSVFLAPCSRSTSEESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPVALQSSGLYSLSSVVTPVSSSLGTKTCTCNVDHKPSNTKVDKRVESKYGPPCPCCP APEAAGGPSVFLFPPPKDITLMIISRTPEVTCVVDDVSQEDPEVQFNWYVTDGVEVHNAKTKPREEQFNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSLSCAVKGF YPSDIAVEWESENQOPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLG		
HER2-30R/ 55Q/102S + LC-WT- trastuzumab/ CD28sup × CD3mid L1 linker IgG4 FALA BP # 10	3	118	EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWARTYPTQGYTRYADSVKGRFTIS ADTSKNTAYLQMNSLRAEDTAVYYCRGVYVYALSPFDYWGQGLTVSSASTKGPSVFLAPCSRSTSES TAALGCLVKDYFPEPVTWSWNSGALTSGVHTFPVALQSSGLYSLSSVVTPVSSSLGTKTCTCNVDHKPSNTK VDKRVESKYGPPCPCCPAPEFLLGPPSVFLFPPPKDITLMIISRTPEVTCVVDDVSQEDPEVQFNWYVTDGVEV NAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE MTKNQVSLWLCLVKGFYPSDIAVEWESENQOPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVM MHEALHNHYTQKSLSL		
HER2-30R/ 55Q/102S + LC-WT- trastuzumab/ CD28sup × CD3mid L1 linker IgG4 FALA BP # 10	4	119	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNANNTYLSWYLQKPGKAPKLLIYKVSNRFSGVPDFRGSGSG TDFTLKRISRVEAEVDGVVYCYCGQGTQYPFTFGSGTKVEIKRVAAPSVIFPPSDEQLKSGTASVVCCLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSLTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2-30R/ 56A/102S + LC-WT- trastuzumab/ CD28sup × CD3mid L1 linker IgG4 FALA BP # 11	1	120	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNANNTYLSWYLQKPGQSPSOLIYKVSNRFSGVPDFRGSGSG TDFTLKRISRVEAEVDGVVYCYCGQGTQYPFTFGSGTKVEIKGQPKAAAPDIQMTQSPSSLASVGDRVTITCQASQ NIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSTDFLTILTISLQPEDIATYYCQQGQTYPYTFG QGKTLIEKTKGPSRTVAAPSVIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSLTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2-30R/ 56A/102S + LC-WT- trastuzumab/ CD28sup × CD3mid L1 linker IgG4 FALA BP # 11	2	121	EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRLSDDTAVYYCTRSHYGLWDWNFDVGKGTTVVSSQVQLVESGGGVQPGRSLR LSAACASGFTFKAWMHWRQAPGKQLEWVAQIKDKNSNSYATYYADSVKGRFTISRDDSKNLTLQMNSLR AEDTAVYYCRGVYVYALSPFDYWGQGLTVSSRTASTKGPSVFLAPCSRSTSEESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPVALQSSGLYSLSSVVTPVSSSLGTKTCTCNVDHKPSNTKVDKRVESKYGPPCPCCP APEAAGGPSVFLFPPPKDITLMIISRTPEVTCVVDDVSQEDPEVQFNWYVTDGVEVHNAKTKPREEQFNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSLSCAVKGF YPSDIAVEWESENQOPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLG		

TABLE 1 - continued

Trispecific binding protein polypeptide sequences					
Molecule	Poly-peptide Number (acc. to formula)	SEQ ID NO.	Sequence		
	3	122	EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTNAYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSFYAMDYWGQGTLLTVSSASTKGPSVFPLAPCSRSTSES TAALGCLVKDYPFPEPVTVWSNSGALTSGVHTPAPLQSSGLYSSLSSVTVFSSSLGTTKTYTCNVDHKPSNTK VDKRVESKGPPCPCCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVGVEVHN NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE MTKNQVSLWLCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSG		
	4	123	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFSRSRGTDFTL TISSLQPEDFATYYCQOHYTPPTFGQGTKEIKRTVAAPSFIIFPPSDEQLKSGTASVCLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2-30R/ 56A/102E/ CD28sup x CD3mid L1 linker IgG4 FALA BP # 12	1	124	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLWYIQLQKPGQSPQSLIYKVSNRFSGVPDFRS TDFTLKISRVEAEDVGVYYCGQGTQYFPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQ NIYVWLWYQQKPGKAPKWKYKASNLHTGVPSRFSGSQSGTDFTLTISSLQPEDFATYYCQCGQTYPYTF QGTTKLEIKTKGPSRTVAAPSFIIFPPSDEQLKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	125	QVQLVQSGAEVVKPGASVKVSKCASGYTFTSYYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRSDDTAVYYCTRSHYGLWDNFVWKGTTTVVSSSQVQLVESGGGVQPGRSLR LSCAAQSGFTFTKAWMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSNTLYLQMNSL AEDTAVYYCRGYYAALSPFDYWGQGTLLTVSSRTASTKGPSVFPLAPCSRSTSEESTAALGCLVKDYPFPEPV VSWNSGALTSGVHTFPVALQSSGLYSSLSSVTVFSSSLGTTKTYTCNVDHKPSNTKVDKRVESKGPPCP APEAAGGSPVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVGVEVHNAKTKPREEQFNSTY VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE YPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLG		
	3	126	EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARTYPTNAYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSFYAMDYWGQGTLLTVSSASTKGPSVFPLAPCSRSTSES TAALGCLVKDYPFPEPVTVWSNSGALTSGVHTPAPLQSSGLYSSLSSVTVFSSSLGTTKTYTCNVDHKPSNTK VDKRVESKGPPCPCCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVGVEVHN NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE MTKNQVSLWLCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSG		
	4	127	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFSRSRGTDFTL TISSLQPEDFATYYCQOHYTPPTFGQGTKEIKRTVAAPSFIIFPPSDEQLKSGTASVCLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2- WT + trastuzumab/ CD28sup x CD3mid (32/35QQ) L1 linker IgG4 FALA BP # 15	1	128	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAAQTYLWYIQLQKPGQSPQSLIYKVSNRFSGVPDFRS TDFTLKISRVEAEDVGVYYCGQGTQYFPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQ NIYVWLWYQQKPGKAPKWKYKASNLHTGVPSRFSGSQSGTDFTLTISSLQPEDFATYYCQCGQTYPYTF QGTTKLEIKTKGPSRTVAAPSFIIFPPSDEQLKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	129	QVQLVQSGAEVVKPGASVKVSKCASGYTFTSYYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRSDDTAVYYCTRSHYGLWDNFVWKGTTTVVSSSQVQLVESGGGVQPGRSLR LSCAAQSGFTFTKAWMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSNTLYLQMNSL AEDTAVYYCRGYYAALSPFDYWGQGTLLTVSSRTASTKGPSVFPLAPCSRSTSEESTAALGCLVKDYPFPEPV VSWNSGALTSGVHTFPVALQSSGLYSSLSSVTVFSSSLGTTKTYTCNVDHKPSNTKVDKRVESKGPPCP APEAAGGSPVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVGVEVHNAKTKPREEQFNSTY VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE YPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLG		
	3	130	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSFYAMDYWGQGTLLTVSSASTKGPSVFPLAPCSRSTSES TAALGCLVKDYPFPEPVTVWSNSGALTSGVHTPAPLQSSGLYSSLSSVTVFSSSLGTTKTYTCNVDHKPSNTK VDKRVESKGPPCPCCPAPEAAGGSPVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVGVEVHN NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE EMTKNQVSLWLCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSG		
	4	131	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFSRSRGTDFTL TISSLQPEDFATYYCQOHYTPPTFGQGTKEIKRTVAAPSFIIFPPSDEQLKSGTASVCLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		

TABLE 1 - continued

Trispecific binding protein polypeptide sequences			
Molecule	Poly-peptide Number (acc. to formula)	SEQ ID NO	Sequence
HER2 / CD28 _{sup} × CD3 _{mid} DKTHT linkers on HC/LC) IgG4 FALA BP # 25	1	132	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNANNANTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDFRSGSG TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLASVGDRVITITCQA SQNIYWLWYQOKPGKAPWKYKASNLHTGVPSRFSGSGETDFTLTISLQPEDIATYYCQQGQTYPYTFGQG TKLEIKDKTHTRTVAAPSFIFFPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSLTLSKADYEHKVYACEVTHQGLSSPVTKSFNRGEC
	2	133	QVQLVQSGAEVVKPGAVKVSKCASGYTFTSYYIHWVRQAPQGQLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRSDDTAVYYCTRSHYGLDWNFDWVGKTTVTVSSDKTHTQVQLVESGGVVQPG RSLRLSCAASGFTFTKAWMHWRQAPGKOLEWVAQIKDKMSNYATYYADSVKGRFTISRDSDKNLTYLQM NSLRAEDTAVYYCRGVYYALSPFDYWQGTLTVTSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK DYPPEPVTWSNGALTSGVHTFPVALQSSGLYSLSSVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKY GPPCPCCPAPEAGGSPVFLPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTYRVSVSVLVHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSL CAVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVHEALHNHYT QKSLSLSLG
	3	134	EVLVSEGGLVQPGGSLRLSCAASGFNIKDTYIHWRQAPGKGLEWARIYPTNGYTRYADSVKGRFTIS ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDFYAMYDYGQGTLTQVSSASTKGPSVFPLAPCSRSTSE TAALGCLVCKDYPPEPVTWSWNSGALTSGVHTFPVALQSSGLYSLSSVTVPSSSLGTTKTYTCNVDHKPSNTK VDKRVESKYGPPCPCCPAPEAAGGSPVFLPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV HNAKTKPREEQFNSTYRVSVSVLVHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLG
	4	135	DIQMTQSPSSLASAVGDRVITICRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSRSRGTD FTLTISLQPEDFATYYCQQHHTTPPTFGQGTKEIKRTVAAPSFIFFPSDEQLKSGTASVVCLNNFY PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSLTLSKADYEHKVYACEVTHQGLSSPVTKSFNRGEC
HER2 / CD28 _{sup} × CD3 _{mid} (32/33/3435 ENLR (LC) ; DKTHT linkers on HC/LC) IgG4 FALA BP # 26	1	136	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDFRSGSG SGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLASVGDRVITITCQA SQNIYWLWYQOKPGKAPWKYKASNLHTGVPSRFSGSGETDFTLTISLQPEDIATYYCQQGQTYPYTFGQG TKLEIKDKTHTRTVAAPSFIFFPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSLTLSKADYEHKVYACEVTHQGLSSPVTKSFNRGEC
	2	137	QVQLVQSGAEVVKPGAVKVSKCASGYTFTSYYIHWVRQAPQGQLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRSDDTAVYYCTRSHYGLDWNFDWVGKTTVTVSSDKTHTQVQLVESGGVVQPG RSLRLSCAASGFTFTKAWMHWRQAPGKOLEWVAQIKDKMSNYATYYADSVKGRFTISRDSDKNLTYLQM NSLRAEDTAVYYCRGVYYALSPFDYWQGTLTVTSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK DYPPEPVTWSNGALTSGVHTFPVALQSSGLYSLSSVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKY GPPCPCCPAPEAGGSPVFLPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTYRVSVSVLVHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSL CAVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVHEALHNHYT QKSLSLSLG
	3	138	EVLVSEGGLVQPGGSLRLSCAASGFNIKDTYIHWRQAPGKGLEWARIYPTNGYTRYADSVKGRFTIS ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDFYAMYDYGQGTLTQVSSASTKGPSVFPLAPCSRSTSE TAALGCLVCKDYPPEPVTWSWNSGALTSGVHTFPVALQSSGLYSLSSVTVPSSSLGTTKTYTCNVDHKPSNTK VDKRVESKYGPPCPCCPAPEAAGGSPVFLPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV HNAKTKPREEQFNSTYRVSVSVLVHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLG
	4	139	DIQMTQSPSSLASAVGDRVITICRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSRSRGTDFTL TISLQPEDFATYYCQQHHTTPPTFGQGTKEIKRTVAAPSFIFFPSDEQLKSGTASVVCLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSLTLSKADYEHKVYACEVTHQGLSSPVTKSFNRGEC
HER2 / CD28 _{sup} × CD3 _{mid} (32/33/3435 ENLQ (LC) ; DKTHT linkers on HC/LC) IgG4 FALA BP # 27	1	140	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDFRSGSG SGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLASVGDRVITITCQA SQNIYWLWYQOKPGKAPKLLIYKASNLHTGVPSRFSGSGETDFTLTISLQPEDIATYYCQQGQTYPY TFGQGTKEIKDKTHTRTVAAPSFIFFPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSTYSLSSLTLSKADYEHKVYACEVTHQGLSSPVTKSFNRGEC

TABLE 1 - continued

Trispecific binding protein polypeptide sequences					
Molecule	Poly-peptide Number (acc. to formula)	SEQ ID NO	Sequence		
	2	141	QVQLVQSGAEVVVKPGASVKVSKASGYTFTSYYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRSDDTAVYYCTRSHYGLDWNFDVGKGTTVVSSDKHTQVQLVESGGGVQPG RSLRLSCAASGFTFTKAWMHWRQAPGKOLEWVAQIKDKNSNSYATYYADSVKGRFTISRDDSKNTLYLQM NSLRAEDTAVYYCRGVYYALSPFDYWGQGTLVTVSSDKHTASTKGPSVFLAPCSRSTSESTAALGCLVK DYPPEPVTVWSNNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKY GPPCPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVGVEVHNAKTKPREE QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPVQVCTLPPSQEEMTKNQVSL CAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYT QKSLSLSLGL		
	3	142	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTIS ADTSKNTAYLQMNLSRAEDTAVYYCYSRWGGDFYAMDYWGQGTLVTVSSASTKGPSVFLAPCSRSTSES TAALGCLVKDVFPEPVTVWSNNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTK VDKRVESKYGPPCPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVGVEV HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPVQVYTLPPCQE EMTKNQVSLWLCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLGL		
	4	143	DIQMTQSPSSLASAVGDRVTITCRASQDVNTAVAQYQQKPGKAPKLLIYSASFYSGVPSRSGSRSGTDFTL TISSLQPEDFATYYCQHHTTPPTFGQGTTKEIKRTVAAPSIVIFPPSDEQLKSGTASVVCLNNNFYPREA KVQWKVDNALQSGNSQESVTEQDSKDTSYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER2 / CD28 _{sup} × CD3 _{mid} (32/33/3435 ENLF (LC) ; DKTHT linkers on HC/LC) IgG4 FALA BP # 28	1	144	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLWSYLQKPGQSPQSLIYKVSNRFSGVPDFRGSG SGTDTKLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQ SQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRSFGSGSGTDFDTLTISSLQPEDIAITYCQQGQTYPY TFGQGTTKEIKDKTHTRTVAAPSIVIFPPSDEQLKSGTASVVCLNNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDTSYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	145	QVQLVQSGAEVVVKPGASVKVSKASGYTFTSYYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRSDDTAVYYCTRSHYGLDWNFDVGKGTTVVSSDKHTQVQLVESGGGVQPG RSLRLSCAASGFTFTKAWMHWRQAPGKOLEWVAQIKDKNSNSYATYYADSVKGRFTISRDDSKNTLYLQM NSLRAEDTAVYYCRGVYYALSPFDYWGQGTLVTVSSDKHTASTKGPSVFLAPCSRSTSESTAALGCLVK DYPPEPVTVWSNNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKY GPPCPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVGVEVHNAKTKPREE QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPVQVCTLPPSQEEMTKNQVSL CAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYT QKSLSLSLGL		
	3	146	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTIS ADTSKNTAYLQMNLSRAEDTAVYYCYSRWGGDFYAMDYWGQGTLVTVSSASTKGPSVFLAPCSRSTSES TAALGCLVKDVFPEPVTVWSNNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTK VDKRVESKYGPPCPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVGVEV HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPVQVYTLPPCQE EMTKNQVSLWLCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLGL		
	4	147	DIQMTQSPSSLASAVGDRVTITCRASQDVNTAVAQYQQKPGKAPKLLIYSASFYSGVPSRSGSRSGTDFTL TISSLQPEDFATYYCQHHTTPPTFGQGTTKEIKRTVAAPSIVIFPPSDEQLKSGTASVVCLNNNFYPREA KVQWKVDNALQSGNSQESVTEQDSKDTSYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
anti- Her2/CD3/3CD28 IgG4 FALA BP #29	1	148	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNAINTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDFRGSG TDFTKLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQ NIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRSFGSGSGTDFDTLTISSLQPEDIAITYCQQGQTYPYFG QGTTKEIKTKGPSRTVAAPSIVIFPPSDEQLKSGTASVVCLNNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDTSYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	149	QVQLVQSGAEVVVKPGASVKVSKASGYTFTSYYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRSDDTAVYYCTRSHYGLDWNFDVGKGTTVVSSSVQQLVESGGGVQPGRSLR LSCAASGFTFTKAWMHWRQAPGKOLEWVAQIKDKNSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLR AEDTAVYYCRGVYYALSPFDYWGQGTLVTVSSRTASTKGPSVFLAPCSRSTSESTAALGCLVKDVFPEPV VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKYGPPCPC APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVGVEVHNAKTKPREEQFNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPVQVCTLPPSQEEMTKNQVSLCAVKG YPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYTQKSLSL SLG		
	3	150	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTIS ADTSKNTAYLQMNLSRAEDTAVYYCYSRWGGDFYAMDYWGQGTLVTVSSASTKGPSVFLAPCSRSTSES TAALGCLVKDVFPEPVTVWSNNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTK VDKRVESKYGPPCPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVGVEV		

TABLE 1 - continued

Trispecific binding protein polypeptide sequences					
Molecule	Poly-peptide Number (acc. to formula)	SEQ ID NO	Sequence		
			HNAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSG		
	4	151	DIQMTQSPSLSASAVGDRVTICRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRSGRSRGTDFTL TISSLQPEDFATYCYCQOHYTPPTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVUCLNNNFYPRE AKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
HER230R/55Q/ 102E/ CD28 _{sup} × CD3 _{mid} (32/33/3435 ENLR (LC); DKTHT linkers on HC/LC) IgG4 FALA BP # 31	1	152	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDFRGSGSG GTDFTLKISRVEAEDVGVYCCQGTQYPFTFGSGTKVEIKDKTHDIQMTQSPSLSASVGDRVTITCQA NIYVWLWYQQKPGKAPWYKASNLHTGVPSRSGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPYTFQG GTKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVUCLNNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	153	QVQLVQSGAEVVVKPGAVSKVSKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIATAYMELSLRSDDTAVYYCTRSHYGLDWNFDVWGKTTVTVSSDKTHIQVQLVESGGGVQPG RSLRLSCAASGFTFKAWMHWRQAPGKQLEWVAQIKDKNSNYATYYADSVKGRFTISRDSDKNTLYLQM NSLRAEDTAVYYCRGVYYALSPDFYWGQGTIVTUVSSDKTHASTKGPSVFLAPCSRSTSESTAALGCLVK DYFPEPVTWSNGALTSGVHTFPVALQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKY GPPCPCPAPEAAGGPSVFLFPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVGDGEVHNNAKTKPREE QFNSTYRVSVSLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSL CAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVHEALHNHYT QKSLSLSG		
	3	154	EVLQVQSGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWARIYPTQGYTRYADSVKGRFTIS ADTSKNTAYLQMSLRAEDTAVYYCSRWGEGFYAMDYWGQGTIVTUVSSASTKGPSVFLAPCSRSTSSES TAALGCLVKDYPFEPVTWSNGALTSGVHTFPVALQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTK VDKRVESKYGPPCPCPAPEAAGGPSVFLFPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVGDGEV HNAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSG		
	4	155	DIQMTQSPSLSASAVGDRVTICRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRSGRSRGTDFTL TISSLQPEDFATYCYCQOHYTPPTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVUCLNNNFYP REAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
CD38VH1/ CD28 ^{sup} × CD3 _{mid} ENLR DKTHT IgG4 FALA BP # 1	1	156	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDFRGSGSG SGTDFTLKISRVEAEDVGVYCCQGTQYPFTFGSGTKVEIKDKTHDIQMTQSPSLSASVGDRVTITCQA SQNIYVWLWYQQKPGKAPKLLIYKASNLHTGVPSRSGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPY TFQGQGTLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVUCLNNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSTYSLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		
	2	157	QVQLVQSGAEVVVKPGAVSKVSKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIATAYMELSLRSDDTAVYYCTRSHYGLDWNFDVWGKTTVTVSSDKTHIQVQLVESGGGVQPG RSLRLSCAASGFTFKAWMHWRQAPGKQLEWVAQIKDKNSNYATYYADSVKGRFTISRDSDKNTLYLQM NSLRAEDTAVYYCRGVYYALSPDFYWGQGTIVTUVSSDKTHASTKGPSVFLAPCSRSTSESTAALGCLVK DYFPEPVTWSNGALTSGVHTFPVALQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKY GPPCPCPAPEAAGGPSVFLFPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVGDGEVHNNAKTKPREE QFNSTYRVSVSLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSL CAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVHEALHNHYT QKSLSLSG		
	3	158	QVQLVQSGAEVVVKPGAVSKVSKASGYTFTSYAMHWVKEAPGQRLEWIGIYYPGQGGTNYQKFQGRAT LTADTSASTAYMELSLRSDDTAVYFCARTGGLRRAYFTYWQGQTLTVTUVSSASTKGPSVFLAPCSRSTSSES TAALGCLVKDYPFEPVTWSNGALTSGVHTFPVALQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTK VDKRVESKYGPPCPCPAPEAAGGPSVFLFPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVGDGEV HNAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSG		
	4	159	DIVLTQSPATLSSLSPGERATISCRASQSVSSYQGQFMHWYQQKPGQPRLLIYGASSRATGIPARFSGSG GSCTDFTLTISPLEPEDFAVYYCQQNKEDPWFGGGTTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVC LLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTSKADYEKHKVYACEVTHQGLSS PVTKSFNRGEC		
CD38hh992/ CD28 ^{sup} × CD3 _{mid} ENLR DKTHT IgG4 FALA BP # 5'	1	160	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDFRGSGSG GTDFTLKISRVEAEDVGVYCCQGTQYPFTFGSGTKVEIKDKTHDIQMTQSPSLSASVGDRVTITCQA NIYVWLWYQQKPGKAPWYKASNLHTGVPSRSGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPYTFQGQ TKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVUCLNNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC		

TABLE 1 - continued

Trispecific binding protein polypeptide sequences						
Molecule	Poly-peptide Number (acc. to formula)	SEQ ID NO	Sequence			
	2	161	QVQLVQSGAEVVKPGAVSVKVKSCASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTISIAYMELSLRSLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGVVQPGRSRLRLSAAASGFTFTKAWMHWRQAPGKOLEWVAQIKDKNSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWGQGTILTVTSSDKTHTASTKGPSVFLAPCSRSTSESTAALGCLVKDYPPEPVTVWSNGALTSVGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKYGPPCPCPAPAEAGGGSVFLFPPPKPDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQSLCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLG			
	3	162	QVQLVQSGAEVVKPGAVSVKVKSCASGYTFTSYIHWVRQAPGQGLEWMMGGFDPEDGETIYAQKFQGRVIMTEDSTDATYMEMMNSLRSDETAIYYCTTGRFFDWFWQGTILTVSSASTKGPSVFLAPCSRSTSESTAALGCLVKDYFPEPVTVWSNGALTSVGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKYGPPCPCPAPAEAGGGSVFLFPPPKPDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQSVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLG			
	4	163	EII1LTQSPAILSLSPGERATLSCRASQSVISRFLSWYQVKPGLAPRLLIYGASTRATGIPVPRFSGSGSGTDFSLTISLSPQEDCAVYYCQODNSLPIFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC			
CD38hyb5739/ CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA BP # 6'	1	164	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGTDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYQPTFEGSGTKVEIKDKTHTDIQMTQSPSSLASVGDRVITTCQASQNIYVWLWYQOKPGKAPKWKYKASNLHTGPVSRFSGSGSGTDFTLTISLQPEDIAITYYCQGQTYTFQGQGTKEIKDKTHTRTVAAAPSVFIFPPSDEQLKSGTASVCLLNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC			
	2	165	QVQLVQSGAEVVKPGAVSVKVKSCASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTISIAYMELSLRSLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTOVOLVESGGVVQPGRSRLRLSAAASGFTFTKAWMHWRQAPGKOLEWVAQIKDKNSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWGQGTILTVTSSDKTHTASTKGPSVFLAPCSRSTSESTAALGCLVKDYPPEPVTVWSNGALTSVGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKYGPPCPCPAPAEAGGGSVFLFPPPKPDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQSLCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLG			
	3	166	QVQLQSGSPELVRPGTSVKVSKCASGYAFTTYLVEWIQKRPQGLEWIGVINPGSGSTNYNEKFKGKATLTDVRSSTTAYMLHLSLTSDDASAVYFCRSGTVEIYVWYQOKPGKAPKWKYKASNLHTGPVSRFSGSGTDFTLKISRVEAEDVGVYYCGQGTQYQPTFEGSGTKVEIKDKTHTDIQMTQSPSSLASVGDRVITTCQASQNIYVWLWYQOKPGKAPKWKYKASNLHTGPVSRFSGSGSGTDFTLTISLQPEDIAITYYCQGQTYTFQGQGTKEIKDKTHTRTVAAAPSVFIFPPSDEQLKSGTASVCLLNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC			
	4	167	DIVMTQSQKFSMASVGDRVSICTKASQNVGATAWYQQQPGHSPKQLIYSASNRTYGTVPDRFTGSGAGTDFTLTISNIQSEDLDAYFCQYQSTYPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVCLLNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC			
CD38hyb6284/ CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA BP # 7	1	168	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYQPTFEGSGTKVEIKDKTHTDIQMTQSPSSLASVGDRVITTCQASQNIYVWLWYQOKPGKAPKWKYKASNLHTGPVSRFSGSGSGTDFTLTISLQPEDIAITYYCQGQTYTFQGQGTKEIKDKTHTRTVAAAPSVFIFPPSDEQLKSGTASVCLLNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC			
	2	169	QVQLVQSGAEVVKPGAVSVKVKSCASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTISIAYMELSLRSLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGVVQPGRSRLRLSAAASGFTFTKAWMHWRQAPGKOLEWVAQIKDKNSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWGQGTILTVTSSDKTHTASTKGPSVFLAPCSRSTSESTAALGCLVKDYPPEPVTVWSNGALTSVGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKYGPPCPCPAPAEAGGGSVFLFPPPKPDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQSLCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLG			
	3	170	QVQLLQSGAELVRPGVSVKISCTGSGYSFTNYAVHWVKQSHVKSLEWIGVISPYGDTTYNQKFTGKATMTVDKSSSTAYMELARLTSDESAIYFCARRFEFGFYYSMDYWGQGTSTVVTSSASTKGPSVFLAPCSRSTSESTAALGCLVKDYFPEPVTVWSNGALTSVGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTTKTYTCNVDHKPSNTKVDKRVESKYGPPCPCPAPAEAGGGSVFLFPPPKPDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQSLCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLG			

TABLE 1 - continued

Trispecific binding protein polypeptide sequences					
Molecule	Poly-peptide Number (acc. to formula)	SEQ ID NO	Sequence		
	4	171	DVVMIQTPLSLPVLQSGDQASISCRPSQSLVHNSNGNTYLNWYLQRPGQSPKLLIYKVSKRFSGVPDFRGSGSG TDFTLKRISRVEAEDLGVYLCQSQSTHVPFTGSGTQLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS FNRGEC		
CD38hh1195/ CD28sup × CD3mid_ENLQ DKTHT IgG4 FALA BP # 8	1	172	DIVMTQTPLSLVTPGQPASISCKSSQSLVHENLQTYLSWYLOKPGQSPQSLIYKVSNRFSGVPDFRGSGSG GTDFTLKRISRVEAEDVGVYCCQGTQYPFTGSGTKEIKDTHTDIQMTQSPSSLASAVGDRVTITCQASQ NIYVWLWNWYQQKPGKAPKWYKASNLHTGVPSRSFSGSGSGTDFTLTISSLQPEDIAHYCQQGQTYPTFGQ GKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFRNRC QVQLVQSGAEVVKPGASVKVSCKASGYFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRLSDDTAVYYCTRSHYGLWDNFVWGKGTTVVSDDKTHTQVQLVESGGVVQPG RSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKNSYATYADSVKGRFTISRDSDKNTLYLQM NSLRAEDTAVYYCRGVYIALSPFDYWGQGTILTVTSSDKTHTASTKGPSVFLAPCSRSTSESTAALGCLVK DYPPEPVTWSNGALTSGVHTFPAVLQSSGLYSSLVTPSSSLGTTKTYTCNVDHKPNTKVDKRVESKY GPPCPCCPAPEAAGGSPVFLFPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAAKTKPREE QFNSTYRVSVSLTVLHQDWLNGKEYKCKVSNKGLPSSIETKTISAKGQPREPQVCTLPSSQEMTKNQVSL CAVKGFYPSDIAVEWESENQOPENNYKTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYT QKSLSLSLG		
	2	173	QVQLVQSGAEVVKPGASVKVSCKASGYFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRLSDDTAVYYCTRSHYGLWDNFVWGKGTTVVSDDKTHTQVQLVESGGVVQPG RSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKNSYATYADSVKGRFTISRDSDKNTLYLQM NSLRAEDTAVYYCRGVYIALSPFDYWGQGTILTVTSSDKTHTASTKGPSVFLAPCSRSTSESTAALGCLVK DYPPEPVTWSNGALTSGVHTFPAVLQSSGLYSSLVTPSSSLGTTKTYTCNVDHKPNTKVDKRVESKY GPPCPCCPAPEAAGGSPVFLFPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAAKTKPREE QFNSTYRVSVSLTVLHQDWLNGKEYKCKVSNKGLPSSIETKTISAKGQPREPQVCTLPSSQEMTKNQVSL CAVKGFYPSDIAVEWESENQOPENNYKTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYT QKSLSLSLG		
	3	174	QVQLVESGGVVQPGRSRLSCAASGFTFSSYGMWYVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTI SRDNNSKNTLYLQMNSLRAEDTAVYHCARDPGLRYFDGDMWDVGQGTTVTVSSASTKGPSVFLAPCSRST SESTAALGCLVKDYFPEPVTSWNSGALTSGVHTFPAVLQSSGLYSSLVTPSSSLGTTKTYTCNVDHKPNTKVD NTKVDKRVESKYGPPCPCCPAPEAAGGSPVFLFPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG VEVHNAAKTKPREEQFNSTYRVSVSLTVLHQDWLNGKEYKCKVSNKGLPSSIETKTISAKGQPREPQVYTLPP CQEEMTKNQVSLWCLVKGFYPSDIAVEWESENQOPENNYKTPVLDSDGSFFLVSKLTVDKSRWQEGNVF CSVMEALHNHYTQKSLSLSLG		
	4	175	DIQLTQSPSFSLASVGDRVTITCRASQGISSYLAQYQKPGKAPKLLIIFAASLHSGVPSRSFSGSGSGTEF TTLTISSLQPEDFATYYCQQLNSFPYTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR EAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFRNRC QVQLVQSGAEVVKPGASVKVSCKASGYFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRLSDDTAVYYCTRSHYGLWDNFVWGKGTTVVSDDKTHTQVQLVESGGVVQPG RSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKNSYATYADSVKGRFTISRDSDKNTLYLQM NSLRAEDTAVYYCRGVYIALSPFDYWGQGTILTVTSSDKTHTASTKGPSVFLAPCSRSTSESTAALGCLVK DYPPEPVTWSNGALTSGVHTFPAVLQSSGLYSSLVTPSSSLGTTKTYTCNVDHKPNTKVDKRVESKY GPPCPCCPAPEAAGGSPVFLFPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAAKTKPREE QFNSTYRVSVSLTVLHQDWLNGKEYKCKVSNKGLPSSIETKTISAKGQPREPQVCTLPSSQEMTKNQVSL CAVKGFYPSDIAVEWESENQOPENNYKTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYT QKSLSLSLG		
CD38hh1370/ CD28sup × CD3mid_ENLQ DKTHT IgG4 FALA BP # 9	1	176	DIVMTQTPLSLVTPGQPASISCKSSQSLVHENLQTYLSWYLOKPGQSPQSLIYKVSNRFSGVPDFRGSG SGSGTDFTLKRISRVEAEDVGVYCCQGTQYPFTGSGTKEIKDTHTDIQMTQSPSSLASAVGDRVTI TCQASQNIYVWLWNWYQQKPGKAPKLLIYKASNLHTGVPSRSFSGSGSGTDFTLTISSLQPEDIAHYCQQ GOTYPTFQGTKEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFRNRC QVQLVQSGAEVVKPGASVKVSCKASGYFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRLSDDTAVYYCTRSHYGLWDNFVWGKGTTVVSDDKTHTQVQLVESGGVVQPG RSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKNSYATYADSVKGRFTISRDSDKNTLYLQM NSLRAEDTAVYYCRGVYIALSPFDYWGQGTILTVTSSDKTHTASTKGPSVFLAPCSRSTSESTAALGCLVK DYPPEPVTWSNGALTSGVHTFPAVLQSSGLYSSLVTPSSSLGTTKTYTCNVDHKPNTKVDKRVESKY GPPCPCCPAPEAAGGSPVFLFPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAAKTKPREE QFNSTYRVSVSLTVLHQDWLNGKEYKCKVSNKGLPSSIETKTISAKGQPREPQVCTLPSSQEMTKNQVSL CAVKGFYPSDIAVEWESENQOPENNYKTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCVMHEALHNHYT QKSLSLSLG		
	2	177	QVQLVESGGVVQPGRSRLSCAASGFTFSSYGMWYVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTI SGDNNSKNTLYLQMNSLRAEDTAVYYCARMFRGAFDYWGQGTILTVTSSASTKGPSVFLAPCSRSTSESTA LGCLVKDYFPEPVTSWNSGALTSGVHTFPAVLQSSGLYSSLVTPSSSLGTTKTYTCNVDHKPNTKVD RVESKYGPPCPCCPAPEAAGGSPVFLFPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTYRVSVSLTVLHQDWLNGKEYKCKVSNKGLPSSIETKTISAKGQPREPQVYTLPPCQEEMT KNQVSLWCLVKGFYPSDIAVEWESENQOPENNYKTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCVMHE ALHNHYTQKSLSLSLG		
	3	178	QVQLVESGGVVQPGRSRLSCAASGFTFSSYGMWYVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTI SGDNNSKNTLYLQMNSLRAEDTAVYYCARMFRGAFDYWGQGTILTVTSSASTKGPSVFLAPCSRSTSESTA LGCLVKDYFPEPVTSWNSGALTSGVHTFPAVLQSSGLYSSLVTPSSSLGTTKTYTCNVDHKPNTKVD RVESKYGPPCPCCPAPEAAGGSPVFLFPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTYRVSVSLTVLHQDWLNGKEYKCKVSNKGLPSSIETKTISAKGQPREPQVYTLPPCQEEMT KNQVSLWCLVKGFYPSDIAVEWESENQOPENNYKTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCVMHE ALHNHYTQKSLSLSLG		
	4	179	AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRSFSGSGSGTDFTL TISGLQPEDSATYYCLQDYIYYPYTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFRNRC QVQLVQSGAEVVKPGASVKVSCKASGYFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRLSDDTAVYYCTRSHYGLWDNFVWGKGTTVVSDDKTHTQVQLVESGGVVQPG RSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKNSYATYADSVKGRFTISRDSDKNTLYLQM NSLRAEDTAVYYCRGVYIALSPFDYWGQGTILTVTSSDKTHTASTKGPSVFLAPCSRSTSESTAALGCLVK DYPPEPVTWSNGALTSGVHTFPAVLQSSGLYSSLVTPSSSLGTTKTYTCNVDHKPNTKVDKRVESKY GPPCPCCPAPEAAGGSPVFLFPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAAKTKPREE		
CD38hu5739/ CD28sup × CD3mid_ENLQ DKTHT IgG4 FALA	1	181	DIVMTQTPLSLVTPGQPASISCKSSQSLVHENLQTYLSWYLOKPGQSPQSLIYKVSNRFSGVPDFRGSG SGSGSGTDFTLKRISRVEAEDVGVYCCQGTQYPFTGSGTKEIKDTHTDIQMTQSPSSLASAVGD RVTITCQASQNIYVWLWNWYQQKPGKAPKLLIYKASNLHTGVPSRSFSGSGSGTDFTLTISSLQPEDIA TYYCQQGQTYPYTFGQGTKEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFRNRC QVQLVQSGAEVVKPGASVKVSCKASGYFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRLSDDTAVYYCTRSHYGLWDNFVWGKGTTVVSDDKTHTQVQLVESGGVVQPG RSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKNSYATYADSVKGRFTISRDSDKNTLYLQM NSLRAEDTAVYYCRGVYIALSPFDYWGQGTILTVTSSDKTHTASTKGPSVFLAPCSRSTSESTAALGCLVK DYPPEPVTWSNGALTSGVHTFPAVLQSSGLYSSLVTPSSSLGTTKTYTCNVDHKPNTKVDKRVESKY GPPCPCCPAPEAAGGSPVFLFPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAAKTKPREE		
	2	182	QVQLVQSGAEVVKPGASVKVSCKASGYFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRLSDDTAVYYCTRSHYGLWDNFVWGKGTTVVSDDKTHTQVQLVESGGVVQPG RSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKNSYATYADSVKGRFTISRDSDKNTLYLQM NSLRAEDTAVYYCRGVYIALSPFDYWGQGTILTVTSSDKTHTASTKGPSVFLAPCSRSTSESTAALGCLVK DYPPEPVTWSNGALTSGVHTFPAVLQSSGLYSSLVTPSSSLGTTKTYTCNVDHKPNTKVDKRVESKY GPPCPCCPAPEAAGGSPVFLFPPKPKDLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAAKTKPREE		

TABLE 1 - continued

Trispecific binding protein polypeptide sequences

Molecule	Poly-peptide Number (acc. to formula)	SEQ ID NO.	Sequence
			QFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSL CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYT QKSLSLSLG
	3	183	QVQLVQSGAEVKKPGASVKSCKASGYAFTTYLVEIRQRPQGLEWMGVINPGSGSTNYAQKFQGRVT MTVDRSSTTAYMELSLRSDDTAVYYCARYGTYGQGTLTVTSSASTKGPSVFLAPCSRSTSESTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTPVSSSLGTKTYTTCNVDHKPSNTKVDKR ESKYGPPCPCPAPEAAGGPSVFLFPKPDKTLMSRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTK PREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQ VSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALH NHYTQKSLSLSLG
	4	184	DIQMTQSPSSLASVGDRVTITCRASQNVTAVAWYQQKPGKSPKQLIYSASNRYTGVPSPRFSGSGSGTDF LTISLQLPEDLATYYCQGYSTYPFTPGQGTKEIKRTVAAPSVIDFPPSDEQLKSGTASVVCLLNNFYPRE AKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLKADYEHKHVYACEVTHQGLSSPVTKSFNRGE
CD38hu6284/ CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA	1	185	DIVMTQTPLSLSVTPGPQASI SCKSSQSLVHENLQTYLSWYI LQKPGQSPQSLIYKVSNRFSGVPDRFSG GSGTDFTLKIISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTOQSPSSLASVGDRVTITC QASQNIYVWLNWYQQKPGKAPKLIIYKASNLHTGVPSRFSGSGSGTDFTLTISLQLPEDIATYYCQGQ PYPTFGQGTKEIKDTHTRTVAAPSVIDFPPSDEQLKSGTASVVCLLNNFYPREAKVQWVQKVDNALQSGN SQESVTEQDSKDSTYSLSSTLTLKADYEHKHVYACEVTHQGLSSPVTKSFNRGE
	2	186	QVQLVQSGAEVKKPGASVKSCKASGYFTSYIHWVRQAPQGLEWIGSI YPGNVNTNYAQKFQGRATL TVDTISIAYMELSLRSDDTAVYYCTRSHYGLDWNFDVWKGHTTVVSSDKTHQTQVQLVESGGVVQPG RSLRLSCAASGPTFTKAWMHWRQAPGKQLEWVAQIKDKSNSYATYADSVKGRFTISRDKSNTLYLQM NSLRAEDTAVYYCRGVYYALSFPDYGQGTILTVSSDKTHTASTKGPSVFLAPCSRSTSESTAALGCLVK DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTPVSSSLGTKTYTTCNVDHKPSNTKVDKR ESKYGPPCPAPEAAGGPSVFLFPKPDKTLMSRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQV SLCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYT QKSLSLSLG
	3	187	QVQLVQSGAEVKKPGASVKSCKASGYFTSYIHWVRQAPQGLEWIGSI YPGNVNTNYAQKFQGRATL MTVDKSSSTAYMELSLRSDDTAVYYCARRFEGFYSMDYWGQGTIVTSSASTKGPSVFLAPCSRSTSE STAALGCLVKDIFYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTPVSSSLGTKTYTTCNVDHKPSNT KVDKRVESKYGPPCPAPEAAGGPSVFLFPKPDKTLMSRTPEVTCVVVDVSQEDPEVQFNWYVDG VEVHNAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP REPQVYTLPPCQEEMTKNQVSLCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVS KLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
	4	188	DVVMTQSPLSPVTLGQOPASISCRPSQSLVHSNGNTYLNWYQQRPGQSPKLLIYKVSKRFSGVPDRFSGSG SDFTLKISRVEAEDVGVYYCSQSTHVPFTGGGTKEIKRTVAAPSVIDFPPSDEQLKSGTASVVCLLNNFYP REAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLKADYEHKHVYACEVTHQGLSSPVTKSFNR EC

TABLE 6
Trispecific binding protein polynucleotide sequences

TABLE 6-continued

TABLE 6-continued

Trispecific binding protein polynucleotide sequences							
Polyptide Number (acc. to formula)	SEQ ID NO	Molecule	Sequence				
			GGGTGCTCTCGTGAAGGACTACTTTCCGCCCCGTCCTGACAACTCTGGCTCTGACAAGGGCGTG CACACTTTCAGCCTGCTGCCAGCAAGCAGCCGGCTGTACTCTGTGAGAGCTGCTGACAGTCGCCAGAGC TGGGACCZAGAACCTACCTGTACCTGTACCTGTACCTGTACCTGTACCTGTACCTGTACCTGTACCTGTAC AGTAGGCCCCCTCGCCCTGCTCCAGCAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCT CCZAGAACCTCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCT GAGGTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCT AACAGACTACCGGCTGCTGCCAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCT AAGGGTCAACAGGGCTTACGGGCTTACGGGCTTACGGGCTTACGGGCTTACGGGCTTACGGGCTTACGGGCT TTCTPACCCAGCAGCATTCAGCAGCTGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCT GTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCT GTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCT GAAGTCAAGTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCT GGCTCAACATCCGGAACTCTACCTGCTGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCT ATCTACCCACZAGGGTACACGATAAGCTGCTGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAG AAGGACAACGGCTTACCTGTAGATAACAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAG GGCZAGGGTTCTAGCCATTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCT CCATGGGTGTTCCCTGCTGAGCAGAGCATCAGCAAACTAACAGCTGGGAGCTGGGAGCTGGGAGCTGGGAG ACTATTTCCGAGCCGTTGACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG GCTCAGAGAGCAGCCCTACTCTGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCT CAGCTAACTGTAACAGGAACTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCT CACCCTTSCCAGCCCCCTGAGAAGTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGG CCCTCTG ATGATAGCAGGAACTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCT TGGPACTGGAGCZGCTGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCT GGTGGCTGCTGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCT GGGCCTGCGCAGCTCACTGAGAAACCATCAGAAGGCAAGGGCAGCAGGGCAGCAGGGCAGCAGGGCAGC GCCCTTGGCAGGAAATGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCT ATTGCGTGGAAATGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGG GGTGTATCTTCTACTCAAGCTGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGG TGATCAGAGGGCTCCAGTCAACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTAC CAGGTGAGCTGGTGGCTGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCT GGCTPACACCTTACAGCTACTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTAC ATCTACCCGGCAACTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG ATCAGCAGCCGCTACTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTAC TACGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT CAGGGCAGTGGTGGGAATCTGGGGCTGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGG GGCTPACACCTTACCCAGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT ATCAGGAAAGGCAACGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT GACAGAAAGAACCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT GTGPACTANGCCCTGAGCCCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT CCGCAAGCTAAAGGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT GGGCCTGCTGCTGAGGACTACTCTGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT CACACTTTCAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT TGGGACCZAGAACCTACCTGTACCTGTACCTGTACCTGTACCTGTACCTGTACCTGTACCTGTACCT CCAGGGACACTCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT	3	195		
			CAGGGCTGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCT GGCTPACACCTTACAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT ATCAGGAAAGGCAACGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT TACGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT CAGGGCAGTGGTGGGAATCTGGGGCTGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGGGAGCTGG GGCTPACACCTTACCCAGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT ATCAGGAAAGAACCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT GACAGAAAGAACCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT GTGPACTANGCCCTGAGCCCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT CCGCAAGCTAAAGGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT GGGCCTGCTGCTGAGGACTACTCTGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT CACACTTTCAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT TGGGACCZAGAACCTACCTGTACCTGTACCTGTACCTGTACCTGTACCTGTACCTGTACCTGTACCT CCAGGGACACTCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT	4	196		

TABLE 6-continued

TABLE 6-continued

TABLE 6-continued
Trinucleotidic binding protein polynucleotide complexes

TABLE 6-continued

Trispecific binding protein polynucleotide sequences								
Polyptide Number (acc. to formula)	SEQ ID NO	Molecule	Sequence					
4	204		CACCTGTTAACGGGACCAAAAGGCCAACACAAAGGTGGCAAGGGGGATTAAGTACGGGCCCTCCCG CCCTCTTGGCCASGCCCTGAAAGTGCGGGACCCCTCGTTCCCTGTTCCCTCCCAAAAGCCAAAGCACCCTG ATGATAGCGGGACCCCTGAAAGTGCGGGACCCCTCGTTCCCTGTTCCCTGTTCCAGGAATCCGAGTGTGAT TGCTACGTGAAAGTCACAGCCACGGCTAAGGAAACTCCGTTGGTGTGATGTTGGTGTGATGTTGGTGTGAT GGGGCTGGCCAGCTGACATGGAAAGCTGAGGAAACCATCTGAGGAAAGCTGAGGAAAGCTGAGGAAAGCTGAG GCCCTTGGCTGGAGATGAGGAAAGCTGAGGAAAGCTGAGGAAAGCTGAGGAAAGCTGAGGAAAGCTGAGGAA ATTGGCTGTTAACGGGAAATGGGAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCA GGCTATTCCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG TGATGCAAGGGCCCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG CAGGTCAGTGGTTCAGTGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG GGCTCACCTTTAACGGCTFACTATCATCCTGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG ATCTAACCCGGCAAGGTGAAACATGGAAACTGGAAACATGGAAACTGGAAACATGGAAACTGGAAACATGGAAACT ATCAGCACGGCTTATGGAAACATGGAAACTGGAAACATGGAAACTGGAAACATGGAAACTGGAAACATGGAAACT TACGGCTGTGATGGAACTTGCACTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG CAGGTCAGTGGTGGAAACTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG GGCTTACCTTCAAAAGGGCTGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG ATCAGGACTAGAGGAAACAGCTTACGGCACTTACGGCACTTACGGCACTTACGGCACTTACGGCACTTACGGCACT GACAGAAAGACAACCTGAACTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG GTGTCTATGCCCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG CCGCAAGCTAAAGGGCCCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG GGGCTGCTCTGGTGAAGGACTACTTTCGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG CACACCTTTCAGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG TGGGACCAAGAACCTTACACCTGTAACGTGACCAAGGCCAGAACTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG AGTAGGGCCCTCCCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG CCCCAGGAAACCTCCCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG GAGGGCAGITCAAACTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG AACACGACCTTACCCCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG AAGGGTCTCAAAACAGGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG CAAGTGTGTGACCCCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG TTCTAACCGGAAATTCTGGTGGGATGGGAGCAAGGGCCAGGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG GTGTCTAGCTGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG GACATCTGGTGTGACCCCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG AGCCGGAGCTGG TCCTGATCTGGATCTGGATCTGGATCTGGATCTGGATCTGGATCTGGATCTGGATCTGGATCTGGATCTGGATCTGGATCTGGATCTGG TCACCTTGGCTGG TCACCTTGGCTGG GCCCTGAGCTGG GGCTGG TCATGGCAGCTGG ACCAAGGGCCCTGG GCACGACCTTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG CCCTGG I1964 FALA BP #10	1	1	LHER2-30R/ 55S/102S + LC- WT - trastuzumab/ CD38sup x CD3mid L1 linker		

TABLE 6-continued

TABLE 6-continued

TABLE 6-continued

TABLE 6-continued

TABLE 6-continued

TABLE 6-continued

TABLE 6-continued
Immunoprecipitated binding protein polymers in relation to recombinant

TABLE 6-continued

TABLE 6-continued

Trispecific binding protein polynucleotide sequences							
Polypeptide Number (acc. to formula)	SEQ ID NO	Sequence					
THEER2 / CD3 _{mab} (32/33) / 3435 ENIUR (Lc) ; DKPHT Linkers Dion HC/LC Ig94 FALA BP # 26	1	GACATCGTGTGACCCAGACCCCCCTGAGCTTGAGCAGACCTGGACAGCTGGCAAGCATCAGCTGGAAAGAGC AGCCGAGACCTGGTGTGACCCAGACCCCCCTGAGCTTGAGCAGACCTGGCAAGCATCAGCTGGAAAGCC TCCCCTGATCTAACAGTGTGTCAGTCAGGATCAGAAGATTCAGGATCTCGGGGAGCTGCTGTTATCTGCAAGA TCACCCCTGAGCTGGCAGATAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG TCACCTTGTGAGCTGGCAGATAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GCAGGCTGTGAGCTGGCAGATAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG ACTGCTATAGCAGAAGAGCCGGCGCAAGGGCCCAAGCTGGTGTGACCCAGGAGGAGGAGGAGGAGGAGGAGGAG CCAGGAGATTTCAGCAGGCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG CACCTTAATCTGGAG GACCACACCCGGTAGGCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GCCCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTG AGAGGGCAACAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG ACACTGAGAAAGGGAGAATGAGAAGAGAAGAGAAGAGAAGAGAAGAGAAGAGAAGAGAAGAGAAGAGAAGAGA GTGACAAAGGCTTAAACGGGGGGAGTGT CAGGGCAGTGGGCGAGCTGGGCAAGCTGGGCAAGCTGGGCAAGCTGGGCAAGCTGGGCAAGCTGGGCAAGCTGG GGCTAACCTTTAACGGGGTACATTAACGGGGTACATTAACGGGGTACATTAACGGGGTACATTAACGGGGTACATTA ATCTPACCCGGCAAGCTGGTGAACACCACTGGGCAAGCTGGGCAAGCTGGGCAAGCTGGGCAAGCTGGGCAAGCTGG ATACGACCCCTTACATGGAAACTAGGG TAACGGCTGTGGATTGG CAGGGCAGTGGTGG GGCTTACACCTTCAACAAAGGCGCTGG ATCAAGGAAAGGAAACAGGAACTGG GACACCAAGAACACCTGGTACACTGG GTGTACTATGGCCCTGG CCGGCAAGCAAAAAGGCCATCTGG GGGTGCCCTGTGAGGACTACTTCCAGCCGG CACACCTTTCAGCGGTGGTGG TGGGACCAAGAACCTGG AGTAGGGGCTTCCTGG CCCAAGGG GAGGGCAGTGGCACTTGG AACAGGGACCTTACGG AAGGGTGTCAACAGGGCTGG CAAGGGTGTGACCTTCCCTTAAGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG TTCTPACCCGGCAAGGATTCGG GTGCTGTGGCTGGCTGG GAAGGGCAGTGGTGAATCTGG GGCTTCAACATCAAGAACACCTTACGG ATCTACCCCAAGGGTACATGG AAGAACACCCCTTACTGG GG CATCGTGTGGTGTGGCTGG CTACTTCCGGAGGG CTGGAGAGGG	225				
	2	226					
	3						

TABLE 6-continued

Trispecific binding protein polynucleotide sequences								
Polyptide Number (acc. to formula)	SEQ ID NO	Sequence						
CD38hypb5739/ CD38sup x CD38mid ENLQ DKRHTI 194 FAFLA IBP #6	1 253	GACATCGTGTGATGACCCAGACCCCCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCGAGTCAGCTGCAAGAGC AGCCGAGAGCCTGGTGTGACAGAACTTCGAGACACTGGCCAGGAGCCAGCCAGCCAGCCAGCCAG TCCCGATCTAACAGTGTGTCGCAACAGAATTCAAGGGCCTGGTGTGAGGAGATTCGAGGAGCAGCTGCAGGAGCAGCCAG TCACCTTGAGATGAGTGGCAGGAGCAGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAG TCACCTTGAGCTGGCAGGAGCAGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAG GCAGCTGTGTTGCAAGTGGCAGGAGCAGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAG ACTGTTATAGCAGAGAAGGCGGCAAGGGCCCAAGCTGGTGTGATGATCAAGGGAGCAGCTGGCAGGAGCAGCTGGCAGGAGCAGCTGGC CCAGAGATTTCTGGAG CACCTACTACTGGCGGCAAGGGCCCAAGCTGGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GACCACACCGTAAGGAG GCCTTGTTGTCTGGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCT AGAGGGCAACAGCAGAAGGAG ACAGCTGAGCAGGAGCAAGGTGTGAGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG AGTGAACAGAGCTTAACTGGGGAGGAG CAGGTGCAAGTGGCAGGAGCAGGAG GGCTAACACCTTAAAGCTGAGTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAGTGT ATCAGACCCCTAAATGAACTAGGAACTAGGAACTAGGAACTAGGAACTAGGAACTAGGAACTAGGAACTAGGAACTAGGAACTAGGAA TACGGCCCTGGATTTGGAACTTGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG GGCTTACACCTTCAACAAAGGCTGAGTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAG ATCAGAGAACAGAACCTAGGAACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAG GACACAAAGAACACCCCTGACCTTGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG GTGTACATCTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAG CCGGCAAGCAAAAGGCCATCTGGTGTCTCTGGCCAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG GGGTGCTCTGTGAGGACTACTTCTCAAGCTCTGAGCTCTGAGCTCTGAGCTCTGAGCTCTGAGCTCTGAGCTCTGAGCTCTGAG CACACCTTTCAGCGGTGTCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG TGGGACCAAGAACCTGACCTTGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG AGTAGGGCCCTCCCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCC CCAGAGAACCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCC GAGGGCAGTCAATTGGTAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG AACAGCAGACCTTACAGGGCTGGCCAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT AAGGGTCCACAGAACGGCTGGCCAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG CAAGTGTGACCTTCCTCCCTAGCAGGAGAGTGAACAGAACCTAGTGAACAGAACCTAGTGAACAGAACCTAGTGAACAGAAC TTCTACCCAGCAGAACATTGGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT GTGCTGACAGCTGGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT GTGTTAGCT CAGGTAGCTGACAGTGTGCCAGACTCTAGTGAACAGAACCTAGTGAACAGAACCTAGTGAACAGAACCTAGTGAACAGAAC GCTAGCCCTTACCCCTACCTGGAGTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG TCAATCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG AGCACACAGCCCTAACCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG ATGGGATTTGGGCAAGGGCACACCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG CCCTTGAGAGAACACAGAACCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT ACCGTGTCTGGCTCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT ACTCTCTGAGAACCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT	2 254	CAGGTGCAAGTGGCAGGAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GGCTAACACCTTAAAGCTGAGTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAG ATCAGACCCCTAAATGAACTAGGAACTAGGAACTAGGAACTAGGAACTAGGAACTAGGAACTAGGAACTAGGAACTAGGAACTAG TACGGCCCTGGATTTGGAACTTGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG GGCTTACACCTTCAACAAAGGCTGAGTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAG ATCAGAGAACAGAACCTAGGAACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAG GACACAAAGAACACCCCTGACCTTGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG GTGTACATCTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAGTGTACATCACTACAG CCGGCAAGCAAAAGGCCATCTGGTGTCTCTGGCCAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG GGGTGCTCTGTGAGGACTACTTCTCAAGCTCTGAGCTCTGAGCTCTGAGCTCTGAGCTCTGAGCTCTGAGCTCTGAGCTCTGAG CACACCTTTCAGCGGTGTCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG TGGGACCAAGAACCTGACCTTGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG AGTAGGGCCCTCCCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCC CCAGAGAACCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCCCTCTGGCC GAGGGCAGTCAATTGGTAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG AACAGCAGACCTTACAGGGCTGGCCAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT AAGGGTCCACAGAACGGCTGGCCAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG CAAGTGTGACCTTCCTCCCTAGCAGGAGAGTGAACAGAACCTAGTGAACAGAACCTAGTGAACAGAACCTAGTGAACAGAAC TTCTACCCAGCAGAACATTGGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT GTGCTGACAGCTGGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT GTGTTAGCT CAGGTAGCTGACAGTGTGCCAGACTCTAGTGAACAGAACCTAGTGAACAGAACCTAGTGAACAGAACCTAGTGAACAGAAC GCTAGCCCTTACCCCTACCTGGAGTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG TCAATCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG AGCACACAGCCCTAACCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG ATGGGATTTGGGCAAGGGCACACCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG CCCTTGAGAGAACACAGAACCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT ACCGTGTCTGGCTCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT ACTCTCTGAGAACCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCT	3 255			

TABLE 6-continued
Immunoprecipitation binding protein polymerside reactivities

TABLE 6-continued

TABLE 6-continued

TABLE 6-continued

TABLE 6-continued

TABLE 6-continued

Trispecific binding protein polynucleotide sequences				
Polyptide Number (acc. to formula)	SEQ ID NO	Sequence	Molecule	
2	270	AGAGGGCAACGGUAGGAAAGGCTGACCAGGAGAACGGCTCACCTAAGCCTGAGGAGAACCCG ACACTGAGCAAGGGGAGTACAGGAGGACAAGGTAGCCCTCGAAGTGAACCAACAGGCTGTCTAGCCCC GTGACCAAGGACTTAAACGGGGCAAGTGT CAGGTGCACTGGTCAGTGTGCCCGAGGTCTGGAACCTGCGCTCTGGTGCAGGGCTGACAGTGCGAGC GGCTACACCTTCAACAGTTCAACAGTCAATACATGCACTGGGAGAACGGCTGAGGAGAACGGCTGAGC ATCTACCCCGCAAGTGTGACACCCACTAGGCAAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGC ATCAGACCGCTTAATGGAACITGAAGTGAAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGC TACGCCCTGCAATTGGAACTTCAACGGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGC CAGGTCAGTGGTGAATTTGGGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGC GGCTTACCTTCAACGGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGC ATCAGAGCAZAGGAACTACCCACTAATGCACTGGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGC GACACAAAGGAGAACCCCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGC GTGTACTATGCCCTTAAGCCCTGGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGC CCGCAGACAAAGGCCATCGENGTCCCTCGGCCCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGC GGGTCCTGTGAGGAGACTTTCAGGCTGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTG CACACCTTTCAGCGGTGCTCCAGGCTGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTG TGGGACZAGACATTAACCTGTAACCTGTAACCTGTAACCTGTAACCTGTAACCTGTAACCTGTAACCTGTA AGTAGGGCCCTCCCTGCTCCCTCCAGGCTGGGAGACCTGGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG CCZAGAGACACCTTAATGATAGCAGGGACCCGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG GAGGTGCACTGCAATTGGPAGCTGGAGGCTGGAGGCTGAGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGC AACAGCACCTACAGGGCTGGCTGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTG AAGGGTCCZACAGGGCTGGCTGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTG CAAGGTGTAACCTCCCCTAGCAGGGAG TTCTACCCZAGCAGGAACTGGGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG GTGZGAGCAGGGAGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTG AACAGCACCTACAGGGCTGGCTGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTG AAGGGTCCZACAGGGCTGGCTGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTG CAAGGTGTAACCTCCCCTAGCAGGGAG GTGZGAGCAGGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTG GTGZGAGCAGGGCTGGCTGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG GCACACCCGAGCAACCTGGAACTGGGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG GCACACCCGAGCAACCTGGAACTGGGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG ACGGTATATGGCAGGGAACTGGGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTG CCCTTGAGGAGAACACAGGGAACTGGGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG ACGGTGTCTCTGGAATTCGGGCTGAGTGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTG ACTCTGTGAGCAGCTGCGAGCTGCGAGCTGGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG AGCCAGACACCAAGGGTGAAGGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG AAGGTGCGCCGGGAACTGGGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTG AGTGAACCTGGGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG GCTGAGACAGGACTGCTGAACGGAAAGAGTAZAGTGAAGGGTCAACAGGGTCAACAGGGTCAACAGGGTCAACAGGGTCAACAGGGTCAACAGGG GAAAACATAGCAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCA GACCAAGAACGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCA AAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCA AGTGAACCTGGGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG GCTGAGACAGGACTGCTGAACGGAAAGAGTAZAGTGAAGGGTCAACAGGGTCAACAGGGTCAACAGGGTCAACAGGGTCAACAGGGTCAACAGGG GAAAACATAGCAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCA GACATAGCAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCA AAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCA AACCCACTACCCZAGGAAAGGGCTGGCTGAGTGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGGCTGAGGAGAACGG GACATAGCAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCA AGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCAAGGGCA 		
3	271			
4				

TABLE 6-continued

TABLE 6 - continued
Trispecific binding protein polynucleotide sequences


Molecule	Polyptide Number (acc. to formula)	SEQ ID NO	Sequence
3	275		CAGGTTTCACTGGTTTCAAGTCTGGCGCGAAGTGAAGAAACCTGGGCCCTGTGAAGGTTCTCTGCAAGGCCAGC GGCTAAAGCTTACCAATTAGGCCTGCAAGGTCATGGCTTCAAGCCATAGCCATAGCCCATAGCCAGAAGTGAAGTGGCTG ATCAGGCCCTACTAGGGCTTACATGGACTAGGAACTGAGACTGAGAAGCTGAGAAGGCGAGAAGCTGAGAACCTGGCAAGAGC GAGGAACTGGCTTCAACTAAGCACTGGACTACAGCACTGGACTACCTGGCCAGGGCACCCCTGGCTTAAAGCTCTGCTGAGAAGATC CATGGGTTTCAACTAAGCACTGGACTACAGCACTGGACTACCTGGCCAGGGCACCCCTGGCTTAAAGCTCTGCTGAGAAGATC CATGGCTGTTCTGGCCCTTGCCGCTTGAAGCAAGGAAAGCAACCACTGAACTGGCTCTGAGAAGCTGGCTGAGAAGCTGGCTG CTACTTTCCGAGCCGGTGGACCGTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTG CTCCAGAGACGGCCGGCTGTAATCTCTGAGAAGCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTG ACCTGTAACCTGGGACCAAGGCCCAGCAAGGCTTCAAGGCTTCAAGGCTTCAAGGCTTCAAGGCTTCAAGGCTTCAAGGCTTCAAGG CTTCCCTTGCCCAAGGCCCTGTGAGCTGGGGGAGACCTTCCCTGGCTTCTGTTCTGTTCTGTTCTGTTCTGTTCTGTTCTGTTCTG TGATCAGCCGGACCCGGAACTGACTGAGCTGGCTGTTGGCTGTTGGCTGTTGGCTGTTGGCTGTTGGCTGTTGGCTGTTGGCTG GGTAACCTGGAGGGCTGGGAAGTGCACAAAGGCCAAAGCAACCCAGGCCAGAGGAAAGTGTAAAGCTAACGACCTAACCG GTGGCTGTCCTGGCTGTAACCTGGCTGACCTGGCTGACCTGGCTGACCTGGCTGACCTGGCTGACCTGGCTGACCTGGCTGAC GGCTTCCACCTCCATGGCAAGGAAACCATACTGAGAAGCTGGCAAGGCCAGGGCTGCAAGCTTCAAGGCTTCAAGGCTTCAAGG CCCCCTTGCAAGGAAAGAAGCACTGAGAAGCTGGCAAGGCCAGGGCTGCAAGCTTCAAGGCTTCAAGGCTTCAAGGCTTCAAGG TTGCCTGGATGGGAGAGAGAGGAAAGGCAAGGCCAGGGCTGCAAGCTTCAAGGCTTCAAGGCTTCAAGGCTTCAAGGCTTCAAGG GCTCATTTCTCTTFACTCTAACGCTGTAAGCTGGCAAGGCTGCAAGCTGGCAAGGCTGCAAGGCTGCAAGCTGGCAAGGCTG GATGCAAGCAAGCCCTTCACACCACTAACACCACTAACACCACTAACACCACTAACACCACTAACACCACTAACACCACTAACAC GACCGTCTGATCAACAGACCCCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT GCCAGAGGCCCTGTGCAAGGAAACGCTACTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGC TGTCTGATCTAACGGTGTCAAAGCGGTTCAAGCGGTTCAAGCGGTTCAAGCGGTTCAAGCGGTTCAAGCGGTTCAAGCGGTTCA CACCCCTGAAATTAGGAGAGCTGGAAAGCTGGCAAGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT GACCTTGGCGGGAAACAAGTGGAAAGTAAAGCTGGCAAGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG GAGGAGCAGCTGAAGTGGCAACGCCCTGCAAGGCAAGGCCACTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG AGTGGAAAGGGAGCAACGCCCTGCAAGGCAAGGCCACTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG ACCTAAGCTGGCAAGGCCACTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG ACCCACAGGGCCCTGTCTAGCCCTGACCTAACAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG
4	276		

III. Trispecific and/or Trivalent Binding Proteins for Treating and/or Preventing HIV/AIDS

[0459] Certain aspects of the present disclosure relate to trispecific and/or trivalent binding proteins. Any of the CDRs or variable domains of any of the antigen binding proteins described herein may find use in a trispecific binding protein of the present disclosure. Trispecific binding proteins of various formats are contemplated. In some embodiments, the binding protein of the disclosure is a trispecific and/or trivalent binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

V_{L1} is a first immunoglobulin light chain variable domain; V_{L2} is a second immunoglobulin light chain variable domain;

V_{L3} is a third immunoglobulin light chain variable domain; V_{H1} is a first immunoglobulin heavy chain variable domain; V_{H2} is a second immunoglobulin heavy chain variable domain;

V_{H3} is a third immunoglobulin heavy chain variable domain; C_L is an immunoglobulin light chain constant domain;

C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

L_1 , L_2 , L_3 and L_4 are amino acid linkers;

and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

[0460] In some embodiments, the first polypeptide chain and the second polypeptide chain have a cross-over orientation that forms two distinct antigen binding sites. In some embodiments, the V_{H1} and V_{L1} form a binding pair and form the first antigen binding site. In some embodiments, the V_{H2} and V_{L2} form a binding pair and form the second antigen binding site. In some embodiments, the third polypeptide and the fourth polypeptide form a third antigen binding site. In some embodiments, the V_{H3} and V_{L3} form a binding pair and form the third antigen binding site.

[0461] In some embodiments, the term "HIV" as used herein means Human Immunodeficiency Virus. As used herein, the term "HIV infection" generally encompasses infection of a host, particularly a human host, by the human

immunodeficiency virus (HIV) family of retroviruses including, but not limited to, HIV I, HIV II, HIV III (also known as HTLV-II, LAV-1, LAV-2). HIV can be used herein to refer to any strains, forms, subtypes, clades and variations in the HIV family. Thus, treating HIV infection will encompass the treatment of a person who is a carrier of any of the HIV family of retroviruses or a person who is diagnosed with active AIDS, as well as the treatment or prophylaxis of the AIDS-related conditions in such persons.

[0462] In some embodiments, the term "AIDS" as used herein means Acquired Immunodeficiency Syndrome. AIDS is caused by HIV.

[0463] In some embodiments, the terms "CD4bs" or "CD4 binding site" refer to the binding site for CD4 (cluster of differentiation 4), which is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells.

[0464] In some embodiments, the term "glycoprotein 160" or "gp160 protein" refers to the envelope glycoprotein complex of HIV and which is a homotrimer that is cleaved into gp120 and gp41 subunits.

[0465] In some embodiments, the term "MPER" refers to the membrane-proximal external region of glycoprotein 41 (gp41), which is a subunit of the envelope protein complex of retroviruses, including HIV.

[0466] In some embodiments, the term "glycan" refers to the carbohydrate portion of a glycoconjugate, such as a glycoprotein, glycolipid, or a proteoglycan. In the disclosed binding proteins, glycan refers to the HIV-1 envelope glycoprotein gp120.

[0467] In some embodiments, e.g., as used in reference to a binding protein for treating and/or preventing HIV/AIDS, the term "T-cell engager" refers to binding proteins directed to a host's immune system, more specifically the T cells' cytotoxic activity as well as directed to a HIV target protein.

[0468] In some embodiments, the term "trimer apex" refers to apex of HIV-1 envelope glycoprotein gp120.

[0469] In some embodiments, a "neutralizing" binding protein as used herein refers to a molecule that is able to block or substantially reduce an effector function of a target antigen to which it binds. As used herein, "substantially reduce" means at least about 60%, preferably at least about 70%, more preferably at least about 75%, even more preferably at least about 80%, still more preferably at least about 85%, most preferably at least about 90% reduction of an effector function of the target antigen.

[0470] In some embodiments, e.g., as used in reference to a binding protein for treating and/or preventing HIV/AIDS, the terms "treatment" or "treat" as used herein refer to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those having the disorder as well as those prone to have a disorder or those in which the disorder is to be prevented. In particular embodiments, binding proteins can be used to treat humans infected with HIV, or humans susceptible to HIV infection, or ameliorate HIV infection in a human subject infected with HIV. The binding proteins can also be used to prevent HIV in a human patient.

[0471] It should be understood as that treating humans infected with HIV include those subjects who are at any one of the several stages of HIV infection progression, which, for example, include acute primary infection syndrome (which can be asymptomatic or associated with an influenza-like illness with fevers, malaise, diarrhea and neuro-

logic symptoms such as headache), asymptomatic infection (which is the long latent period with a gradual decline in the number of circulating CD4⁺T cells), and AIDS (which is defined by more serious AIDS-defining illnesses and/or a decline in the circulating CD4 cell count to below a level that is compatible with effective immune function). In addition, treating or preventing HIV infection will also encompass treating suspected infection by HIV after suspected past exposure to HIV by e.g., contact with HIV-contaminated blood, blood transfusion, exchange of body fluids, "unsafe" sex with an infected person, accidental needle stick, receiving a tattoo or acupuncture with contaminated instruments, or transmission of the virus from a mother to a baby during pregnancy, delivery or shortly thereafter.

[0472] In some embodiments, one or more of the antigen binding sites binds an HIV target protein. In some embodiments, V_{H3}; and V_{L3} form a third antigen binding site that binds an HIV target protein. In some embodiments, V_{H1} and V_{L1} form a first antigen binding site that binds a T cell target protein, V_{H2} and V_{L2} form a second antigen binding site that binds a T cell target protein, and V_{H3} and V_{L3} form a third antigen binding site that binds an HIV target protein. In some embodiments, V_{H1} and V_{L1} form a first antigen binding site that binds a T cell target protein, V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, and V_{H3} and V_{L3} form a third antigen binding site that binds an HIV target protein. In some embodiments, V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide, V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, and V_{H3} and V_{L3} form a third antigen binding site that binds an HIV target protein.

[0473] In some embodiments, the binding proteins specifically bind to one or more HIV target proteins (e.g., as described infra) and one or more target proteins on a T-cell including T cell receptor complex. These T-cell engager binding proteins are capable of recruiting T cells transiently to target cells and, at the same time, activating the cytolytic activity of the T cells. The T-cell engager trispecific antibodies can be used to activate HIV-1 reservoirs and redirect/activate T cells to lyse latently infected HIV-1⁺ T cells. Examples of target proteins on T cells include but are not limited to CD3 and CD28, among others. In some embodiments, the trispecific binding proteins may be generated by combining the antigen binding domains of two or more monospecific antibodies (parent antibodies) into one antibody. See International Publication Nos. WO 2011/038290 A2, WO 2013/086533 A1, WO 2013/070776 A1, WO 2012/154312 A1, and WO 2013/163427 A1. The binding proteins of the disclosure may be prepared using domains or sequences obtained or derived from any human or non-human antibody, including, for example, human, murine, or humanized antibodies.

[0474] In some embodiments of the disclosure, the trivalent binding protein is capable of binding three different antigen targets. In one embodiment, the binding protein is trispecific and one light chain-heavy chain pair is capable of binding two different antigen targets or epitopes and one light chain-heavy chain pair is capable of binding one antigen target or epitope.

[0475] In some embodiments, a binding protein of the present disclosure binds one or more HIV target proteins and one or more T cell target proteins. In some embodiments, the binding protein is capable of specifically binding one HIV

target protein and two different epitopes on a single T cell target protein. In some embodiments, the binding protein is capable of specifically binding one HIV target protein and two different T cell target proteins (e.g., CD28 and CD3). In some embodiments, the first and second polypeptide chains of the binding protein form two antigen binding sites that specifically target two T cell target proteins, and the third and fourth polypeptide chains of the binding protein form an antigen binding site that specifically binds an HIV target protein. In some embodiments, the one or more HIV target proteins are one or more of glycoprotein 120, glycoprotein 41, and glycoprotein 160. In some embodiments, the one or more T cell target proteins are one or more of CD3 and CD28.

[0476] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:362 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:362; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:363 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:363; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:364 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:364; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:365 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:365.

[0477] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:366 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:366; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:367 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:367; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:368 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:368; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:369 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:369.

[0478] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:370 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:370; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:371 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:371; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:372 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:372; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:373 or an

second polypeptide chain comprises the amino acid sequence of SEQ ID NO:467 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:467; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:468 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:468; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:469 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:469.

[0502] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:470 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:470; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:471 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:471; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:472 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:472; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:473 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:473.

[0503] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:474 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:474; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:475 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:475; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:476 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:476; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:477 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:477.

[0504] Exemplary and non-limiting polypeptides that may find use in any of the trispecific binding proteins described herein are provided in Table 4A.

Anti-HIV Binding Sites

[0505] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds an HIV target protein or polypeptide.

[0506] In some embodiments, the HIV target protein is glycoprotein 120, glycoprotein 41, or glycoprotein 160. In some embodiments, a binding protein binds one or more of: glycoprotein 120, glycoprotein 41, and glycoprotein 160. Exemplary HIV target proteins include, without limitation, MPER of the HIV-1 gp41 protein, a CD4 binding site of the HIV-1 gp120 protein, a glycan in the V3 loop of the HIV-1 gp120 protein, or a trimer apex of the HIV-1 gp120 protein or gp160. For example, in some embodiments, a binding protein of the present disclosure comprises an antigen binding site that binds a CD4 binding site of the HIV-1 gp120 protein. Exemplary antigen binding sites that bind HIV

target proteins contemplated for use herein include, without limitation, those described in International Publication No. WO2017/074878, such as those from antibodies CD4BS "a", CD4BS "b", MPER, MPER_100W, V1/V2 "a", V1/V2 "b", or V3.

[0507] In some embodiments, a binding protein comprising an antigen binding site that binds an HIV target protein is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds an HIV target protein is a trispecific binding protein comprising four polypeptides that form three antigen binding sites.

[0508] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of NCPIN (SEQ ID NO:302) a CDR-H2 sequence comprising the amino acid sequence of WMKPRHGAVSYARQLQG (SEQ ID NO:303), and a CDR-H3 sequence comprising the amino acid sequence of GKYCTARDYYNWDFEH (SEQ ID NO:304); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of RTSQYGSLA (SEQ ID NO:305), a CDR-L2 sequence comprising the amino acid sequence of SGSTRAA (SEQ ID NO:306), and a CDR-L3 sequence comprising the amino acid sequence of QQYEF (SEQ ID NO:307). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of NCPIN (SEQ ID NO:302) a CDR-H2 sequence comprising the amino acid sequence of WMKPRHGAVSYARQLQG (SEQ ID NO:303), and a CDR-H3 sequence comprising the amino acid sequence of GKYCTARDYYNWDFEH (SEQ ID NO:304); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of RTSQYGSLA (SEQ ID NO:305), a CDR-L2 sequence comprising the amino acid sequence of SGSTRAA (SEQ ID NO:306), and a CDR-L3 sequence comprising the amino acid sequence of QQYEF (SEQ ID NO:307).

[0509] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTTAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAV (SEQ ID NO:309) or IKPQYGAT (SEQ ID NO:310); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTTAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAV (SEQ ID NO:309) or IKPQYGAT (SEQ ID NO:310); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid

sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTF-TAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAV (SEQ ID NO:309); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTF-TAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAV (SEQ ID NO:309); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTF-TAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAT (SEQ ID NO:310); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTF-TAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAT (SEQ ID NO:310); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314).

[0510] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of DCTLN (SEQ ID NO:315) a CDR-H2 sequence comprising the amino acid sequence of WLKPRWGAVN-YARPLQG (SEQ ID NO:316), and a CDR-H3 sequence comprising the amino acid sequence of GKNCDYNWD-FEH (SEQ ID NO:317); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of RTSQYGS LA (SEQ ID NO:318), a CDR-L2 sequence comprising the amino acid

sequence of SGSTRAA (SEQ ID NO:319), and a CDR-L3 sequence comprising the amino acid sequence of QQYEF (SEQ ID NO:320). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of DCTLN (SEQ ID NO:315) a CDR-H2 sequence comprising the amino acid sequence of WLKPRWGAVN-YARPLQG (SEQ ID NO:316), and a CDR-H3 sequence comprising the amino acid sequence of GKNCDYNWD-FEH (SEQ ID NO:317); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of RTSQYGS LA (SEQ ID NO:318), a CDR-L2 sequence comprising the amino acid sequence of SGSTRAA (SEQ ID NO:319), and a CDR-L3 sequence comprising the amino acid sequence of QQYEF (SEQ ID NO:320).

[0511] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site with a VH domain comprising an extended heavy chain FR3 loop of antibody VRC03, e.g., as described in Liu, Q. et al. (2019) *Nat. Commun.* 10:721.

[0512] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVRLSQSGGQMKPGDSMRISCRASGYE-FINCPINWIRLAPGKRPEWMGWMKPRHG AVSYAR-QLQGRVTMTRDMYSETAFLERSLTSDDTAVYFC-TRGKYCTARDYYNWD FEHWGQGTPTVSS (SEQ ID NO:344), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

SLTQS PGTLSSLSPGETAIIS-CRTSQYGS LA WYQQRPGQAPRLVIYSGSTRAA-GIPDRFS GSRWGPDPDYNLTISNL ESGDFGVYYCQQY-EFFGQGTKVQVDIK (SEQ ID NO:346). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:344, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:346. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:344, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:346.

[0513] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVRLSQSGGQMKKPGDSMRISCRASGYE-FINCPINWIRLAPGKRPEWMGWMKPRHG AVSYAR-QLQGRVTMTRQLSQDPDDPDWGTAFLERSLTSDD-TAVYFCTRKYCTA RDYYNWDFEHWGQGTPVTVSS (SEQ ID NO:345), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SLTQSPGTLSSLSPGETAIIS-CRTSQYGSLAWYQQRPQAPRLVYSGSTRAA-GIPDRFS GSRWGPDPYNLTISLESGDFGVYYCQQY-EFFFGQGTKVQVDIK (SEQ ID NO:346). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:345, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:346. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:345, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:346.

[0514] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of RAHLVQSGTAMKKPGASVRVSCQTSGYTFATHIL-FWFRQAPGRGLEWVGWIKPQY GAVNFGGG-FRDRVTLTRDVYREIAYMDIRGLKPDDTAVYY-CARDRSYGDSSWALD AWGQGTTVVVSA (SEQ ID NO:347), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of YIHVTQSPSSLSVSIGDRVTI NCQTSQGVGSDLHWYQHKPGRAPKLLIHTSS-VEDGV PSRFSGSGFHTSFNLTDLQADDI-ATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:347, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:347, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350.

[0515] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at

least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of RAHLVQSGTAMKKPGASVRVSCQTSGYTFATHIL-FWFRQAPGRGLEWVGWIKPQY GATNFGGG-FRDRVTLTRDVYREIAYMDIRGLKPDDTAVYY-CARDRSYGDSSWALD AWGQGTTVVVSA (SEQ ID NO:348), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of YIHVTQSPSSLSVSIGDRVTI NCQTSQGVGSDLHWYQHKPGRAPKLLIHTSSVEDGV PSRFSGSGFHTSFNLTDLQADDI-ATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:348, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:348, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350.

[0516] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of RAHLVQSGTAMKKPGASVRVSCQTSGYTFATHIL-FWFRQAPGRGLEWVGWIKPQY GAVNFGGG-FRDRVTLTRQLSQDPDDPDWGIAYMDIRGLKPDDTAVYYCARDRSYGC DSSWALDAWGQGTTVVVSA (SEQ ID NO:349), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of YIHVTQSPSSLSVSIGDRVTI NCQTSQGVGSDLHWYQHKPGRAPKLLIHTSSVEDGV PSRFSGSGFHTSFNLTDLQADDI-ATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:349, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:349, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350.

[0517] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVQSGGQMKPGESMRISCRASGYE-FIDCTLNWIRLAPGKRPEWMGWLKPRW GAVNYAR-PLQGRVTMTRQLSQDPDDPDWGTAFELRLSLTVDD-TAVYFCTRGKNCD YNWDFEHWGRGTPVIVSS (SEQ ID NO:351), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of LTQSPGTLSSLSPGETAIIS-CRTSQYGSLAWYQQRPGQAPRLVYSGSTRAA-GIPDRFSG SRWGPDPYNTLNLESQDFGVYYCQQY-EFFGQGTVQVDIK (SEQ ID NO:352). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:351, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:352. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:351, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:352.

[0518] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds an HIV target protein, an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD38 antigen binding sites described above represent V_{H3} and V_{L3} and form a third antigen binding site that binds an HIV target protein. In some embodiments, V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide, V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, and the VH and VL domains of any of the anti-HIV antigen binding sites described above and/or in Table 1A represent V_{H3} and V_{L3} and form a third antigen binding site that binds an HIV target protein.

[0519] Sequences of exemplary anti-HIV antigen binding sites are provided in Table 1A. In some embodiments, a binding protein comprising an anti-HIV antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-HIV antibody described in Table 1A. In some embodiments, a binding protein comprising an anti-HIV antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-HIV antibody described in Table 1A.

TABLE 1A

Anti-HIV binding protein sequences.					
Type	Sequence	Molecule	Description	SEQ ID NO	Sequence
CDR	VRC07_523	(anti-Env gp120 CD4bs)	CDR-H1	302	NCPIN
	(anti-Env gp120 CD4bs)		CDR-H2	303	WMKPRHGAVSYARQLQG
			CDR-H3	304	GKYCTARDYYNWDFEH
			CDR-L1	305	RTSQYGSLA
			CDR-L2	306	SGSTRAA
			CDR-L3	307	QQYEF
	N6		CDR-H1	308	GYTFTAH
	(anti-Env gp120 CD4bs)		CDR-H2	309	IKPQYGAV
			Original CDR-H2 rw52	310	IKPQYGAT
			CDR-H3	311	DRSYGDSSWALDA
VRC01.23			CDR-L1	312	QGVGSD
			CDR-L2	313	HTS
			CDR-L3	314	CQVLQF
			CDR-H1	315	DCTLN
			CDR-H2	316	WLKPRWGAVNYARPLQG
			CDR-H3	317	GKNCDYNWDFEH
			CDR-L1	318	RTSQYGSLA
			CDR-L2	319	SGSTRAA
			CDR-L3	320	QQYEF
	Variable domain	VRC07_523	VH	344	QVRLSQSGGQMKPGDSMRISCRASG YEFINCPIWIRLAPGKRPEWMGW KPRHGAVSYARQLQGRVTMTRDMYS ETAFELRLSLSLTSDDTAVYFCTRGKYC TARDYYNWDFEHWGQGTPVTVSS
FR3-03		VH		345	QVRLSQSGGQMKPGDSMRISCRASG YEFINCPIWIRLAPGKRPEWMGW KPRHGAVSYARQLQGRVTMTRQLSQ DPDDPDWGTAFELRLSLSLTSDDTAVYF CTRGKYCTARDYYNWDFEHWGQG PTVSS

TABLE 1A-continued

Anti-HIV binding protein sequences.			
Sequence Type	Molecule	Description	SEQ ID NO Sequence
	VL	346	SLTQSPGTLSLSPGETAIISCRTSQYGS LA ^W YQQRPGQAPRLVIYSGSTRAGI PDRFSGSRWGP ^D YNLTISNLESQDFG VYCQOYEFFGGG ^G TKVQVVDIK
N6	VH	347	RAHLVQSGTAMKKPGASVRVSCQTS GYTF ^T AHILFWFRQAPGRGLEWVGWI KPQYGAVNF ^G GGFRDRVT ^L TRDVYR EIAYMDIRGLKPD ^D TA ^V YYCARDRSY GDSSWALDAWGQGTTVVVA
	rw52 VH	348	RAHLVQSGTAMKKPGASVRVSCQTS GYTF ^T AHILFWFRQAPGRGLEWVGWI KPQYGATNF ^G GGFRDRVT ^L TRDVYR EIAYMDIRGLKPD ^D TA ^V YYCARDRSY GDSSWALDAWGQGTTVVVA
	FR3-03 VH	349	RAHLVQSGTAMKKPGASVRVSCQTS GYTF ^T AHILFWFRQAPGRGLEWVGWI KPQYGAVNF ^G GGFRDRVT ^L TRQLSQ DPDPPDWGIAYMDIRGLKPD ^D TA ^V Y YCARDRSYGDSSWALDAWGQGTTVVVA
	VL	350	YIHVTQSPS ^S LSVSIGDRV ^T INCQTSQG VGSDLHWYQHKPGRAPKLLIHH ^T SS EDGVPSRFSGSGFHTSFNLITSDLQAD DIATYYCQVLQFFGRGSRLHIK
VRC01.23	VH	351	QVQLVQSGGQM ^K KPGESMR ^I SCRAS GYEFIDCTLNWIRLAPGKRPEWMGW LKPRWGAVNYARPLQGRVTMTRQLS QDPDDPDWGTAFLELRSLTVDDTAV YFC ^T RGKNC ^D YNWDFEHWGRGTPVI VSS
	VL	352	LTQSPGTLSLSPGETAIISCRTSQYGS ^L AWYQQRPGQAPRLVIYSGSTRAGI ^P DRFSGSRWGP ^D YNLTISNLESQDFG ^V YYCQOYEFFGG ^G TKVQVVDIK

Anti-CD28 Binding Sites

[0520] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a CD28 polypeptide. In some embodiments, the CD28 polypeptide is a human CD28 polypeptide, also known as Tp44. Human CD28 polypeptides are known in the art and include, without limitation, the polypeptides represented by NCBI Accession Numbers XP_011510499.1, XP_011510497.1, XP_011510496.1, NP_001230007.1, NP_001230006.1, or NP_006130.1, or a polypeptide produced from NCBI Gene ID Number 940. In some embodiments, a binding protein comprising an antigen binding site that binds a CD28 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD28 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD28 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, and one of which binds a CD3 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD28 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, and one of which binds a CD3 polypeptide.

tide, one of which binds a CD3 polypeptide, and one of which binds an HIV target protein.

[0521] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYY (SEQ ID NO:332), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:333), and a CDR-H3 sequence comprising the amino acid sequence of TRSHY-GLDWNFDV (SEQ ID NO:334); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:335), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:336), and a CDR-L3 sequence comprising the amino acid sequence of QQGQ-TYPY (SEQ ID NO:337). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYY (SEQ ID NO:332), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:333), and a CDR-H3 sequence comprising the amino acid sequence of TRSHY-GLDWNFDV (SEQ ID NO:334); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:335), a CDR-L2 sequence comprising the amino acid

sequence of KAS (SEQ ID NO:336), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTYPY (SEQ ID NO:337).

[0522] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVQSGAEVVVKPGASVKVSCKASGYTFT-
SYYIHWVRQAPGQGLEWIGSIYPGVN
NTNYAQKFQGRATLTVDTSISTAYMELSRLRSDD-
TAVYYCTRSHYGLDWNFDVWG KGTTVTSS (SEQ ID NO:360), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLASAVGDRVTITCQASQ
NIYVWLWYQQKPGKAPKLLIYKASNLHTG
VPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQGQTY-
PYTFGQGTKLEIK (SEQ ID NO:361). In some embodiments, a binding protein of the present disclosure comprises

some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD28 antigen binding sites described above represent V_{H1} and V_{L1} and form a first antigen binding site that binds a CD28 polypeptide. In some embodiments, the VH and VL domains of any of the anti-CD28 antigen binding sites described above represent V_{H1} and V_{L1} and form a first antigen binding site that binds a CD28 polypeptide, V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, and V_{H3} and V_{L3} and form a third antigen binding site that binds an HIV target protein.

[0524] Sequences of exemplary anti-CD28 antigen binding sites are provided in Table 2. In some embodiments, a binding protein comprising an anti-CD28 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-CD28 antibody described in Table 2A. In some embodiments, a binding protein comprising an anti-CD28 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-CD28 antibody described in Table 2A.

TABLE 2A

Anti-CD28 binding protein sequences.				
Sequence Type	Molecule	Description	SEQ ID NO	Sequence
CDR	Anti-CD28 (sup)	CDR-H1	332	GYTFTSYY
		CDR-H2	333	IYPGNVNT
		CDR-H3	334	TRSHYGLDWNFDV
		CDR-L1	335	QNIYVW
		CDR-L2	336	KAS
		CDR-L3	337	QQGQTYPY
Variable Domain	Anti-CD28 (sup)	VH	360	QVQLVQSGAEVVVKPGASVKVSCKAS GYTFTSYYIHWVRQAPGQGLEWIGSI YPGNVNTNYAQKFQGRATLTVDTSIS TAYMELSRLRSDDTAVYYCTRSHY LDWNFDWKGKTTVTSS
		VL	361	DIQMTQSPSSLASAVGDRVTITCQASQ NIYVWLWYQQKPGKAPKLLIYKAS NLHTGVPSRFSGSGSGTDFTLTISSLQ EDIATYYCQQGQTYTFGQGTKLEI K

an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:360, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:361. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:360, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:361.

[0523] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds an HIV target protein, an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In

Anti-CD3 Binding Sites

[0525] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a CD3 polypeptide. In some embodiments, the CD3 polypeptide is a human CD3 polypeptide, including CD3-delta (also known as T3D, IMD19, and CD3-DELTA), CD3-epsilon (also known as T3E, IMD18, and TCRE), and CD3-gamma (also known as T3G, IMD17, and CD3-GAMMA). Human CD3 polypeptides are known in the art and include, without limitation, the polypeptides represented by NCBI Accession Numbers XP_006510029.1 or NP_031674.1, or a polypeptide produced from NCBI Gene ID Numbers 915, 916, or 917. In some embodiments, a binding protein comprising an antigen binding site that binds a CD3 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or

multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, and one of which binds a CD3 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds an HIV target protein.

[0526] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSN-SYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVH₁NX₂X₃TY, wherein X₁ is E or Q, X₂ is A or L, and X₃ is Q, R, or F (SEQ ID NO:594), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, the CDR-L1 sequence of the V_{L2} domain comprises an amino acid sequence selected from the group consisting of QSLVHQNAQTY (SEQ ID NO:325), QSLVHENLQTY (SEQ ID NO:326), QSLVHENLFTY (SEQ ID NO:327), and QSLVHENLRTY (SEQ ID NO:328).

[0527] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSN-SYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHQNAQTY (SEQ ID NO:325), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHQNAQTY (SEQ ID NO:325), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331).

NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331).

[0528] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSN-SYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLQTY (SEQ ID NO:326), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLQTY (SEQ ID NO:326), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331).

[0529] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSN-SYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLFTY (SEQ ID NO:327), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLFTY (SEQ ID NO:327), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331).

[0530] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid

sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSN-SYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLRTY (SEQ ID NO:328), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLRTY (SEQ ID NO:328), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331).

[0531] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSNYATYYADSVKGRFTISRDDSNTLYLQMNSLRAE-DTAVYYCRGVYYALSPFDY WGQGTLTVSS (SEQ ID NO:353), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to an amino acid sequence selected from the group consisting of DIVMTQTPLSLSVTPGQPASICKSSQLVHQNAQ-TYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQQGTQYPFTFGSGTKVEIK (SEQ ID NO:355), DIVMTQTPLSLSVTPGQPASICKSSQLVHQNAQ-TYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQQGTQYPFTFGSGTKVEIK (SEQ ID NO:356), DIVMTQTPLSLSVTPGQPASICKSSQLVHENLFTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQQGTQYPFTFGSGTKVEIK (SEQ ID NO:357), and DIVMTQTPLSLSVTPGQPASICKSSQLVHENLFTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQQGTQYPFTFGSGTKVEIK (SEQ ID NO:358). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353,

and/or an antibody light chain variable (VL) domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, and SEQ ID NO:358. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and an antibody light chain variable (VL) domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, and SEQ ID NO:358.

[0532] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSNYATYYADSVKGRFTISRDDSNTLYLQMNSLRAE-DTAVYYCRGVYYALSPFDY WGQGTLTVSS (SEQ ID NO:353), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTPGQPASICKSSQLVHQNAQ-TYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQQGTQYPFTFGSGTKVEIK (SEQ ID NO:355). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:355. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:355.

[0533] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLS-CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKNSNYATYYADSVKGRFTISRDDSNTLYLQMNSLRAE-DTAVYYCRGVYYALSPFDY WGQGTLTVSS (SEQ ID NO:353), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTPGQPASICKSSQLVHENLFTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQQGTQYPFTFGSGTKVEIK (SEQ ID NO:358).

TYLSWYLQKPGQSPQSLIYKVSN
RFSGVPDRFSGSGSGTDFTLKISRVEAE-
DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:356). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:356. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:356.

[0534] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLS-
CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKS
NSYATYYADSVKGRFTISRDDSNTLYLQMNSLRAE-
DTAVYYCRGVYYALSPFDY WGQGTLTVSS (SEQ ID NO:353), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTGQPASICKSSQSLVHENLF-TYLSWYLQKPGQSPQSLIYKVSNR

FSGVPDRFSGSGSGTDFTLKISRVEAE-
DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:357). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:357. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:357.

[0535] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLS-

CAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKS
NSYATYYADSVKGRFTISRDDSNTLYLQMNSLRAE-
DTAVYYCRGVYYALSPFDY WGQGTLTVSS (SEQ ID NO:353), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTGQPASICKSSQSLVHENLF-TYLSWYLQKPGQSPQSLIYKVSN
RFSGVPDRFSGSGSGTDFTLKISRVEAE-
DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:358). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:358. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:358.

[0536] Advantageously, anti-CD3 binding sites are described herein with high affinity binding to human CD3 polypeptides and potential manufacturing liabilities (e.g., deamidation sites) removed.

[0537] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds an HIV target protein, an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD3 antigen binding sites described above represent V_{H2} and V_{L2} and form a second antigen binding site that binds a CD3 polypeptide. In some embodiments, V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide, the VH and VL domains of any of the anti-CD3 antigen binding sites described above and/or in Table 3 represent V_{H2} and V_{L2} and form a second antigen binding site that binds a CD3 polypeptide, and V_{H3} and V_{L3} form a third antigen binding site that binds an HIV target protein.

[0538] Sequences of exemplary anti-CD3 antigen binding sites are provided in Table 3. In some embodiments, a binding protein comprising an anti-CD3 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-CD3 antibody described in Table 3A. In some embodiments, a binding protein comprising an anti-CD3 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-CD3 antibody described in Table 3A.

TABLE 3A

Anti-CD3 binding protein sequences.				
Sequence Type	Molecule	Description	SEQ ID NO	Sequence
CDR	Anti-CD3 (mid)	CDR-H1 original	321	GFTFTKAW
		CDR-H2 original	322	IKDKSNSYAT
		CDR-H3 original	323	RGVYYALSPFDY
		CDR-L1 original	324	QSLVHNNANTY
		CDR-L1 QQ	325	QSLVHQNAQTY
		CDR-L1 ENLQ	326	QSLVHENLQTY
		CDR-L1 ENLF	327	QSLVHENLFTY
		CDR-L1 ENLR	328	QSLVHENLRTY
		CDR-L1 DNAQ	329	QSLVHDNAQTY
		CDR-L2 original	330	KVS
		CDR-L3 Original	331	GQGTQYPFT
		consensus	594	QSLVHX ₁ NX ₂ X ₃ TY, wherein X ₁ is E or Q, X ₂ is A or L, and X ₃ is Q, R, or F
		CDR-L1		
Variable domain	Anti-CD3 (mid)	VH	353	QVQLVESGGVVQPGRSRLSCAASG FTFTKAWMHWVRQAPGKQLEWVAQ IKDKSNSYATYYADSVKGKRFTISRDSS KNTLYLQMNSLRAEDTAVYYCGRGVY YALSPFDYWQGGTLVTVSS
		VL Original	354	DIVMTQTPLSLSVTPGQPASICKSSQS LVHNNNANTYLSWYLQKPGQSPQSLIY KVSNRFSGVPDFRFSGSMSGTDFTLKIS RVEAEDVGVYYCGQGTQYPFTFGSG TKVEIK
		VL 32/35 QQ	355	DIVMTQTPLSLSVTPGQPASICKSSQS LVHQNAQTYLSWYLQKPGQSPQSLIY KVSNRFSGVPDFRFSGSMSGTDFTLKIS RVEAEDVGVYYCGQGTQYPFTFGSG TKVEIK
		VL ENLQ	356	DIVMTQTPLSLSVTPGQPASICKSSQS LVHENLQTYLSWYLQKPGQSPQSLIY KVSNRFSGVPDFRFSGSMSGTDFTLKIS RVEAEDVGVYYCGQGTQYPFTFGSG TKVEIK
		VL ENLF	357	DIVMTQTPLSLSVTPGQPASICKSSQS LVHENLFTYLSWYLQKPGQSPQSLIY KVSNRFSGVPDFRFSGSMSGTDFTLKIS RVEAEDVGVYYCGQGTQYPFTFGSG TKVEIK
		VL ENLR	358	DIVMTQTPLSLSVTPGQPASICKSSQS LVHENLRTYLSWYLQKPGQSPQSLIY KVSNRFSGVPDFRFSGSMSGTDFTLKIS RVEAEDVGVYYCGQGTQYPFTFGSG TKVEIK
		VL DNAQ	359	DIVMTQTPLSLSVTPGQPASICKSSQS LVHDNAQTYLSWYLQKPGQSPQSLIY KVSNRFSGVPDFRFSGSMSGTDFTLKIS RVEAEDVGVYYCGQGTQYPFTFGSG TKVEIK

Linkers

[0539] In some embodiments, the linkers L₁, L₂, L₃, and L₄ range from no amino acids (length=0) to about 100 amino acids long, or less than 100, 50, 40, 30, 20, or 15 amino acids or less. The linkers can also be 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acids long. L₁, L₂, L₃, and L₄ in one binding protein may all have the same amino acid sequence or may all have different amino acid sequences.

[0540] Examples of suitable linkers include, for example, GGGGSGGGGS (SEQ ID NO:341), GGGGSGGGSGGGGS (SEQ ID NO: 342). S, RT,

TKGPS (SEQ ID NO: 340), GQPKAAP (SEQ ID NO: 339), GGSGSSGG (SEQ ID NO: 343), and DKTHT (SEQ ID NO:338), as well as those disclosed in International Publication Nos. WO2017/074878 and WO2017/180913. The examples listed above are not intended to limit the scope of the disclosure in any way, and linkers comprising randomly selected amino acids selected from the group consisting of valine, leucine, isoleucine, serine, threonine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, glycine, and proline have been shown to be suitable in the binding proteins.

[0541] The identity and sequence of amino acid residues in the linker may vary depending on the type of secondary structural element necessary to achieve in the linker. For example, glycine, serine, and alanine are best for linkers having maximum flexibility. Some combination of glycine, proline, threonine, and serine are useful if a more rigid and extended linker is necessary. Any amino acid residue may be considered as a linker in combination with other amino acid residues to construct larger peptide linkers as necessary depending on the desired properties.

[0542] In some embodiments, the length of L₁ is at least twice the length of L₃. In some embodiments, the length of L₂ is at least twice the length of L₄. In some embodiments, the length of L₁ is at least twice the length of L₃, and the length of L₂ is at least twice the length of L₄. In some embodiments, L₁ is 3 to 12 amino acid residues in length, L₂ is 3 to 14 amino acid residues in length, L₃ is 1 to 8 amino acid residues in length, and L₄ is 1 to 3 amino acid residues in length. In some embodiments, L₁ is 5 to 10 amino acid residues in length, L₂ is 5 to 8 amino acid residues in length, L₃ is 1 to 5 amino acid residues in length, and L₄ is 1 to 2 amino acid residues in length. In some embodiments, L₁ is 7 amino acid residues in length, L₂ is 5 amino acid residues in length, L₃ is 1 amino acid residue in length, and L₄ is 2 amino acid residues in length.

[0543] In some embodiments, L₁, L₂, L₃ and L₄ each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:341), GGGGSGGGGSGGGGS (SEQ ID NO: 342), S, RT, TKGPS (SEQ ID NO: 340), GQPKAAP (SEQ ID NO: 339), and GGSGSSGS (SEQ ID NO: 42). In some embodiments, L₁, L₂, L₃ and L₄ each independently comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:341), GGGGSGGGGSGGGGS (SEQ ID NO:342), S, RT, TKGPS (SEQ ID NO:340), GQPKAAP (SEQ ID NO: 339), and GGSGSSGS (SEQ ID NO:343). In some embodiments, L₁ comprises the sequence GQPKAAP (SEQ ID NO: 339), L₂ comprises the sequence TKGPS (SEQ ID NO:340), L₃ comprises the sequence S, and L₄ comprises the sequence RT.

[0544] In some embodiments, at least one of L₁, L₂, L₃ or L₄ comprises the sequence DKTHT (SEQ ID NO:338). In some embodiments, L₁, L₂, L₃ and L₄ comprise the sequence DKTHT (SEQ ID NO:338).

Fc Regions and Constant Domains

[0545] In some embodiments, a binding protein of the present disclosure comprises a second polypeptide chain further comprising an Fc region linked to C_{H1}, the Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains. In some embodiments, a binding protein of the present disclosure comprises a third polypeptide chain further comprising an Fc region linked to C_{H1}, the Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains. In some embodiments, a binding protein of the present disclosure comprises a second polypeptide chain further comprising an Fc region linked to C_{H1}, the Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising an Fc region linked to C_{H1}, the Fc region

comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains.

[0546] In some embodiments, a binding protein of the present disclosure comprises a full-length antibody heavy chain or a polypeptide chain comprising an Fc region. In some embodiments, the Fc region is a human Fc region, e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region. In some embodiments, the Fc region includes an antibody hinge, C_{H1}, C_{H2}, C_{H3}, and optionally C_{H4} domains. In some embodiments, the Fc region is a human IgG1 Fc region. In some embodiments, the Fc region is a human IgG4 Fc region. In some embodiments, the Fc region includes one or more of the mutations described infra. In some embodiments, the Fc region is an Fc region of one of the heavy chain polypeptides (e.g., polypeptide 2 or 3) of a binding protein shown in Table 4. In some embodiments, the heavy chain constant region is a constant region of one of the heavy chain polypeptides (e.g., polypeptide 2 or 3) of a binding protein shown in Table 4. In some embodiments, the light chain constant region is a constant region of one of the light chain polypeptides (e.g., polypeptide 1 or 4) of a binding protein shown in Table 4A.

[0547] In some embodiments, a binding protein of the present disclosure includes one or two Fc variants. The term “Fc variant” as used herein refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage receptor, FcRn (neonatal Fc receptor). Exemplary Fc variants, and their interaction with the salvage receptor, are known in the art. Thus, the term “Fc variant” can comprise a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises regions that can be removed because they provide structural features or biological activity that are not required for the antibody-like binding proteins of the invention. Thus, the term “Fc variant” comprises a molecule or sequence that lacks one or more native Fc sites or residues, or in which one or more Fc sites or residues has been modified, that affect or are involved in: (1) disulfide bond formation, (2) incompatibility with a selected host cell, (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC).

[0548] In some embodiments, a binding protein of the present disclosure (e.g., a trispecific binding protein) comprises a “knob” mutation on the second polypeptide chain and a “hole” mutation on the third polypeptide chain. In some embodiments, a binding protein of the present disclosure comprises a “knob” mutation on the third polypeptide chain and a “hole” mutation on the second polypeptide chain. In some embodiments, the “knob” mutation comprises substitution(s) at positions corresponding to positions 354 and/or 366 of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S354C, T366W, T366Y, S354C and T366W, or S354C and T366Y. In some embodiments, the “knob” mutation comprises substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S354C and T366W. In some embodiments, the “hole” mutation comprises substitution(s) at positions corresponding to positions 407 and, optionally, 349, 366, and/or 368 and of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are Y407V or

Y407T and optionally Y349C, T366S, and/or L368A. In some embodiments, the “hole” mutation comprises substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

[0549] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution(s) at positions corresponding to positions 366 and optionally 354 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366W or T366Y and optionally S354C; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution(s) at positions corresponding to positions 407 and optionally 349, 366, and/or 368 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y407V or Y407T and optionally Y349C, T366S, and/or L368A.

[0550] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution(s) at positions corresponding to positions 407 and optionally 349, 366, and/or 368 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y407V or Y407T and optionally Y349C, T366S, and/or L368A; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution(s) at positions corresponding to positions 366 and optionally 354 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366W or T366Y and optionally S354C.

[0551] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution at position corresponding to position 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitution is T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution(s) at positions corresponding to positions 366, 368, and/or 407 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366S, L368A, and/or Y407V.

[0552] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution(s) at positions corresponding to positions 366,

368, and/or 407 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366S, L368A, and/or Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution at position corresponding to position 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitution is T366W.

[0553] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the first and/or second Fc regions are human IgG1 Fc regions. In some embodiments, the first and/or second Fc regions are human IgG4 Fc regions.

[0554] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, S354C, T366W, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, Y349C, T366S, L368A,

Y407V, and R409K. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, Y349C, T366S, L368A, Y407V, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, S354C, T366W, and R409K.

[0555] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 354, and 366 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, S354C, and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 349, 366, 368, and 407 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 349, 366, 368, and 407 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 354, and 366 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, S354C, and T366W.

[0556] In some embodiments, a binding protein of the present disclosure comprises one or more mutations to reduce effector function, e.g., Fc receptor-mediated antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and/or antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_{H1}, the first Fc region

comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; wherein the third polypeptide chain further comprises a second Fc region linked to C_{H1}, the second Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG1 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A and L235A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG1 Fc regions, and wherein the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A and L235A. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_{H1}, the first Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; wherein the third polypeptide chain further comprises a second Fc region linked to C_{H1}, the second Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG1 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG1 Fc regions, and wherein the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG4 Fc regions, and the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A. In some embodiments, the binding protein comprises a second polypeptide chain further comprising a first Fc region linked to C_{H1}, the first Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising a second Fc region linked to C_{H1}, the second Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A.

[0557] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A,

L235A, S354C, T366W, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, Y349C, T366S, L368A, Y407V, and R409K. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, Y349C, T366S, L368A, Y407V, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, S354C, T366W, and R409K.

[0558] In some embodiments, the Fc region is a human IgG4 Fc region comprising one or more mutations that reduce or eliminate Fc γ I and/or Fc γ II binding. In some embodiments, the Fc region is a human IgG4 Fc region comprising one or more mutations that reduce or eliminate Fc γ I and/or Fc γ II binding but do not affect FcRn binding. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 228 and/or 409 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S228P and/or R409K. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 234 and/or 235 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are F234A and/or L235A. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 228, 234, 235, and/or 409 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S228P, F234A, L235A, and/or R409K. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid mutations at substitutions corresponding to positions 228, 233-236, and/or 409 of human IgG4 according to EU Index. In some embodiments, the amino acid mutations are S228P; E233P, F234V, L235A, and a deletion at 236; and/or R409K.

[0559] In some embodiments, the Fc region comprises one or more mutations that reduce or eliminate Fc receptor

binding and/or effector function of the Fc region (e.g., Fc receptor-mediated antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and/or antibody-dependent cellular cytotoxicity (ADCC)).

[0560] In some embodiments, the Fc region is a human IgG1 Fc region comprising one or more amino acid substitutions at positions corresponding to positions 234, 235, and/or 329 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are L234A, L235A, and/or P329A. In some embodiments, the Fc region is a human IgG1 Fc region comprising amino acid substitutions at positions corresponding to positions 298, 299, and/or 300 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are S298N, T299A, and/or Y300S.

[0561] In some embodiments, a binding protein of the present disclosure comprises one or more mutations to improve stability, e.g., of the hinge region and/or dimer interface of IgG4 (See e.g., Spiess, C. et al. (2013) J. Biol. Chem. 288:26583-26593). In some embodiments, the mutation comprises substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, the binding protein comprises a second polypeptide chain further comprising a first Fc region linked to C_{H1}, the first Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising a second Fc region linked to C_{H1}, the second Fc region comprising an immunoglobulin hinge region and C_{H2} and C_{H3} immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG4 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, a binding protein of the present disclosure comprises knob and hole mutations and one or more mutations to improve stability. In some embodiments, the first and/or second Fc regions are human IgG4 Fc regions.

[0562] In some embodiments, the Fc region is a human IgG1 Fc region comprising one or more amino acid substitutions at positions corresponding to positions 234, 235, and/or 329 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are L234A, L235A, and/or P329A. In some embodiments, the Fc region is a human IgG1 Fc region comprising amino acid substitutions at positions corresponding to positions 298, 299, and/or 300 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are S298N, T299A, and/or Y300S.

Nucleic Acids

[0563] Other aspects of the present disclosure relate to isolated nucleic acid molecules comprising a nucleotide sequence encoding any of the binding proteins described herein. Exemplary and non-limiting nucleic acid sequences are provided in Table 5A.

[0564] Other aspects of the present disclosure relate to kits of polynucleotides, e.g., that encode one or more polypeptides of a binding protein as described herein. In some embodiments, a kit of polynucleotides of the present disclosure comprises one, two, three, or four polynucleotides of

a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:563, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:564, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:565; (w) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:566, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:567, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:568, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:569; (x) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:570, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:571, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:572, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:573; (y) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:574, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:575, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:576, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:577; (z) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:578, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:579, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:580, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:581; (aa) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:582, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:583, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:584, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:585; (bb) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:586, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:587, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:588, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:589; or (cc) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:590, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:591, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:592, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:593.

[0565] Other aspects of the present disclosure relate to a vector system comprising one or more vectors encoding a first, second, third, and fourth polypeptide chain of any of the binding proteins described herein. In some embodiments, the vector system comprises a first vector encoding the first polypeptide chain of the binding protein, a second vector encoding the second polypeptide chain of the binding protein, a third vector encoding the third polypeptide chain of the binding protein, and a fourth vector encoding the fourth polypeptide chain of the binding protein, e.g., as shown in the polynucleotides of Table 5. In some embodiments, the vector system comprises a first vector encoding the first and second polypeptide chains of the binding protein, and a second vector encoding the third and fourth polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and third polypeptide chains of the binding protein,

and a second vector encoding the second and fourth polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and fourth polypeptide chains of the binding protein, and a second vector encoding the second and third polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first, second, third, and fourth polypeptide chains of the binding protein. The one or more vectors of the vector system may be any of the vectors described herein. In some embodiments, the one or more vectors are expression vectors. In some embodiments, the first, second, third, and fourth polynucleotides are present on one or more expression vectors, e.g., one, two, three, or four expression vectors.

[0566] Standard recombinant DNA methodologies are used to construct the polynucleotides that encode the polypeptides which form the binding proteins, incorporate these polynucleotides into recombinant expression vectors, and introduce such vectors into host cells. See e.g., Sambrook et al., 2001, MOLECULAR CLONING: A LABORATORY MANUAL (Cold Spring Harbor Laboratory Press, 3rd ed.). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications, as commonly accomplished in the art, or as described herein. Unless specific definitions are provided, the nomenclature utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Similarly, conventional techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, delivery, and treatment of patients.

[0567] In some embodiments, the isolated nucleic acid is operably linked to a heterologous promoter to direct transcription of the binding protein-coding nucleic acid sequence. A promoter may refer to nucleic acid control sequences which direct transcription of a nucleic acid. A first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence of a binding protein if the promoter affects the transcription or expression of the coding sequence. Examples of promoters may include, but are not limited to, promoters obtained from the genomes of viruses (such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus, Simian Virus 40 (SV40), and the like), from heterologous eukaryotic promoters (such as the actin promoter, an immunoglobulin promoter, from heat-shock promoters, and the like), the CAG-promoter (Niwa et al., Gene 108(2):193-9, 1991), the phosphoglycerate kinase (PGK)-promoter, a tetracycline-inducible promoter (Masui et al., Nucleic Acids Res. 33:e43, 2005), the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, and the promoter of the yeast alpha-mating factors. Polynucleotides encoding binding proteins of the present disclosure may be under the control of a constitutive promoter, an inducible promoter, or any other suitable promoter described herein or other suitable promoter that will be readily recognized by one skilled in the art.

[0568] In some embodiments, the isolated nucleic acid is incorporated into a vector. In some embodiments, the vector is an expression vector. Expression vectors may include one or more regulatory sequences operatively linked to the polynucleotide to be expressed. The term “regulatory sequence” includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Examples of suitable enhancers may include, but are not limited to, enhancer sequences from mammalian genes (such as globin, elastase, albumin, α -fetoprotein, insulin and the like), and enhancer sequences from a eukaryotic cell virus (such as SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, adenovirus enhancers, and the like). Examples of suitable vectors may include, for example, plasmids, cosmids, episomes, transposons, and viral vectors (e.g., adenoviral, vaccinia viral, Sindbis-viral, measles, herpes viral, lentiviral, retroviral, adeno-associated viral vectors, etc.). Expression vectors can be used to transfect host cells, such as, for example, bacterial cells, yeast cells, insect cells, and mammalian cells. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art, and can be used to transfet any cell of interest.

Host Cells

[0569] Other aspects of the present disclosure relate to a host cell (e.g., an isolated host cell) comprising one or more isolated polynucleotides, vectors, and/or vector systems described herein. In some embodiments, an isolated host cell of the present disclosure is cultured in vitro. In some embodiments, the host cell is a bacterial cell (e.g., an *E. coli* cell). In some embodiments, the host cell is a yeast cell (e.g., an *S. cerevisiae* cell). In some embodiments, the host cell is an insect cell. Examples of insect host cells may include, for example, *Drosophila* cells (e.g., S2 cells), *Trichophisia ni* cells (e.g., High Five™ cells), and *Spodoptera frugiperda* cells (e.g., Sf21 or Sf9 cells). In some embodiments, the host cell is a mammalian cell. Examples of mammalian host cells may include, for example, human embryonic kidney cells (e.g., 293 or 293 cells subcloned for growth in suspension culture), Expi293™ cells, CHO cells, baby hamster kidney cells (e.g., BHK, ATCC CCL 10), mouse sertoli cells (e.g., TM4 cells), monkey kidney cells (e.g., CV1 ATCC CCL 70), African green monkey kidney cells (e.g., VERO-76, ATCC CRL-1587), human cervical carcinoma cells (e.g., HELA, ATCC CCL 2), canine kidney cells (e.g., MDCK, ATCC CCL 34), buffalo rat liver cells (e.g., BRL 3A, ATCC CRL 1442), human lung cells (e.g., W138, ATCC CCL 75), human liver cells (e.g., Hep G2, HB 8065), mouse mammary tumor cells (e.g., MMT 060562, ATCC CCL51), TRI cells. MRC 5 cells, FS4 cells, a human hepatoma line (e.g., Hep G2), and myeloma cells (e.g., NS0 and Sp2/0 cells).

[0570] Other aspects of the present disclosure relate to a method of producing any of the binding proteins described herein. In some embodiments, the method includes a) culturing a host cell (e.g., any of the host cells described herein) comprising an isolated nucleic acid, vector, and/or vector system (e.g., any of the isolated nucleic acids, vectors, and/or vector systems described herein) under conditions such that the host cell expresses the binding protein; and b) isolating the binding protein from the host cell. Methods of culturing host cells under conditions to express a protein are

well known to one of ordinary skill in the art. Methods of isolating proteins from cultured host cells are well known to one of ordinary skill in the art, including, for example, by affinity chromatography (e.g., two step affinity chromatography comprising protein A affinity chromatography followed by size exclusion chromatography).

Pharmaceutical Compositions for Treating and/or Preventing HIV/AIDS

[0571] Therapeutic or pharmaceutical compositions comprising binding proteins are within the scope of the disclosure. Such therapeutic or pharmaceutical compositions can comprise a therapeutically effective amount of a binding protein, or binding protein-drug conjugate, in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration.

[0572] Acceptable formulation materials are nontoxic to recipients at the dosages and concentrations employed.

[0573] The pharmaceutical composition can contain formulation materials for modifying, maintaining, or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption, or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine, or lysine), antimicrobials, antioxidants (such as ascorbic acid, sodium sulfite, or sodium hydrogen-sulfite), buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates, or other organic acids), bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose, or dextrins), proteins (such as serum albumin, gelatin, or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents, hydrophilic polymers (such as polyvinylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfactants or wetting agents (such as pluronics; PEG; sorbitan esters; polysorbates such as polysorbate 20 or polysorbate 80; triton; tromethamine; lecithin; cholesterol or tyloxapal), stability enhancing agents (such as sucrose or sorbitol), tonicity enhancing agents (such as alkali metal halides—e.g., sodium or potassium chloride—or mannitol sorbitol), delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES (18th Ed., A. R. Gennaro, ed., Mack Publishing Company 1990), and subsequent editions of the same, incorporated herein by reference for any purpose).

[0574] The optimal pharmaceutical composition will be determined by a skilled artisan depending upon, for example, the intended route of administration, delivery format, and desired dosage. Such compositions can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the binding protein.

[0575] The primary vehicle or carrier in a pharmaceutical composition can be either aqueous or non-aqueous in nature.

For example, a suitable vehicle or carrier for injection can be water, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include sorbitol or a suitable substitute. In one embodiment of the disclosure, binding protein compositions can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents in the form of a lyophilized cake or an aqueous solution. Further, the binding protein can be formulated as a lyophilizate using appropriate excipients such as sucrose.

[0576] The pharmaceutical compositions of the disclosure can be selected for parenteral delivery or subcutaneous. Alternatively, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.

[0577] The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.

[0578] When parenteral administration is contemplated, the therapeutic compositions for use can be in the form of a pyrogen-free, parenterally acceptable, aqueous solution comprising the desired binding protein in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which a binding protein is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid), beads, or liposomes, that provides for the controlled or sustained release of the product which can then be delivered via a depot injection. Hyaluronic acid can also be used, and this can have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

[0579] In one embodiment, a pharmaceutical composition can be formulated for inhalation. For example, a binding protein can be formulated as a dry powder for inhalation. Binding protein inhalation solutions can also be formulated with a propellant for aerosol delivery. In yet another embodiment, solutions can be nebulized.

[0580] It is also contemplated that certain formulations can be administered orally. In one embodiment of the disclosure, binding proteins that are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract where bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the binding protein. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders can also be employed.

[0581] Another pharmaceutical composition can involve an effective quantity of binding proteins in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

[0582] Additional pharmaceutical compositions of the disclosure will be evident to those skilled in the art, including formulations involving binding proteins in sustained- or controlled-delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices can include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and gamma ethyl-L-glutamate, poly(2-hydroxyethyl-methacrylate), ethylene vinyl acetate, or poly-D(-)-3-hydroxybutyric acid. Sustained-release compositions can also include liposomes, which can be prepared by any of several methods known in the art.

[0583] Pharmaceutical compositions to be used for in vivo administration typically must be sterile. This can be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method can be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration can be stored in lyophilized form or in a solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[0584] Once the pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder. Such formulations can be stored either in a ready-to-use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.

[0585] The disclosure also encompasses kits for producing a single-dose administration unit. The kits can each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this disclosure are kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lyosyringes).

[0586] The effective amount of a binding protein pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the binding protein is being used, the route of administration, and the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician can titrate the dosage and modify the route of administration to obtain the optimal therapeutic effect.

[0587] Dosing frequency will depend upon the pharmacokinetic parameters of the binding protein in the formulation being used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition can therefore be administered as a single dose, as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages can be ascertained through use of appropriate dose-response data.

[0588] The route of administration of the pharmaceutical composition is in accord with known methods, e.g., orally; through injection by intravenous, intraperitoneal, intracerebral (intraparenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal, or intralesional routes; by sustained release systems; or by implantation devices. Where desired, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device.

[0589] The composition can also be administered locally via implantation of a membrane, sponge, or other appropriate material onto which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed-release bolus, or continuous administration.

[0590] The pharmaceutical compositions can be used to prevent and/or treat HIV infection. The pharmaceutical compositions can be used as a standalone therapy or in combination with standard anti-retroviral therapy.

[0591] The disclosure also relates to a kit comprising a binding protein and other reagents useful for detecting target antigen levels in biological samples. Such reagents can include a detectable label, blocking serum, positive and negative control samples, and detection reagents. In some embodiments, the kit comprises a composition comprising any binding protein, polynucleotide, vector, vector system, and/or host cell described herein. In some embodiments, the kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing a condition (e.g., HIV infection) and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). In some embodiments, the label or package insert indicates that the composition is used for preventing, diagnosing, and/or treating the condition of choice. Alternatively, or additionally, the article of manufacture or kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer,

such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Methods and Uses for Binding Proteins in Treating and/or Preventing HIV/AIDS

[0592] Certain aspects of the present disclosure relate to methods of preventing HIV infection in a patient, treating HIV infection in a patient, preventing AIDS in a patient, and treating AIDS in a patient, using any of the binding proteins or pharmaceutical compositions disclosed herein. Any of the binding proteins or pharmaceutical compositions disclosed herein may find use in a method of the present disclosure, e.g., methods for preventing HIV infection in a patient, treating HIV infection in a patient, preventing AIDS in a patient, and treating AIDS in a patient.

[0593] FIG. 19 illustrates an exemplary and non-limiting format for a trispecific binding protein that may be employed in the methods and uses described herein. As shown in FIG. 20, a proposed mechanism by which the binding protein shown in FIG. 19 may result in elimination of the HIV reservoir cells in a patient involves: (1) activation of latently infected CD4+ T cells via the anti-CD28 and anti-CD3 arms of the trispecific binding protein; (2) recruitment of CD8+ T cells to activated, latently infected CD4+ T cells via anti-Env and anti-CD3 arms; (3) activation of engaged CD8+ T cells via the anti-CD28 and anti-CD3 arms; and (4) killing of latently infected CD4+ T cells through a Perforin/Granzyme mechanism. Advantageously, this mechanism is thought to activate and subsequently kill HIV-1 reservoir cells, providing a novel strategy for attacking the HIV-1 reservoir in a patient.

[0594] In some embodiments, the methods of the present disclosure comprise administering to the patient a therapeutically effective amount of at least one of the binding proteins or pharmaceutical compositions described herein.

[0595] In some embodiments, the at least one binding protein is administered in combination with an anti-retroviral therapy (e.g., an anti-HIV therapy). In some embodiments, the at least one binding protein is administered before the anti-retroviral therapy. In some embodiments, the at least one binding protein is administered concurrently with the anti-retroviral therapy. In some embodiments, the at least one binding protein is administered after the anti-retroviral therapy. In some embodiments, the at least one binding protein is co-administered with any standard anti-retroviral therapy known in the art.

[0596] In some embodiments, administration of the at least one binding protein or pharmaceutical composition results in elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, administration of the at least one binding protein results in neutralization of one or more HIV virions and results in elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, the patient is a human.

TABLE 4A

Trispecific binding protein polypeptide sequences.								
Polyptide Number	SEQ ID NO	Sequence						
Trispecific 1 VRC07_523/ CD2sup x CD3mid IgG1 LALA/P329A	1 362	DIVMTOTPLSISVTCPQASLSCKSSQSLHMNNTYIWKPGQSPSOLITYKVSNBRSFGVDRFSGSGSGTDFTLKISR APKLITYKASNLHTGPSPRSIGSGSTDFLTISLQPEIATYQCGQGTYPFGQCTKLEIKTKGRSRTYAAPSFTIFPPS DEQLKSGTASVCLNNPYREAKWQKVNALQSGNSQESVTEQSKDSTSLSLSTLISKADYEKHKVACEVTHQG LSSPVTKSFRGEC	YMLSLRSRSDTAVTYCTRHYGLDNFDWGKGHTTVTSSQVLESGGGVQPGRLRLSCAASGFTFKAWMH WVROAQPKOLEWAQIKDKNSNATYYADSVKGRETI SRDSDKNTLYLQMNISLRAEDTAVYCYRGVYTALSPPDYWG QGTLVTVSSRTPASTTGPSVPLAPSSKTTGGTAALGLCLVMDYFEPVTVSWNSGALTQGKTFPAVLOSGLYSLSSVVT VPSSSIGTQTYICNTHKPNTIKVKVEKSCDKTHCPCPAPEAACGPSPVLEFPKPKDTLMISRTPEVTCVVVDVSH EDPEVFNPWYDGVEVHNAATKPREQYNTSYRUVSVLTLHQDWLNGKEYKCKVSNKALAAPTEKITISKAGQPREP QVCLTPSPRDELTKNOVISCAVKGKFPSIDAVENESNGPENNYKTTIPVLDSDGSFLVLSKLTVDKSRWQGNVFCSC VMHEALHNHTQSKLSLSPG	QVRLSOSGGMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGMKPRHGAYSYAROGRYTMTRDYMSET AFLELRSLTSDDTAVYFCTRGKCYKTPARDYNWDEERWGOOTPVTVSSASTKGPEVPLAPS SKTSGTAAALGLCLVQDF PEPVITWSNMGALTSCGVHTPAVLOQSSGlyLSSVTVTPSSLGTOYTICNVNHPKSNTKVDKVKVEPKSCDKHTCPCPA PEAAGGSPVFLPPCPKDITMISRPEVTCVVVDVSHEDDEVKFWYDGEVHNAATKPREQYNTSYRUVSVLTLVH ODWLNGKEYKCKVSNKALAAPTEKITISKAKGQPREPQTYLPPCDELTINQSLWCLVKGPFYSDIAWEENGOPEN NYKTIPVLSLDSGSPFLYSLSTVDPDSRWOOGNVSCTVMEALHNHYTOSLSPG	SLTQSBRGTLISLSPGETAISCTSQYGSLLMWQEPGQARPLVYGSSTRAGIPDRFSGSRWPEDYNTLISNLESQDFGVYY COQYERFGQGTKVQDICKTAAPEAEVIFPSDEOLKSGASVCLNNPYREAKVQKVNALQSGNSQESVTEQDSK DSTYLSLSLTLISKADYEKHKVAAEVTRGSLSPVTKSFRGEC	DIVMTOTPLSISVTCPQASLSCKSSQSLHMNNTYIWKPGQSPSOLITYKVSNBRSFGVDRFSGSGSGTDFTLKISR VEAEDGYVTCGQGTOYPFVFSKTKVEIYGKPAIDPDMTOEPSSLSASVSDRVTITCQASONIYMLNWFOOKPGK APKLITYKASNLHTGPSPRSIGSGSTDFLTISLQPEIATYQCGQGTYPFGQCTKLEIKTKGRSRTYAAPSFTIFPPS DEQLKSGTASVCLNNPYREAKWQKVNALQSGNSQESVTEQSKDSTSLSLSTLISKADYEKHKVACEVTHQG LSSPVTKSFRGEC	QYOLYOSGAEVVKPGASVKVSKASGYTFSYIWKPGQSPSOLITYKVSNBRSFGVDRFSGSGSGTDFTLKISR YMLSLRSRSDTAVTYCTRHYGLDNFDWGKGHTTVTSSQVLESGGGVQPGRLRLSCAASGFTFKAWMH WVROAQPKOLEWAQIKDKNSNATYYADSVKGRETI SRDSDKNTLYLQMNISLRAEDTAVYCYRGVYTALSPPDYWG QGTLVTVSSRTPASTTGPSVPLAPSSKTTGGTAALGLCLVMDYFEPVTVSWNSGALTQGKTFPAVLOSGLYSLSSVVT VPSSSIGTQTYICNTHKPNTIKVKVEKSCDKTHCPCPAPEAACGPSPVLEFPKPKDTLMISRTPEVTCVVVDVSH DEEVRENWYDGVEVHNAATKPREQYNTSYRUVSVLTLHQDWLNGKEYKCKVSNKALAAPTEKITISKAGQPREPQ VCTLPSPRDELTKNOVISCAVKGKFPSIDAVENESNGPENNYKTTIPVLDSDGSFFLVSKLTVDKSRWQGNVFCSC VMHEALHNHTQSKLSLSPG	QVRLSOSGGMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGMKPRHGAYSYAROGRYTMTRDYMSET AFLELRSLTSDDTAVYFCTRGKCYKTPARDYNWDEERWGOOTPVTVSSASTKGPSKTFPLAPS SKTSGTAAALGLCLVQDF PEPVITWSNMGALTSCGVHTPAVLOQSSGlyLSSVTVTPSSLGTOYTICNVNHPKSNTKVDKVKVEPKSCDKHTCPCPA PELGGSPVFLPPCPKDITMISRPEVTCVVVDVSHEDDEVKFWYDGEVHNAATKPREQYNTSYRUVSVLTLVH DWLNGKEYKCKVSNKALAAPTEKITISKAKGQPREPQYUPTPCDELTINQSLWCLVKGPFYSDIAWEENGOPENNY KTPPPVLDSDGSFFLVSKLTVDKSRWQGNVFCSCVMHEALHNHTQSKLSLSPG
Trispecific 2 VRC07_523/ CD2sup x CD3mid IgG1 MMAS	1 366	DIVMTOTPLSISVTCPQASLSCKSSQSLHMNNTYIWKPGQSPSOLITYKVSNBRSFGVDRFSGSGSGTDFTLKISR VEAEDGYVTCGQGTOYPFVFSKTKVEIYGKPAIDPDMTOEPSSLSASVSDRVTITCQASONIYMLNWFOOKPGK APKLITYKASNLHTGPSPRSIGSGSTDFLTISLQPEIATYQCGQGTYPFGQCTKLEIKTKGRSRTYAAPSFTIFPPS DEQLKSGTASVCLNNPYREAKWQKVNALQSGNSQESVTEQSKDSTSLSLSTLISKADYEKHKVACEVTHQG LSSPVTKSFRGEC	YMLSLRSRSDTAVTYCTRHYGLDNFDWGKGHTTVTSSQVLESGGGVQPGRLRLSCAASGFTFKAWMH WVROAQPKOLEWAQIKDKNSNATYYADSVKGRETI SRDSDKNTLYLQMNISLRAEDTAVYCYRGVYTALSPPDYWG QGTLVTVSSRTPASTTGPSVPLAPSSKTTGGTAALGLCLVMDYFEPVTVSWNSGALTQGKTFPAVLOSGLYSLSSVVT VPSSSIGTQTYICNTHKPNTIKVKVEKSCDKTHCPCPAPEAACGPSPVLEFPKPKDTLMISRTPEVTCVVVDVSH DEEVRENWYDGVEVHNAATKPREQYNTSYRUVSVLTLHQDWLNGKEYKCKVSNKALAAPTEKITISKAGQPREPQ VCTLPSPRDELTKNOVISCAVKGKFPSIDAVENESNGPENNYKTTIPVLDSDGSFFLVSKLTVDKSRWQGNVFCSC VMHEALHNHTQSKLSLSPG	QVRLSOSGGMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGMKPRHGAYSYAROGRYTMTRDYMSET AFLELRSLTSDDTAVYFCTRGKCYKTPARDYNWDEERWGOOTPVTVSSASTKGPSKTFPLAPS SKTSGTAAALGLCLVQDF PEPVITWSNMGALTSCGVHTPAVLOQSSGlyLSSVTVTPSSLGTOYTICNVNHPKSNTKVDKVKVEPKSCDKHTCPCPA PELGGSPVFLPPCPKDITMISRPEVTCVVVDVSHEDDEVKFWYDGEVHNAATKPREQYNTSYRUVSVLTLVH DWLNGKEYKCKVSNKALAAPTEKITISKAKGQPREPQYUPTPCDELTINQSLWCLVKGPFYSDIAWEENGOPENNY KTPPPVLDSDGSFFLVSKLTVDKSRWQGNVFCSCVMHEALHNHTQSKLSLSPG				
2 367	2 368	DIVMTOTPLSISVTCPQASLSCKSSQSLHMNNTYIWKPGQSPSOLITYKVSNBRSFGVDRFSGSGSGTDFTLKISR VEAEDGYVTCGQGTOYPFVFSKTKVEIYGKPAIDPDMTOEPSSLSASVSDRVTITCQASONIYMLNWFOOKPGK APKLITYKASNLHTGPSPRSIGSGSTDFLTISLQPEIATYQCGQGTYPFGQCTKLEIKTKGRSRTYAAPSFTIFPPS DEQLKSGTASVCLNNPYREAKWQKVNALQSGNSQESVTEQSKDSTSLSLSTLISKADYEKHKVACEVTHQG LSSPVTKSFRGEC	YMLSLRSRSDTAVTYCTRHYGLDNFDWGKGHTTVTSSQVLESGGGVQPGRLRLSCAASGFTFKAWMH WVROAQPKOLEWAQIKDKNSNATYYADSVKGRETI SRDSDKNTLYLQMNISLRAEDTAVYCYRGVYTALSPPDYWG QGTLVTVSSRTPASTTGPSVPLAPSSKTTGGTAALGLCLVMDYFEPVTVSWNSGALTQGKTFPAVLOSGLYSLSSVVT VPSSSIGTQTYICNTHKPNTIKVKVEKSCDKTHCPCPAPEAACGPSPVLEFPKPKDTLMISRTPEVTCVVVDVSH DEEVRENWYDGVEVHNAATKPREQYNTSYRUVSVLTLHQDWLNGKEYKCKVSNKALAAPTEKITISKAGQPREPQ VCTLPSPRDELTKNOVISCAVKGKFPSIDAVENESNGPENNYKTTIPVLDSDGSFFLVSKLTVDKSRWQGNVFCSC VMHEALHNHTQSKLSLSPG	QVRLSOSGGMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGMKPRHGAYSYAROGRYTMTRDYMSET AFLELRSLTSDDTAVYFCTRGKCYKTPARDYNWDEERWGOOTPVTVSSASTKGPSKTFPLAPS SKTSGTAAALGLCLVQDF PEPVITWSNMGALTSCGVHTPAVLOQSSGlyLSSVTVTPSSLGTOYTICNVNHPKSNTKVDKVKVEPKSCDKHTCPCPA PELGGSPVFLPPCPKDITMISRPEVTCVVVDVSHEDDEVKFWYDGEVHNAATKPREQYNTSYRUVSVLTLVH DWLNGKEYKCKVSNKALAAPTEKITISKAKGQPREPQYUPTPCDELTINQSLWCLVKGPFYSDIAWEENGOPENNY KTPPPVLDSDGSFFLVSKLTVDKSRWQGNVFCSCVMHEALHNHTQSKLSLSPG				

TABLE 4A-continued
Trispecific binding protein polypeptide sequences.

Molecule	Polyptide Number (acc. to formula)	SEQ ID NO	Sequence
Trispecific 3 VRC07_523/ CD28sup_x CD3mid_QQ FALA_409K	4	369	SLTQSPGTLSLSPGETAILISORTSQYGSILAWYQPQQAIRLVYSGSTRAGIPDRFGSRNGPDYNTLISLESQDFGVYY CQYEFQGQTKVQDIDKRVVAAPSVFIFPSDEQLSKTNSVRGECA DSTYSLSLSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFRGECA
Trispecific 3 VRC07_523/ CD28sup_x CD3mid_QQ IgG4	1	370	DIVMTOTPLSLSVTPCQPAISCKSSQSLVHNANTYLSTYLOKPGQPOSILYKVSNRFSGYBDRFGSGSGTDFTLKISR VEADFGVYTCQGQTKYQPFPSGKTVKEIGQPKAPDQMTQSPSSLS2SVGDRTITCQASQNTIYWLWNTQQPKG APKLIIYKAMNLHTGVPSPRSQSGSGTDFLTISSLQPEIATYCCQGQTYPTFGQGTLEIKTKGPRTYAAPSFTFPPS DEQLKGSTKPSLTSVCLANNFYREAKYQKVNDAQGNSQSVTBDSDTYSLSLSSSTLISKADYEKHKVYACEVTHQG LSSPVTKSFRGECA
Trispecific 3 VRC07_523/ CD28sup_x CD3mid_QQ IgG4	2	371	YQQLVOSGAEVVKPGASVIKUSCKASGYTFISYYTHWROAQQGLEWIGSIYPGVNNTYAQKFQGRATLTVDTSISTA YMELSRLSLRSLDDTAIVYCTRSHYGLDWNEDWKGKGTIVTIVSSQYOLVSEGCVYTOPCERSLSCASGFTFKWMMH WVROAEGKQOLEWAQIKDKNSNSATYADVKGRRTI SRDSDSKNTLYLQNSNSLRAEDTAVYCYCQGVYTAALSPPYWQ OGTLYTVSSRTASTKGPSVPLAPCSRSTSEESTAAALGCLVKDYFPEPVTSWNGALISVGWHTPPAVLQSGLYSLSSVYT PSSSLGTTKTTICNDVHPKPSNTKVKDRVEYSGKPPDFTLQPSKDTLMSITKPSLSSVTKVPSLQKPSLSSVTKVPSLQKPSL PPSVTIVDGEVHNATKPKPEEQTNTYRVSUTLHQMLNGKEYKCVSNKGLPSSIEKTISKADYKHKVYACEVTHQG LNGKEYKCKVSNKGLPSSIEKTISKADYKHKVYACEVTHQG LHNHYTOKSLSLIG
Trispecific 3 VRC07_523/ CD28sup_x CD3mid_QQ IgG4	3	372	QVRLSQQGQMKKPGDSMRISCRASGYEFINCPINWIRLAPKRPBKPEWGMKPRHGAWSYAROLOGRTMTRDYMSET AFIELRSLSLSDTAVYCTRSHYGLDWNEDWKGKGTIVTIVSSASTKGPSPVFLAPCSSTSSEATAALGCLVKDYF PEPVITWSNGALITSEVHTPAVLOSGLSSVYTOPCQGKPPDFTLQPSKDTLMSITKPSLSSVTKVPSLQKPSLSSVTKVPSLQKPSL AGGPSSVLFPPKPKDFTLMSITKPSLSSVTKVPSLQKPSLSSVTKVPSLQKPSLSSVTKVPSLQKPSLSSVTKVPSLQKPSL LNGKEYKCKVSNKGLPSSIEKTISKADYKHKVYACEVTHQG TPPVLDSDGSPFLYSLPSLSSPVTKSFRGECA SLTQSPGTLSLSPGETAILISORTSQYGSILAWYQPQQAIRLVYSGSTRAGIPDRFGSRNGPDYNTLISLESQDFGVYY CQYEFQGQTKVQDIDKRVVAAPSVFIFPSDEQLSKTNSVRGECA DSTYSLSLSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFRGECA
Trispecific 4 VRC07_523/ CD28sup_x CD3mid_QQ IgG4	1	374	DIVMTOTPLSLSVTPCQPAISCKSSQSLVHNANTYLSTYLOKPGQPOSILYKVSNRFSGYBDRFGSGSGTDFTLKISR VEADFGVYTCQGQTKYQPFPSGKTVKEIGQPKAPDQMTQSPSSLS2SVGDRTITCQASQNTIYWLWNTQQPKG APKLIIYKAMNLHTGVPSPRSQSGSGTDFLTISSLQPEIATYCCQGQTYPTFGQGTLEIKTKGPRTYAAPSFTFPPS DEQLKGSTKPSLTSVCLANNFYREAKYQKVNDAQGNSQSVTBDSDTYSLSLSSSTLISKADYEKHKVYACEVTHQG LSSPVTKSFRGECA
Trispecific 4 VRC07_523/ CD28sup_x CD3mid_QQ IgG4	2	375	YQQLVOSGAEVVKPGASVIKUSCKASGYTFISYYTHWROAQQGLEWIGSIYPGVNNTYAQKFQGRATLTVDTSISTA YMELSRLSLRSLDDTAIVYCTRSHYGLDWNEDWKGKGTIVTIVSSQYOLVSEGCVYTOPCERSLSCASGFTFKWMMH WVROAEGKQOLEWAQIKDKNSNSATYADVKGRRTI SRDSDSKNTLYLQNSNSLRAEDTAVYCYCQGVYTAALSPPYWQ OGTLYTVSSRTASTKGPSVPLAPCSRSTSEESTAAALGCLVKDYFPEPVTSWNGALISVGWHTPPAVLQSGLYSLSSVYT PSSSLGTTKTTICNDVHPKPSNTKVKDRVEYSGKPPDFTLQPSKDTLMSITKPSLSSVTKVPSLQKPSLSSVTKVPSLQKPSL PPSVTIVDGEVHNATKPKPEEQTNTYRVSUTLHQMLNGKEYKCVSNKGLPSSIEKTISKADYKHKVYACEVTHQG LNGKEYKCKVSNKGLPSSIEKTISKADYKHKVYACEVTHQG LHNHYTOKSLSLIG
Trispecific 4 VRC07_523/ CD28sup_x CD3mid_QQ IgG4	3	376	QVRLSQQGQMKKPGDSMRISCRASGYEFINCPINWIRLAPKRPBKPEWGMKPRHGAWSYAROLOGRTMTRDYMSET AFIELRSLSLSDTAVYCTRSHYGLDWNEDWKGKGTIVTIVSSASTKGPSPVFLAPCSRTSESTAALGCLVKDYF PEPVITWSNGALITSEVHTPAVLOSGLSSVYTOPCQGKPPDFTLQPSKDTLMSITKPSLSSVTKVPSLQKPSLSSVTKVPSLQKPSL AGGPSSVLFPPKPKDFTLMSITKPSLSSVTKVPSLQKPSLSSVTKVPSLQKPSLSSVTKVPSLQKPSLSSVTKVPSLQKPSL LNGKEYKCKVSNKGLPSSIEKTISKADYKHKVYACEVTHQG TPPVLDSDGSPFLYSLPSLSSPVTKSFRGECA PPSQEMTRQIVSLSAVKGFPSSDIAVETESNGOPENNTKTPVLDSDGSPFLVSKLTVDRSRQEWNVFCSVMHEA LHNHYTOKSLSLIG

TABLE 4A-continued
Trispecific binding protein polypeptide sequences

Trispecific binding protein polypeptide sequences																								
Polypeptide Number (acc. to formula)	SEQ ID NO.	Sequence	Molecule	Polypeptide Number (acc. to formula)	SEQ ID NO.	Sequence																		
Trispecific 6 VR07_523 / ICD38sup x ICDmid_QQ IgG4	377	SLTQPGLSLSPGHETAILSCRISQYGSLLAWYQPGQAPRLVYSGSTRAGIPDRFGSRGPDYNLTISNLSDFGVY COOYFFGCGTQVODIRETKVAAPSFTFPPSDIQLKESTASTVCLLNFYPREAKTQWVKNDALQSENQSESVTEQDSK DSTISLSLSTLTLSKADYEHKVYACEVTHQGLSSPVTKSFRNGEC	FALFA/409K_DKHTH linker	1	378	DIVMTPLSLSVTPGPASISCKSSOSLVHQNAOTYLWQKGQPSQSLIYKVSNRFSGYPDRFGSGSGTDDFTLKLISR VEAEVGIVYCGOGQYPTFGSCTKVEIKDKHTIDIMTQPSLSSAVGDVTITQASQNYIYWLWYQOKPGRAP KLIIYKASNLHTGVPSRFQSGSGTDPFLTISLQPEDATIYQCGQTYPTFGQGTKEIKDTKHTRTVTAZPSVTFIFFFFPSD BQLKSGTASTVCLLNFYPREAKTQWVKYDNALQSGNSQESVTDQSDSTYSLSLTSKADYEHKVYACEVTHQGL SSPVTKSFRNGEC	QVOVQSGAEVVKPGASVKVSKASGYETTSYYIHWVROAPGCGLEWIGSYPGNQNTINYAQKFQGRATLTVDTSISTA YMELPLRSDDTAVYTCYTRSHGLDWNFDWKGCTTIVTSSQVQGELSRLUSCAASGFTPKAWMH WVROAPGKOLEWAQIKDESKNSATAYYDPSVPLAQTSPNLAQTSISESTAGLVLVWPPVTSWNSGALPSLSSGGLYLSLSVVTV PSSGIGTKYTCVNDHKPANTKVDKRVETKREPEQINSTRVSVLTLHODWLNKEYKCKVSNMGLPSSIEKTISAKQPPREPQCVTL VQFNITYDGVHEVNAKTRKPREPEQINSTRVSVLTLHODWLNKEYKCKVSNMGLPSSIEKTISAKQPPREPQCVTL PPSOEMTKNOVSISCAVKGFYPSDIAVEWESNCOPENNYKTPVPLSDGSFLVSKLTVDKSRWQEGNVPSCSVMHEA LHNHTQKSLSLIG	2	379	QVRLQSOGGMKQKCDMSRISCRASGYEFLNCPIWIRLAPGKRPENNGMKPBRHAGVSYARLOGRVTMTRDMSSET APLERSLTSDDTAVYFCPTRKYKCTARDYKNDDEBWQGQPTVVSASTKGPSVPLAPCPSRSTSETAAQCLVLDYF PEPYTVSMNSGALTSGVHPTPAVQSGHYSLSVTVTPSSIGTQTYTCVNDHKP-SNTKVDKRVETKREPEQINSTRVSVLTLHODW AGGPVVLFPKPKDFTLMSRPEVTCVVDVSPFQMVYQEVANAKTRKPREEQINSTRVSVLTLHODW LNGKRYKCKVSNKQGSSSTEKTISKQGPREPOVYTLPCOEMTKNOVSNMCLVKGFYPSDIAVEWESNCOPENNYK TPPVLDSDGSFLVSKLTVDKSRWQEGNFTCSUWHEALHNHYTQKSLSLIG	380	381	SLTQPGLSLSPGHETAILSCRISQYGSLLAWYQPGQAPRLVYSGSTRAGIPDRFGSRGPDYNLTISNLSDFGVY COOYFFGCGTQVODIRETKVAAPSFTFPPSDIQLKESTASTVCLLNFYPREAKTQWVKNDALQSENQSESVTEQDSK DSTISLSLSTLTLSKADYEHKVYACEVTHQGLSSPVTKSFRNGEC	QVRLQSOGGMKQKCDMSRISCRASGYEFLNCPIWIRLAPGKRPENNGMKPBRHAGVSYARLOGRVTMTRDMSSET APLERSLTSDDTAVYFCPTRKYKCTARDYKNDDEBWQGQPTVVSASTKGPSVPLAPCPSRSTSETAAQCLVLDYF PEPYTVSMNSGALTSGVHPTPAVQSGHYSLSVTVTPSSIGTQTYTCVNDHKP-SNTKVDKRVETKREPEQINSTRVSVLTLHODW AGGPVVLFPKPKDFTLMSRPEVTCVVDVSPFQMVYQEVANAKTRKPREEQINSTRVSVLTLHODW LNGKRYKCKVSNKQGSSSTEKTISKQGPREPOVYTLPCOEMTKNOVSNMCLVKGFYPSDIAVEWESNCOPENNYK TPPVLDSDGSFLVSKLTVDKSRWQEGNFTCSUWHEALHNHYTQKSLSLIG	1	382	DIVMTPLSLSVTPGPASISCKSSOSLVHQNAOTYLWQKGQPSQSLIYKVSNRFSGYPDRFGSGSGTDDFTLKLISR VEAEVGIVYCGOGQYPTFGSCTKVEIKDKHTIDIMTQPSLSSAVGDVTITQASQNYIYWLWYQOKPGRAP KLIIYKASNLHTGVPSRFQSGSGTDPFLTISLQPEDATIYQCGQTYPTFGQGTKEIKDTKHTRTVTAZPSVTFIFFFFPSD BQLKSGTASTVCLLNFYPREAKTQWVKYDNALQSGNSQESVTDQSDSTYSLSLTSKADYEHKVYACEVTHQGL SSPVTKSFRNGEC	QVQLQSGAEVVKPGASVKVSKASGYETTSYYIHWVROAPGCGLEWIGSYPGNQNTINYAQKFQGRATLTVDTSISTA YMELPLRSDDTAVYTCYTRSHGLDWNFDWKGCTTIVTSSQVQGELSRLUSCAASGFTPKAWMH WVHOWTQAPGKOLEWAQIKDKNSNATAYYDPSVPLAQTSPNLAQTSISESTAGLVLVWPPVTSWNSGALPSLSSGGLYLSLSVVTV YWGQCTLYTVSSDQKHTASTKGPEVFPLAPSISSTSGETAALGCLVIDYFPEPVTVSMNSGALTSGVHPTPAVQSGL SLSSTVTPVSSSLGTYCQVNHEKP-SNTKVDKRVETKREPEQINSTRVSVLTLHODWLNKEYKCKVSNKALPAPIEKTISKAK GQPRPQCVTLPPSREDELTQKVSLSCAVKGFTPSDIAVEWESNGQEPNNYKTPVPLSDGSFLVSKLTVDKSRWQEGN NVFESSVMEALHNHYTQKSLSLIG	2	383	QVRLQSOGGMKQKCDMSRISCRASGYEFLNCPIWIRLAPGKRPENNGMKPBRHAGVSYARLOGRVTMTRDMSSET APLERSLTSDDTAVYFCPTRKYKCTARDYKNDDEBWQGQPTVVSASTKGPSVPLAPCPSRSTSETAAQCLVLDYF PEPYTVSMNSGALTSGVHPTPAVQSGHYSLSVTVTPSSIGTQTYTCVNDHKP-SNTKVDKRVETKREPEQINSTRVSVLTLHODW AGGPVVLFPKPKDFTLMSRPEVTCVVDVSPFQMVYQEVANAKTRKPREEQINSTRVSVLTLHODW LNGKRYKCKVSNKQGSSSTEKTISKQGPREPOVYTLPCOEMTKNOVSNMCLVKGFYPSDIAVEWESNCOPENNYK TPPVLDSDGSFLVSKLTVDKSRWQEGNFTCSUWHEALHNHYTQKSLSLIG	3	384	QVRLQSOGGMKQKCDMSRISCRASGYEFLNCPIWIRLAPGKRPENNGMKPBRHAGVSYARLOGRVTMTRDMSSET APLERSLTSDDTAVYFCPTRKYKCTARDYKNDDEBWQGQPTVVSASTKGPSVPLAPCPSRSTSETAAQCLVLDYF PEPYTVSMNSGALTSGVHPTPAVQSGHYSLSVTVTPSSIGTQTYTCVNDHKP-SNTKVDKRVETKREPEQINSTRVSVLTLHODW AGGPVVLFPKPKDFTLMSRPEVTCVVDVSPFQMVYQEVANAKTRKPREEQINSTRVSVLTLHODW LNGKRYKCKVSNKQGSSSTEKTISKQGPREPOVYTLPCOEMTKNOVSNMCLVKGFYPSDIAVEWESNGQEPNNYKTPVPLSDGSFLVSKLTVDKSRWQEGN NVFESSVMEALHNHYTQKSLSLIG

TABLE 4A-continued

Trispecific binding protein polypeptide sequences.					
Molecule	Polyptide Number (acc. to formula)	SEQ ID NO	Sequence		
Trispecific 9 VRC07_523_FR3-03/ CD28sup_x CD3mid_enlf IgG4 FALA/409K_DKTHT linker	4	385	SLTQSPGTLSLSPGETAILISORTSQYGSILAWYQPQARLVIYSGSTRAGIPDRFGSRNGPDYNTISLNLESQDFGVYY CQYEFQGQTKVQVDIKRVAQYCEVTQHGLSSPVTKSFRGECS DSTYSLSSTLTLSKADYERHKVYACEVTQHGLSSPVTKSFRGECS		
	1	386	DIVMTOTPLSLSVTPGQPASISCKSSQSLVHENLQTYLQKPGQSPSOLIYKVSNRFSGYDREFGSGSGTDFTLKISR EAEDGVYVYCQGTQPFITGKTCVTEIKRTHTDIQTOMTSPSILASVSDRVTITCQASQNIYWLWYQKPGKAPK LLIYKASNLITGVPSRSGSGGTDFTLTSSLQPEDIATYCCQGOTYPTFEGQTKLEIKDTHTRTAASLPSVFIIPP SDE QLKGSPASVYLANNYPRRAKVKQVKDNALQNSQESTEODSKDSTLTLSKADYERHKVYACEVTQHGLS SPVTFENRGEC		
	2	387	YMELSRLRSDDTAVVYCTRHGLDWNEDWKGKTTVITYTSSQYOLVESEGGVYOPGRSLRSLCASAQFTETKAWMH WVRQAQGKOLEWAQIKDKNSNSATYADVKGRRTISRDSDSKTLYLQNSNLSRAEDTAVVYCGVYTAALSPDYWG OGTLYTVSSRTASTKGPSVPLAPSRSRTSESTAALGCLVKDYPPEPVTSWNGALISGVHTPAVLOSGLYSLSSVTV PSSSLTGTTCVNDHKPSNTKVRVPSLPPKDTLMISSRTPEVYQKCYKVSNGLPSSTEKUTSKAQSQREPOVQTL PPSQENMTRKQVNSLSCAVKGFPYPSDIAVETESNGPENNYKTTPVFLVSKLTVDKSRWQEGRNFSCSVMEHA LHNHYTOKSLSLIG		
	3	388	QVRLLSGGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPKRPBEMWMMKPRHGAWSYAROLOGYTMQLSQDP DDPDINGTAFELRSLTSDDAVYCTRKYCTARDYVNWDEBHQGTTVYTCSTKQSPVFLAPSLCASAQFTETKAWMH CLVKDYPPEPVTVSWNSGALTSGVTFPATQSSGTYLPSLSSVTVTPSSSIGTQKTYTCVNDHKP-SNTKVRVPSLCKYGPFCP PCPAPAAAGPSVFLPPKEDTLMISRTPEVYQKCYKVSNGLPSSTEKUTSKAQSQREPOVQTL VVLHQDWLNGKEYKCKVVSNGKQPLSSTEKTIKAKGQPREPOVYTLPPCQEMTMKQVSLSLCKVGFYPSDIAVETESNGQ PENNYKTTPVFLDSDGFFFLYKLVQDNGENVSCEVMHEZLQKQVSLTQKSLIG		
	4	389	SLTQSPGTLSLSPGETAILISORTSQYGSILAWYQPQARLVIYSGSTRAGIPDRFGSRNGPDYNTISLNLESQDFGVYY CQYEFQGQTKVQVDIKRVAQYCEVTQHGLSSPVTKSFRGECS DSTYSLSSTLTLSKADYERHKVYACEVTQHGLSSPVTKSFRGECS		
Trispecific 10 VRC07_523_FR3-03/ CD28sup_x CD3mid_enlf IgG4 FALA/409K_DKTHT linker	1	390	DIVMTOTPLSLSVTPGQPASISCKSSQSLVHENLQTYLQKPGQSPSOLIYKVSNRFSGYDREFGSGSGTDFTLKISR EAEDGVYVYCQGTQPFITGKTCVTEIKRTHTDIQTOMTSPSILASVSDRVTITCQASQNIYWLWYQKPGKAPK LLIYKASNLITGVPERFSGGSGTDFTLTSSLQPEDIATYCCQGOTYPTFEGQTKLEIKDTHTRTAASLPSVFIIPP SDE QLKGSPASVYLANNYPRRAKVKQVKDNALQNSQESTEODSKDSTLTLSKADYERHKVYACEVTQHGLS SPVTFENRGEC		
	2	391	YMELSRLRSDDTAVVYCTRHGLDWNEDWKGKTTVITYTSSQYOLVESEGGVYOPGRSLRSLCASAQFTETKAWMH WVRQAQGKOLEWAQIKDKNSNSATYADVKGRRTISRDSDSKTLYLQNSNLSRAEDTAVVYCGVYTAALSPDYWG OGTLYTVSSRTASTKGPSVPLAPSRSRTSESTAALGCLVKDYPPEPVTSWNGALISGVHTPAVLOSGLYSLSSVTV PSSSLTGTTCVNDHKPSNTKVRVPSLPPKDTLMISSRTPEVYQKCYKVSNGLPSSTEKUTSKAQSQREPOVQTL VVLHQDWLNGKEYKCKVVSNGKQPLSSTEKTIKAKGQPREPOVYTLPPCQEMTMKQVSLSLCKVGFYPSDIAVETESNGQ PFSQEMTRQVSLSCAVKGFPYPSDIAVETESNGPENNYKTTPVFLDSDGFFFLYKLVQDNGENVSCEVMHEZLQKQVSLTQKSLIG		
	3	392	QVRLLSGGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPKRPBEMWMMKPRHGAWSYAROLOGYTMQLSQDP DDPDINGTAFELRSLTSDDAVYCTRKYCTARDYVNWDEBHQGTTVYTCSTKQSPVFLAPCSRSTESESTAALG CLVKDYPPEPVTVSWNSGALTSGVTFPATQSSGTYLPSLSSVTVTPSSSIGTQKTYTCVNDHKP-SNTKVRVPSLCKYGPFCP PCPAPAAAGPSVFLPPKEDTLMISRTPEVYQKCYKVSNGLPSSTEKUTSKAQSQREPOVQTL VVLHQDWLNGKEYKCKVVSNGKQPLSSTEKTIKAKGQPREPOVYTLPPCQEMTMKQVSLSLCKVGFYPSDIAVETESNGQ		

TABLE 4A-continued
Trispecific binding protein polypeptide sequences

Tri-specific binding protein polypeptide sequences.																								
Polyptide Number (acc. to formula)	SEQ ID NO	Sequence	Polyptide Number (acc. to formula)	SEQ ID NO	Sequence	Polyptide Number (acc. to formula)	SEQ ID NO	Sequence																
Molecule			Molecule			Molecule																		
Trispecific 11 VRCo7_523_FR3-03/ CD28sup_x CD3m1d_ENLQ	4	393	SLTQSERTPLSLSPGTTAIIISCRTSSOYGLAWYQOPGQAIPRLVYSGSTRAAGIPDRFGSRGPDYNLTISNLESDGQVY CQYEFQGQTKVQDIDKTTTAAPSVFIFPSDEIJKLKGTAATVCLLNFTYPREAKVQWKFVNALQSENQSVEVTQDFQSD DSTYSLSLSTTLSKADYEHKKVYAEVTHQGLSSVTVTSFNRGEC	1	394	DIVMPTPLSLVTGPQGTTAIIISCRTSSOYGLAWYQOPGQAIPRLVYSGSTRAAGIPDRFGSRGPDYNLTISNLESDGQVY EAEDTGVYQCGTQYPFETGSGTVEIKDTKHTTIDQMTQGSPSSASASYGDRVTTICASQNYIYVMLNMYQQPKGAKK LLIYASNLHGTGVPRFSGSGTIPDTLTLSSIQEDIDATYCGQGQTPYTRGQTKLEIKDTKHTTVAAPSFLFPPSDE QLKSGTAASTVCLLNFTYPREAKVQWKFVNALQSENQSVEIQDQSKDSTYSLSSLTTLSKADYEHKKVYACEVTHQGLS SPVTKSFRNGEC	2	395	QVQLQSGAEVVKPGAVSKVSKCKASGTYTFSYYIHWVRAQPGQGIEWIGSYTQPMNNTYQAQFQGRATLTVDTSISTA YMFSLRSRSDTAAVYCTRSHYGLLWDWKGKGTTVTFSDKTHTQVOLVESGGVYQPGRSRURLSAASGTTFTKA WMHWTQAPGKOLEVAAQIKDKNSNATYAAQDSYKGTFRTISDOSKNTLYLQMNLSRAEDTAVYYCRGYYIALSPD YWQGQLTVTVDSDKHTTASTKGPSFTPLASSKTSVGGTAALGCUKVOPFPEPYTWSNHSVGSVTSQGTTFPAVLOSSGLY SLSSTVTPPSSSLGQTYICVNNTPEQYQVHPSNPKVDKWPKSDKDTKQVPEQYQVHPSNPKVDKWPKSDKDTKQVPE VVDVSHEDPEVKENPVYDGVBEVHNATKTPREEQYQVHPSNPKVDKWPKSDKDTKQVPEQYQVHPSNPKVDKWPKSD GQPREPOVCTLPSPDELTKLKNQVSISCAVGFYPSDIAYEWEINGQOPENNYKTPVLDSDGSFFLVSKLTVDFKSRWQG NVFSVSMHEALTHNTYQTSALHNTYQTSALHNTYQTSALHNTYQTSALHNTYQTSALHNTYQTSALHNTYQTSALHNTYQ QVRLQSGGQMKKPKPDMSMRTSCRAYGEYEFINCPIMWIRLAPGKPEPEWGMKPRPHGAVSYAROLQGRYVMTROLQDQP DDPDNGTAFELLRSLSTSDDIAVYCTRGKCTARYIYMWDEHNGQGTPVTVSASTKGPSVPLAPSSKSSTGGTAAL GCLVVDYFPPEVTVWNSGALTSGHTPEVPLVQSLSSVYTPSSSLGQTOTYICVNHHKPSPNTVTDKVKYEPKSCDKT HTCPVCPAPELGGSVFLEPPKPKDFTLWVDPVTCVVDVSYDVGTEVHAKTPREEQYQVHPSNPKVDKWPKSDKDT SVTLVHODWLNGKEYKVKVSNKALAPATEKTIKAKGQPREQYQVHPSNPKVDKWPKSDKDTKQVPE NGOPENNYKTPVLDSDGSFPLVSKLTVDFKSRWQGTTFPAVLOSSGLYFCSVMEALHNHYTQKSLSLSPG	3	396	SLTQSGTSLSPGTTAIIISCRTSSOYGLAWYQOPGQAIPRLVYSGSTRAAGIPDRFGSRGPDYNLTISNLESDGQVY CQYEFQGQTKVQDIDKTTTAAPSVFIFPSDEIJKLKGTAATVCLLNFTYPREAKVQWKFVNALQSENQSVEVTQDFQSD DSTYSLSLSTTLSKADYEHKKVYAEVTHQGLSSVTVTSFNRGEC	4	397	DIVMPTPLSLVTGPQGTTAIIISCRTSSOYGLAWYQOPGQAIPRLVYSGSTRAAGIPDRFGSRGPDYNLTISNLESDGQVY EAEDTGVYQCGTQYPFETGSGTVEIKDTKHTTIDQMTQGSPSSASASYGDRVTTICASQNYIYVMLNMYQQPKGAKK LLIYASNLHGTGVPRFSGSGTIPDTLTLSSIQEDIDATYCGQGQTPYTRGQTKLEIKDTKHTTVAAPSFLFPPSDE QLKSGTAASTVCLLNFTYPREAKVQWKFVNALQSENQSVEIQDQSKDSTYSLSSLTTLSKADYEHKKVYACEVTHQGLS SPVTKSFRNGEC	1	398	QVQLQSGAEVVKPGAVSKVSKCKASGTYTFSYYIHWVRAQPGQGIEWIGSYTQPMNNTYQAQFQGRATLTVDTSISTA YMFSLRSRSDTAAVYCTRSHYGLLWDWKGKGTTVTFSDKTHTQVOLVESGGVYQPGRSRURLSAASGTTFTKA WMHWTQAPGKOLEVAAQIKDKNSNATYAAQDSYKGTFRTISDOSKNTLYLQMNLSRAEDTAVYYCRGYYIALSPD YWQGQLTVTVDSDKHTTASTKGPSFTPLASSKTSVGGTAALGCUKVOPFPEPYTWSNHSVGSVTSQGTTFPAVLOSSGLY SLSSTVTPPSSSLGQTYICVNNTPEQYQVHPSNPKVDKWPKSDKDTKQVPE VVDVSHEDPEVKENPVYDGVBEVHNATKTPREEQYQVHPSNPKVDKWPKSDKDTKQVPE GQPREPOVCTLPSPDELTKLKNQVSISCAVGFYPSDIAYEWEINGQOPENNYKTPVLDSDGSFFLVSKLTVDFKSRWQG NVFSVSMHEALTHNTYQTSALHNTYQTSALHNTYQTSALHNTYQTSALHNTYQTSALHNTYQTSALHNTYQTSALHNTYQ QVRLQSGGQMKKPKPDMSMRTSCRAYGEYEFINCPIMWIRLAPGKPEPEWGMKPRPHGAVSYAROLQGRYVMTROLQDQP DDPDNGTAFELLRSLSTSDDIAVYCTRGKCTARYIYMWDEHNGQGTPVTVSASTKGPSVPLAPSSKSSTGGTAAL GCLVVDYFPPEVTVWNSGALTSGHTPEVPLVQSLSSVYTPSSSLGQTOTYICVNHHKPSPNTVTDKVKYEPKSCDKT HTCPVCPAPELGGSVFLEPPKPKDFTLWVDPVTCVVDVSYDVGTEVHAKTPREEQYQVHPSNPKVDKWPKSDKDT SVTLVHODWLNGKEYKVKVSNKALAPATEKTIKAKGQPREQYQVHPSNPKVDKWPKSDKDTKQVPE NGOPENNYKTPVLDSDGSFPLVSKLTVDFKSRWQGTTFPAVLOSSGLYFCSVMEALHNHYTQKSLSLSPG	2	399	SPLTYSLSLSTTLSKADYEHKKVYAEVTHQGLSSVTVTSFNRGEC	3	400	SPLTYSLSLSTTLSKADYEHKKVYAEVTHQGLSSVTVTSFNRGEC
Trispecific 12 VRCo7_523_FR3-03/ CD28sup_x CD3m1d_ENLQ	1	398	SLTQSERTPLSLSPGTTAIIISCRTSSOYGLAWYQOPGQAIPRLVYSGSTRAAGIPDRFGSRGPDYNLTISNLESDGQVY CQYEFQGQTKVQDIDKTTTAAPSVFIFPSDEIJKLKGTAATVCLLNFTYPREAKVQWKFVNALQSENQSVEVTQDFQSD DSTYSLSLSTTLSKADYEHKKVYAEVTHQGLSSVTVTSFNRGEC	1	399	SLTQSERTPLSLSPGTTAIIISCRTSSOYGLAWYQOPGQAIPRLVYSGSTRAAGIPDRFGSRGPDYNLTISNLESDGQVY CQYEFQGQTKVQDIDKTTTAAPSVFIFPSDEIJKLKGTAATVCLLNFTYPREAKVQWKFVNALQSENQSVEVTQDFQSD DSTYSLSLSTTLSKADYEHKKVYAEVTHQGLSSVTVTSFNRGEC	2	400	SPLTYSLSLSTTLSKADYEHKKVYAEVTHQGLSSVTVTSFNRGEC															

TABLE 4A-continued
Trispecific binding protein polypeptide sequences.

Molecule	Polyptide Number (acc. to formula)	SEQ ID NO	Sequence
Tri-specific 13 N6 / CD28sup x CD3mid IgG4	4	401	SLTQSPGTLSLSPGETAILISORTSQYGSILWQRPQQRVLIYSGSTRAAGIPDRESGSRNGPDYNTISNLQESGDFGVYY CQYEFQGQTKVQVDIKRVAAPSVFIFPSDEQLSKVTSNRGEK
Tri-specific 13 N6 / CD28sup x CD3mid IgG4	1	402	DIVMTOTPLSLSVTPGQPASISCKSSQSLVHNHANTYLWQKPGQPOSILYKVSNRSGVYDRESGSGGTDFTLKR VEADFGVYTGQGQTKVQVDIKRVAAPSVFIFPSDEQLSKVTSNRGEK
Tri-specific 13 N6 / CD28sup x CD3mid IgG4	2	403	LSSPTVKSFRGECL YQVLVOSGAEVVKPGASVIKUSCKSSQSLVHNHANTYLWQKPGQPOSILYKVSNRSGVYDRESGSGGTDFTLKR YMEFLSRLRSDDTAVYCYCTRHYSGLDWNFDWGKGHTVITYSSQVOLVSGGGVYTOPGRSLRSLCASAQFTETKAWMH WVRQAEGKQLEWAQIKDKNSNSATYADVKGRFTI SRLDSKNTLYLQNSNSLAEDTAVYCYCGVYTAQSLPFPYWG OGTLVTVSSRTASTKGPSVPLAPSRSRTSESTAALGCLVKDYFPEPVTSWNSGALISVGWHPAVLQSGLYSLSSVYT PSSSLGTTKTYTCNDHKPSNTKVRVSYGPPCPVCPAPPVAGCSPVLPKDTUMI SRLDSKNTLYLQNSNSLAEDTAVYCYCGVYTAQSLP QENWYTDGEVHNAAKTKPREEQNSTYRVSLVLTQHDQMLNGKEYKCKVSNKGPLSSLEKTISKAKGQPREPOVCTLP PSQEENTKNGVSISSLSCAVKGYPDSIAVENSNGQPENNTKTPVPLSDGSFLVSKLTVDKSRMWEQNVFCSVMHEAL HNHYTIOKSLSLISLG
Tri-specific 13 N6 / CD28sup x CD3mid IgG4	3	404	RAHLVOSGTMKPGASVRSVQTSQYGTFAHILFWRQAPGRGLEWGMWIKPOGYAVNGGGFRDRYTLTRDVYREIA YMDIIRGLPKDTAVYCYCTRHYSGLDWNFDWGKGHTVITYSSQVOLVSGGGVYTOPGRSLRSLCASAQFTETKAWMH VTVSMNSGALTSGVHTFPAVLQSSLYLSSVYTSSIGTQKTYTCNDHKPSNTKVRVSYGPPCPVCPAPPVAGC SVELPPPKPDTLMISRTPEVTCVYDVSQEDPEVQENWYDGEVHNAAKTKPREEQNSTYRVSLVLTQHDQMLNG EYKCKVSNKGPLSSLEKTISKAKGQPREPOVYTLPPCQEMNTKNGVSLWCLVKGFYPSDIAVENSNGQPENNYKTPPVL DSDGSFELYSKLTDKSRMWEQNTVSCSYTMHNTQKSLPLSLLG
Tri-specific 13 N6 / CD28sup x CD3mid IgG4	4	405	YTHVOTSPSSLVSIGCDRVYINCGTQGVSQDLSLHWYQHKGGRAPLSSLLTSSYDGYPSRFSGSFHTSFLNTISDLOADDI ATTYCVLQFGRGRSLHIRTVAAPSVFIFPSDEQLKSGTASVYCLINNFYPREAKYQKVDNALQNSQSVEQVTOQD SKDSTSLSLSSLTLTSKADYKHKVYACEVTHQGLSSPVTEFSRGC
Tri-specific 14 N6 / CD28sup x CD3mid IgG4	1	406	YMEFLSRLRSDDTAVYCYCTRHYSGLDWNFDWGKGHTVITYSSQVOLVSGGGVYTOPGRSLRSLCASAQFTETKAWMH APKLIYKANLHTGVPSSRGSGGTDFTLITISLQEPNATYCOGQTYTPFGOCTKLEIQTGSPRTAQPSYFIFPS DEQLSKSTASYVCLNNFYREAKYQKVDNALQNSQSVEQNTKNGVSLWCLVKGFYPSDIAVENSNGQPENNYKTPPVL LSSPTVKSFRGECL
Tri-specific 14 N6 / CD28sup x CD3mid IgG4	2	407	YQVLVOSGAEVVKPGASVIKUSCKSSQSLVHNHANTYLWQKPGQPOSILYKVSNRSGVYDRESGSGGTDFTLKR YMEFLSRLRSDDTAVYCYCTRHYSGLDWNFDWGKGHTVITYSSQVOLVSGGGVYTOPGRSLRSLCASAQFTETKAWMH WVRQAEGKQLEWAQIKDKNSNSATYADVKGRFTI SRLDSKNTLYLQNSNSLAEDTAVYCYCGVYTAQSLPFPYWG OGTLVTVSSRTASTKGPSVPLAPSRSRTSESTAALGCLVKDYFPEPVTSWNSGALISVGWHPAVLQSGLYSLSSVYT PSSSLGTTKTYTCNDHKPSNTKVRVSYGPPCPVCPAPPVAGCSPVLPKDTUMI SRLDSKNTLYLQNSNSLAEDTAVYCYCGVYTAQSLP QENWYTDGEVHNAAKTKPREEQNSTYRVSLVLTQHDQMLNGKEYKCKVSNKGPLSSLEKTISKAKGQPREPOVCTLP PPSQEMTKQPSLSCAVKGYPDSIAVENSNGOPENNTKTPVPLSDGSFLVSKLTVDKSRMWEQNVFCSVMHEAL HNHYTIOKSLSLISLG
Tri-specific 14 N6 / CD28sup x CD3mid IgG4	3	408	RAHLVOSGTMKPGASVRSVQTSQYGTFAHILFWRQAPGRGLEWGMWIKPOGYAVNGGGFRDRYTLTRDVYREIA YMDIIRGLPKDTAVYCYCARURSYGDSWALDAWGQGTTVVSAASTKGPSVPLAPSRSRTSESTAALGCLVKDYFPEP VTVSMNSGALTSGVHTFPAVLQSSLYLSSVYTSSIGTQKTYTCNDHKPSNTKVRVSYGPPCPVCPAPPVAGC GPSVFLFPPPKPDTUMISRTPEVTCVYDVSQEDPEVQENWYDGEVHNAAKTKPREEQNSTYRVSLVLTQHDQMLNG GKEYKCKVSNKGPLSSLEKTISKAKGQPREPOVCTLP PVLDSDGSFPLYSKLTVDKSRMWEQNVFCSVMHEALHNHYTIOKSLSLISLG

TABLE 4A-continued
Trispecific binding protein polypeptide sequences.

Molecule	Polyptide Number (acc. to formula)	SEQ ID NO	Sequence
Tri-specific 15 N6 / CD28sup x CD3mid_QQ IGG4 FALA / 409K	4	409	YIHVTQSPSSLSVSIQGDRTVLTNCQTSQGVISLQKPGQSPSOLIYKVSNRSGVYDGVSRSGSGEHTSFENLTISDLQADDI ATYYCoyLQPFGRGSRLHIRTVAAPSVEFPPSPDEQIKVYACEVTHQGLSSPVTKSFRNGC SKDSTYSLSLTLTSKADYKHKVYACEVTHQGLSSPVTKSFRNGC
Tri-specific 16 N6 / CD28sup x CD3mid_QQ IGG4 FALA / 409K _ DKTHT linker	1	410	DIVMTOTPLSLSVTPQCPASISCKSSQSLVHNAQTYLQKPGQSPSOLIYKVSNRSGVYDGVSRSGSGEHTSFENLTISDLQKISR VEADYGVYTCGQGTQYPPFGSGTKVEIGQPKAPDQTMQTSQSPSSLSVSIQGDRTVLTQASQNTYIWLNWQQKPGK APKLIIYKASNLHTGPSRSRSGSGTDFPDTISSLQPELIAATYCCQGQTYPTFGQTKLEIJKGPSPRTVTAAPSTVIFPPS DEQLKGSTAVSVCLANNFYREAKYQKVNDAQGNSQSVTBDSDSTSLSLTLTSKADYKHKVYACEVTHQG LSSPVTKSFRNGC
	2	411	YQQLVOSGAEVVKPGASVIKVSCKASGYTFISYYTHWRQAGQGLEWISIYPGVNVNTYQAQFQGRATLTVDTSISTA YMEISRLRSDDTTAVYYCTRSHYLQDWNEDWQKGKTTVTVTSSQVOLVSGGCVTOPCERSLSCAASGFTETRWMH WVRQAFGKQLEWAQJQIKDKNSNSATYAYDVKGRETI SRSIDSKNTLYLQNSNSLAEDTAVYYCQGVYTAALSPPYWQ OGTLVTVSSRTASTKGPSVSPLAGPSCSRSTSESTAALGCLVKDYPPEPVTSWNSGALISVGWHPAVLQSGLYSLSSVYT PSSSLGTKTTCVNDHKPSNTKVDKRVSEYKTPPPDQFPPKPDQDLMISSTPEVTCVVVDVSQEDPE PSSQENWVYDGEVENAKTIPREQENSTYRVSUTLTVLHQDWLNGKEYKCKVSNKGLPSSIEKNTISKANGPREPOVCTL PSSQENWVYDGEVENAKTIPREQENSTYRVSUTLTVLHQDWLNGKEYKCKVSNKGLPSSIEKNTISKANGPREPOVCTL LHNHYTOKSLISLIG
	3	412	RAHDLIGRLKPDATTAVYYCTRSHYLQDWNEDWQKGKTTVTVTSSQVOLVSGGCVTOPCERSLSCAASGFTETRWMH YMDIIRGLKPDATTAVYYCTRSHYLQDWNEDWQKGKTTVTVTSSQVOLVSGGCVTOPCERSLSCAASGFTETRWMH VTVSVMSNAGALTSGVHTFPVALQSSLGSLYSSVLTLPCCDEEMITKVNQSLWICLVLGKTFPSDIAVEWEENGOPENNYKTP PVLDSGDSFPLYSKLTVDSLWQEGNVSSEMSMHLNNTYQKSLISLIG
	4	413	YIHVTQSPSSLSVSIQGDRTVLTNCQTSQGVISLQKPGQSPSOLIYKVSNRSGVYDGVSRSGSGEHTSFENLTISDLQADDI ATYYCoyLQPFGRGSRLHIRTVAAPSVEFPPSPDEQIKVYACEVTHQGLSSPVTKSFRNGC
Tri-specific 16 N6 / CD28sup x CD3mid_QQ IGG4 FALA / 409K _ DKTHT linker	1	414	DIVMTOTPLSLSVTPQCPASISCKSSQSLVHNAQTYLQKPGQSPSOLIYKVSNRSGVYDGVSRSGSGEHTSFENLTISDLQKISR VEADYGVYTCGQGTQYPPFGSGTKVEIGQPKAPDQTMQTSQSPSSLSVSIQGDRTVLTQASQNTYIWLNWQQKPGK KLLIIYASNLHTGPSRSGSGTDFPDTISSLQPELIAATYCCQGQTYPTFGQTKLEIJKGPSPRTVTAAPSTVIFPPS SKDSTYSLSLTLTSKADYKHKVYACEVTHQGLSSPVTKSFRNGC
	2	415	YQQLVOSGAEVVKPGASVIKVSCKASGYTFISYYTHWRQAGQGLEWISIYPGVNVNTYQAQFQGRATLTVDTSISTA YMEISRLRSDDTTAVYYCTRSHYLQDWNEDWQKGKTTVTVTSSQVOLVSGGCVTOPCERSLSCAASGFTETRWMH WVRQAFGKQLEWAQJQIKDKNSNSATYAYDVKGRETI SRSIDSKNTLYLQNSNSLAEDTAVYYCQGVYTAALSPPYWQ OGTLVTVSSRTASTKGPSVSPLAGPSCSRSTSESTAALGCLVKDYPPEPVTSWNSGALISVGWHPAVLQSGLYSLSSVYT PSSSLGTKTTCVNDHKPSNTKVDKRVSEYKTPPPDQFPPKPDQDLMISSTPEVTCVVVDVSQEDPE PSSQENWVYDGEVENAKTIPREQENSTYRVSUTLTVLHQDWLNGKEYKCKVSNKGLPSSIEKNTISKANGPREPOVCTL PSSQENWVYDGEVENAKTIPREQENSTYRVSUTLTVLHQDWLNGKEYKCKVSNKGLPSSIEKNTISKANGPREPOVCTL PQVCLLPPSSEBMTKVNQSLCAVKGTFPSDIAVEWEENGOPENNYKTP CSVMHALHHTYOKSLISLIG
	3	416	RAHDLIGRLKPDATTAVYYCTRSHYLQDWNEDWQKGKTTVTVTSSQVOLVSGGCVTOPCERSLSCAASGFTETRWMH YMDIIRGLKPDATTAVYYCTRSHYLQDWNEDWQKGKTTVTVTSSQVOLVSGGCVTOPCERSLSCAASGFTETRWMH VTVSVMSNAGALTSGVHTFPVALQSSLGSLYSSVLTLPCCDEEMITKVNQSLWICLVLGKTFPSDIAVEWEENGOPENNYKTP PSSVFLFPPKPDQDTUMISRPEVTCVVVDVSQEDDEVONWYDGEVENAKTIPREQENSTYRVSUTLTVLHQDWLNGKEYKCKVSNKGLPSSIEKNTISKANGPREPOVCTL GKEYKCKVSNKGLPSSIEKNTISKANGPREPOVCTL PVLDSDGSFPLYSKLTVDSLWQEGNVSSEMSMHLNNTYQKSLISLIG

TABLE 4A-continued
Trispecific binding protein polypeptide sequences.

Molecule	Poly peptide Number (acc. to formula)	SEQ ID NO	Sequence
Tri specific 17 N6 / CD28sup x CD3mid IgG4 FALA / 409K_DKHT linker	4	417	YIHVTQSPSSLSVSIQGDRTVLTNCQTSQGVISLQKPGQSPSLLYIKVSNRFRSGYDREFGSGSGTDFTLKISR ATYYCIVLQPFGRGSRLHIRTVAAPSVFLEPPSDBEQLKSGVTFKVKYFACEVTHQGLSSPVTKVSENRGC SKDSTSLSLTLTSKADYKHKVYFACEVTHQGLSSPVTKVSENRGC
Tri specific 18 N6 / CD28sup x CD3mid IgG4 FALA / 409K_DKHT linker	1	418	DIVMTOTPLSLSVTPQCPASLSCKSSQSLVHNANTYLSWYIKQPGQSPSLLYIKVSNRFRSGYDREFGSGSGTDFTLKISR VEADVGIVYTCGQGTQYPPFGSGTKVEIKDKHTIDQMTQSPSSLAVQVGRFTVLSKDTKHTDPLTISLOPEDIATYQCGQTYPPFGQGKLEIKDKTHIRTVAAAPSVFLEPPSD KLLIYKASNLHGTGVPSSRSQSGSGTDFTLKHTDPLTISLOPEDIATYQCGQTYPPFGQGKLEIKDKTHIRTVAAAPSVFLEPPSD EQLKSGTASTVCLLNFYPEAKVQKVDALQNSQEVTEQPSKDSKTDSTYSLSTLTSKADYKHKVYACEVTHQGL SSPVTKVSENRGC
Tri specific 19 N6 / CD28sup x CD3mid_QQ IgG1_NNAs_DKHT linker	2	419	QVQLVOSGAEVVKGPGASVKSIVKUSCKASGYTFISYIHWVQAPGQGLEWISIYPGNVNTYIAQFQGRATLTVDTISISTA YMEISLRSLRSDDTAIVYCYCTRHYSYLDWNEDWKGKTTVTVTSKDKHTDQVQLESGGGVYVOPGRSLURSLCAASGFITPTKA WMHWVROAPGRQLEVAQIDKDSKNSYATYADSVGRFTSRDSDSKNTYLQONSLRAIDTAVYTCRGYVYALSPFD YNGQGTLVTVTSISKHTTASTKGPSYTPLACCSRSTSESTZALGCLVQDYFPEPYTVSWNSGALTSGVHTPAVLOSSGLYS LSSVYVTPSSSLGTTGKTDHRSKTDKHTASTKGPSYTPLACCSRSTSESTZALGCLVQDYFPEPYTVSWNSGALTSGVHTPAVLOSSGLYS EPQVCTLPSSPQREMTPKNOVSLSUCAVKGFYPSDIAVWEWSNGOPENNYKTP CSYMHRAHLHYTQSLSLIG RAHLVOSGTMANKKPGASVRSVCSQTSQGTFIAHILFWRQAPGRGLEWISWIKPOYGAVNGGFRDRVLTTRDVYREIA YMDILRGKPDATAVYKCFTRHYSYLDWNEDWKGKTTVTVTSKDKHTDQVQLESGGGVYVOPGRSLURSLCAASGFITPTKA VTVSWSNGALTSGVHTPATEQVLSVYTPSSSIGTKTTCYDNDHKPNTKVDKRVETKPEQEMITKQSVLCLVKGTFPSDIAVEWEWSNGOPENNYKTP PVLDSGSPFLYPSKLTVDSRWEQENVSSEMSVYHNTYQKPGQPLHNTYQKSLSLIG 4
Tri specific 19 N6 / CD28sup x CD3mid_QQ IgG1_NNAs_DKHT linker	4	421	YIHVTQSPSSLSVSIQGDRTVLTNCQTSQGVISLQKPGQSPSLLYIKVSNRFRSGYDREFGSGSGTDFTLKISR ATYYCIVLQPFGRGSRLHIRTVAAPSVFLEPPSDBEQLKSGVTFKVKYFACEVTHQGLSSPVTKVSENRGC SKDSTSLSLTLTSKADYKHKVYFACEVTHQGLSSPVTKVSENRGC
Tri specific 19 N6 / CD28sup x CD3mid_QQ IgG1_NNAs_DKHT linker	1	422	DIVMTOTPLSLSVTPQCPASLSCKSSQSLVHNANTYLSWYIKQPGQSPSLLYIKVSNRFRSGYDREFGSGSGTDFTLKISR VEADVGIVYTCGQGTQYPPFGSGTKVEIKDKHTIDQMTQSPSSLAVQVGRFTVLSKDTKHTDPLTISLOPEDIATYQCGQTYPPFGQGKLEIKDKTHIRTVAAAPSVFLEPPSD KLLIYKASNLHGTGVPSSRSQSGSGTDFTLKHTDPLTISLOPEDIATYQCGQTYPPFGQGKLEIKDKTHIRTVAAAPSVFLEPPSD EQLKSGTASTVCLLNFYPEAKVQKVDALQNSQEVTEQPSKDSKTDSTYSLSTLTSKADYKHKVYACEVTHQGL SSPVTKVSENRGC
Tri specific 19 N6 / CD28sup x CD3mid_QQ IgG1_NNAs_DKHT linker	2	423	QVQLVOSGAEVVKGPGASVKSIVKUSCKASGYTFISYIHWVQAPGQGLEWISIYPGNVNTYIAQFQGRATLTVDTISISTA YMEISLRSLRSDDTAIVYCYCTRHYSYLDWNEDWKGKTTVTVTSKDKHTDQVQLESGGGVYVOPGRSLURSLCAASGFITPTKA WMHWVROAPGRQLEVAQIDKDSKNSYATYADSVGRFTSRDSDSKNTYLQONSLRAIDTAVYTCRGYVYALSPFD YNGQGTLVTVTSISKHTTASTKGPSYTPLACCSRSTSESTZALGCLVQDYFPEPYTVSWNSGALTSGVHTPAVLOSSGLYS LSSVYVTPSSSLGTTGKTDHRSKTDKHTASTKGPSYTPLACCSRSTSESTZALGCLVQDYFPEPYTVSWNSGALTSGVHTPAVLOSSGLYS VVDVSHEDPEYKENNYDGEVHNATKPKPEEQXNAASRVTSVTLHOMWLNGKEYKCKVSNKALPALEKUTISAK QPREPQVTLPPSRDELINQVSLSCAVKGFYPSDIAVEWEWSNGOPENNYKTP NVECSYMHRAHLHYTQSLSLSPG RAHLVOSGTMANKKPGASVRSVCSQTSQGTFIAHILFWRQAPGRGLEWISWIKPOYGAVNGGFRDRVLTTRDVYREIA YMDILRGKPDATAVYCARRSYGDSSWALDAWGQTIVTVSAASTKGPSVPLAPSRSKTSQGTFIAHILFWRQAPGRGLEWISWIKPOYGAVNGGFRDRVLTTRDVYREIA VTVSWSNGALTSGVHTPATEQVLSVYTPSSSIGTKTTCYDNDHKPNTKVDKRVETKPEQEMITKQSVLCLVKGTFPSDIAVEWEWSNGOPENNYKTP LGGPSYELFPKPKDPLMIRTPETCVVDDVSHEDPEYKENNYDGEVHNATKPKPEEQXNAASRVTSVTLHOMWLNGKEYKCKVSNKALPALEKUTISAK LINGKEYKCKVSNKALPALEKUTISAK TPPVLDSDGSPFLYPSKLTVKSRMVOQGVNTSCSYVMEAHLYHYTOKSLSLSPG
3	424		

TABLE 4A-continued
Trispecific binding protein polypeptide sequences.

Molecule	Polypeptide Number (acc. to formula)	SEQ ID NO	Sequence
Tri-specific 21 N6 / CD28 ^{sup} × CD3 _{mid} _DNAQ IGG4 FALA ₄ /409K_DKHT linker	4	425	YIHVTQSPSSLSVSIQGDRTVLTNCQTSQGVISLQKPGQSPSLLYKVSNRSGSGTDFESENLTISDLOADDI ATYYCQYLQFFGRGSLHIRTVAAPSVFVQLRKSGTFSVTCNSRQVTKYACEVTHQGLSSPVTNSRGE SKDSTSLSLTLTSKADYKHKVYACEVTHQGLSSPVTNSRGE
Tri-specific 22 N6 / CD28 ^{sup} × CD3 _{mid} _ENLQ IGG4 FALA ₄ /409K_DKHT linker	1	426	DIVMTOTPLSLSVTPQGPASLSCKSSQSLHDNAQTLYKPGQSPSLLYKVSNRSGSGTDFESENLTISDLOADDI WMAEDVGVYTCQGQTYPPFTGSGTVEIKDKHTDQIMQPSQPSLSSKQVTKYACEVTHQGLSSPVTNSRGE KLIYKASNLHGTGVPSSRSQSGSDIDPTLTISSLOPQDTATYCOGQTYKPEFGQGKLEIKDKTHIRTVAAAPSVEFIPPSD EQLKSCSTASTVCLNNFYPBEAKVQKVDALQNSQEVETEQPSKDSKTSLSLTLTSKADYKHKVYACEVTHQGL SPVTNSRGE
	2	427	QVQLVOSGAEVVKPGASVKSQKASGYTFPSYTHWVRQAPGQGLEWISIYPGNVNTVYQKFQGRATLTVDTSISTA YMEISRLSRSLSDDTAVYCYCTRSHYGLDWNEDWKGKTTVTVTSSDKHTHQVQLVESGGGVVQGRSURLSZASGFTFTKA WMHWVRQAPGQOLEVNAQIDKSNSYATYADSVGRFTSRDSDSKNTLYLQNSLRASTDATVYCRGYYALSPFD YNGQGTLVTVTSDDKHTTASTKGPSYTPLACCSRSTSESTALGCLVQDYPPEPYTVSWNSGALTSGVHTPAVLOSSGLYS LSSVYTVPSLPSLGLTQVTKDVKRVEISKYGPVCPPEAGGSVFLFPKDPDTLMISRTPETCVVVD VSOEDEVONWYDGVEVNAKTPREEFNSTTVVSLTVLHODWLNGKEYKCKVSKNGLPSSIEKTISAKGQPR EPQVCTLPSPSOPREMTPKNOVLSUCAVKGFYPSDIAVEWEWSNGOPENNYKTP CSVMHLAHHYTOKSLSLIG
	3	428	RAHLVOSGTMKPGASVRSVCSQTCGTFPSYTHWVRQAPGQGLEWISIYPGNVNTVYQKFQGRATLTVDTSISTA YMDILRGKPDATVYCYCTRSHYGLDWNEDWKGKTTVTVTSSDKHTHQVQLVESGGGVVQGRSURLSZASGFTFTKA VTVSVMSGALTSGVHTFPVATLQSSGLYSSVYDGVEVNAKTPREEFNSTTVVSLTVLHODWLNGKEYKCKVSKNGLPSSIEKTISAKGQPR VFLDSGSPFLYPSKLTVDSRWEQGVNSSVMLHNTYQKSLSLIG
	4	429	YIHVTQSPSSLSVSIQGDRTVLTNCQTSQGVISLQKPGQSPSLLYKVSNRSGSGTDFESENLTISDLOADDI ATYYCQYLQFFGRGSLHIRTVAAPSVFVQLRKSGTFSVTCNSRQVTKYACEVTHQGLSSPVTNSRGE SKDSTSLSLTLTSKADYKHKVYACEVTHQGLSSPVTNSRGE
	1	430	DIVMTOTPLSLSVTPQGPASLSCKSSQSLHDNAQTLYKPGQSPSLLYKVSNRSGSGTDFESENLTISDLOADDI EAEDVGVYTCQGQTYPPFTGSGTVEIKDKHTDQIMQPSQPSLSSKQVTKYACEVTHQGLSSPVTNSRGE LLIYKASNLHGTGVPFRFSGSGTDFEQLKSCSTASTVCLNNFYPBEAKVQKVDALQNSQEVETEQPSKDSLTSLSLTLTSKADYKHKVYACEVTHQGLS SPVTNSRGE
	2	431	QVQLVOSGAEVVKPGASVKSQKASGYTFPSYTHWVRQAPGQGLEWISIYPGNVNTVYQKFQGRATLTVDTSISTA YMEISRLSRSLSDDTAVYCYCTRSHYGLDWNEDWKGKTTVTVTSSDKHTHQVQLVESGGGVVQGRSURLSZASGFTFTKA WMHWVRQAPGQOLEVNAQIDKSNSYATYADSVGRFTSRDSDSKNTLYLQNSLRASTDATVYCRGYYALSPFD YNGQGTLVTVTSDDKHTTASTKGPSYTPLACCSRSTSESTALGCLVQDYPPEPYTVSWNSGALTSGVHTPAVLOSSGLYS LSSVYTVPSLPSLGLTQVTKDVKRVEISKYGPVCPPEAGGSVFLFPKDPDTLMISRTPETCVVVD VSOEDEVONWYDGVEVNAKTPREEFNSTTVVSLTVLHODWLNGKEYKCKVSKNGLPSSIEKTISAKGQPR EPQVCTLPSPSOPREMTPKNOVLSUCAVKGFYPSDIAVEWEWSNGOPENNYKTP CSVMHLAHHYTOKSLSLIG
	3	432	RAHLVOSGTMKPGASVRSVCSQTCGTFPSYTHWVRQAPGQGLEWISIYPGNVNTVYQKFQGRATLTVDTSISTA YMDILRGKPDATVYCYCTRSHYGLDWNEDWKGKTTVTVTSSDKHTHQVQLVESGGGVVQGRSURLSZASGFTFTKA VTVSVMSGALTSGVHTFPVATLQSSGLYSSVYDGVEVNAKTPREEFNSTTVVSLTVLHODWLNGKEYKCKVSKNGLPSSIEKTISAKGQPR VFLDSGSPFLYPSKLTVDSRWEQGVNSSVMLHNTYQKSLSLIG

TABLE 4A-continued
Trichoderma binding protein polymers dimensions

Trispecific binding protein polypeptide sequences.						
Molecule	Polypeptide Number (acc. to formula)	SEQ ID NO	Sequence			
TRI-specific 23 N6_CD28sup x CDmid_ENLR_I94	4	433	YIHTQSPSSLSVSGDRVTINCQSQGVSFLHQQKPGRAFPLLIHHTSSYEDGVPSRFSGSFHITSFNLTISDLOADDI ATYYCQVLOPGRGRRLHKRTVAAPSFLFPPDEBQLSGTASVCLNNFYREAKVQWVQDNALOGSGNSQESTVQD SKDSTSLSLTLTSKADYEKHKVYACEVTHQGLS SPVTKS FNGEC			
TRI-specific 23 N6_CD28sup x CDmid_ENLR_I94	4	434	DIVMTOTPLSLSVTPGPQASISCKSSOSLYHENLRTYSLWQKGQSPQSLIYKVSNRFSGVYDGFDRSGSGSTDFTLKISRVAEEDGVYVCGGTYCPFTGSGMVEIKDQKHTDIDOMTQSPSSLASVGDRVTITCQSONQIYVWLNWYQOKPGKAKPLLIYASNLHGTGVPSRFSGSGSTDFLTISLQDEDIATYQCGQPYPTFQGLEIKDKTHTRTVAAPSFLFPPSDEQLKSTASYTVCUCLNNFYREAKVQWVQDNALOGSGNSQESTVQDQSKDSTSLSLTLTSKADYEKHKVYACEVTHQGLSSPVTKS FNGEC			
TRI/AlA/409K_DKHT linker	2	435	QVQLQSGAEVVKPGAVSKVSKCAGTETSYIHWVROAPGQGELWIGSIYPGNVNNTYAQKFQGRATLVDTTSISTA YMEILRLRSIDDTAVYVCTSHYGLWNEDWGKGTITVTSDDKHTQYQVLESGGGVVQPGRSURLSLAASGFTFTA WMHHRQAPRKQLEWVAQIKDKSNSIATYADSYKGRFTISRDSSKNTLYLQMNLSLRAEDTAYYCRGYYALISPFD YWQGQTLVTVPSDKHTAATSKGPSPVFLAPCSRTSESTAAALGLVQDVFPEVTSWNSGALTSGVHTFPAVLQSSLLYS LSSTVTPPSSSLGTTYTCNDHEPFSNTVYDKRVEISKYQPPCPAPAAAGGSPVFLPPKTDUMISRPBEVTCVVD VSQEDEVQENWVYDGVYEHNAKTPREQENSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSIERTISAKGQPR EPOVTLPPQOEEMTKNOVSLSCAVKGFPDSIAWEWENGOPENNYKTTPVYLDSDSFFLVSKLTVDKSRMOWEGNVECSVMEHALNHYTQKSLSLG			
TRI/AlA/409K_DKHT linker	3	436	RAHILQSGTAMKKPQAVSVRSVCSGTYTETAHILWFRQAPGRGLEMWIKPQYGAVENTGGGRDRVTLTRDVRETA YMDLIGLKPDIDTAVYCARDSYGSWSWALDAWQGTITVVSAASTKGPSPVFLAPCSRSTSLSLAALGCLVQDVFPEEP VTVSNTSGALTSGVHTFPAVLQSSLLYSIISVTVPSSSLGTTYTCNDHEPFSNTVYDKRVEISKYQGPCCPPCPAPEAG GPSPVFLPPKTDUMISRPBEVTCVVDDEQENWVYDGVYEHNAKTPREQENSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSIERTISAKGQPR EPLDDGSKFSFLYSLKATIVDKSRMOWEENVSUVMHEALNHYTQKSLSLG			
TRI/AlA/409K_DKHT linker	4	437	YIHTQSPSSLSVSGDRVTINCQSQGVSFLHQQKPGRAFPLLIHHTSSYEDGVPSRFSGSFHITSFNLTISDLOADDI ATYYCQVLOPGRGRRLHKRTVAAPSFLFPPDEBQLSGTASVCLNNFYREAKVQWVQDNALOGSGNSQESTVQD SKDSTSLSLTLTSKADYEKHKVYACEVTHQGLS SPVTKS FNGEC			
TRI-specific 24 N6_CD28sup x CDmid_ENLR_I94	1	438	DIVMTOTPLSLSVTPGPQASISCKSSOSLYHENLRTYSLWQKGQSPQSLIYKVSNRFSGVYDGFDRSGSGSTDFTLKISRVAEEDGVYVCGGTYCPFTGSGMVEIKDQKHTDIDOMTQSPSSLASVGDRVTITCQSONQIYVWLNWYQOKPGKAKPLLIYASNLHGTGVPSRFSGSGSTDFLTISLQDEDIATYQCGQPYPTFQGLEIKDKTHTRTVAAPSFLFPPSDEQLKSTASYTVCUCLNNFYREAKVQWVQDNALOGSGNSQESTVQDQSKDSTSLSLTLTSKADYEKHKVYACEVTHQGLSSPVTKS FNGEC			
TRI/AlA/409K_DKHT linker	2	439	QVQLQSGAEVVKPGAVSKVSKCAGTETSYIHWVROAPGQGELWIGSIYPGNVNNTYAQKFQGRATLVDTTSISTA YMEILRLRSIDDTAVYVCTSHYGLWNEDWGKGTITVTSDDKHTQYQVLESGGGVVQPGRSURLSLAASGFTFTA WMHHRQAPRKQLEWVAQIKDKSNSIATYADSYKGRFTISRDSSKNTLYLQMNLSLRAEDTAYYCRGYYALISPFD YWQGQTLVTVPSSSLGTTYTCNDHEPFSNTVYDKRVEISKYQPPCPAPAAAGGSPVFLPPKTDUMISRPBEVTCVVD VSQEDEVQENWVYDGVYEHNAKTPREQENSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSIERTISAKGQPR EPOVTLPPQOEEMTKNOVSLSCAVKGFPDSIAWEWENGOPENNYKTTPVYLDSDSFFLVSKLTVDKSRMOWEGNVECSVMEHALNHYTQKSLSLG			
TRI-specific 24 N6_CD28sup x CDmid_ENLR_I94	3	440	RAHILQSGTAMKKPQAVSVRSVCSGTYTETAHILWFRQAPGRGLEMWIKPQYGAVENTGGGRDRVTLTRDVRETA VTVSNTSGALTSGVHTFPAVLQSSLLYSIISVTVPSSSLGTTYTCNDHEPFSNTVYDKRVEISKYQGPCCPPCPAPEAG GPSPVFLPPKTDUMISRPBEVTCVVDDEQENWVYDGVYEHNAKTPREQENSTYRVSVLTVLHQDWLNGKEYKCKVSNKGLPSIERTISAKGQPR EPLDDGSKFSFLYSLKATIVDKSRMOWEENVSUVMHEALNHYTQKSLSLG			

TABLE 4A-continued
Trispecific binding protein polypeptide sequences.

Molecule	Poly peptide Number (acc. to formula)	SEQ ID NO	Sequence
Trispecific 25 N6_rw52/ CD2sup_x CD3mid_ENLQ IgG4 FALA/409K_DKTHT linker	4	441	YIHVTQSPSSLSVSIQGDRTVLTNCQTSQGVISLQKPGQSPSOLIYKVSNRSGVYDGRSGSGFHTSFNLITISLDQADDI ATYYCQYLQFFGRGSLHIRTVAAPSVFVLPFPSPDQLKRGSPVTKSGTENKE SKDSTYSLSSLTLSKADYKHKVYACEVTHQGLSSPVTKE
Trispecific 26 N6_rw52/ CD2sup_x CD3mid_ENLF IgG4 FALA/409K_DKTHT linker	1	442	DIVMTOTPLSLSVTPGQCPASLSCKSSOLIYKVSNRSGVYDGRSGSGFHTSFNLITISLDQADDI EAEDVGYVYCQGTQPFITGKPTGTRVEIKRTHTDIQTWMLWYQQPKGKAPK LLIYKASNLITGVPSRSGSGCTDFLTLSLQPEDIATYCCQGOTYPTFEGQTKLEIKDTHTRTAASFVETPPSDE QLKGSGTASVTLANFYPRAKVQKVDNIALQNSQESTEODSKDTYSLSSLTLSKADYKHKVYACEVTHQGLS SPVTKEFNRC
Trispecific 26 N6_rw52/ CD2sup_x CD3mid_ENLF IgG4 FALA/409K_DKTHT linker	2	443	YQVLVSGAEVVKPGASVVKUSKASGGTFSYIHWVQAPGQGLEWISIYPGRNVNTVYAKQFGRATLTVDTSISTA YMELSRLSRSDDTAVYCYCTRHGLDNWDWGKGTIVTVTSKDKHTQVQLVESGGGVYVOPGRSLRSLRAIDTAVYCRGYYALSPFD WMHWVROAPGQOLEWVQIJDKSNSYATYADFSGRFTSRDSDKNTLYLQNSLRAIDTAVYCRGYYALSPFD YNGQGTIVLTVTSSDKHTTASTKGPSYTPLACCSRSTSESTALGCLVQDYFPEPYTVSWNSGALTSGVHTPAVLOSSGLYS LSSVYTVPSLQSLGTTCTVNDHRSKNTKDVRKPSVTKGKPSYTPLACCSRSTSESTALGCLVQDYFPEPYTVSWNSGALTSGVHTPAVLOSSGLYS VSOEDEVONWYDGVEVNAKTKPREEQNSITYRVSTVLIHQDWLNGKEYKCKVSKNGLPSSTIETLISKAKGQPR EPQVCTLPPSPBEMPTKNOVSLSUCAVKGFYPSDIAVEWEWSNGOPENNYKTP CSVMHEALHHYTOKSLSLIG
Trispecific 26 N6_rw52/ CD2sup_x CD3mid_ENLF IgG4 FALA/409K_DKTHT linker	3	444	RAHLVOSGTMKPGASVRSVPLQSGTQFIAHILFWRQAPGQGLEWISIWPQYATNGGFRDRVLTLDVREIA YMDIRGKPDATAVYCYCTRHGLDNWDWGKGTIVTVTSKDKHTQVQLVESGGGVYVOPGRSLRSLRAIDTAVYCRGYYALSPFD VTVSMNSGALTSGVHTPSVQISSLGTTCTVNDHRSKNTKDVRKPSVTKGKPSYTPLACCSRSTSESTALGCLVQDYFPEPYTVSWNSGALTSGVHTPAVLOSSGLYS VSOEDEVONWYDGVEVNAKTKPREEQNSITYRVSTVLIHQDWLNGKEYKCKVSKNGLPSSTIETLISKAKGQPR EPQVCTLPPSPBEMPTKNOVSLSUCAVKGFYPSDIAVEWEWSNGOPENNYKTP CSVMHEALHHYTOKSLSLIG
Trispecific 26 N6_rw52/ CD2sup_x CD3mid_ENLF IgG4 FALA/409K_DKTHT linker	4	445	YIHVTQSPSSLSVSIQGDRTVLTNCQTSQGVISLQKPGQSPSOLIYKVSNRSGVYDGRSGSGFHTSFNLITISLDQADDI ATYYCQYLQFFGRGSLHIRTVAAPSVFVLPFPSPDQLKRGSPVTKSGTENKE SKDSTYSLSSLTLSKADYKHKVYACEVTHQGLSSPVTKE
Trispecific 26 N6_rw52/ CD2sup_x CD3mid_ENLF IgG4 FALA/409K_DKTHT linker	1	446	DIVMTOTPLSLSVTPGQCPASLSCKSSOLIYKVSNRSGVYDGRSGSGFHTSFNLITISLDQADDI EAEDVGYVYCQGTQPFITGKPTGTRVEIKRTHTDIQTWMLWYQQPKGKAPK LLIYKASNLITGVPSRSGSGCTDFLTLSLQPEDIATYCCQGOTYPTFEGQTKLEIKDTHTRTAASFVETPPSDE QLKGSGTASVTLANFYPRAKVQKVDNIALQNSQESTEODSKDTYSLSSLTLSKADYKHKVYACEVTHQGLS SPVTKEFNRC
Trispecific 26 N6_rw52/ CD2sup_x CD3mid_ENLF IgG4 FALA/409K_DKTHT linker	2	447	YQVLVSGAEVVKPGASVVKUSKASGGTFSYIHWVQAPGQGLEWISIYPGRNVNTVYAKQFGRATLTVDTSISTA YMELSRLSRSDDTAVYCYCTRHGLDNWDWGKGTIVTVTSKDKHTQVQLVESGGGVYVOPGRSLRSLRAIDTAVYCRGYYALSPFD YNGQGTIVLTVTSSDKHTTASTKGPSYTPLACCSRSTSESTALGCLVQDYFPEPYTVSWNSGALTSGVHTPAVLOSSGLYS LSSVYTVPSLQSLGTTCTVNDHRSKNTKDVRKPSVTKGKPSYTPLACCSRSTSESTALGCLVQDYFPEPYTVSWNSGALTSGVHTPAVLOSSGLYS VSOEDEVONWYDGVEVNAKTKPREEQNSITYRVSTVLIHQDWLNGKEYKCKVSKNGLPSSTIETLISKAKGQPR EPQVCTLPPSPBEMPTKNOVSLSUCAVKGFYPSDIAVEWEWSNGOPENNYKTP CSVMHEALHHYTOKSLSLIG
Trispecific 26 N6_rw52/ CD2sup_x CD3mid_ENLF IgG4 FALA/409K_DKTHT linker	3	448	RAHLVOSGTMKPGASVRSVPLQSGTQFIAHILFWRQAPGQGLEWISIWPQYATNGGFRDRVLTLDVREIA YMDIRGKPDATAVYCYCTRHGLDNWDWGKGTIVTVTSKDKHTQVQLVESGGGVYVOPGRSLRSLRAIDTAVYCRGYYALSPFD VTVSMNSGALTSGVHTPSVQISSLGTTCTVNDHRSKNTKDVRKPSVTKGKPSYTPLACCSRSTSESTALGCLVQDYFPEPYTVSWNSGALTSGVHTPAVLOSSGLYS VSOEDEVONWYDGVEVNAKTKPREEQNSITYRVSTVLIHQDWLNGKEYKCKVSKNGLPSSTIETLISKAKGQPR EPQVCTLPPSPBEMPTKNOVSLSUCAVKGFYPSDIAVEWEWSNGOPENNYKTP CSVMHEALHHYTOKSLSLIG

TABLE 4A-continued
Trispecific binding protein polypeptide sequences.

Molecule	Poly peptide Number (acc. to formula)	SEQ ID NO	Sequence
Trispecific 27 N6_rw52/ CD2sup_x CD3mid_ENLF IgG1_NMAS_DKTH linker	4	449	YIHVTQSPSSLSVSIQGDRTVLTINCQTSQGVISLWYQHKEGRAPKLILHHTSSSEGGVSRSGSGFHTSFNLITISDLOADDI ATYYCQYLQFFGRGSLHIRTVAAPSVEFPPSDBEQLKSGTFSVKGKPTENKEVTHQGLSSPVTKEVTHQGLS SKDSTYSLSSLTLSKADYKHKVYACEVTHQGLSSPVTKEVTHQGLS
Trispecific 28 N6_PR3-03/ CD2sup_x CD3mid_ENLF IgG4 FALA/409K_DKTH linker	1	450	DIVMTOTPLSLSVTPGQPASLSCKSQSLVHENLFTYLQKPGQSPSOLIYKVSNRSGVYDRFGSGSGTDFTLKISR EAEDVGYVYCQGTQPFPTGSGTKEVTKHTHD1QMTQSPSSLSVSIQGDRTVLTICQTSQGVISLWYQHKEGRAPKLILHHTSSSEGGVSRSGSGFHTSFNLITISDLOADDI LLIYKASNLITLGVPFRFSGGSQGTDFTLTISSLQPEDEIATYYCQGQTYTFEGQTKLEIKDTHTRTAAPSVEFIPPSDE QLKGTSATSYCLLANNYPRAKVQKVDNIALQNSQESTEODSKDTYSLSSLTLSKADYKHKVYACEVTHQGLS SPVTKEFNRGEC
	2	451	YQVLVOSGAEVVKPGASVKSQCKASGYTFISYIHWVQAPGQGLEWISIYPGRNVNTVNAQKFQGRATLTVDTSIISTA WMHWVROAPGQOLEWVQIJDKSNYATYADFSGRFTLSRDSKNTLYLQNSLRAIDTAVTTCYCRGYYALSPFD YNGQGTLVUTVSSDKHTASTKGPSYPLASSKSTSGTFAZALGCLVQDXYPEPYTVSWNSGALTSGVHTPAVLOSSGLY SLSSVTVPPSSLGLQTGYCNHPPSNTVDPKTDKVKYBPKSDKTHCPKTDKVKYBPKSDKTHCPKTDKVKYBPKSDKTHCPKTDKVKYBPKSD GQPREFOVCTLPSPRDENTLNQVSLSUCAVGFYPSDIAVEWESNGOPENNTKTTPVLDGSEFLVSKLTVDKSRWQCG NVECSVMHEALHHYTOKSLSLSPG
	3	452	RAHLVOSGAEVVKPGASVRSQCKASGYTFISYIHWVQAPGQGLEWISIYPGRNVNTVNAQKFQGRATLTVDTSIISTA YMD1RGLKPDATVYXCARBSYGSWDAWQGOTTVWSAESTKQFSDVPLASSTSKTSGTAAALCLVQDYEPEP VTVSSVNSGALTSGVHTFPATLOSSGLYSLSSVTVPPSSGQTQYI_CYNTHKPENTKVDKVEKVEKVEKVEKVEKVEKVEKVEKVEKVEK LGGPSVLEPPKPKDFTLMSRTPEVTCVYDVSHDPEVKEFWVYDGEVEMHNACTKPRBQYNNASRVVSVLTVHQDW LNGKEKTKCKSYNKLAPKELTISAKGOREPOVYTLPCPDELTKNQSVLSLWVKGFPYPSDIAVEWESNGOPENNTKT TPPVLDGSEFLVSKLTVDKSRWQCGVNEVSYMEALHHYTOKSLSLSPG
	4	453	YIHVTQSPSSLSVSIQGDRTVLTINCQTSQGVISLWYQHKEGRAPKLILHHTSSSEGGVSRSGSGFHTSFNLITISDLOADDI ATYYCQYLQFFGRGSLHIRTVAAPSVEFPPSDBEQLKSGTFSVKGKPTENKEVTHQGLSSPVTKEVTHQGLS SKDSTYSLSSLTLSKADYKHKVYACEVTHQGLSSPVTKEVTHQGLS
	1	454	DIVMTOTPLSLSVTPGQPASLSCKSQSLVHENLFTYLQKPGQSPSOLIYKVSNRSGVYDRFGSGSGTDFTLKISR EAEDVGYVYCQGTQPFPTGSGTKEVTKHTHD1QMTQSPSSLSVSIQGDRTVLTICQTSQGVISLWYQHKEGRAPKLILHHTSSSEGGVSRSGSGFHTSFNLITISDLOADDI LLIYKASNLITLGVPFRFSGGSQGTDFTLTISSLQPEDEIATYYCQGQTYTFEGQTKLEIKDTHTRTAAPSVEFIPPSDE QLKGTSATSYCLLANNYPRAKVQKVDNIALQNSQESTEODSKDTYSLSSLTLSKADYKHKVYACEVTHQGLS SPVTKEFNRGEC
	2	455	YQVLVOSGAEVVKPGASVKSQCKASGYTFISYIHWVQAPGQGLEWISIYPGRNVNTVNAQKFQGRATLTVDTSIISTA WMHWVROAPGQOLEWVQIJDKSNYATYADFSGRFTLSRDSKNTLYLQNSLRAIDTAVTTCYCRGYYALSPFD YNGQGTLVUTVSSDKHTASTKGPSYPLACRSRSTSESTALGCLVQDXYPEPYTVSWNSGALTSGVHTPAVLOSSGLY LS SVTVPSSSLIGKTIVCNIDHRPSNKKDKEVSKGPCCPAPEAGGSVFLFPKPKDFTLMSRTPEVTCVVD VSOEDEVONWYDGVENAKTUPREEEFNSTRVSVSTVLIHDMWINGKEYKCKVSYNKGIPSSIEETISKAKGOPR FPQVCTLPSSBEETMKVQISLCAVKGFPYPSDIAVEWESNGOPENNYKTTPVLDGSEFLVSKLTVDKSRWQEGNVS CSVMHEALHHYTOKSLSL
	3	456	RAHLVOSGMKPGASVRSQCKASGYTFISYIHWVQAPGQGLEWISIYPGRNVNTVNAQKFQGRATLTVDTSIISTA DDPDNGLAYMD1RGLKPKDFTLMSRTPEVTCVYDGVENAKTUPREEEFNSTRVSVSTVLIHDMWINGKEYKCKVSYNKGIPSSIEETISKAKGOPR VQDYPPEPVTVSSNSGALTIGKTIVCNIDHRPSNKKDKEVSKGPCCPAPEAGGSVFLFPKPKDFTLMSRTPEVTCVVD PAPEAGGPSPYFLFPKPKDFTLMSRTPEVTCVYDGVENAKTUPREEEFNSTRVSVSTVLIHDMWINGKEYKCKVSYNKGIPSSIEETISKAKGOPR HODWLNGKEYKCKVSYNKGIPSSIEETISKAKGOPRFPYPSDIAVEWESNGOP NNYKUTTPVLDGSEFLYSLKLTVDKSRWQEGNVSCTSYMEALHHYTOKSLSL

TABLE 4A-continued
Trispecific binding protein polypeptide sequences.

Trispecific binding protein polypeptide sequences							
Polypeptide Number (acc. to formula)	SEQ ID NO	Sequence					
Molecule							
Trispecific 29 N6_FR3_03/ ICD_8sup_x CDmid_ENLF I9G4	4	457 YIHTQSPSSLSVTPGPASISCKSSOSLIVENLYTQLKGOSPOSILYKVSNRFSGVPDFRGSGSGTDDFTLKLISRVA ATYYCQVLOFFGRGRSLHLIKRTVAPASVTFPPSDEQIKSGTATSVUCLANNFYPREAKVQWVQDNALQGSNSQESTVQE SKDSYSSLSSTLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGC					
	1	458 DIVMTOPLSLSVTPGPASISCKSSOSLIVENLYTQLKGOSPOSILYKVSNRFSGVPDFRGSGSGTDDFTLKLISRVA EAEDGVVYCGOGCQTYPFPGSGTKEVLEIDKTHTDIQTOMTQSPSSLSASVGDRVTITCASAQNLYVWLNWYQOKPGKAKP LLITKASNLHGTGPSPFSSSGSDTDFLTISLLOPEDIATYCOQGTYPTFGQGKLEIDKTHTRTVAAAPSVFIFPPSDE OLKSTASYUCLANNFYPREAKVQWVNDALOSNSQESVTEQDSDKSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGC					
	2	459 QVLOVSGAEVVKPGASVKSCKASGYTETSYIHWVROAPGCGLEWIGSYIPGNVNNTYNAOKFOGRATLTVDTSISTA YMEPLLRSDDTAVVYCTPSHYGLDWNFDWGKCTTIVTSSDKTHIQVOLVSEGGVVQPGERSLRLSQAASGETFTKA WMHHRVRAPEKQLEWAQIKDKNSNATYADSYKGRFTISRDSSKNTLYLQNNSLRAEDETAVYCCGTYVYALSPFD YWGQQTIVTSSDKTHTASTTKGPSPVTPALPCSRSTESTAHLGKDVDTSGWTFPPVTVSNMGLWDYFPEPVTVSNMGLWS LSSTVTPPSSSLGNTKTYTCNDVKHPSPNTKVDKREVEKSYGPPCPCPAPEAAAGGSPVTFPPPKDUTMISRAPEVTCVVD VSQEDPEQENWVYDGVVHNAKTPREQOFNSTYRVSVLTLHQDWLNGREYKCKVTSNKGLPSIEKTIKAKGQPR EPOVCTLPPEQEEEMTKNQVSLSCAVKGFYPSDLAVEWENGOPENNTKTPVPLDSDSFFLVSKLTVDKSERWQEGNVFS CSVNHEALHNHYTOKSLSLG					
	3	460 RAHLMVSGAMKKPGASVRSVCSGTYFTAHLLFWFROAPGRGLEMWGKPOGYAVNFGGGFRDRVLTROLSDPP DDPDIGIAYMDIRGKPDATTAVYCARDESYGDSWALDAWGQCTTVVSSAATTKGPSPVFLPACSGSTSESTAALGCL VKDYPEPTVSNMGLATSGVHIFPAVLOSSGYSSVSVTTPSSSLGTTKTYTCNDVKHPSPNTKVDKREVEKYGPPCPCC PAPEAGGGSVFLFPKPDTIIMLQVTPVTCVVDVSDEPQVFMVYDGVVHNAKTPREQOFNSTYRVSVLTLV HODWINGKREYKCKVTSNKGLPSSIEKTIKAKTPEQPVOTLPPCOEMPTKNOVSPSCSTMHEALHNHYTOKSLSLG NNYKTTIPVLDLSDGSSFLYSLKLTVDKSRMEOGVNPSCSTMHEALHNHYTOKSLSLG					
	4	461 YIHTQSPSSLSVSGDRVTINCOTSGYGSIDLHWYOKHGRPAKLLIHTTSEVEDGVPSRFSGSGFHTSENLTISDQADDI ATYYCQVLOFFGRGRSLHLIKRTVAPASVTFPPSDEQIKSGTATSVUCLANNFYPREAKVQWVQDNALQGSNSQESTVQE SKDSYSSLSSTLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGC					
Trispecific 30 N6_FR3_03/ ICD_8sup_x CDmid_ENLF I9G1_NMAS_DKHT linker	1	462 DIVMTOPLSLSVTPGPASISCKSSOSLIVENLYTQLKGOSPOSILYKVSNRFSGVPDFRGSGSGTDDFTLKLISRVA EAEDGVVYCGOGCQTYPFPGSGTKEVLEIDKTHTDIQTOMTQSPSSLSASVGDRVTITCASAQNLYVWLNWYQOKPGKAKP LLITKASNLHGTGPSPFSSSGSDTDFLTISLLOPEDIATYCOQGTYPTFGQGKLEIDKTHTRTVAAAPSVFIFPPSDE OLKSTASYUCLANNFYPREAKVQWVNDALOSNSQESVTEQDSDKSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGC					
	2	463 QVLOVSGAEVVKPGASVKSCKASGYTETSYIHWVROAPGCGLEWIGSYIPGNVNNTYNAOKFOGRATLTVDTSISTA YMEPLLRSDDTAVYCTPSHYGLDWNFDWGKCTTIVTSSDKTHIQVOLVSEGGVVQPGERSLRLSQAASGETFTKA WMHHRVRAPEKQLEWAQIKDKNSNATYADSYKGRFTISRDSSKNTLYLQNNSLRAEDETAVYCCGTYVYALSPFD YWGQQTIVTSSDKTHTASTTKGPSPVTPALPCSRSTESTAHLGKDVDTSGWTFPPVTVSNMGLWDYFPEPVTVSNMGLWS LSSTVTPPSSSLGNTKTYTCNDVKHPSPNTKVDKREVEKSYGPPCPCPAPEAAAGGSPVTFPPPKDUTMISRAPEVTCV VVDYHEDPEVKENWVYDGVVHNAKTPREQOFNSTYRVSVLTLHQDWLNGREYKCKVTSNKGLPSIEKTIKAKGQPR GQPRBEPQVCTLPPEQEEEMTKNQVSLSCAVKGFYPSDLAVEWENGOPENNTKTPVPLDSDSFFLVSKLTVDKSERWQEG NNYFSSVMHEALHNHYTOKSLSLG					
	3	464 DDPDGIAAMDIRGKPDATTAVYCARDESYGDSWALDAWGQCTTVVSSAATTKGPSPVFLPACSGSTSESTAALGCL LVKDFHPEPTVSNMGLATSGTQYTCNDVKHPSPNTKVDKREVEKYGPPCPCCPAPELGGPSVFLPPKPKDTLMISRAPEVTCV CPPCAPELGGPSVFLPPKPKDTLMISRAPEVTCVVDVSDEPEVKENWVYDGVVHNAKTPREQOFNSTYRVSVLTLHQDWLNG KEYTKCKVTSNKGLPSIEKTIKAKTPEQPVOTLPPCOEMPTKNOVSPSCSTMHEALHNHYTOKSLSLG					

TABLE 4A-continued
Trispecific binding protein polypeptide sequences.

TABLE 4A-continued
Trispecific binding protein polypeptide sequences.

Trispecific binding protein polypeptide sequences					
Molecule	Polypeptide Number (acc to formula)	SEQ ID NO	Sequence		
Trispecific 35	1	473	LTQSGTSLSPGETAIISCRTSQYSLAWYQQRPGLQAPRLVITYGSTRAGIPLDRFSGSRNGPDVNLTISNLESDDFGVYYCQYFFGQCTKVOIDIRETVAAPSFTVPPSDIQLKETASTVCLLNFYPREAKYQMKVNDALQSGNSQESVTEDSKDSTYLSLSTTLTSRDAEYHKVYACEVTHQGLSSPVTKSFNRGE		
VR01.23 / CD38 sup x CD38 mid _ ENLF	2	474	DIVMTOTPLSLSTPFGOPASISCKSSOLVHENLFTYLWLOKPGQSPOSILLYKVENRFSGYPDREFGSGSGTDTFLKLISRVEAEDGVYICGQGQTYPFINGSGTKVEIKDTKHTDIQNTQSPSLSLASVGDRVTITCOASQNIYVWLNWYQOPKGAKPLLIYKASMLHGTGPSPRESGSGTDTFLTISLLOPEDATYICQGQTYPTYQGITLEIKDTKHTPTVAAPSVTFPPSDEQLKSTASTVCLLNFYPREAKYQMKVNDALQSGNSQEVTEQPSKDSYSLSSLTSKADYEHKVYACEVTHQGLSSPVTKSFNRGE		
IG4/409K_DKHT linker	2	475	QVQLVSGAEGVKPQASVKVSKASGYTFTSYIHWVROAPGQGLEWIGSIYQGNVNTINYAQKFQGRATLVDTISISTAQMELSPRLSDDTAVYCYTCSHYGLDWNFDWGKCTTVTMSDKTHTQVOLVSEGGLVYQPGERSLRLSCAASGFTETKAZWMHRYRQAPAKQOLEMVAQIKDKENSYATYADSVKGRFTISRDQKCLTLYLQNSRNLRAEDTAVYICRQVYIALSPFDYWGGQTLYVPSDSLGIKYTCNDVHEKPSNTVTDKREVSKTGPCCPCKPDTUMISRPEVTCVVDLSSTVTPSSSLGIKYTCNDVHEKPSNTVTDKREVSKTGPCCPCKPDTUMISRPEVTCVVDVSQEPEVQENWYDGVETHNATKYPREQEFNSTYRVSVLTLHQDMLNGKEYKCKVSNKGIPSTSEKTIKAKGQPRPBPQVTLPPQEEEMTKNOVLSLCAVKGFPYPSDIAVEWESNGQPENNYKTTPVLDSDGFELVSKLTVDKSRWQEGNVFSCSYNHEALNHYTQKSLSLSCIGQVQLVSGGMMKKEPEMSMISCRASGYEFIDCTLNWIRLAPGRPEWNGWLKPWRGAVNARYPLQRGVTMTRLSQDPDDPDTGTAFLERLSLTVDDTAVIFCTRGKNDYINMDEERWGRGTPVIVSASTKGPSPVPLAPCSRSTSESTAALGLVLKDYPFPVVITYWSNSGALITSGWHTLSSVTPVPESSLGHTCNVDRHPSNTVTDKREVESKYGPPCPCPQAPEAAGGPSYFLPPPKPDTUMISRPEVTCVVDVSQEDPEVQENWYDGVETHNATKYPREOEMTNTYRVSVLTLHQDMLNGKEYKCKVSNKGIPSTSEKTIKAKGQPRPBPQVTLPPQEEEMTKNOVLSLCAVKGFPYPSDIAVEWESNGQPENNYKTTPVLDSDGFELVSKLTVDKSRWQEGNVFSCSYNHEALNHYTQKSLSLSCIGQVQLVSGTSLSPGETAIISCRTSQYSLAWYQQRPGLQAPRLVITYGSTRAGIPLDRFSGSRNGPDVNLTISNLESDDFGVYYCQYFFGQCTKVOIDIRETVAAPSFTVPPSDIQLKETASTVCLLNFYPREAKYQMKVNDALQSGNSQESVTEDSKDSTYLSLSTTLTSRDAEYHKVYACEVTHQGLSSPVTKSFNRGE		
	3	476			
	4	477			

TABLE 5
Trispecific binding protein polynucleotide sequences

TABLE 5 -continued

TABLE 5-continued

Tri-specific binding protein polynucleotide sequences			
Polyptide Number (acc. to formula)	SEQ ID NO	Sequence	
		GGCCACCTACTACGCCGAGAGCCGTTTACCATCAGCGGGACAGAACACCCCTGTACCTG TAGTGAATGGCTGGCCGCTGGCCGCTGGCCGCTGGCCGCTGGCCGCTGGCCGCTGGCCGCTGG CCCTAGCAAGCAAGCAACCTGGGAAAGGGAACTGGGCTGGCCGCTGGCCGCTGGCCGCTGG ACCGTGTCTGGATTCTGGGCTGGCCGCTGGCCGCTGGCCGCTGGCCGCTGGCCGCTGGCC AGCTGAGAGCCGGTGTGACACGTCAGCTGGCCGCTGGCCGCTGGCCGCTGGCCGCTGGCC CAAGAACACAGGGCAAGAGGAAAGGGCAACACGGCAACACGGCAACACGGCAACACGGCA CCGGACAGGGGGCTTCTGGTTCGGTCCGGTCAAGGGGGCTGGCCGCTGGCCGCTGGCC CGAAGTGACCTGGCTGGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG AAGTGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCA GCTGACCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCA AAAACATAGCAAGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGG CCAAGAACAGGGTCTCTGAGTGTGCTGAGTGTGCTGAGTGTGCTGAGTGTGCTGAGTGT GGCCAGGCAACCAACTGGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGG GACAGTGCAAGTCCGGTGGAGGGCAAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG TACACCCAGAAGTCCCTGAGCTGAGCTGGGG 	
3	484	CAAGTGCGGTGCTCAAGTGTGGGGCGAGAAGAAACCGGGCGAGACAGTATGGGATCAGCTGAGAGCGAGCG GCTAGGAGTTTCAATAACTTCCCCTATGCAACTGCACTGGCCGCTGGCCGCTGGCCGCTGGCC AAGCCGAGACGGGGCTGTCTACCCAGAACAGCTGGCCGCTGGCCGCTGGCCGCTGGCC ACACAGCTCTCTGGAACTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGG ACGGCCGATGGTCTCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGG TCAAGGACTACTTCCCAGACGCTGGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG CTGTGCTCTAGCTCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGG AGTACAGCTGCAACTGTAATGGGCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGG CTACATCTGCAACTGTAATGGGCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGG AGACACCCTCTGATCTCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGG AGTCAACTGTAATGGGCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGG CTCCGTGTGGTCAAGCTTCACTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGG ACAAAGCCCTTCACTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGG CTGGCCCTTCACTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGGGACTCTGG ACATGGCGTGTGAGTGGGAGGAATGGGAGGAACAGCACTAGAACACAGCA GGGGTCTCTCTTCTTCAACTACCCAGGAGAACAGCAAGGAGGGAGGGAAACCTCT GCTGCAAGGCTTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGT 	
4	485	AGCTGCAAGAGCCCTGGCTGGTCACTGGCAGAGCAAGGAGAACAGGAGAACAGGAG ACGGAGCTGGCTGGPATCAGAGAGCCCTGGCTGGTCACTGGCAGAGCAAGGAGAACAGGAG CGCGGAATCCGATAGTTAGGGTCACTGGCTGGTCACTGGCAGAGCAAGGAGAACAGGAG GGCAGCTGGCTGGTCACTGGCTGGTCACTGGCTGGTCACTGGCAGAGCAAGGAGAACAGGAG TACCTGGTGGCTGGCAACTCTTCACTGGCTGGTCACTGGCTGGTCACTGGCAGAGCAAGGAGAACAGGAG GCCCTGCTGCAAACTTCACTGGCTGGTCACTGGCTGGTCACTGGCTGGTCACTGGCAGAGCAAGGAGAACAGGAG CAGGAAGGGTGTGAGCGAGGAAGGAGAACAGCACTGGCTGGTCACTGGCTGGTCACTGGCAGAGCAAGGAGAACAGGAG GATPACAGGAGAGCAAGGTGTAGGCTGGCTGGTCACTGGCTGGTCACTGGCTGGTCACTGGCAGAGCAAGGAGAACAGGAG ACCGGGGGAGTGT 	

TABLE 5-continued

TABLE 5-continued

TABLE 5-continued

TABLE 5 - continued

TABLE 5 - continued

TABLE 5-continued

TABLE 5-continued

TABLE 5 - continued

TABLE 5 -continued

TABLE 5-continued

TABLE 5 -continued

TABLE 5-continued

TABLE 5-continued

TABLE 5 - continued

Trispecific binding polynucleotide sequences						
Poly peptide Number (acc. to formula)	SEQ ID NO	ID	Sequence	Molecule		
4	521	TACATCACCCTGAGCCAGAAGGCCCAAGCAGCCTGTGTCATCGGGCAGAAGACTGCCCAGACCTTCAGTGCACAGAGCTGCAAAAGAGCA TCAGGGCGTGGCAGGAGCTGCACTGGTATCAGCAGAAAGCTGGAGAGGCCAAAGCTGGAGCTGCACTGGTGGTGAAGCTGCAAAAGAGCA AGCAGGTGAGAAAGATGCGCTGCGCCAGAAGCTGGAGAGGCCAAAGCTGGAGCTGCACTGGTGGTGAAGCTGCAAAAGAGCA TCTGAGAGGGCGAGAACATTGGCAGAACATTCAGCTGGAGAGGCCAAAGCTGGAGCTGCACTGGTGGTGAAGCTGCAAAAGAGCA AGCCTAACGGCTGCGCCGCTTCCAGAACCTTCACATGGCGAGAGGCCAAAGCTGGAGCTGCACTGGTGGTGAAGCTGCAAAAGAGCA GTGTCGTGTCGTGAAACACTTCACCCCGCGAGGCCAAAGCTGGAGCTGCACTGGTGGTGAAGCTGCAAAAGAGCA ACAGCAGGAAAGCTGAGCGAGCAGCAAGGAAAGGAACTCCACCTAACGGTGGAGCTGCACTGGTGGTGAAGCTGCAAAAGAGCA GGCCGCTAACAGAGAACCTGGTGGAGCTGCACTGGTGGAGCTGCACTGGTGGTGAAGCTGCAAAAGAGCA TTCAACGGGGGAGGT				
Trispecific 14 N6/CD28sup x CD4mid 1994	1	GACATGTTGATGACCCAGACTCCCTGAGCTGAGCGGTGACACCTGGAGACCTGGTGGAGCTGCAAAAGAGCA GCAGAGGCCCTGGGAGAACCTGGAGCTGCACTGGTGGAGCTGCAAAAGAGCA CCTGAGCTTAAGGGCTCCAAACAGATTCAAGGTTGAGCTGGAGCTGCACTGGTGGAGCTGCAAAAGAGCA TCCTGAGAGATCAGGGCGTGGAGGGAGCTGGAGCTGGAGCTGCAAAAGAGCA TTTGCGAGGCGCACCAAGCTGGAAATCTAACGGCCAGCCCAGGGCCAGCTGGAGCTGCAAAAGAGCA GCAGCGCTGCTGGCCAGCTGGAGGGAGCTGGAGCTGCAAAAGAGCA TGGTAACTAGAGAACGGCGCAAGGGCCAGCTGGAGGGAGCTGGAGCTGCAAAAGAGCA GCAGATTTCTGGAGGGCTGGGAGCTGGAGCTGGAGCTGCAAAAGAGCA TACTAGTGGCTGAGGAGCCAGAGCTTACACCTTGGCTGAGGAGCTGGAGCTGCAAAAGAGCA CCAGCGCTAACGGCGTGGAGGGCTGGAGCTGGAGCTGGAGCTGCAAAAGAGCA GTGCGNTGCTGCTGAAACAACCTAACGGCCAGGGCCAAAGTGGAGTGGAGCTGGAGCTGCAAAAGAGCA GCAAAGGCCAGGAAACGGTGAACGGAGAACAGAACGGTGAACCTAACGGCCAGGGCTGTAGGAGCTGCAAAAGAGCA CAAGGGCGCACTACGGAGGAGAACAAAGCTGGTAGCCCTCGGAAGTGA AGCTTAAACGGGGGGAGTGT				
2	523	CAGGGTCACTGGTGGAGCTGGCCGAGCTGGTGGAGCTGGCCCTCTGTGAAGGTGTCTGGAAAGGGCAGCG CTACACCTTAACTGGAGTAACTACATCCACTGGTGGCTGGAGCTGGACTGGTGGAGCTGGAAAGTCACTGGAGCTGGAGCATCT ACCCGGCGCTAACTGGAGACTGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG CACCCTGCTAACGGCGTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG TGGATTTGGAGACTTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG GGCGGGGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG GGATGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG CGGGAGCTAACGGCGTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG CAGGGTGAAGTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAGCTGGAG AGCTTAAACGGGGGGAGTGT				

TABLE 5-continued

TABLE 5-continued

TABLE 5-continued

TABLE 5-continued

T1-specific binding protein polynucleotide sequences				
Polyptide Number (acc. to formula)	SEQ ID NO	Sequence		
Molecule				
		ACCTCTGACTCTGAGATGAAAGCAGCTGGGCGGAGAACCCGGGCTGTGTTACTCTGCGGGCGTGTACTATGCCCT GAGCCGCTTGATTAATGGGGCCAGGGAAACCTCTGGTACCGTGTACTCTGAGTATAAGCACCACGCCAGCAAGG GCCCATGGGTCCTCTGGCCACGGCTGGGCTGACCTCTGGAAATCTGGCTCTGGTACCTGAGTGTGACGACCTTTCAGCGTG GACTACTTTCTGGAGGGCCGTCGGCTGACTCTCTGGAGGAGGCGCTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG CTCCAGAGGAGGGCTGGGCTGACTCTCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG CTGGTAACTGGAGCAAGGGCCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG CTTGGCCAGGGCCCTGAAAGTCTGGCTCTGGTCTCTGGTCTCTGGTCTCTGGTCTCTGGTCTCTGGTCTCTGGTCTCTGG AGCGGGACCCCGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGA GGACCCGGTGGAAAGTCACAAGCCGCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GTGTGTAACCTGGCTGCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GCTCCATCGGAAACCTAGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GGAAAGATGACCAAGAACGGTGTCCCCAGGTGTCTAGCTGTGCCTGAAGGGCTTACCCAGGGGAGCATGGCGTGGAA TGGGAGAGGAGGAGGGCAGGGCAGGGCAGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GGTGTGCAAGTGAACGGTGGAGCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG CTGGCAACCAACTACCCAGAAAGTCCCTGTCCTGGAGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG GCCTACACCGTACCGGCCACATGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGG AAGGCCACATACTGGCCCTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG AGATCCCTACATGGACATCGGGGGCTGAGCCCTAGAAGCCGGCTGAGCTCTGGGAGGAGGAGGAGGAGGAGGAGGAG CGGGAGAGG CATCGGTGTTCTGGGCCCTCTGGGCTCTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG TACTTCTCCGAGGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCT CAGAGAG TAACGGAGACACACCCAGCAACCCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GCCCAACCCCTGGTGAAGGTTGG GGGACCCGGAAAGTGAACCTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGT GGCTGGAGAAAGTGAACACGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAG CTGACCGTGTGGCACAGGAGGACTGGCTGAAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG CCATGGAGAAACCTAGGGAG AGAGATGACCAAGAACGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGT TCCGAAGTGTGAGAACGGAG ACAACCAACTACCCAGAAAGTCCCTGTCCTGGAGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 		
3	532			
		AGAGG GCCTACACCGTACCGGCCACATGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGG AAGGCCACATACTGGCCCTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG AGATCCCTACATGGACATCGGGGGCTGAGCCCTAGAAGCCGGCTGAGCTCTGGGAGGAGGAGGAGGAGGAGGAGGAG CGGGAGAGG CATCGGTGTTCTGGGCCCTCTGGGCTCTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG TACTTCTCCGAGGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCTCTGGCT CAGAGAG TAACGGAGACACACCCAGCAACCCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GCCCAACCCCTGGTGAAGGTTGG GGGACCCGGAAAGTGAACCTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGT GGCTGGAGAAAGTGAACACGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAGGCAAG CTGACCGTGTGGCACAGGAGGACTGGCTGAAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG CCATGGAGAAACCTAGGGAG AGAGATGACCAAGAACGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGT TCCGAAGTGTGAGAACGGAG ACAACCAACTACCCAGAAAGTCCCTGTCCTGGAGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 		
	533			
		TACATCACCTGAGCCAGAGGAGGCCACAGCGCTGTCGTTGTCATCGGGCGAGAGTGGACATCAACTGCCCAGAACCT TCAGGGCGTGGGGAGGAGCTGGCTGACTGGTACCTGTTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG AGCAGGGTGAAGATGGCGCTGGCCACAGAATTTCGGGAGCCTGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG TCTGGAGGCGTGGAGCTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGG AGCGTACGGTGTGGAGCTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGG GTGTGGCTGTGAAAGACGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGG AGCGTACGGTGTGGAGCTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGG GGCCCAACTACGGTGTGGAGCTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGG TTCAACGGTGTGGAGCTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGG 		

TABLE 5 - continued

TABLE 5-continued

TABLE 5 -continued

TABLE 5-continued

TABLE 5 -continued

TABLE 5-continued

TABLE 5 - continued

TABLE 5-continued

TABLE 5-continued

TABLE 5 - continued

TABLE 5 - continued

TABLE 5-continued

TABLE 5-continued

Tri-specific binding protein polynucleotide sequences			
Polyptide Number (acc. to formula)	SEQ ID NO	Sequence	
Tri-specific 27 N6_rv52/ CD38sup x CDmid_	566	GACATGTTGATGCCAGACCCCCCTGAGCTGAGCACACCTTGACAGCCCTGTCAGGATCATGGTGCAGAGGA GCCAGAGGCCCTGGTGAAGGAAACCTTCACTTGAGATCTGGTGTGATCTGGTGAAGACCCGCCAGGTC CTGATGTTACAGGGTTCACAAAGATTCAGCGGTGTCGCCAGAGATCTCGGACAGGCTCTGGACCCGACTTCAC CCTGAGGATAGGCCGGTGGAAAGCCGAGGACTGGCGTGTGACTATTGTGTCAGGCCACCACTGGTCACT TGGCAAGGCCAACGGGAAATTAAGGAAACAAACCACTTGATACTGAGATCAAGGAGGAAAGGCTGAGCT GTCAGCAGGGTGGGAGAGGAGGAACTGGGAAACCTTGAGATCAAGGAGGAAAGGCTGAGTGTGATCTGGTAC AGCAGAGGCCGGTGGGAGGAGGAACTGGGAAACCTTGAGATCAAGGAGGAAAGGCTGAGTGTGATCTGGTAC TTCCTGCAAGGCCGGTGGGAGGAGGAACTGGGAAACCTTGAGATCAAGGAGGAAAGGCTGAGTGTGATCTGGTAC GCCAGGAGGCCGGTGGGAGGAGGAACTGGGAAACCTTGAGATCAAGGAGGAAAGGCTGAGTGTGATCTGGTAC TAGGTTAGGGGCACTACCCCTAACCTTGAGGAGGAGGAACTGGGAAACCTTGAGATCAAGGAGGAAAGGCTGAG GCCTGTTGAA AACCTTGAGGAGGAGGAAATGGCASTGGGGCAAGAACATGCCCTGCAAGGGGAAACAG CCAGGAAGGGTGGCAGGAGGAGGAGGAGGAACTGGGAAACCTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GACTAGGAG ACCAGGGGGCAGGTGT DKDHT linker	
	567	CAGGTCAGCTGGTGGAGTCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG CTACACTTACCAAGTACTACATCCACTCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG ACCCGGCAAGTGAGCAACTAAGCCAGGGAGGTTCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG CACCGCCTAATGGAACTGAGCTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG TGGATTGGAACCTTGCAAGTGTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG GCTGTTGGGAATCTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG TCACCAAGGGCTGGTGAATGCACTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG GAGCAACAGCTAACGGCAACTACTACCCGAGACGGCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG ACCCCTTACCTGAGTGAACAGCTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG GAGGCCCTTGGTGAATTACTGGGGGGCAAGGAACCTCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG GCCCGAGGAGGTTCCCTCTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG GACTTTCCTGGAG CTGCAACTTCCAGGGCTGTAAGCCGCTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG CTGCAACCTGTAAGCCGCTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG CACCTTCTCCCTTGTGCTCTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG CTCTGGTAACTGAG ATTGAGAGCTGGTGAAGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGCCCTCTGTGAGGTGTCCTGGAAAGGCCAGGG GGTGTGTTCTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACT GCCCTTGGCTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGGGGGAGGTCTGTTAAACCTGGGG CCCAAGGAG GCCGTTGAAATGGGAG CATTCTCTGGTGTCAAGGTGAATGTGCAAGTCCGGTGGGAGGAACTAACAAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG CACAGGGCCCCCTGCAAAACCACTACACCCAGAGTCTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACTGGTCACT AGAGCCACCTGGGGTGGAGTCTGGCACCGCCATGAGAAAACAGGCCCCCTCTGGTGGGGTCTCTGGTCAAGACAAGGCCAGGG GCTAACCTTACCGCCACATCCCTTCTGGTCACTGGGAG AAGCCCAAGPATGGGGCCACACTTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGG AGATCCCTACATGGACAACTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGG CCGGCAGAGCTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGGGGAGGTCTGGGG CATGGTCTGGGGCAACCTCCAGGAG CATGGTCTGGGGCAACCTCCAGGAG 568	
Tri-specific 27 N6_rv52/ CD38sup x CDmid_	5		

TABLE 5-continued

TABLE 5-continued

TABLE 5 - continued

TABLE 5-continued

Tri-specific binding protein polynucleotide sequences			
Polyptide Number (acc. to formula)	SEQ ID NO	Sequence	
		NTGGGCTGCCTCGTGTGAAAGGACTACTTTCCGAGCGTGTGACCAAGGGGGT GCACCCATTTCAGCGTGTCTCCAGCGACCTTAACCCGACCAAGGGTGGAGAGCC TGGGACCACTAAGAACCTAACCTTAACCCGACCAAGGGTGGAGAGCC GTAGCGCCTCCCTGCCCTCCCTGCCCTCCCTGCCCTCCCTGCCCTCCCTGCC CAAGGACACCCCTGTATGATAAGCGGGAAAGTGAATCTGGGAGATCTCGAG GTGCAAGTAAATTGGTACCTGGCAAGGGGAAAGTGTAAACA GCACCTACGGGTGGTCCCGTGTGACCGTGAAGGGCAAGGAAAGTACAAGTGG GTCCGACAAAGGGCTGCCAGTCATCGAAAGAACCATCGAAAGGGCAAGGGC TATACCCCTGCCCTTGCCAGGAGATGACCAAGAACCGGTGTGCTCTGGTCT CAAGGACATTGGCTGGATGGAGGAGCAAGGGCAGGCCAGAACACTAACAGA AGCGACAGGGCTCACCTGGTACTCTCAAGGAGATGACCAAGGGCAAGGGC CTCCGTGATGCACTGGCCCTGCAAAACCTAACCCGAAATGCTGGTCT TACATCGACGGCCAGGCGCTGCGGAGCTGGGAGATGGGAGGAGGAGGAG TAGGGGCTGGCGAGCTGGGAGCTGGGAGCTGGGAGGAGGAGGAGGAG AGCAAGCTGAAAGATGGGCTGGGAGATGGGAGGAGGAGGAGGAGGAG TCTGACGGCGAACATGGCACCTACTATGGTCAAGTGGCTGGGCT AGCTAACGTGGCCCTCCAGCGCTGGTGTGAGTGGCTGGGAGGAGGAG GTGTCGCGCTGGGAGCTGGGAGGAGGAGGAGGAGGAGGAGGAG GAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GGCGACTAACGAGAACGGTGTGACCGAGGAGGAGGAGGAGGAG TTCACCGGGGGAGTGT 	
4	577	TACAGCTGACGGCCAGGCGCTGCGGAGCTGGGAGGAGGAGGAGGAG TAGGGGCTGGCGAGCTGGGAGCTGGGAGGAGGAGGAGGAGGAG AGCAAGCTGAAAGATGGGCTGGGAGATGGGAGGAGGAGGAGGAG TCTGACGGCGAACATGGCACCTACTATGGTCAAGTGGCTGGGCT AGCTAACGTGGCCCTCCAGCGCTGGTGTGAGTGGCTGGGAGGAG GTGTCGCGCTGGGAGCTGGGAGGAGGAGGAGGAGGAGGAGGAG GAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GGCGACTAACGAGAACGGTGTGACCGAGGAGGAGGAGGAG TTCACCGGGGGAGTGT 	
Trispecific 30	1	GACATCGTGTATGACCCAGCCCCCTGAGCCCTGAGCGTGTACACCTGGAGCAGCATAGCTGCAAGAGCA GCCAGAGGCTGTGTCAGGAACTCTGGAGACTACCTGAGCTGGTGTATGCGAAAGGCGGAGAGGCGCCAGTC CTGATCTCAAGCTGTCACAGATTCAGGCTGGGAGGAGGAGGAGGAG CTCTGAATGATGCGCTGGGAGGAGGAGGAGGAGGAGGAGGAG TTTGGCAAGGGCACTAACGGTCAAGGAAATCGGAGGAGGAGGAG TGTCTGCGCTGGGAGCTGGGAGGAGGAGGAGGAGGAGGAG CAGGAGAAGCCGCAAGGCCCAGTGTGATCTCAAGGAGGAGGAG GCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG TACGTGTGCGCTGGGAGGAGGAGGAGGAGGAGGAGGAG GCCCTGCTGACAAACTTGTACCCCTGAGGAGGAGGAGGAG CAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG GACTAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG ACCGGGGGAGTGT 	
N6_F3 - 03 / CD2 ^{sup} x CD3 ^{mid} EN1 ^{lo} Ig1 ₋ NNAs ₋ DKTHT linker	578	CTAGGTCAGCTGGGAGCTGGGAGGAGTCTGGGAGGAGGAGG CTACACCCTTACCAAGCTACTACATCCACTGGGAGGAGGAGGAGG ACCCGGGZACGTGAACTACGCCAAGACTACGCCACTGGGAGGAGG CACGGCCTACATGAACTGGGAGGAGGAGGAGGAGGAGGAGG TGGATTTGGZACTTGTGACGTGAGCTGGGAGGAGGAGGAGG GCTGTGGZGATCTGGGAGGAGGAGGAGGAGGAGGAGGAGG TACCAAGGGCTGATGCACTGGGAGGAGGAGGAGGAGGAGG GAGGAAACAGGTACGCCACCTAAGCGGAGACGGCTGGT 	
2	579	CAGGTGGCAGCTGGGAGCTGGGAGGAGTCTGGGAGGAGGAGG CTACACCCTTACCAAGCTACTACATCCACTGGGAGGAGGAGGAGG ACCCGGGZACGTGAACTACGCCAAGACTACGCCACTGGGAGGAGG CACGGCCTACATGAACTGGGAGGAGGAGGAGGAGGAGGAGG TGGATTTGGZACTTGTGACGTGAGCTGGGAGGAGGAGGAGG GCTGTGGZGATCTGGGAGGAGGAGGAGGAGGAGGAGGAGG TACCAAGGGCTGATGCACTGGGAGGAGGAGGAGGAGGAGG GAGGAAACAGGTACGCCACCTAAGCGGAGACGGCTGGT 	

TABLE 5 -continued

TABLE 5-continued

TABLE 5-continued

TABLE 5 - continued

TABLE 5 - continued

TABLE 5-continued

Tri specific binding protein polynucleotide sequences			
Polyptide Number (acc. to formula)	SEQ ID NO	Sequence	
		GCGCNGCCTCGTGAAGGACTACTTCCGGAGCCCGTGAACCGTGTCCTGGCANTNTGACAAGGGGGTGCAC CACCTTTCAAGCCCTGCTCGTCAAGCCAGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG GCACAAAGGACTTAACCTGTAACCTGTAACCTGTAACCTGTAACCTGTAACCTGTAACCTGTAACCTGTAACCTG GGACACCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCT CAGTICAATTGTGATG CTAACCGGGTTGG AACAGGGGCTGCCAGTCATGAGAAAACCATGAGAAAACCATGAGAAAACCATGAGAAAACCATGAGAAAACCATG CCTGCGCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCTGCGCCCT GACATTGGCGTGGGATGGAGAAGAGATGACCAAGAACCCGAGTGGAGAACGGCCAGCCGGCAAGAACCTAAAGA ACGGGCTCAITCTCTGACTCAAGTGAACCGTGGCAAGAGCCGGTGGCAAGAGCCGGTGGCAAGAGCAAGGTGCTC GTGATGCAAGGGCTGCAACCAACCAACCAAGAAGTCCCTGTCCTGTCCTGGC	
4	59_3	CTGACACAGGCGCTGGCACCTCTACTGAGGCCAGGGGAGCCATCATGCTGGCGACAAGCCATACTCG CGAGCCTGGCGCTGGTATAGGCGAGGCGTGGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCG CGGATCCCGATAGATTAGGCGCTGGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCG GACTTCGGGTTGACTCTGCGAGCTAGGCGTGGTCTGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCG GGTGGCGCCTGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCG GCTGAGACACTCTGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAGGCGAG GAAAGCGTGAACGGCGAGAAGGACTTACCTACGCTGAGAAGGACTTACCTACGCTGAGAAGGACTTACCTAC ACGGAGAAGAACAGGTGTAACGGCTGGAGTGGAGTGGAGTGGAGTGGAGTGGAGTGGAGTGGAGTGGAGTGG GGGGAGTGT	

EXAMPLES

[0597] The Examples that follow are illustrative of specific embodiments of the disclosure, and various uses thereof. They are set forth for explanatory purposes only, and should not be construed as limiting the scope of the invention in any way.

Example 1: Development of Trispecific HER2/CD28xCD3 Antibodies and Variant Anti-CD3 Binding Sites

[0598] Immuno-oncology is a promising, emerging therapeutic approach to disease management in cancer. The immune system is the first line of defense against cancer development and progression. There is now large evidence that T cells are able to control tumor growth and prolong the survival of cancer patients in both early and late stages of disease. However, T cells specific for tumors can be limited in a number of ways preventing them from controlling the disease.

[0599] In order to remove the limitations on T cells induced by uncontrolled tumors, novel antibodies were developed in the trispecific antibody format depicted in FIG. 1A to specifically activate the T cells to engage HER2 expressing cancer cells. These novel trispecific antibodies are able to bind to three targets: HER2, CD3, and CD28. Anti-HER2 and anti-CD3 binding sites were further optimized for high affinity binding and reduction in potential manufacturing liabilities.

[0600] HER2 amplification and overexpression can be found in molecular subtypes of breast cancer, and also in gastric, ovarian, lung and prostate carcinomas. Optimal activation of T cells requires two factors: (1) Antigen recognition and (2) Co-stimulation. Using the trispecific HER2/CD28xCD3 trispecific binding proteins described herein, Signal 1 is provided by an agonist anti-CD3 binding site, and Signal 2 is provided by an agonist anti-CD28 binding site (see, e.g., FIG. 1D). It is thought that the trispecific antibodies described in the subsequent Examples recruit T cells to the tumor via HER2 and activate the engaged T cells by binding to CD3 and CD28. The resulting activation induces the killing potential of the immune cells against the nearby tumor cells.

Materials and Methods

Production and Characterization of Antibodies

[0601] Trispecific antibody variants were produced by transient transfection of expression plasmids into Expi293 cells. 5 days after transfection, the supernatant from transfected cells was collected, quantified and normalized by absorbance at 280 nm on Nano Drop. The binding of supernatant to corresponding antigens were determined by ELISA and the absorbance of parental HER2 WT tri Ab was set as 1.0. The fold changes of other variants were calculated by dividing the corresponding absorbance to that of parental Ab.

[0602] Trispecific antibody variants were purified using protein A affinity purification followed by SEC purification. The binding of purified antibodies to corresponding antigens were determined by ELISA. The EC₅₀ were determined based on the binding curve generated by Graphpad Prism7.

Results

[0603] Trispecific Ab variants were produced with several mutations in the binding arms in order to mitigate potential manufacturing liabilities, e.g., deamidation sites. A binding ELISA assay was performed to assess binding of the indicated trispecific antibodies to each of the three targets: HER2, CD3, and CD28. In FIG. 1B, HER2/CD3xCD28 trispecific antibodies with the indicated anti-HER2 or anti-CD3 variants were compared to parental Trispecific Ab. Introducing some sets of mutations (e.g., 32/33 QQ and 33/35QQ) into the VL domain of the anti-CD3 binding site led to dramatically reduced binding to CD3, whereas 32/35 QQ mutations retained near wild-type binding. MS peptide analyses showed that binding sites with the DNAQ mutations in CDR-L1 (SEQ ID NO:63) were still subject to greater than 15% deamidation, whereas ENLQ (SEQ ID NO:281), ENLF (SEQ ID NO:282), and ENLR (SEQ ID NO:283) led to less than 5% deamidation. Importantly, these variants also retained binding to CD3.

[0604] In addition, binding curves for the indicated antibodies binding to human HER2, human CD28, and CD3 are provided in FIG. 1C. The EC₅₀ values of selected trispecific antibody variants are provided in Table E.

TABLE E

Trispecific antibody	Binding Affinity (ELISA)(nM) EC ₅₀		
	HER2	Human CD3	Human CD28
HER2 (WT-trastuzumab)/CD28supxCD3mid (32/35 QQ (LC); DKTHT linkers on HC/LC) IgG4 FALA	162.3	566.4	1321
HER2 (30R/55Q/102E + LC-WT-trastuzumab)/CD28supxCD3mid (32/35 QQ (LC); DKTHT linkers on HC/LC) IgG4 FALA	93.66	364.8	871.9
HER2-30R/55Q/102E/CD28supxCD3mid (32/33/35QQ) DKTHT linker IgG4 FALA	83.89	3222	1024
HER2 (30R/55Q/102E + LC-WT-trastuzumab)/CD28supxCD3mid (DNAQ (LC); DKTHT linkers on HC/LC) IgG4 FALA	111.2	725.7	1053
HER2 (30R/55Q/102E + LC-WT-trastuzumab)/CD28supxCD3mid (32/35QQ (LC); L1 linker) IgG4 FALA	111.5	412.5	1345
HER230R/55Q/102E/CD28supxCD3mid (32/33/3435 ENLR (LC); DKTHT linkers on HC/LC) IgG4 FALA	123.9	81.53	878.8
HER2 (30R/56A/102S + LC-WT-trastuzumab)/CD28supxCD3mid (32/35QQ185E) IgG4 FALA	516.0	5494	3631

TABLE E-continued

Trispecific antibody	Binding Affinity (ELISA)(nM) EC50		
	HER2	Human CD3	Human CD28
HER2-30R/55Q/102E + LC-30Q/CD28supxCD3mid (32/35QQ) 185S L1 linker IgG4 FALA	1540	10616	2036
HER2-30R/55Q/102E/ CD28supxCD3mid (32/33/35QSQ) 185S L1 linker IgG4 FALA	467.0	19382	1814
HER2-30R/55Q/102E/ CD28supxCD3mid (32/33/35QSQ) 185E L1 linker IgG4 FALA	478.6	19756	1739
HER2/CD28supxCD3mid DKTHT linkers on HC/LC) IgG4 FALA	228.9	671.2	752
HER2/CD28supxCD3mid (32/33/3435 ENLIF (LC); DKTHT linkers on HC/LC) IgG4 FALA	195.9	773.3	1466
HER2/CD28supxCD3mid (32/33/3435 ENLQ (LC); DKTHT linkers on HC/LC) IgG4 FALA	212.1	10558	2405
HER2/CD28supxCD3mid (32/33/3435 ENLR (LC); DKTHT linkers on HC/LC) IgG4 FALA	166.2	381.9	1051
anti-Her2/CD3/3CD28 IgG4 FALA	176.1	516.2	870.6

[0605] Without wishing to be bound by theory, as depicted in FIG. 1D, it is believed that HER2/CD3/CD28 trispecific antibodies recruit T cells to cancer cells through the anti-HER2 and anti-CD3/CD28 arms. Further, it is believed that engaged T cells are activated by the anti-CD28/CD3 arms. Killing of cancer cells is believed, without wishing to be bound by theory, to occur through T cell mediated mechanisms (e.g., Perforin, granzyme). Without wishing to be bound to theory, it is contemplated that similar mechanisms may allow for killing of other types of tumors by substituting antigen binding sites that recognize other tumor target proteins.

Example 2: Development of Trispecific CD38/CD3xCD28 Antibodies

[0606] Trispecific CD38/CD3xCD28 antibodies were developed and characterized for binding to CD38, CD3 and CD28 polypeptides.

Materials and Methods

Generation of CD38, CD28xCD3 Trispecific Antibodies

[0607] A panel of anti-CD38, anti-CD3, and anti-CD28 antibodies, as well as human IgG4 Fc domains were used to generate CD38/CD28xCD3 trispecific antibodies in the trispecific antibody format depicted in FIG. 2A.

[0608] Trispecific binding proteins were produced by transient transfection of 4 expression plasmids into Expi293 cells using ExpiFectamine™ 293 Transfection Kit (Thermo Fisher Scientific) according to manufacturer's protocol. Briefly, 25% (w/w) of each plasmid was diluted into Opti-MEM, mixed with pre-diluted ExpiFectamine reagent for 20-30 minutes at room temperature (RT), and added into Expi293 cells (2.5×10^6 cells/ml). An optimization of transfection to determine the best ratio of plasmids was often used in order to produce the trispecific binding protein with good yield and purity.

[0609] 4-5 days post transfection, the supernatant from transfected cells was collected and filtered through 0.45 μ m filter unit (Nalgene). The trispecific binding protein in the supernatant was purified using a 3-step procedure. First, protein A affinity purification was used, and the bound Ab was eluted using "IgG Elution Buffer" (Thermo Fisher Scientific). Second, product was dialyzed against PBS (pH 7.4) overnight with 2 changes of PBS buffer. Any precipitate was cleared by filtration through 0.45 μ m filter unit (Nalgene) before next step. Third, size-exclusion chromatography (SEC) purification (HiLoad 16/600 Superdex 200 pg, or HiLoad 26/600 Superdex 200 pg, GE Healthcare) was used to remove aggregates and different species in the prep. The fractions were analyzed on reduced and non-reduced SDS-PAGE to identify the fractions that contained the monomeric trispecific binding protein before combining them. The purified antibody can be aliquoted and stored at -80° C. long term.

ELISA Binding Assay

[0610] Binding affinities to each target antigen by the CD38/CD28xCD3 T cell engagers were measured by ELISA. Briefly, each antigen was used to coat the 96-well Immuno Plate (Thermo Fisher Scientific) overnight at 4° C. using 200 ng/well in PBS(pH7.4) of each antigen. The coated plate was blocked using 5% skim milk+2% BSA in PBS for one hour at RT, followed by washing with PBS+0.25% Tween 20 three times (Aqua Max 400, Molecular Devices). Serial dilution of antibodies (trispecific and control Abs) were prepared and added onto the ELISA plates (100 μ l/well in duplicate), incubated at room temperature (RT) for one hour, followed by washing 5 times with PBS+0.25% Tween 20. After washing, the HRP conjugated secondary anti-human Fab (1:5000, Cat. No. 109-035-097, Jackson ImmunoResearch Inc) was added to each well and incubated at RT for 30 minutes. After washing 5 times with PBS+0.25% Tween 20, 100 μ l of TMB Microwell Peroxidase Substrate (KPL, Gaithersburg, MD, USA) was added to each well. The reaction was terminated by adding 50 μ l 1M H₂SO₄, and OD450 was measured using SpectraMax M5 (Molecular Devices) and analyzed using SoftMax Pro6.3 software (Molecular Devices). The final data was transferred to GraphPad Prism software (GraphPad Software, CA, USA), and plotted. EC50 was calculated using the same software.

Measurement of Trispecific Antibody Binding Using SPR

[0611] Human CD38-His antigens were used (Cambridge Biologics, Cambridge, MA) for full kinetic analysis. Kinetic

characterization of purified antibodies was performed using SPR technology on a BIACORE 3000 (GE Healthcare). A capture assay using human IgG1 specific antibody capture and orientation of the investigated antibodies was used. For capture of Fc containing protein constructs the human antibody capture kit (GE Healthcare) was used. For capture of His tagged antigen, anti-His antibody capture kit (GE Healthcare) was used. The capture antibody was immobilized via primary amine groups (11000 RU) on a research grade CM5 chip (GE Life Sciences) using standard procedures. The analyzed antibody was captured at a flow rate of 10 μ L/min with an adjusted RU value that would result in maximal analyte binding signal of typically 30 RU. Binding kinetics were measured against the trispecific antibodies. Assay buffer HBS EP (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% Surfactant P20) was used at a flow rate of 30 μ L/min. Chip surfaces were regenerated with the regeneration solution of the respective capture kit. Kinetic parameters were analyzed and calculated in the BIA evaluation program package v4.1 using a flow cell without captured antibody as reference and the 1:1 Langmuir binding model with mass transfer.

Daratumumab Competition Binding Assay

[0612] For Daratumumab competition binding assay, Daratumumab was amine coupled to the active surface of CM5 chip. Reference surface was left blank and used to subtract any non-specific binding of injected molecules. Recombinant CD38-His (Sino Biological, Part #10818-H08H) was injected over the Daratumumab surface followed by injection of test antibodies. If a monospecific anti-CD38 antibody recognized an epitope on CD38 which was different from that of Daratumumab, injection of the antibody resulted in an increased SPR signal. If an antibody recognized an overlapping epitope as Daratumumab, injection of the antibody did not increase SPR signal.

Results

[0613] The binding affinities of selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains for human CD38 were determined by SPR. The association rate constant (K_{on}), dissociation rate constant (K_{off}), and the K_D of the selected trispecific antibodies are provided in Table A. The selected trispecific antibodies showed various degrees of affinities against human CD38 antigen.

TABLE A

Binding characteristics of selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains for human CD38 determined by SPR.			
Anti-CD38 binding domain	k_{on} ($M^{-1}s^{-1}$)	k_{off} (s^{-1})	K_D (M)
CD38VH1	5.55E+05	1.58E-03	2.85E-09
CD38hhy992	1.35E+06	1.75E-04	1.29E-10
CD38hyb6284	7.85E+05	5.12E-04	6.52E-10

TABLE A-continued

Binding characteristics of selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains for human CD38 determined by SPR.			
Anti-CD38 binding domain	k_{on} ($M^{-1}s^{-1}$)	k_{off} (s^{-1})	K_D (M)
CD38hyb5739	9.80E+05	5.46E-03	5.57E-09
CD38hhy1195	1.27E+06	1.80E-02	1.42E-08
CD38hhy1370	3.76E+05	3.29E-04	8.76E-10

[0614] The binding affinities of selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains for human CD3, human CD28, human CD38 and cynomolgus monkey CD38 were then determined by ELISA as described above. As shown in FIGS. 2B-2E, the selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains showed various affinities to human (FIG. 2B) and cynomolgus monkey CD38 (FIG. 2C), but similar affinity to human CD3 (FIG. 2D) and CD28 (FIG. 2E). EC50 values were then calculated by GraphPad Prism 7.02 using variable slope model with four-parameter logistic curve. The EC50 values of the selected trispecific antibodies for human CD3, human CD28, human CD38 and cynomolgus monkey CD38 are provided in Table B. Control antibody was a human IgG4 isotype control.

TABLE B

EC50 values of selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains for human CD3, human CD28, human CD38 and cynomolgus monkey CD38.				
Anti-CD38 binding domain	EC50 (pM)			
	hCD38	Cyno CD38	hCD3	hCD28
CD38VH1	7244	2128	6742	725
CD38hhy992	229	912	33593	809
CD38hyb6284	253	290	8222	711
CD38hyb5739	984	1628	10791	825
CD38hhy1195	102537	37701	7631	697
CD38hhy1370	587	553	24968	1257

[0615] An SPR competition assay was carried out to determine whether anti-CD38 antibodies hhy6284, hhy992, hhy5379, or hhy 1195 (tested in monospecific antibody format) compete with Daratumumab for binding to CD38. Following CD38 injection over Daratumumab (immobilized on SPR sensor chip), the test antibodies (or Daratumumab) were injected over the Daratumumab/CD38 complex. As shown in FIG. 3, injection of Hyb6264, hhy992, Hyb5379, and Hhy1195 increased SPR signal, indicating that these antibodies recognized the epitopes on CD38 which are different from the epitope which Daratumumab recognizes. As expected, injection of free Daratumumab (a competitive binding control) did not increase the SPR signal.

[0616] Binding of anti-CD38 antibodies to human or cynomolgus CD38 polypeptides is summarized in Table B2.

TABLE B2

Summary of anti-CD38 binding characteristics to human or cynomolgus CD38.

Name	ELISA huCD38 EC50 nM	ELISA cynoCD38 EC50 nM	FACS huCD38 EC50 nM	FACS cynoCD38 EC50 nM	SPR huCD38 KD M	SPR cynoCD38 KD M
AntiCD38_hyb_5739	0.12	0.09	0.3	0.5		
AntiCD38_hyb_6284	0.11	0.13	0.4	0.7		
AntiCD38_hhy_992	0.09	0.08	100	288	3.65E-10	6.12E-09
AntiCD38_hhy_1195	1.4	0.86	38	15	4.00E-08	2.60E-08

[0617] Anti-CD38 antibodies were also tested for competitive binding to daratumumab in SPR assay. For daratumumab competition binding assay, daratumumab was amine coupled to the active surface of CM5 chip. Reference surface was left blank and used to subtract any non-specific binding of injected molecules. Recombinant CD38-His (Sino Biological, Part #10818-H08H) was injected over the daratumumab surface followed by injection of test antibodies. If an antibody recognizes an epitope on CD38 which is different from that of daratumumab, injection of the antibody will result in an increased SPR signal. If an antibody recognizes an overlapping epitope as daratumumab, injection of the antibody will not increase SPR signal. According to the results of these assays the tested antibodies hhy992, hyb6284, hhy 1195 and hhy 1370 did not compete with daratumumab.

Example 3: Trispecific CD38/CD3xCD28 Antibodies Promote Lysis of Human Multiple Myeloma and Lymphoma Tumor Cells

[0618] An in vitro cell lysis assay was used to determine whether trispecific CD38/CD3xCD28 antibodies had anti-tumor cell activity using human multiple myeloma and lymphoma cells.

Materials and Methods

In Vitro Killing Assay Against Tumor Cells Using Human T Cells

[0619] Target tumor cells were labeled with the membrane dye PKH-26 (Sigma) and co-cultured for 24 hours with human PBMC or enriched CD8 T cells as effector cells at E:T ratio of 10:1(E:T=3:1 using enriched CD8 T cells) in the presence of indicated concentrations of tri-specific or relevant control antibodies. Peripheral blood mononuclear cells were isolated from normal human donors by Ficoll separation, and autologous CD8+ or pan-T cells were enriched using kits from Miltenyi Biotech (San Diego, CA). The extent of cell lysis in the target cells was determined by staining with a LIVE/DEAD™ Fixable Violet Dead Cell

Stain Kit (Life Technologies) and measured by the number of dead cells in the labelled target cell population by running the samples on an LSRFortessa instrument (BD Biosciences) followed by analysis using the Flowjo software (Treestar).

In Vitro Killing Assay Against Tumor Cells Using Human T Cells in the Presence of Daratumumab

[0620] 5 nM Daratumumab or isotype control antibodies were pre-incubated with PKH-26 labeled target tumor cells (10^5 cells/well) for 30 minutes, followed by addition of trispecific TCEs at indicated concentrations, and human PBMCs (E:T=10:1). 24 hours later, the extent of cell lysis in the target cells was determined by staining with a LIVE/DEAD™ Fixable Violet Dead Cell Stain Kit (Life Technologies) and measured by the number of dead cells in the labelled target cell population by running the samples on an LSRFortessa instrument (BD Biosciences) followed by analysis using the Flowjo software (Treestar).

Results

[0621] The in vitro cell killing activity of CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains was determined using a human multiple myeloma cell line NCI-H929 that expresses both CD38 and CD28. The assay was carried out in the presence of 5 nM Daratumumab or isotype control antibodies (present during the assay period). As shown in FIGS. 4A-4B, all tested trispecific antibodies led to cell lysis in a concentration-dependent manner in the presence and absence of Daratumumab. The EC50 values were then calculated in the presence and absence of Daratumumab (Table C). The cell killing activities of trispecific antibodies CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA with the CD38VH1 or CD38hhy1370 anti-CD38 binding domains were reduced by Daratumumab, while trispecific antibodies with the CD38hyb5739, CD38hyb6284, or CD38hhy 1195 anti-CD38 binding domains exhibited between 3-8 fold reductions in cell killing activity in the presence of Daratumumab (Table C).

TABLE C

In vitro killing activity against human multiple myeloma cell line NCI-H929 (CD38+/CD28+) by CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains in the presence of Daratumumab.

EC50 (pM)	Anti-CD38 binding domains					
	CD38VH1	CD38hhy992	CD38hyb5739	CD38hyb6284	CD38hhy1195	CD38hhy1370
With Dara	29.82	125.8	9.115	33.65	89.27	255.4

TABLE C-continued

In vitro killing activity against human multiple myeloma cell line NCI-H929 (CD38+/CD28+) by CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains in the presence of Daratumumab.						
EC50	Anti-CD38 binding domains					
(pM)	CD38VH1	CD38hhy992	CD38hyb5739	CD38hyb6284	CD38hhy1195	CD38hhy1370
With human IgG1	1.063	13.43	2.736	4.37	16.97	9.599

[0622] In addition, an in vitro cell lysis assay was used to measure the cell killing activity of selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains using a human lymphoma cell line OCI-LY19 that expresses CD38 but not CD28. The assay was carried out in the presence of 5 nM Daratumumab or isotype control antibodies which were present in the assay period. As shown in FIGS. 5A-5B, all tested trispecific led to cell lysis in a concentration-dependent manner in the presence and absence of Daratumumab. The EC50 values were then calculated in the presence and absence of Daratumumab (Table D). The cell killing activity of CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with CD38VH1 anti-CD38 binding domain was reduced by about 24 fold by Daratumumab, while trispecific antibodies with the CD38hhy992, CD38hyb5739, CD38hyb6284, CD38hhy1195, or CD38hhy1370 anti-CD38 binding domains also exhibited reductions in cell killing activity in the presence of Daratumumab (Table D).

TABLE D

In vitro killing activity against human lymphoma cell line OCI-LY19 (CD38+/CD28-) by selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains in the presence of Daratumumab.						
EC50	Anti-CD38 binding domains					
(pM)	CD38VH1	CD38hhy992	CD38hyb5739	CD38hyb6284	CD38hhy1195	CD38hhy1370
With Dara	135.9	133.3	219.1	81.05	715.2	209.8
With human IgG1	5.662	57.32	60.97	42.07	296.4	58.54

Example 4: CD38/CD28xCD3 Trispecific Antibodies Promote CMV-Specific Immune Response

[0623] As part of adaptive immunity, T cell immunity plays a crucial role in controlling viral infection and cancer, possibly eliminating infected cells and malignant cells which result in clearance of viral infection or cure of cancer. In chronic infectious diseases such as Herpes viral infection (HSV, CMV, EBV, etc.), HIV, and HBV viruses establish their persistence in humans by various mechanisms including immune suppression, T cell exhaustion, and latency establishment. Nevertheless, viral infection generally induces viral antigen specific immunity including antigen specific CD8 T cells that can readily recognize infected cells for controlling or killing through cytokine release or cytotoxic T cell (CTL) mediated killing processes. Thus, viral

antigen specific T cell activation and/or amplification in vivo and/or ex vivo provide therapeutic strategies against chronic viral infections.

[0624] Anti-CD38/CD28xCD3 trispecific antibodies were developed and evaluated for their potential in activating T cells, and promoting proliferation and/or amplification of antigen specific T cells. These trispecific Abs can effectively expand CD4 and CD8 effector and memory populations, including antigen specific CD8 T central memory and effector memory cells in vitro. Specifically, in vitro expansion of CMV and EBV specific CD8 central memory and effector memory cells were demonstrated. The anti-CD38/CD28xCD3 trispecific antibodies described herein exhibited novel properties by engaging CD3/CD28/CD38, providing signaling pathways to stimulate and expand T cells, which may offer an effective strategy treating chronic infectious diseases such as HSV, CMV, EBV, HIV-1, and HBV infections.

[0625] In this Example, the ability of CD38/CD28xCD3 trispecific antibodies to promote activation and expansion of CMV-specific T cells was determined.

Materials and Methods

In Vitro T Cell Proliferation Measurement

[0626] T cells were isolated from human PBMC donors by negative selection using a magnetic Pan T Cell Isolation Kit (Miltenyi Biotec GmbH, Germany). Antibodies were coated onto 96-well cell culture plates by preparing the antibodies in sterile PBS and dispensing 50 µL into each well (350 ng/well). The plates were then incubated at 37° C. for at least 2 hours and then washed with sterile PBS. The untouched T cells were added to the antibody-coated plates (5×10^5 cells/mL) and incubated at 37° C. for multiple days. The cells were passaged with new cell culture media onto fresh antibody-coated plates on Day 4. In certain experiments with 7 days incubation, only fresh medium was added without changing to fresh antibody-coated plate. The cells

were collected at specific time points and cell numbers calculated using CountBright™ counting beads.

In Vitro T Cell Proliferation Assay and T Cell Subset Determination

[0627] Peripheral blood mononuclear cells were isolated from blood of healthy human donors collected by Research Blood Components, LLC (Boston, MA). The PBMCs were added to antibody-coated plates (350 ng/well) (5×10^1 cells/mL), as previously described above, and incubated at 37° C. for 3 and 7 days. The cells were collected at specific time points and analyzed by flow cytometry for T cell subsets: naïve (CCR7+CD45RO-), Tem (CCR7+CD45RO+), Tem (CCR7- CD45RO+), Tregs (CD4+ Foxp3+ CD25hi). CMV pp65-specific and EBV BMLF-specific CD8+ T cells were detected using fluorescent-conjugated pentamer restricted to the PBMC donors' HLA/viral peptide (A*02:01/NLVPM-VATV, SEQ ID NO:284), (A*02:01/GLCTLVAML, SEQ ID NO:285), respectively (ProImmune, Oxford, UK). PBMC was obtained from HemaCare (Van Nuys, CA) for donors with known CMV or EBV infection. PMBC from donors negative for the restricting HLA type was used as negative control. Staining was done as per manufacturer's protocol.

Quantification of CMV-Specific T-Cells

[0628] As indicated above Peripheral blood mononuclear cells (PBMCs) were isolated from blood of known CMV-infected human donors and added to plates containing the trispecific antibody or control antibody. The plates were incubated at 37° C. The cells were collected at specific time points and analyzed by flow cytometry.

Results

[0629] CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains ΔVH1CD38 (control). CD38VH1, CD38hhy992, CD38hyb5739, CD38hyb6284, CD38hhy 1195, and CD38hhy 1370 were tested as described above using PBMCs isolated from CMV-infected human donor D (FIGS. 6A-6J) and CMV-infected human donor E (FIGS. 7A-7J). All tested CD38 trispecific Abs activated and promoted the proliferation of CMV-specific T cells, leading to increases in CMV-specific CD8+ T cells (cells/well) with different potency and kinetics in a dose response manner over the 7 day experiment (CMV Donor D, FIGS. 6A-6B; CMV Donor E, FIGS. 7A-7B). In addition, all tested CD38 trispecific Abs promoted the amplification (cells/well) of CMV-specific central memory (T_{cm}) (CMV Donor D, FIGS. 6C-6D; CMV Donor E, FIGS. 7C-7D) and effector memory (T_{em}) CD8+ T cells (CMV Donor D, FIGS. 6E-6F; CMV Donor E, FIGS. 7E-7F), which were both amplified dramatically in 7 days. FIGS. 6G-6J (CMV Donor D) and FIGS. 7G-7J (CMV Donor E) provide time courses showing the percent of CMV-specific T_{cm} and T_{em} cells at days 0, 3, and 7 of the 7-day experiments described above.

[0630] Taken together, these data indicate that CD38/CD28xCD3 trispecific antibodies promote activation and expansion of CMV-specific T cells, such as CMV-specific CD8+ T cells, CMV-specific effector memory (T_{em}) CD8+ T cells, and CMV-specific central memory (T_{cm}) CD8+ T cells.

Example 5: CD38/CD28xCD3 Trispecific Antibodies Promote EBV-Specific Immune Response

[0631] Next, the ability of CD38/CD28xCD3 trispecific antibodies to promote activation and expansion of Epstein-Barr virus (EBV)-specific T cells was determined.

Materials and Methods

Quantification of EBV-Specific T-Cells

[0632] As indicated above, peripheral blood mononuclear cells (PBMCs) were isolated from blood of known EBV-infected human donors and added to plates containing the trispecific antibody or control antibody. The plates were incubated at 37° C. for up to 11 days. The cells were collected at specific time points and analyzed by flow cytometry.

Results

[0633] CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains ΔVH1CD38 (control), CD38VH1, CD38hhy992, CD38hyb5739, CD38hyb6284, CD38hhy 1195, and CD38hhy 1370 were also tested as described above using PBMCs isolated from EBV-infected donor C (FIGS. 8A-8J) and EBV-infected donor D (FIGS. 9A-12). All tested CD38 trispecific Abs activated T cells and promoted the proliferation of EBV-specific T cells, leading to increases in EBV-specific CD8+ T cells (cells/well) with different potency and kinetics in a dose response manner over the 7 day experiment (EBV Donor C, FIGS. 8A-8B; EBV Donor D, FIGS. 9A-9B). In addition, all tested CD38 trispecific Abs promoted the amplification (cells/well) of EBV-specific central memory (T_{cm}) (EBV Donor C, FIGS. 8C-8D; EBV Donor D, FIGS. 9C-9D) and effector memory (T_{em}) CD8+ T cells (EBV Donor C, FIGS. 8E-8F; EBV Donor D, FIGS. 9E-9F), which were both amplified dramatically in 7 days. FIGS. 8G-8J (EBV Donor C) and FIGS. 9G-12 (EBV Donor D) provide time courses showing the percent of EBV-specific T_{cm} and T_{em} cells at days 0, 3, and 7 of the 7-day experiments described above.

[0634] Taken together, these data indicate that CD38/CD28xCD3 trispecific antibodies promote activation and expansion of EBV-specific T cells, such as EBV-specific CD8+ T cells, EBV-specific effector memory (T_{em}) CD8+ T cells, and EBV-specific central memory (T_{cm}) CD8+ T cells.

Example 6: Anti-Tumor Effects of Her2/CD28 x CD3 Trispecific Antibody in Tumor-Bearing Mice

[0635] In this Example, the Her2/CD28 x CD3 trispecific antibody was tested for anti-tumor effects in a ZR-75-1 tumor bearing Nod scid gamma (NSG) mouse model engrafted with in vitro expanded T cells.

Materials and Methods

[0636] NSG mice were divided into 5 groups of 10 mice each. On Day 0, ZR-75-1 human breast cancer cells were implanted into the mammary fat pad with 50% matrigel into each mouse at 5 million cells/mouse. On Days 17/18, expansion of human CD3+ T cells was begun. Randomization of mice occurred on Day 24 when tumors were approximately 150 mm³. On Day 25, all mice were engrafted with

in vitro expanded human CD3+ T cells at 10 million cells in 300 μ L/mouse (1QW, 1 IP injection).

[0637] Starting on Day 25, one group of mice received doses of vehicle alone (8% w/v sucrose, 0.05% w/v polysorbate 80, 10 mM histidine, pH 5.5), while the other 4 groups received Her2/CD28 x CD3 trispecific antibody, both at 10 mL/kg. Groups receiving trispecific antibody were dosed at 100, 10, 1, or 0.1 μ g/kg. Antibody or vehicle was administered 1QW intravenously in 2 doses (e.g., Days 25 and 32). Blood and tumor tissue was collected on Day 38 or 39.

Results

[0638] Her2/CD28 x CD3 trispecific antibody (binding protein #2 from Table 1, corresponding to SEQ ID Nos:104-107) was compared to vehicle control for its effects on human breast tumor growth in the NSG mouse model engrafted with in vitro expanded human T cells described above. Treatment with Her2/CD28 x CD3 trispecific antibody at the highest dose (100 μ g/kg) led to the most significant inhibition of tumor growth and regression, although the 10 μ g/kg dose also showed anti-tumor effects (FIGS. 13A & 13D). No significant body weight loss was observed (FIG. 13B). Individual tumor volumes over time from each trispecific antibody treatment group are provided in FIG. 13C.

[0639] Next, the effect of trispecific antibody treatment on individual immune cell subsets was examined. Human CD45+, human CD8+, and human CD4+ cell populations were measured by flow cytometry, as well as mouse CD45+ cells (FIGS. 14A-14C). Highest dose (100 μ g/kg) of trispecific antibody led to depletion of human CD4+ cells, and this effect was dose dependent (FIGS. 14B & 14C). Counts of human CD8+ cells were largely unaffected by trispecific antibody administration.

[0640] The effect of trispecific antibody treatment on tumor infiltrating lymphocytes (TILs) was also assessed by immunohistochemical (IHC) staining for human CD45, CD4, and CD8. Using H&E staining, tumors from the low dose groups (1 μ g/kg or 0.1 μ g/kg trispecific antibody) were generally of comparable size as the vehicle control group. As shown in FIGS. 15A-15C, human TILs were increased in the group receiving the low dose of Her2/CD28 x CD3 trispecific antibody, but human TILs were sparse in the high dose group. IHC images were also examined quantitatively (FIGS. 16A-16C). These results indicated significant reductions in CD45+ and CD8+ cells in the higher trispecific antibody dose groups (100 μ g/kg and 10 μ g/kg).

[0641] Compared to vehicle control, tumors from the high dose trispecific antibody treatment groups (100 μ g/kg or 10 μ g/kg) were characterized by sparse TILs. Moderate to large numbers of CD45+, CD4+, or CD8+ human TILs were observed in the 1 μ g/kg and 0.1 μ g/kg trispecific antibody treatment groups. These TILs were mostly present at the tumor edges but occasionally extended deeper into the tumor core.

[0642] In conclusion, these results demonstrate that treatment of ZR-75-1 breast tumor bearing NSG mice engrafted with in vitro activated T cells using 2 intravenous doses of HER2-targeting, T cell-engaging trispecific antibody at 100 μ g/kg or 10 μ g/kg resulted in significant reductions in tumor volume and, concomitantly, a significant decrease in TILs. At the 1 μ g/kg trispecific antibody dose, there was a marginal and inconsistent trend for increased TILs as compared to vehicle control.

Example 7: Effect of Anti-HER2 and Anti-CD3 Antigen Binding Domain Sequences in Her2/CD28 x CD3 Trispecific Antibody on Cancer Cell Killing

[0643] This Example describes the effect of anti-Her2 and anti-CD3 variable domain sequences on target cell killing. In this Example, a Her2/CD28 x CD3 trispecific antibody ("control") with wild-type trastuzumab antigen binding domain and an anti-CD3 antigen binding domain without 32/35 QQ mutations in the VL domain (see Example 1) was compared with Her2/CD28 x CD3 trispecific antibodies #1-6 from Table 1, corresponding to SEQ ID Nos: 100-103, 104-107, 286-289, 290-293, 294-297, and 298-301, respectively.

Materials and Methods

[0644] CD8+ T cells were isolated from human PBMCs from healthy donor using a magnetic bead isolation kit (Miltenyi Biotec). The T cells were used as effector cells against breast cancer cell lines expressing various levels of HER2 at 3:1 (Effector:Target) ratio. The cells were incubated with experimental or control trispecific antibody for 2 days before flow cytometry acquisition using viability dye (Invitrogen) and PKH26 target cell staining (Sigma). Mean EC50 for target cell lysis was calculated from 2-3 PBMC donors for each trispecific Ab.

Results

[0645] All trispecific antibodies were characterized for in vitro cell lysis of three HER2+ breast cancer target cell lines: HCC1954, BT20, and MDA-MB-231. HCC1954 breast cancer cells were found to express high levels of HER2, as assessed by flow cytometry (up to 150,000 receptors/cell), IHC (3+), or the HercepTest HER2 expression assay (3+) (FIG. 17A). BT20 breast cancer cells were found to express intermediate levels of HER2, as assessed by flow cytometry (~60,000 receptors/cell), IHC (1+), or the HercepTest HER2 expression assay (1+) (FIG. 17C). MDA-MD-231 breast cancer cells were found to express low levels of HER2, as assessed by flow cytometry (~9,000 receptors/cell), IHC (0+), or the HercepTest HER2 expression assay (0) (FIG. 17E). Results of the cell killing assays targeting HCC1954, BT20, or MDA-MB-231 are shown in FIGS. 17B, 17D, and 17F, respectively, comparing binding protein #2 vs. control or binding proteins #1 and #5 vs. control. The results demonstrated that the Her2/CD28 x CD3 trispecific antibodies having 30R/55Q/102E mutations in the anti-HER2 arm and 32/35 QQ mutations in the VL domain of the anti-CD3 arm showed improved target cell killing against all three cell lines, particularly at lower antibody concentrations.

[0646] Mean EC50 (pM) for in vitro cell killing was determined for all trispecific antibodies targeting the three breast cancer cell lines noted above (HCC1954, BT20, and MDA-MB-231) as well as the gastric cancer cell lines OE19 (high HER2 expression) and GSU (intermediate HER2 expression). Generally, the Her2/CD28 x CD3 trispecific antibodies having mutations in the anti-HER2 arm and in the VL domain of the anti-CD3 arm showed a lower EC50 (and thus superior cell killing) against all three breast cancer cell lines (FIG. 18A) and both gastric cancer cell lines (FIG. 18B). These results demonstrate that, while all trispecific antibodies are able to induce cell killing of HER2+ cells, the mutated trispecific antibodies consistently displayed improved cell killing efficacy against multiple target cell types.

SEQUENCE LISTING


The patent application contains a lengthy sequence listing. A copy of the sequence listing is available in electronic form from the USPTO web site (<https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20250250337A1>). An electronic copy of the sequence listing will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

1-50. (canceled)

51: A method for expanding T cells, comprising contacting a T cell with a binding protein comprising four polypeptide chains that form de-three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

V_{L1} is a first immunoglobulin light chain variable domain;
 V_{L2} is a second immunoglobulin light chain variable domain;

V_{L3} is a third immunoglobulin light chain variable domain;

V_{H1} is a first immunoglobulin heavy chain variable domain;

V_{H2} is a second immunoglobulin heavy chain variable domain;

V_{H3} is a third immunoglobulin heavy chain variable domain;

C_L is an immunoglobulin light chain constant domain;

C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

L_1 , L_2 , L_3 and L_4 are amino acid linkers;

wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and

wherein V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide;

wherein V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, wherein the V_{H2} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSN-

SYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V_{L2} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVH₁NX₂X₃TY, wherein X₁ is E or Q, X₂ is A or L, and X₃ is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65); and wherein V_{H3} and V_{L3} form a third antigen binding site that binds a tumor target protein.

52: The method of claim 51, wherein the T cell expresses a chimeric antigen receptor (CAR) on its cell surface or comprises a polynucleotide encoding a CAR.

53: The method of claim 51, wherein the T cell is a memory T cell or an effector T cell.

54-60. (canceled)

61: The method of claim 53, wherein the memory T cell is a CD8+ or CD4+ memory T cell.

62: The method of claim 53, wherein the memory T cell is a central memory T cell (T_{CM}) or effector memory T cell (T_{EM}).

63-78. (canceled)

79: The method of claim 51, wherein the V_{H1} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYY (SEQ ID NO:49), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:50), and a CDR-H3 sequence comprising the amino acid sequence of TRSHY-GLDWNFDV (SEQ ID NO:51), and the V_{L1} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:52), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:53), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTYPY (SEQ ID NO:54).

80: The method of claim 79, wherein the V_{H1} domain comprises the amino acid sequence of QVQLVQS-GAEVVKPGASVKVSCKASGYTFT-SYYIHWVRQAPGQGLEWIGSIYPGNVNT-NYAQKFQGRATLTVDTSISTAYMELSRLRSDD-TAVYYCTRSHYGLDWNFDWGKGTT VTVSS (SEQ ID NO:91), and/or the V_{L1} domain comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVITTCQA-SQNIYVWLWYQQKPGKAPKLIIYKASNLLHTGVP-SRFSGGSGSTDFTLISSLQPEDIATYYCQQGQTYPY-TFGQGTKLEIK (SEQ ID NO:92).

81: The method of claim 51, wherein the CDR-L1 sequence of the V_{L2} domain comprises an amino acid sequence selected from the group consisting of QSLVHQNAQTY (SEQ ID NO:59), QSLVHENLQTY

(SEQ ID NO:60), QSLVHENLFTY (SEQ ID NO:61), and QSLVHENLRTY (SEQ ID NO:62).

82: The method of claim 81, wherein the V_{H2} domain comprises the amino acid sequence of QVQLVES-GGGVVQPGRSRLS-CAASGFTFTKAWMHWVRQAPGKQLEW YAQIKDKSNS YATYYADSVKGFRFTISRDDSKNT-LYLQMNSLRAEDTAVYYCRGVYYALSPFDYWQGQ TLTVSS (SEQ ID NO:93) or QVQLVES-GGGVVQPGRSRLS-CAASGFTFTKAWMHWVRQAP GQLEWVAQIKDKSNS YATYYASSVKGRFTISRDD-SKNTLYLQMNSLRAEDTAVYYCRGVYYAL- SPFDYWQGQ TLTVSS (SEQ ID NO:595), and/or the V_{L2} domain comprises an amino acid sequence selected from the group consisting of DIVMTQTPLSLSVTPGQPA-SISCKSSSQLVHQNAQ-TYLSWYLQKPGQSPQSLIYKVSNRF SGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:95), DIVMTQTPLSLSVTPGQPA-SISCK-SSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVSNRFS GVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:96), DIVMTQTPLSLSVTPGQPA-SISCK-SSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVSNRFS GVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:97), and DIVMTQTPLSLSVTPGQPA-SISCK-SSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVSNRFS GVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:98).

83-128. (canceled)

129: The method of claim 51, wherein the tumor target protein is a CD38 polypeptide.

130: The method of claim 129, wherein the CD28 polypeptide is a human CD28 polypeptide, wherein the CD3 polypeptide is a human CD3 polypeptide, and wherein the CD38 polypeptide is a human CD38 polypeptide.

131: The method of claim 129, wherein:

- (a) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:13), a CDR-H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO:14), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:15), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVSSYQGF (SEQ ID NO:16), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:17), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:18);
- (b) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYLTTEFS (SEQ ID NO:19), a CDR-H2 sequence comprising the amino acid sequence of FDPEDGET (SEQ ID NO:20), and a CDR-H3 sequence comprising the amino acid sequence of TTGRFFDW (SEQ ID NO:21), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVISRF (SEQ ID NO:22), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:23), and a CDR-L3 sequence comprising the amino acid sequence of QQDSNLPIT (SEQ ID NO:24);

(c) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYAFTTYL (SEQ ID NO:25), a CDR-H2 sequence comprising the amino acid sequence of INPGSGST (SEQ ID NO:26), and a CDR-H3 sequence comprising the amino acid sequence of ARYAYGY (SEQ ID NO:27), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QNVGTA (SEQ ID NO:28), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:29), and a CDR-L3 sequence comprising the amino acid sequence of QQYSTYPFT (SEQ ID NO:30);

(d) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYSFTNYA (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of ISPYYGDT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARRFEFGFYYSMDY (SEQ ID NO:33), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHSNG-NTY (SEQ ID NO:34), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:35), and a CDR-L3 sequence comprising the amino acid sequence of SQSTHVPLT (SEQ ID NO:36);

(e) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARDPGLRYFDGGMDV (SEQ ID NO:39), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QGISSY (SEQ ID NO:40), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:41), and a CDR-L3 sequence comprising the amino acid sequence of QQLNSFPYT (SEQ ID NO:42); or

(f) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:43), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:44), and a CDR-H3 sequence comprising the amino acid sequence of ARMFRGAFDY (SEQ ID NO:45), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:46), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:47), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:48).

132: The method of claim 131, wherein:

- (a) the V_{H3} domain comprises the amino acid sequence of QVQLVQSGAEVVKPGASVKVSCKASGYTFTSY-AMHWVKEAPGQRLEWIGYIYPGQGG TNYNQKFQGRATLTADTSASTAYMELSSLRSED-TAVYFCARTGGLRRAYFTYWGQGTL VTVSS (SEQ ID NO:79), and/or the V_{L3} domain comprises the amino acid sequence of DIVLTQSPATLSLSPGER-ATISCRASQSVSSYQGFMHWYQQKPGQP-PRLLIYGAASSRAT GIPARFSGSGSGTDFTLTISPLEPED-FAVYYCQQNKEDPWTFFGGTKLEIK (SEQ ID NO:80);
- (b) the V_{H3} domain comprises the amino acid sequence of QVQLVQSGAEVKKP- GASVKVSCKVSGYTLTEFSIHWVRQAPGQ-

- GLEWMGGFDPEDGE TIYAQKFQGRVIMTEDT-
STDTAYMEMNSLRSEDTAIYYCTTGRFFDWFWG
QGTLTVVSS (SEQ ID NO:81), and/or the V_{L_3} domain
comprises the amino acid sequence of EIILTQ-
SPAIALSLSPGERATLSCRASQSVIS-
RFLSWYQVKPGLAPRLLIYGASTRATGIPVRF
SGSGSGTDFTSLTISSLQPEDCAVYYCQQDSNL-
PITFGQGTRELIK (SEQ ID NO:82);
(c) the V_{H_3} domain comprises the amino acid sequence of
QVQLVQSGAEVKPGASVKVSCKASGYAFT-
TYLVEWIRQRPGQGLEWMGVINPGSGT
NYAQKFQGRVTMTVDRSSTTAYMELSLRSDD-
TAVYYCARYAYGYWGQGTAVT (SEQ ID
NO:83), and/or the V_{L_3} domain comprises the amino
acid sequence of DIQMTQSPSSLASVGDRVTTI-
CRASQNVGTAVAWYQQKPGKSPKQLIYSASN-
RYTGVP SRFSGSGSTDFTLTISLQPED-
LATYYCQQYSTYPFTFGQGTKEIK (SEQ ID
NO:84);
(d) the V_{H_3} domain comprises the amino acid sequence of
QVQLVQSGAEVKPGASVKVSCK-
ASGYSFNTYAVHWVRQAPGQGLEWMGVIS-
PYYG DTTYAQKFQGRVTMTVDKSSSTA
YMELSLRSDDTAVYYCARR-
FEGFYYSMDYWGQG TLTVT (SEQ ID NO:85), and/or the V_{L_3} domain comprises the amino acid
sequence of DVVMTQSPLSLPVTLGQPASICRSP-
SQSLVHSNGNTYLNWYQQRPGQSPKLLIYKV-
SKRF SGVPDRFSGSGSGTDFTLKISRVEAE-
DVGVYYCSQSTHVPLTFGGGTKEIK (SEQ ID
NO:86);
(e) the V_{H_3} domain comprises the amino acid sequence of
QVQLVESGGGVVQPGRSRLSCLASGFTFSSYGM-
WVWRQAPGKGLEWVAVIYDGSN KYY-
ADSVKGRTFISRDNSKNTLYLQMNSLRAED-
TAVYHCARDPGLRYFDGGMDVWQG
GTTVTVT (SEQ ID NO:87), and/or the V_{L_3} domain
comprises the amino acid sequence of DIQLTQSPSFL-
SASVGDRVTTICRASQGISSY-
LAWYQQKPGKAPKLIFAASTLHSGVPSR
FSGSGSGTEFTLTISLQPEDFATYYCQLNSFPY-
TFGQGTKEIK (SEQ ID NO:88);
(f) the V_{H_3} domain comprises the amino acid sequence of
QVQLVESGGGVVQPGRSRLS-
CAASGFTFSSYGMWVWRQAPGKGLEWVAVI-
WYDGSN KYYADSVKGRTFISGDNSKNTLYLQM
NSLRAEDTAVYYCARMFRGAFDYWGQGTAVT
VSS (SEQ ID NO:89), and/or the V_{L_3} domain
comprises the amino acid sequence of AIQMTQSPSSL-
SASVGDRVTTICRASQ-
GIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPS
RFSGSGSGTDFTLTISLQPEDSATYY-
CLQDYIYPTFGQGTKEIK (SEQ ID NO:90);
(g) the V_{H_3} domain comprises the amino acid sequence of
QVQLQQSGPELVRPGTSVKVSCKASGYAFTTYL-
VEWIKQRPGQGLEWIGVINPGSGTN
YNEKFKGKATLTDRSSTTAYMHLSGLTSDD-
SAVYFCARYAYGYWGQGTAVT (SEQ ID
NO:277), and/or the V_{L_3} domain comprises the amino
acid sequence of DIVMTQSQKFM-
SASVGDRVRSITCKASQNVGTAVAWYQQQPGH-
SPKQLIYSASNRYTGV PDRFTGSGAGTDFTLTIS-
NIQSEDLADYFCQQYSTYPFTFGSGTKLEIK
(SEQ ID NO:278); or

(h) the V_{H_3} domain comprises the amino acid sequence of
QVQLLQSGAELVRPGVSVKIS-
CTGSGYSFTNYAVHWVKQSHVKSLEWIGVIS-
PYYGDTT
YNQKFTGKATMTVDKSSSTAYMELARLTSED-
SAIYFCARRFEGFYYSMDYWGQGTAVT VSS
(SEQ ID NO:279), and/or the V_{L_3} domain comprises
the amino acid sequence of DVVMIQTPLSLPVSLGQDQASICRPSQSLVHSNG-
NTYLNWYLQRPGQSPKLLIYKVSKRF
SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYL-
CSQSTHVPLTFGSQTKLEIK (SEQ ID NO:280).

133: The method of claim 129, wherein:

- (a) the first polypeptide chain comprises the amino acid
sequence of SEQ ID NO:156 or an amino acid
sequence that is at least 95% identical to the amino acid
sequence of SEQ ID NO:156; the second polypeptide
chain comprises the amino acid sequence of SEQ ID
NO:157 or an amino acid sequence that is at least 95%
identical to the amino acid sequence of SEQ ID
NO:157; the third polypeptide chain comprises the
amino acid sequence of SEQ ID NO:158 or an amino
acid sequence that is at least 95% identical to the amino
acid sequence of SEQ ID NO:158; and the fourth
polypeptide chain comprises the amino acid sequence
of SEQ ID NO:159 or an amino acid sequence that is
at least 95% identical to the amino acid sequence of
SEQ ID NO:159;
- (b) the first polypeptide chain comprises the amino acid
sequence of SEQ ID NO:160 or an amino acid
sequence that is at least 95% identical to the amino acid
sequence of SEQ ID NO:160; the second polypeptide
chain comprises the amino acid sequence of SEQ ID
NO:161 or an amino acid sequence that is at least 95%
identical to the amino acid sequence of SEQ ID
NO:161; the third polypeptide chain comprises the
amino acid sequence of SEQ ID NO:162 or an amino
acid sequence that is at least 95% identical to the amino
acid sequence of SEQ ID NO:162; and the fourth
polypeptide chain comprises the amino acid sequence
of SEQ ID NO:163 or an amino acid sequence that is
at least 95% identical to the amino acid sequence of
SEQ ID NO:163;
- (c) the first polypeptide chain comprises the amino acid
sequence of SEQ ID NO:164 or an amino acid
sequence that is at least 95% identical to the amino acid
sequence of SEQ ID NO:164; the second polypeptide
chain comprises the amino acid sequence of SEQ ID
NO:165 or an amino acid sequence that is at least 95%
identical to the amino acid sequence of SEQ ID
NO:165; the third polypeptide chain comprises the
amino acid sequence of SEQ ID NO:166 or an amino
acid sequence that is at least 95% identical to the amino
acid sequence of SEQ ID NO:166; and the fourth
polypeptide chain comprises the amino acid sequence
of SEQ ID NO:167 or an amino acid sequence that is
at least 95% identical to the amino acid sequence of
SEQ ID NO:167;
- (d) the first polypeptide chain comprises the amino acid
sequence of SEQ ID NO:168 or an amino acid
sequence that is at least 95% identical to the amino acid
sequence of SEQ ID NO:168; the second polypeptide
chain comprises the amino acid sequence of SEQ ID
NO:169 or an amino acid sequence that is at least 95%

- identical to the amino acid sequence of SEQ ID NO:169; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:170 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:170; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:171 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:171;
- (e) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:172 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:172; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:173 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:173; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:174 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:174; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:175 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:175;
- (f) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:176 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:176; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:177 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:177; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:178 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:178; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:179 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:179;
- (g) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:181 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:181; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:182 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:182; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:183 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:183; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:184 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:184; or
- (h) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:185 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:185; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:186 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:186; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:187 or an amino acid sequence that is at least 95% identical to the amino

acid sequence of SEQ ID NO:187; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:188 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:188.

134: The method of claim 51, wherein the tumor target protein is a HER2 polypeptide.

135: The method of claim 134, wherein the CD28 polypeptide is a human CD28 polypeptide, wherein the CD3 polypeptide is a human CD3 polypeptide, and wherein the HER2 polypeptide is a human HER2 polypeptide.

136: The method of claim 134, wherein:

(a) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIKDTY (SEQ ID NO:1) or GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3), IYPTQGYT (SEQ ID NO:4), or IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6), SRWGGEGLFYAMDY (SEQ ID NO:7), or SRWGGSGFYAMDY (SEQ ID NO:8), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9) or QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12);

(b) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIKDTY (SEQ ID NO:1), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12);

(c) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTQGYT (SEQ ID NO:4), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGEGFYAMDY (SEQ ID NO:7), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12);

(d) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGSGFYAMDY (SEQ ID NO:8), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12);

- (e) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIRDTY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTQGYT (SEQ ID NO:4), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGSGFYAMDY (SEQ ID NO:8), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12);
- (f) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIRDTY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGEGFYAMDY (SEQ ID NO:7), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12); or
- (g) the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIKDTY (SEQ ID NO:1), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12).

137: The method of claim 136, wherein:

- (a) the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEW-VARIYPTNGYT YADSVKGRFTISADTSKNTAY-LQMNSLRAEDTAVYYCSRWRGGDFYAMDYWG QGT LTVSS (SEQ ID NO:72), EVQLVESGG-GLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEW-VARIYPTQGYTR YADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRWRGGEGFYAMDYWGQGTL VTVSS (SEQ ID NO:73), EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEW-VARIYPTQGYTR YADSVKGRFTISADTSKNTAY-LQMNSLRAEDTAVYYCSRWRGGSGFYAMDYWG QGTL VTVSS (SEQ ID NO:74), EVQLVESGG-GLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEWVARIYPT-NAYTR YADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRWRGGEGFYAMDYWGQGTL VTVSS (SEQ ID NO:75), or EVQLVESGG-GLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEWVARIYPT-NAYTR YADSVKGRFTISADTSKNTAYLQMNSLRAED-TAVYYCSRWRGGEGFYAMDYWGQGTL VTVSS

- (SEQ ID NO:76), and the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSL-SASVGDRVITCRASQDVNTA-VAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFA-TYYCQQHYPPTFGQGKTVEIK (SEQ ID NO:77) or DIQMTQSPSSL-SASVGDRVITCRASQDVNTA-VAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFA-TYYCQQHYPPTFGQGKTVEIK (SEQ ID NO:78);
- (b) the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEW-VARIYPTNGYT YADSVKGRFTISADTSKNTAY-LQMNSLRAEDTAVYYCSRWRGGDFYAMDYWG QGT LTVSS (SEQ ID NO:72), and the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSL-SASVGDRVITCRASQDVNTA-VAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFA-TYYCQQHYPPTFGQGKTVEIK (SEQ ID NO:77);
- (c) the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEW-VARIYPTQGYTR YADSVKGRFTISADTSKNTAY-LQMNSLRAEDTAVYYCSRWRGGEGFYAMDYWG QGTL VTVSS (SEQ ID NO:73), and the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSL-SASVGDRVITCRASQDVNTA-VAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFA-TYYCQQHYPPTFGQGKTVEIK (SEQ ID NO:77);
- (d) the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEWVARIYPT-NAYTR YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWRGGDFYAMDYWG QGTL VTVSS (SEQ ID NO:75), and the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSL-SASVGDRVITCRASQDVNTA-VAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFA-TYYCQQHYPPTFGQGKTVEIK (SEQ ID NO:77);
- (e) the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEW-VARIYPTQGYTR YADSVKGRFTISADTSKNTAY-LQMNSLRAEDTAVYYCSRWRGGSGFYAMDYWG QGTL VTVSS (SEQ ID NO:74), and the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSL-SASVGDRVITCRASQDVNTA-VAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFA-TYYCQQHYPPTFGQGKTVEIK (SEQ ID NO:77);
- (f) the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEWVARIYPT-NAYTR YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWRGGEGFYAMDYWGQGTL VTVSS

VTVSS (SEQ ID NO:76), and the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSL-SASVGDRVTITCRASQDVNTA-VAWYQQKPGKAPKLLIYSASFVLYSGVP SRFSGSRSGTDFTLTISSLQPEDFA-TYYCQQHYTTPPTFGQGKTVKEIK (SEQ ID NO:77); or

(g) the V_{H3} domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLS-CAASGFNIKDTYIHWVRQAPGKGLEW-VARIYPTNGYT RYADSVKGFRFTISADTSKNTAY-LQMNSLRAEDTAVYYCSRWGGDGFYAMDYWG QGT LTVSS (SEQ ID NO:72), and the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSL SASVGDRVTITCRASQDVQTA-VAWYQQKPGKAPKLLIYSASFVLYSGVP SRFSGSRSGTDFTLTISSLQPEDFA-TYYCQQHYTTPPTFGQGKTVKEIK (SEQ ID NO:78).

138: The method of claim 134, wherein:

(a) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:100 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:100; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:101 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:101; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:102 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:102; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:103 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:103;

(b) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:104 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:104; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:105 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:105; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:106 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:106; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:107 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:107;

(c) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:112 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:112; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:113 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:113; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:114 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:114; and the fourth polypeptide chain comprises the amino acid sequence

of SEQ ID NO:115 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:115;

(d) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:128 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:128; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:129 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:129; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:130 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:130; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:131 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:131;

(e) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:136 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:136; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:137 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:137; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:138 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:138; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:139 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:139;

(f) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:140 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:140; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:141 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:141; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:142 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:142; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:143 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:143;

(g) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:144 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:144; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:145 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:145; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:146 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:146; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:147 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:147;


- (h) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:152 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:152; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:153 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:153; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:154 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:154; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:155 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:155;
- (i) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:286 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:286; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:287 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:287; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:288 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:288; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:289 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:289;
- (j) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:290 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:290; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:291 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:291; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:292 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:292; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:293 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:293; or
- (k) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:294 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:294; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:295 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:295; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:296 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:296; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:297 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:297.

139: A method for expanding T cells, comprising contacting a T cell with a binding protein comprising four

polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:



and a second polypeptide chain comprises a structure represented by the formula:



and a third polypeptide chain comprises a structure represented by the formula:



and a fourth polypeptide chain comprises a structure represented by the formula:



wherein:

V_{L1} is a first immunoglobulin light chain variable domain;
 V_{L2} is a second immunoglobulin light chain variable domain;

V_{L3} is a third immunoglobulin light chain variable domain;

V_{H1} is a first immunoglobulin heavy chain variable domain;

V_{H2} is a second immunoglobulin heavy chain variable domain;

V_{H3} is a third immunoglobulin heavy chain variable domain;

C_L is an immunoglobulin light chain constant domain;

C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain;

C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain;

C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain;

hinge is an immunoglobulin hinge region connecting the C_{H1} and C_{H2} domains; and

L_1 , L_2 , L_3 and L_4 are amino acid linkers;
 wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair;

wherein V_{H1} and V_{L1} form a first antigen binding site that binds a CD28 polypeptide, wherein the V_{H1} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYY (SEQ ID NO:49), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:50), and a CDR-H3 sequence comprising the amino acid sequence of TRSHYGLDWNFDV (SEQ ID NO:51), and the V_{L1} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QNIYVV (SEQ ID NO:52), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:53), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTYPY (SEQ ID NO:54);

wherein V_{H2} and V_{L2} form a second antigen binding site that binds a CD3 polypeptide, wherein the V_{H2} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V_{L2} domain comprises a CDR-L1 sequence com-

prising the amino acid sequence of QSLVHQNAQTY (SEQ ID NO:59), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65); and wherein V_{H3} and V_{L3} form a third antigen binding site that binds a HER2 polypeptide wherein the V_{H3} domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIRDTY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTQGYT (SEQ ID NO:4), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGEGFYAMDY (SEQ ID NO:7), and the V_{L3} domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12).

140: The method of claim 139, wherein:

the V_{H1} domain comprises the amino acid sequence of QVQLVQSGAEVVVKPGASVKVSCKASGYTFT-SYYIHWVRQAPGQGLEWIGSIYPGNVNT-NYAQKFQGRATLTVDTSISTAYMELSRLRSDD-TAVYYCTRSHYGLDWNFDVWGKGTT- VTVSS (SEQ ID NO:91), and the V_{L1} domain comprises the amino acid sequence of DIQMTQSPSSL-SASVGDRVTTICQASQNIYVWLNWYQQKPGKA-PKLLIYKASNLLHTGVPSRFSGSQSGTDFTLTISSLQPEDIATYYCQQGQ-TYPYTFGQGTKLEIK (SEQ ID NO:92); the V_{H2} domain comprises the amino acid sequence of QVQLVESGGVVQPGRSRLRLSCAASGFTF-TKAWMHWVRQAPGKQLEWVAQIKDKNSNS-YATYYADSVKGRFTISRDDSKNTLYLQMNSL-RAEDTAVYYCRGVYYALSPFDYWQGQ-TLVTVSS (SEQ ID NO:93); and the V_{L2} domain comprises the amino acid sequence of DIVMTQTPLSLSVTPGQPASICK-SSQLVHQNAQ-TYLSWYLQKPGQSPQSLIYKVSNRF-SGVPDRFSGSGSGTDFTLKISRVEAE-DVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:95); and

the V_{H3} domain comprises the amino acid sequence of EVQLVESGGLVQPGGSLRLS-CAASGFNIRDTYIHWVRQAPGKGLEW-VARIYPTQGYTR-YADSVKGRFTISADTSKNTAY-LQMNSLRAEDTAVYYCSRWGGEGLFYAMDYWG-QGTL VTVSS (SEQ ID NO:73), and the V_{L3} domain comprises the amino acid sequence of DIQMTQSPSSLASAVGDRVTTICRASQDVNTA-VAWYQQKPGKAPKLLIYSASFYLSGVPSRFSGRSGTDFTLTISSLQPEDIATYYCQQHYYTTPPTFGQGTKVEIK (SEQ ID NO:77).

141: The method of claim 139, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:104 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:104; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:105 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:105; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:106 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:106; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:107 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:107.

142: The method of claim 139, wherein L_1 , L_2 , L_3 and L_4 each independently comprise the sequence DKTHT (SEQ ID NO:66).

143: The method of claim 139, wherein the hinge- C_{H2} - C_{H3} domains of the second and the third polypeptide chains are human IgG4 hinge- C_{H2} - C_{H3} domains, and wherein the hinge- C_{H2} - C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A.

144: The method of claim 139, wherein the hinge- C_{H2} - C_{H3} domains of the second and the third polypeptide chains are human IgG4 hinge- C_{H2} - C_{H3} domains, and wherein the hinge- C_{H2} - C_{H3} domains each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K.

145: The method of claim 139, wherein the hinge- C_{H2} - C_{H3} domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the hinge- C_{H2} - C_{H3} domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

146: The method of claim 139, wherein the hinge- C_{H2} - C_{H3} domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the hinge- C_{H2} - C_{H3} domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

* * * * *